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ABSTRACT 
 For a decade, our research group has been developing protocols to prevent and reverse chronic 
diseases.  The present monograph outlines the lessons we have learned from both conducting the 
studies and identifying common patterns in the results.  The main product of our studies is a five-step 
treatment protocol to reverse any chronic disease, based on the following systemic medical principle: at 
the present time, removal of cause is a necessary, but not necessarily sufficient, condition for 
restorative treatment to be effective.  Implementation of the five-step treatment protocol is as follows: 
FIVE-STEP TREATMENT PROTOCOL TO REVERSE ANY CHRONIC DISEASE 
 Step 1: Obtain a detailed medical and habit/exposure history from the patient.   
 Step 2: Administer written and clinical performance and behavioral tests to assess the 
severity of symptoms and performance measures. 
 Step 3: Administer laboratory tests (blood, urine, imaging, etc) 
 Step 4: Eliminate ongoing contributing factors to the chronic disease 
 Step 5: Implement treatments for the chronic disease 
 
 This individually-tailored chronic disease treatment protocol can be implemented with the data 
available in the biomedical literature now.  It is general and applicable to any chronic disease that has 
an associated substantial research literature (with the possible exceptions of individuals with strong 
genetic predispositions to the disease in question or who have suffered irreversible damage from the 
disease).  To prevent any chronic disease, eliminate those contributing factors that serve as a basis for 
Step 4. 
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The views in this monograph are solely those of the author and do not represent the views of the 
Georgia Institute of Technology. 
This monograph is not intended as a substitute for the medical advice of physicians.  The reader 
should regularly consult a physician in matters relating to his/her health and particularly with respect 
to any symptoms that may require diagnosis or medical attention.  Any information in the 
monograph that the reader chooses to implement should be done under the strict guidance and 
supervision of a licensed health care practitioner. 




 Why did I write this monograph, what are its contents, what is new, who is the intended 
audience, and how will readers benefit from it? 
Motivation 
 Non-communicable diseases have overtaken communicable diseases as the leading cause of 
global mortality.  The impacts of non-communicable disease expansion on healthcare and associated 
costs have been dramatic.  In the USA, these costs, and how to deal with them, have become a central 
political issue. 
 The mainstream medical approach emphasizes treatments over prevention for non-
communicable diseases.  Given the expansion of non-communicable diseases, the present treatment-
dominant approach is insufficient.  Greater balance between treatment and prevention is required.    
Eliminating the actionable foundational causes of these diseases is at least as important as applying new 
treatments, if there is to be any hope for full or partial reversal of non-communicable diseases, as well 
as prevention.  
 Toward that end, I developed a systemic medical principle that would form the bedrock of a 
healing protocol for diseases: at the present time, removal of cause is a necessary, but not necessarily 
sufficient, condition for restorative treatment to be effective (where "removal" encompasses 
"neutralization" in those cases where actual "removal" is not possible, and "restoration" encompasses 
restoration of health to the organ/tissue as well as restoration of function).  To prevent diseases, the 
actionable foundational causes shown by the biomedical literature to potentially contribute to the 
diseases need to be removed as comprehensively, thoroughly, and rapidly as possible.  To reverse 
diseases (if irreversible damage has not been done and genetic predisposition to the disease in question 
is not a dominant factor), the preventive steps above need to be implemented as well.  If the preventive 
protocols alone are inadequate for reversing disease progression, they need to be augmented by 
treatments.  The first step in either disease prevention or reversal is to identify the full spectrum of 
potential foundational causes/contributing factors for the disease(s) of interest. 
 Based on our studies of three chronic diseases, we have found:  
 1) much of the information required to identify and eliminate these foundational causes of 
disease is in the biomedical literature already, but is not being extracted and exploited adequately;  
 2) the biomedical literatures for many chronic diseases are large, and extracting these 
foundational causes comprehensively from the literatures is a complex text mining problem; 
 3) the same holds true for treatments and biomarkers.  
Contents 
 The overall theme of the present monograph is preventing and reversing chronic disease based 
on the systemic medical principle described above.  The specific focus of the present monograph is 1) 
summarizing the methodologies used in our chronic disease studies to prevent and reverse these 
diseases, and 2) summarizing the lessons learned and patterns identified from these studies. 
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 There are lengthy appendices in the present monograph describing the text mining/information 
technology advances that allowed 1) the existing and potential chronic disease treatments and 
contributing factors to be extracted efficiently from the large numbers of  journal articles retrieved from 
the premier biomedical literature, and 2) the impacts of these treatments and contributing factors to be 
extracted from the literature.  Major advances were made in the text mining approach for extracting 
both existing and potential treatments and contributing factors from the biomedical literature (and their 
impacts). 
Novelty 
 While the individual existing and potential chronic disease contributing factors and treatments 
identified in this monograph are "known", in the sense that they exist scattered throughout the 
published literature (although the potential chronic disease contributing factors and treatments have 
not been previously associated with the chronic disease in the literature), they have not been integrated 
to the extent they are integrated in this monograph.  The new "insights" in this monograph are:  
 1) the sheer number of existing and potential chronic disease contributing factors, biomarkers, 
and treatments;  
 2) the sheer number of potential combinations of chronic disease contributing factors and 
treatments that have to be identified and researched (many of whose individual components have not 
yet been identified); 
 3) the sheer number of chronic disease biomarkers and symptoms that can be used as 
diagnostics to identify causes and treatments for individual patients; 
 4) the approach for discovering treatments from the non-chronic disease literature, which 
allows both the re-purposing of drugs that have been used for treating other diseases and identification 
of non-drug substances that will correct the abnormal chronic disease biomarker values; 
 5) the chronic disease treatment protocol that can be tailored to any individual patient. 
Audience 
 There are three communities to whom this monograph is targeted.  First is the "chronic disease 
prevention and reversal" community.  This encompasses the public health community, the chronic 
disease research community, medical practitioners involved clinically with chronic disease prevention 
and reversal, caretakers for chronic disease patients, and individuals interested in what the present 
approach has to offer (they should heed the warnings in the Disclaimer).  
 Second is the text mining and information technology community.  This would cover the full 
spectrum of researchers interested in extraction of useful information from any type of text, since the 
techniques developed in this monograph can be readily adapted to extracting useful information from 
myriad types of biomedical and non-biomedical text.   
 Third is the broader medical and health policy community.  The methodology is applicable to 
prevention and reversal of any disease that has an associated substantial research literature. 
 




 The interested reader of this monograph will gain a deeper understanding of the main 
contributing factors to, and treatments available for, the three chronic diseases studied.  The reader will 
also gain an understanding of the broad spectrum of rigorous actions required to prevent and/or 
reverse chronic disease.   Finally, and most importantly, the motivated reader will see that much of what 
is required to prevent and reverse chronic disease may be available in the here and now (for those who 
have not suffered irreversible damage or have an overwhelming genetic predisposition for the chronic 
disease of interest)! 
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1A. Concept for Preventing and Reversing Chronic Diseases 
Non-communicable diseases have become the leading cause of death globally.  They lead to 4-
fold greater mortality than communicable diseases [WHO, 2016].  While the per capita mortality rate for 
infectious diseases has declined precipitously over the past century, the per capita mortality rate for 
non-communicable diseases has remained roughly constant [Hansen et al, 2016].   
Whether this constant per capita mortality trend for non-communicable diseases will continue 
into the future is highly questionable. The chronic diseases we studied have a strong environmental 
component.  There have been many potentially harmful and effectively un-regulated high-technology 
additions to the environment in the past few decades (e.g., non-ionizing radiation (from cell phones, 
Wifi), vaccine combinations, agricultural chemicals, etc., have expanded greatly).  Because of latency 
delays, it is difficult to link the disease and potentially harmful environmental factors that may have 
occurred decades earlier.  As, for example, our Alzheimer’s Disease (AD) study showed [Kostoff et al, 
2018], the adverse impact of recent potentially harmful environmental and dietary additions on AD 
biomarkers and symptoms ominously portends increased incidence and prevalence of AD in the future.  
This holds true for all three chronic diseases we studied. 
Many of the toxic stimuli that are contributing factors to AD also contribute to myriad other 
serious diseases [Kostoff, 2015].  Many of these diseases can be fatal, and may not have the multi-
decadal latencies associated with AD.  Thus, these lethal diseases serve to cull out people who would 
have been high-risk candidates for AD had they lived.  This culling out of high-risk individuals artificially 
depresses and masks the real incidence of AD had these high-risk people survived.  This line of reasoning 
is applicable to the other chronic diseases we studied. 
It was important to understand better what was driving the disparity in mortality trends 
between communicable and non-communicable diseases, and to ascertain whether the text mining 
approaches I had developed for discovering new treatments for disease could help reverse the trend.  
About a decade ago, I undertook a two-pronged approach to examine the biomedical literature 
addressing non-communicable diseases.  The first prong consisted of identifying the contributing factors 
to the non-communicable diseases, and the second prong was to develop treatment protocols for 
preventing and reversing these chronic diseases. 
The first prong was motivated by a TEDx talk given by Dr. Terri Wahls about a decade ago 
[Wahls, 2011].  She was on the faculty of the University of Iowa Medical School when she developed 
Multiple Sclerosis (MS).  As time progressed, she became non-ambulatory, teaching and performing 
other duties in a wheelchair.  Finding no relief from the mainstream medical approaches to MS, she 
researched the causes and potential treatments for MS herself.  Based on her research, she 
hypothesized that poor diet may have been the driving factor behind her downward progression of MS, 
and substitution of a good diet might reverse the disease.  She also hypothesized that a technique called 
Neuromuscular Electrical Stimulation (NMES), which had only been used previously for treating athletic 
injuries, could help reverse the nerve damage caused by the MS. 
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She improved her diet to a higher level, then tried the NMES.  No improvement.  She improved 
her diet to the next higher level, and tried the NMES again.  Still no improvement.  When she further 
improved her diet, the MS began to reverse and NMES began to reverse the nerve damage.  As of a few 
years ago, she was riding horses, hiking, and doing other strenuous activities. 
Her story changed my thinking about disease, and what is necessary to prevent and reverse 
disease.  Treatments were insufficient as long as the factors that contributed to the disease were still 
operable.  As a result, I developed a systemic medical principle that, in its latest incarnation, states: at 
the present time, removal of cause is a necessary, but not necessarily sufficient, condition for 
restorative treatment to be effective.  The principle has two caveats: irreversible damage has not been 
done, and there is not an overwhelming genetic predisposition to the disease in question.  However, in 
most cases, we will not know whether irreversible damage has been done or whether there is an 
effective genetic predisposition to the disease until essentially all the important contributing factors 
have been eliminated.  This principle is general, and applicable to prevention and reversal of any 
disease.  The methodology that has been developed based on this principle is general, and applicable to 
any disease as well. 
To prevent any disease, the foundational causes shown by the literature to underlie the disease 
symptoms and biomarkers need to be identified and removed as comprehensively, thoroughly, and 
rapidly as possible. To reverse any disease (given the above caveats), the preventive steps above need to 
be implemented, and treatments to reverse the disease progression need to be applied. 
The efficacy of the methodology for preventing and reversing any disease depends on how 
thoroughly the foundational causes, treatments, biomarkers, and symptoms of the disease of interest 
have been identified.  As will be shown in this monograph, a wide spectrum of existing foundational 
contributing factors has been identified for the chronic diseases we have studied, and a wide spectrum 
of existing treatments and symptoms and biomarkers has been identified as well.  Combining these 
results allows development of a treatment protocol that can be tailored to individual patients and 
applied to any chronic disease. Most importantly, this treatment protocol (based on the systemic 
medical principal described above) is available with the information at our disposal today! 
1A1. Concept Feasibility 
Currently, the protocol we have developed is a concept.  What evidence exists to demonstrate 
its feasibility?  I will provide an example from AD, but it can be extrapolated to the other chronic 
diseases as well.  In 2017, two books were published on reversing early stage AD [Bredesen, 2017; 
Sherzai and Sherzai, 2017].  All the authors were credible neurologists, with long-standing experience in 
treating neurodegenerative diseases.   
One of the authors is Dale Bredesen.  He is an AD researcher/clinician who has shown that 
"reversal of cognitive decline in patients with early Alzheimer's disease or its precursors, MCI (mild 
cognitive impairment) and SCI (subjective cognitive impairment)" is obtainable today [Bredesen, 2014].  
Basing his approach on optimizing metabolic parameters, Bredesen used a combination of eliminating 
some potential AD contributing factors, substituting positive health practices, and adding dietary 
supplements to achieve his AD/MCI/SCI reversal results.   
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 Sherzai and Sherzai are AD researchers/clinicians who claim to have had very positive 
results with patients based on: "lifestyle intervention as the cure for cognitive decline" [Sherzai and 
Sherzai, 2017].  Their lifestyle modification approach (based on addressing their assumed four main 
pathways to AD: inflammation, oxidation, glucose dysregulation, lipid dysregulation) has five main 
components: nutrition, exercise, stress management, adequate sleep, and mental challenges. 
Bredesen's and the Sherzais' approaches can be viewed as one "footprint" of the more general 
systemic medical principle for preventing or reversing disease described in the current monograph.  Our 
approach is not constrained by hypotheses based primarily on symptoms/pathological mechanisms.  We 
use symptoms, pathological mechanisms, and other abnormal AD characteristics as a guidepost to 
identify causes to be eliminated and treatments to be implemented for individual patients.  Our 
approach is based on cause and effect as evidenced in the premier biomedical literature.  We identify as 
many AD biomarkers and symptoms as exist in the literature, and then relate adverse changes in the 
values of these AD biomarkers and symptoms to potential underlying foundational causes.  Preferably, 
the research findings will identify the biological mechanisms that link a foundational cause to its 
impact(s) on AD biomarkers and symptoms.  However, even in the absence of identifying such 
mechanisms, the linkage is retained.  We also relate beneficial changes in the values of these AD 
biomarkers and symptoms to potential treatments, again, whether or not the biological mechanisms 
that link treatments to positive impacts have been identified. 
Since our approach incorporates the positive aspects of the Bredesen and Sherzai approaches, 
but is far more extensive, we would expect (with some degree of confidence) the results from our 
approach to be at least as beneficial as those from Bredesen and the Sherzais, and possibly be effective 
into the higher stages of AD as well. 
1A2. Concept Cost Impacts 
There are two major benefits that would result from wide-scale implementation of our concept: 
improved health and longevity, and greatly reduced healthcare costs.  I will address the latter in this 
section. 
There are many schemes being proposed in the USA today to reduce the massive level of 
healthcare costs.  They go by the names of Medicare for All, single-payer, public option, universal health 
care, etc.   Essentially all these proposals are book-keeping schemes.  They do little to reduce the 
people, infrastructure, and procedures involved in healthcare.  Rather, they play games with who is 
going to pay the bills, and which scheme will have the greatest political impact.  They are akin to re-
arranging the deck chairs on the Titanic! 
None of these schemes will do very much to reduce total healthcare costs.  We will still 
need myriad specialists, myriad support personnel, myriad diagnostics, myriad drugs, myriad therapies, 
myriad nursing homes, etc, under the mainstream medical approach used today.  Paperwork may be 
reduced, and some savings may result from eliminating the insurance companies, but the bulk 
of healthcare costs will remain.  In fact, bringing in more people to healthcare system coverage under 
these proposals will result in increased total costs, unless drastic changes in healthcare procedures are 
adopted. 
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The only way to reduce healthcare costs substantially is to keep people out of the medical 
system in the first place, wherever possible.  Procedures need to be implemented that will minimize 
peoples’ interactions with the medical system.  Rather than play accounting games to 
reduce healthcare costs a few percent, eliminate as broadly as possible those exposures and substances 
that are known to contribute to disease. 
As the remainder of this monograph will show, we already know most of the factors that 
contribute to non-communicable diseases.  For the chronic diseases we have studied over the past 
decade, there are hundreds of contributing factors for each disease, most of which are not addressed 
under existing medical care.   Additionally, in some recent toxicology studies I have performed to 
support the protocols, I have found there are orders of magnitude differences between exposure limits 
set by Federal regulators and exposures shown to cause damage in the biomedical literature [Kostoff, 
2018]. 
Significant reduction of healthcare costs requires two major steps.  First, the medical profession 
needs to place far more emphasis on reducing contributing factors to disease in their treatment 
protocols, along the lines suggested in this monograph.  This also requires educating patients on the 
importance of this approach for their healing.  This step alone would greatly reduce peoples’ 
interactions with the medical system. 
Second, government at all levels needs to bring the regulated exposure limits in line with the 
findings in the medical literature.  This includes limits on chemical exposures, radiation exposures 
(especially non-ionizing radiation), biotoxin exposures, etc, taking into account potentially synergistic 
effects due to combinations of myriad toxic stimuli exposures.  Implementation of the above two steps 
would lead to far more health improvement and cost reductions than any of the accounting schemes 
under present consideration. 
 1B. Implementation 
My previous work on using text mining to treat diseases had focused almost exclusively on 
discovering new treatments for diseases using Literature-Related Discovery, an off-shoot of Literature-
Based Discovery I had developed about a decade ago [Kostoff RN, 2008, 2011; Kostoff and Briggs, 2008; 
Kostoff and Los, 2013; Kostoff, Block, Stumpf et al, 2008; Kostoff, Briggs, and Lyons, 2008].  I then began 
to expand my text mining approach to identifying contributing factors as well as treatments.  I would 
identify not only potential new contributing factors and treatments for the disease of interest, but 
would also include identifying known contributing factors and treatments for the disease of interest.   
The initial chronic disease I examined was chronic kidney disease (CKD) [Kostoff and Patel, 
2014], the selection of which was requested by a colleague who had been recently diagnosed with Stage 
III CKD.  I developed more powerful LRD techniques to identify potential new treatments, and was able 
to apply these techniques to identify potential new contributing factors.  Equally important, as it turned 
out, I developed new text mining approaches to identify comprehensively the known treatments and 
contributing factors for CKD.  In Appendix 1, I outline the text mining approaches used for the CKD 
study.  The detailed text mining approaches for each of the chronic diseases I studied are presented in 
later appendices. 
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The results from the CKD study were very surprising because of their magnitude and breadth.  
About 800+ contributing factors, about 800+ treatments, and almost 400 biomarkers/symptoms were 
identified from the existing CKD literature.  I believe many more of each were possible, especially those 
appearing infrequently in the CVD literature.  In addition, almost 100 new contributing factors and 
almost 100 new treatments were identified as discovery from the non-CKD literature.  Again, much 
more discovery was possible, since only very simple queries were used, and the analysis of what was 
retrieved was arbitrarily terminated. 
My next published study didn’t focus on a specific disease.  After the CKD study, it became clear 
to me that a much more comprehensive understanding of the broader impacts of potentially toxic 
substances on all diseases simultaneously was required before moving ahead to develop protocols to 
prevent and reverse other diseases.  I conceived of an approach that would identify ‘all’ contributing 
factors to ‘all’ diseases.  This methodology is presented in Appendix 2.  The comprehensive study was a 
massive effort that was limited severely by my computer system capabilities and my time resources.  
The final product was an eBook entitled “Pervasive Causes of Disease” [Kostoff, 2015].  It identified 
about 8,000 causes spread over about 4,000 diseases.  About 800 of the causes were deemed 
‘pervasive’, meaning they impacted at least an arbitrarily-selected threshold number of diseases.  The 
relationships tended to be many-to-one and one-to-many.  One cause could impact many diseases, and 
many causes could impact one disease.   
The cause-disease matrix was very sparse; only a relatively few of the 32,000,000 cells in the 
matrix had values.  Far more cause-disease linkages should be expected.  The various biological systems 
are interconnected (neural, immune, endocrine, circulatory, etc), and an adverse impact of a substance 
on one of these systems would be expected to have a ripple effect on the other intersecting systems.  A 
more comprehensive and adequately-resourced study could have uncovered many more cause-disease 
relationships from the existing literature.  Additionally, even if all the cause-disease relationships had 
been identified from the existing biomedical literature, the matrix still may have been relatively sparse.  
In order for a cell to have an entry, the underlying research would have had to be funded, the research 
conducted, and the research published.  In Chapter 9 of the Pervasive Causes of Disease eBook, I discuss 
reasons why some of this research never sees the light of day, especially for topics that have 
commercial/political/military sensitivity.  Also, in the design and conduct of the research, the 
researchers don’t include the thousands of biomarkers that would cover all these diseases in any one 
experiment or study.  They usually measure a handful of such biomarkers in any one study, selected 
mainly because of mechanism assumptions, and their findings are typically limited to one or a few 
diseases. 
Our next published study focused on Alzheimer’s Disease (AD) [Kostoff, Porter, and Buchtel, 
2018].  Based on lessons learned from the CKD study and the Pervasive Causes of Disease study, we 
developed a more streamlined approach, and were more selective in the number of different text 
mining approaches used to identify contributing factors, treatments, and symptoms/biomarkers.  This 
streamlined methodology is shown in Appendix 3.  We also developed a more formal treatment 
protocol for preventing and reversing AD.  As in the CKD study, we found many hundreds of contributing 
factors, treatments, and biomarkers/symptoms, and could have identified many more of each by using 
additional approaches. 
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In the AD biomedical literature, there are at least 20+ hypotheses (e.g., amyloid hypothesis, tau 
hypothesis, etc).  We assumed all had some validity, and selected three or four biomarkers and 
symptoms to represent each hypothesis in the diagnostic steps of the protocol.  All the AD hypotheses 
identified were centered around AD pathology, specifically, general biomarker abnormalities and 
symptoms (e.g., amyloid plaques, tau hyperphosphorylation, oxidative stress, inflammation, etc) 
associated with AD.  The typically high-technology treatments that accompany these hypotheses focus 
on removing/suppressing these pathological symptoms, rather than removing the causes of these 
symptoms.  These treatments (in the absence of comprehensive cause removal) are not efficacious 
because they violate the systemic medical principle that forms the basis of our methodology. 
Interestingly, there are no foundational causes-based hypotheses of AD, e.g., the Deficient-Diet 
Hypothesis, the Iatrogenic Hypothesis, the Sedentary Lifestyle Hypothesis, the Radiation Exposure 
Hypothesis, the Toxic Chemical Exposure Hypothesis, etc.  There are many articles in the literature 1) 
questioning the validity of each of the above-listed pathology-based AD hypotheses and 2) showing the 
deficiencies in their associated treatments for reversing AD. 
The strategy of identifying symptoms as pathological mechanisms that must be suppressed or 
removed for healing is a mainstay of Western Medicine.  However, another perspective is to view these 
symptoms as having two basic functions: serve as a warning signal that dysfunction exists and actions 
need to be taken to remove the cause of this dysfunction, and serve as a protective mechanism.  
 There are many examples in the biomedical literature supporting the concept of disease 
symptoms as warning signals and protective mechanisms, as shown by the following: 
EXAMPLES OF DISEASE SYMPTOMS AS PROTECTIVE MECHANISMS 
• "the down-regulation of energy metabolism in AD is a protective response of the neurons to the 
reduced level of nutrient and oxygen supply in the microenvironment" [Sun, Feng, Liang et al, 
2012]. 
• "Neurofibrillary tangle formation as a protective response to oxidative stress in Alzheimer’s 
Disease" [Nunomura, Takeda, Moreira et al, 2009]; 
• "Autophagy is a protective response to the oxidative damage to endplate chondrocytes in 
intervertebral disc" [Chen, Lv, Li et al, 2017]; 
• "loss of appetite in the acute phase of illness is indeed an adaptive, protective response that 
improves cell recycling (autophagy) and detoxification" [Schutz, Bally, Stanga et al, 2014]; 
• "Cataract is a self-defence reaction to protect the retina from oxidative damage" [Wegner and  
Khoramnia, 2011]. 
 
Additionally, in his 2017 book [Bredesen, 2017], Bredesen states: "Alzheimer's disease is actually 
a protective response to, specifically, three different processes: inflammation, suboptimal levels of 
nutrients and other synapse-supporting molecules, and toxic exposures."  Other AD researchers have 
drawn similar conclusions.  If Bredesen's view that the AD symptoms serve as a protective response 
against more serious damage is correct, then the mainline drug-based AD treatment approach of 
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suppressing these symptoms without removing the foundational causes that underlie these symptoms 
comprehensively in parallel  
 1) effectively removes the protective shield offered by these symptoms and thereby  
 2) exacerbates the progression of AD! 
Our most recent study focused on Peripheral Neuropathy (PN)/Peripheral Arterial Disease (PAD) 
[Kostoff, 2019].  We improved our techniques for identifying existing contributing factors, treatments, 
and biomarkers/symptoms.  As a result, we identified 800+ contributing factors, 1,000+ treatments, and 
1000+ biomarkers and symptoms.  The PN/PAD methodology is contained in Appendix 4.  Again, 
identifying far more items was possible with a well-funded study. 
A note about the very large number of existing treatments identified in all three chronic 
disease and prevention studies.   In all three, the treatments identified covered research over the 
past ~two-three decades.  Treatments that have 'failed' in human clinical trials are not excluded.  The 
reason for retaining these ‘failed’ treatments is as follows: 
My reading of thousands of abstracts on laboratory experiments and clinical trials of 
potential chronic disease treatments has shown 
 1) in vitro experiments typically performed on cells tend to have reasonably positive 
outcomes, at least for those papers that surface in the peer-reviewed published literature; 
 2) in vivo experiments typically performed on rodents (but other small animals as 
well) tend to also have reasonably positive outcomes, albeit somewhat less than in vitro 
experiments; 
 3) when these potential treatments reach the human clinical trial stage, especially 
the later phases, the success rates plummet! 
The explanation for this discrepancy given most often is the species difference.  Humans are 
different from rodents et al, and their physiological responses to stimuli are different as well.  
However, the toxic experiential and exposure background differences between humans who live in 
the real-world sea of myriad toxic exposures and animals who live in the very controlled environment 
of the laboratory are rarely, if ever, discussed.   
For the three chronic diseases studied, there were many hundreds of potential contributing 
factors identified (ranging from Lifestyle to Occupational/Environmental exposures).  For a given 
individual, some causes have happened in the past, and are no longer happening, but their damage 
trail remains.  Other causes are ongoing, have caused damage, and continue to cause damage.   
Why would anyone expect a human being with such a toxic history to respond to a 
potential treatment the same way that a laboratory animal raised in a controlled environment 
would respond to that treatment?  Furthermore, why would anyone expect a human being with 
such a toxic history to respond to a potential treatment the same way that another human being 
without such a toxic burden would respond to that treatment? 
Consider the previous example of Dr. Terri Wahls, an M.D. who was able to reverse her own 
case of MS [Kostoff, 2012; Kostoff, 2015].  She used two main types of treatments: lifestyle changes 
(mainly dietary) to reverse the MS and NMES to reverse the damage resulting from MS.  It was only 
when her diet achieved substantial improvement that the NMES produced positive effects.   
While Dr. Wahls' experience represents one data point only, it is a very powerful data point.  
Consider its implications.  Suppose a clinical trial were conducted to evaluate the potential for NMES 
to reverse the damage from MS.  Suppose further that Dr. Wahls' dietary-dominant contributing 
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factor to MS and her reaction to NMES were typical of the participants in such a clinical trial.  If the 
participants did not address their diet (with the rigor shown by Dr. Wahls) during the clinical trial, 
they would not respond positively to the NMES (as was the case for Dr. Wahls initially).  The trial 
would be interpreted as a failure of NMES.  However, in this hypothetical example, the NMES 
ineffectiveness is not the reason for the clinical trial's lack of success.  Failure to remove the cause of 
the disease and subsequent damage is the problem!  Failure to remove cause (of the three chronic 
diseases) as a reason for the very limited success of myriad treatments in the clinical trials of the past 
three decades cannot be ruled out. 
That is why even so-called 'failed' treatments were included in the studies of the three 
chronic diseases.  It cannot be stated conclusively which treatments failed because 1) they were 
intrinsically ineffective or 2) their beneficial effects were overwhelmed by the strong negative effects 
of the ongoing causes remaining operable.  In fact, it is unknown whether comprehensive, timely, 
and thorough removal of the relevant contributing factors for each of the three diseases by 
themselves would have obviated the need for many of these treatments! 
 
 
(Return to TOC) 
2. LESSONS LEARNED 
2A. Methodology 
There was no single method that provided the full spectrum of contributing factors or 
treatments or biomarkers for any of the diseases studied.  Each of the methods used added new 
information.  There were four categories of approaches used to identify contributing factors, 
treatments, and biomarkers, and future studies should select at least one approach from each category 
for comprehensiveness. 
2A1. Visual Inspection 
The text mining software [Vantage Point, 2019] used for the studies would import the Medline 
records retrieved for the study, and would parse the records in myriad ways, including all phrases in the 
Title and Abstract and the numbers of records in which they appeared.  The visual inspection approach 
consisted of reading the highest frequency Abstract phrases, and assigning them to contributing factor, 
treatment, biomarker, and other categories of interest.  Usually, the highest frequency 30,000 phrases 
were examined and binned (where appropriate), which meant that the mainline contributing factors, 
treatments, and biomarkers were identified.  Because the Abstract usually contained millions of phrases 
(all single, double, triple, and quadruple word phrases in the Abstract), that meant the vast majority of 
contributing factors, treatments, and biomarkers would have to be identified by other means. 
2A2. MeSH 
 One or both of the MeSH Headings or MeSH Qualifiers was used to target records of interest in 
each of the three chronic disease studies.  If the MeSH Headings were used, those that unambiguously 
reflected contributing factors, treatments, and biomarkers were selected (depending on the desired 
target), and the records in these unambiguous MeSH Heading categories were retrieved.  The records 
were read, and the desired information extracted.  If the MeSH Qualifiers were used to target records of 
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interest, those that unambiguously reflected contributing factors, treatments, and biomarkers were 
selected (depending on the desired target), and the records in the MeSH Qualifier category were 
retrieved.  The records were read, and the desired information extracted.  Effectively, the MeSH 
Headings and MeSH Qualifiers served as linking terms to high information records.  
 2A3. Text 
 To identify candidate contributing factors, treatments, and biomarkers in the lower frequency 
portion of the parsed Abstract field, and to fill in the gaps because 1) not all Medline records have been 
assigned MeSH terms or 2) the assigned MeSH terms are incomplete, a text-based approach was 
necessary. Linking terms strongly associated with contributing factors, treatments, and biomarkers were 
generated through visually inspecting many records containing foundational contributing factors, 
treatments, and biomarkers in the Titles, and identifying those (typically) non-technical terms that 
appeared frequently with the foundational contributing factors, treatments, and biomarkers.  The 
remainder of the parsed Abstract field was searched with use of these linking terms.  The additional 
candidate contributing factors, treatments, and biomarkers were extracted from the retrieved phrases, 
and validated as contributing factors, treatments, and biomarkers. 
 2A4. Dot Product 
 This is essentially a text-based approach, and involves intersecting two lists of phrases.  It was 
used for identifying contributing factors only.  While the visual inspection approach identifies 
comprehensively the higher-frequency foundational causes, the linking term approach is less efficient.  
Not all foundational causes are associated with the finite list of linking terms used.  Even if a 
foundational cause is associated (in the same Abstract) with a linking term, the software effectively 
limits the proximity of the linking term/foundational cause to four words.  Some foundational causes 
can be located much further away from a linking term than four words in an Abstract.   
 To identify additional foundational causes that may have slipped through the cracks from the 
visual inspection and linking term approaches, the dot product approach was developed.  Over 12,000 
potentially toxic substances from myriad other sources (including past foundational causes studies, 
government-approved lists of toxic substances, MeSH-derived causes, etc) were generated, and 
intersected with the millions of Abstract phrases in the core chronic disease literature.  Those phrases in 
common between the two lists were then validated as foundational causes.  While the dot product 
approach was developed specifically for identifying causes, a similar approach could be used for 
identifying treatments, biomarkers, mechanisms, etc. Moreover, given that many authors don't place 
detailed substances in the Title or Abstract, there could be substantial benefits gained by using full-text 
rather than Abstracts.  
 2A5. Specific Methodologies 
 The detailed approach used to identify contributing factors, treatments, and biomarkers for the: 
1) CKD study is shown in Appendix 1; 2) Pervasive Causes of Disease study is shown in Appendix 2; 3) AD 
study is shown in Appendix 3; 4) PN/PAD study is shown in Appendix 4. 
  




2B1. Contributing Factors to Disease 
Many hundreds of foundational contributing factors were identified for each disease examined.  
Appendix 5 contains an extensive presentation of the contributing factors to AD.  It is similar to the 
structure and quantity of contributing factors to the other chronic diseases.  Appendix 6 contains a 
taxonomy of impacts from AD foundational contributing factors.  This structure is similar to the impacts 
from other chronic disease contributing factors. 
2B2. Treatments for Disease 
Many hundreds of treatments were identified for each disease examined.  Appendix 7 contains 
a comprehensive list of the treatments for AD, and Appendix 8 contains a table of treatment benefits for 
AD.  These are similar to the quantity of treatments and treatment impacts for the other chronic 
diseases. 
2B3. Biomarkers and Symptoms 
Many hundreds of biomarkers, and somewhat less symptoms, were identified for each disease 
examined.  Appendix 9 contains a table of biomarkers for PN/PAD, followed by a table of symptoms for 
PN/PAD.  These are similar to the types and quantity of biomarkers and symptoms for the other chronic 
diseases examined. 
2B4. Patterns in Contributing Factors to Disease 
From my perspective, the dominant finding from the three chronic disease studies and the large 
Pervasive Causes of Disease study was the large number and wide spectrum of contributing factors to 
each disease.  The challenge was to identify any underlying structures in this voluminous data, and 
ascertain whether any messages could be gleaned that would support development of protocols to 
prevent and reverse these diseases. 
It became clear that a first-order categorization of the contributing factors could be achieved 
mechanistically.  The contributing factors were divided into six categories (with some overlap): Lifestyle; 
Iatrogenic; Biotoxins; Occupational/Environmental; Psychosocial/Socioeconomic; Genetics.  The latter 
category was not pursued further, since the thrust of the contributing factors was foundational 
contributing factors (those tangible causes over which we had (in theory) some control).  The categories 
proved useful for presenting results. 
The next question was whether there were a few latent categories that would explain the larger 
structure.  It soon became evident that the bulk of contributing factors to disease were 1) the products 
of modern and semi-modern technology, especially technology that was effectively unregulated, and 
from 2) the spinoffs of this modern technology (such as sedentary living, staring at computer screens all 
day, etc).  The problem can be stated summarily as follows: 
 





Direct Technology (the degree of direct impact of technology on foundational causes) plays a strong 
role in Lifestyle, Iatrogenic, and Occupational/ Environmental foundational causes. In addition, through 
its impact on the immune and other critical systems, modern technology may play a role in whether 
exposure to bacteria and viruses translates to symptoms and diseases. Modern technology impacts the 
growing, processing, and preparation of foods, and many of the adverse effects identified in the 
Pervasive Causes of Disease eBook can be traced back to the use (mis-use) of technology in the food 
cycle. The Iatrogenic adverse effects of modern technology result mainly from the high-technology-
based drugs, surgery, diagnostics, and therapy that characterize much of modern medicine today. The 
Occupational/Environmental adverse effects result mainly from the employment of modern 




Inadequate Regulation is coupled strongly to the introduction of high technology in all aspects of life. 
Many of the problems with foods derive from relatively unregulated chemicals, materials, and other 
contaminants entering the food supply during agriculture and animal husbandry. Many of the 
Occupational/Environmental exposures arise from relatively unregulated harmful substances entering 
the workplace and the environment.  This is especially true in less developed countries, but occurs in 
more developed countries as well. Many of the Iatrogenic problems could be traced to drugs, 
diagnostics, therapies, and other procedures entering practice with insufficient front-end long-term 
testing (especially testing on humans), and inadequate evaluation of side-effects. 
 
Two major aspects of Inadequate Regulation revolve around insufficient safety: inadequate safety data 
gathering, and inadequate safety testing. Much of the adverse impact data gathering tends to be from 
passive surveillance systems, where response rates can be an order of magnitude (or more) less than 
real-world incidence rates. Pre-market testing, in many cases, suffers from inadequate sample sizes, 
unrepresentative samples, insufficient long-term testing, and insufficient combination testing to 
identify potential synergistic effects. Insufficient long-term testing on humans is particularly troubling, 
since many serious diseases such as AD may have decadal latency periods from specific toxic stimuli. 
Transgenerational effects could not be excluded without appropriate long-term testing.   
 
Additionally, results from animal testing (which could be long-term from the perspective of many short-
lived animals used in testing) do not necessarily translate to human outcomes.  First, there is a species 
difference, and impacts on one species do not necessarily carry over to the same types of impacts on 
another species.  Second, laboratory animals are raised in relatively pristine environments, and 
subjected to a very few toxic substances during studies on disease contributing factors.  Conversely, 
humans experience many of the contributing factors identified in Pervasive Causes of Disease, and the 
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2B5. Setting Priorities for Preventing and Reversing Chronic Diseases 
 Our most recent chronic disease study was for PN/PAD.  Its core literature was not nearly as 
large as that of the CKD and AD studies, yet substantially more contributing factors, treatments, and 
biomarkers were found relative to the CKD and AD studies.  I attribute that to the experience gained in 
identifying these quantities from having performed the CKD and AD studies, and to the improvements 
made in the identification algorithms. 
 It is clear that future studies of major chronic diseases will generate at least the levels of 
numbers obtained in the PN/PAD studies (on the order of 1,000 each of contributing factors, 
treatments, and biomarkers), and perhaps far more if the studies are resourced adequately.  Given 
these voluminous numbers, some type of priority will need to be assigned to 1) contributing factors to 
eliminate, 2) biomarkers to be used for diagnostics, and 3) treatments to be implemented, 4) in order to 
make the treatment protocol feasible for clinicians. 
 2B5a. Contributing Factors Priorities 
 Contributing factors differ in myriad ways, but two are of interest here: ease of identification, 
and ease of elimination.  Many aspects of diet, recreational substance use, amount of exercise, etc, are 
examples of contributing factors that are easy to identify.  Exposure to environmental and workplace 
toxic substances require targeted measurements, and are far more difficult to identify.  Dietary 
substances, recreational drugs, etc, are (in theory) easy to eliminate.  Toxic exposures not being 
measured are impossible to eliminate. Other toxic exposures in the residential area and in the 
workplace that one cannot avoid (because they can’t afford to move or change jobs) are difficult to 
eliminate. 
 Our three chronic disease studies resulted in development of a five-step protocol.  The protocol 
is shown in summary form for AD in the following table, but applies to any chronic disease: 
FIVE-STEP TREATMENT PROTOCOL TO REVERSE AD 
 
 Step 1: Obtain a detailed medical and habit/exposure history from the patient.   
 Step 2: Administer written and clinical performance and behavioral tests to assess the severity 
of the higher-level symptoms and degradation of executive functions 
 Step 3: Administer laboratory tests (blood, urine, imaging, etc.) 
 Step 4: Eliminate ongoing AD contributing factors 
 Step 5: Implement AD treatments 
 
 For chronic disease, one or more abnormalities in different test results will emerge from Steps 
1-3.  In theory, the contributing factors can be matrixed against biomarkers, symptoms, etc, to ascertain 
which factors are contributing heavily to the abnormalities.  Unfortunately, the results are not that 
clear-cut.  Consider a matrix of contributing factors against biomarkers, specific and general.  For general 
biomarkers, such as inflammation and oxidative stress, there could be hundreds of contributing factors 
that impact these general biomarkers.  For some specific biomarkers, such as excess mercury, the 
contributing factor linkage is much clearer and easier to eliminate.  While there would probably be 
health benefits if the hundreds of contributing factors to inflammation and oxidative stress were 
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eliminated, changes on that order of magnitude are probably not realistic.  Additionally, if a person has 
to be instrumented to ascertain whether he/she is being exposed to the unmeasured contributing 
factors, that would require a long and expensive process in today’s environment. 
 In the AD and PN/PAD studies, an alternative prioritization approach was recommended.  The 
concept is to initiate the contributing factor elimination process by eliminating those factors 1) 
identified in the study and 2) easiest to eliminate and 3) under one’s control (more or less).  I called this 
eliminating the “low-hanging fruit”.  These contributing factors had been identified in all three chronic 
disease studies, and in the Pervasive Causes of Disease study.  I suspect they will appear in most major 
chronic disease studies, but that could be easily checked when these studies are completed.  The 
following table contains the latest incarnation of the “low-hanging fruit” contributing factors: 
"LOW-HANGING FRUIT" RECOMMENDATIONS 
 
1) curb the dietary excesses, and remove the dietary deficiencies, identified in the contributing 
factors list, the medical questionnaire, and the lab tests;  
2) eliminate food additives to the extent knowable and possible, including those dietary excesses that 
derive from food additives (excessive fat, sugar, salt);  
3) minimize high temperature cooking and the subsequent increases in advanced glycation end 
products from certain susceptible foods, heterocyclic amines, acrylamide, and polycyclic aromatic 
hydrocarbons; 
4) reverse the sedentary behavior patterns identified;  
5) remove the foundational impediments to better sleep;  
6) eliminate the use of 'recreational' drugs, including smoking and excessive alcohol;  
7) eliminate the use of medicinal drugs shown in the potential contributing factors list, unless these 
drugs are absolutely necessary; 
8) minimize exposures to some hydrocarbons, such as n-hexane, methyl-n-butyl ketone, carbon 
disulfide, acrylamide, ethylene oxide, trichloroethylene, kerosene, polycyclic aromatic hydrocarbons 
(including those found in smoke), etc; 
9) minimize exposures to some neurotoxic solvents, especially organic solvents;  
10) minimize inhalation and ingestion exposures to pesticides, herbicides, insecticides, and 
fungicides;  
11) minimize exposures to heavy metals in food, in water, and in the air; 
12) minimize exposure to particulates, especially air pollution;  
13) minimize exposures to ionizing radiation and non-ionizing non-visible radiation (such as cell 
phones, cell towers, WiFi, smart meters, etc.);  
14) minimize chronic stress (mental/emotional/psychological); 
 
 Even in the “low-hanging fruit” list, the first half are much more straight-forward to identify and 
eliminate than the second half. 
 2B5b. Biomarkers Priorities 
 There is a gross mismatch between the thousand or so biomarkers identified in our latest 
chronic disease studies (and expected in future chronic disease studies) and the number of biomarkers 
typically used in clinical practice for testing.  The identified biomarkers need to be reduced by almost 
two orders of magnitude (with today’s analytical instrumentation and costs) to be acceptable in clinical 
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practice.  Experience from the AD and PN/PAD studies has shown that the relatively modest numbers of 
general biomarkers identified could serve as a starting point for the reduction process.  In the AD study, 
the hypotheses selected to start the culling process were, for the most part, congruent with the general 
biomarkers identified (e.g., inflammation, oxidative stress, apoptosis, neurodegeneration, etc).  In the 
PN/PAD study, the main general biomarkers identified were used to start the culling process. 
Once the general biomarkers were selected, they were then matrixed against the specific 
biomarkers, and about three specific biomarkers were selected to represent each general biomarker.  
This would result in somewhere between 50 and 100 specific biomarkers to be used in the diagnostics 
tests.  If that proves to be too many for some clinicians, then two specific biomarkers could be selected 
rather than three to represent each general biomarker, and the numbers would drop by about a third. 
 2B5c. Treatment Priorities 
 In the chronic disease studies performed so far, there tended to be relatively few treatments 
universally used by the mainstream medical community.  Realistically, I would expect that trend to 
continue.  However, in all cases I examined, there tended to be significant numbers of papers addressing 
adverse effects (‘side-effects’) of each of these treatments.  They are not without risk.  Additionally, 
when these types of treatments shown to have some risk when tested in isolation are combined with 
other similar treatments, enhanced risk could result from synergies or additive effects. 
 The ~1,000 treatments identified in the latest chronic disease study covered a very wide 
spectrum, and varied significantly in their levels of risk.  There was a core of low-risk treatments that 
impacted most, if not all, of the general biomarkers selected.  Elimination of a contributing factor could 
be viewed as a low-risk treatment.  Substitution of a health-promoting habit for a health-degrading habit 
could be viewed as a treatment.  There are many other types of low-risk treatments possible, and they 
don’t involve drugs, radiation, or surgery.  The latter could be utilized if the former prove to be 
insufficient.  Similar to the recommended prioritization of contributing factor selection starting with the 
“low-hanging fruit”, my recommended prioritization of treatments starts with low-risk treatments 
(identified in the study).  The following table presents some of these low-risk treatments: 
LOWEST-RISK TREATMENTS 
• Exercise (such as aerobic exercise, walking, resistance training, treadmill, calisthenics, 
stretching, balancing) 
• Sleep Improvement (such as quiet environment, minimal light, minimal food before bedtime, 
maintain regular sleep schedule) 
• Stress Reduction (such as tai chi, yoga, massage, aromatherapy, accupuncture, accupressure, 
sensory stimulation, physiotherapy, massage, reflexology, meditation) 
• Diet - Choose foods high in 
o polyphenols (such as cloves, star anise, capers, curry powder, ginger, cinnamon,  
peppermint, oregano, sage, rosemary, thyme, basil, cocoa, tea, red wine, 
chokeberries, elderberries, blueberries, plums, cherries, black currants, blackberries, 
strawberries, raspberries, grapes, flaxseeds, celery seeds, chestnuts, hazelnuts, 
pecans, almonds, walnuts, olives, artichokes, chicory, red onion, spinach, broccoli,  
apples, pomegranates, peaches, apricots, olive oil, canola oil), especially flavonoids 
(such as apples, blueberries, strawberries, red grapes, cabbage, broccoli, onions, 
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capers, dark chocolate, cocoa, tea, red wine), isoflavones/genistein (such as 
soybeans, natto, tempeh, tofu, miso), and anthocyanins (such as blackberries, black 
currants, blueberries, strawberries, cranberries, eggplant, cherries, prunes, raisins, 
and the darker versions of raspberries, cabbage, plums, radish, grapes, plums, 
apples, beans, beets, cabbage, onions, pears, wines) 
o Unrefined carbohydrates (such as whole grains, legumes, fruits, and uncooked 
vegetables) 
o DHA/omega-3 fatty acid (such as salmon, herring, mackerel, anchovy, sardine, trout, 
shark, swordfish, mussel, sea bass, pollock, whiting, flounder, sole, lobster, halibut, 
carp, oyster, crab, mullet, tuna, perch, snapper, shrimp, octopus) 
o Vitamin B12/Folate (such as meat [beef liver, lamb, beef], fish [sardines, mackerel, 
salmon], dairy [feta cheese, cottage cheese], eggs, legumes [chickpeas, fermented 
soy, pinto beans, lentils], fruit [banana, avocado], vegetables [spinach, parsley, 
broccoli, beets, turnip, asparagus,]) 
o Vitamin C (such as fruits [guavas, acerola cherry, kiwifruit, rose hips, strawberries, 
oranges, papayas, vegetables [bell peppers, broccoli, tomatoes, snow peas, kale]) 
o Vitamin D (such as fish [sardines, salmon, mackerel, tuna], liver [beef, calf, cod liver 
oil], dairy [milk, yogurt]; most importantly, sunlight on exposed skin) 
o Vitamin E (such as seeds [sunflower seeds, pumpkin seeds], nuts [almonds, 
hazelnuts, pine nuts], fish [abalone, salmon, trout], fruit [avocado, mango, kiwifruit], 
vegetables [red peppers, turnip greens, spinach, chard, squash, broccoli]) 
o lycopene (such as tomatoes, guavas, watermelon, papaya, grapefruit), 
o oleic acid (such as nuts [almonds, peanuts, pecans, cashews, pistachios, hazelnuts] 
seeds [sesame, sunflower], avocados, olives, and vegetable oils [safflower, almond, 
olive, sesame, sunflower]), 
o luteolin (such as dried oregano, celery seed, hot peppers, peppermint, sage, 
rosemary, juniper berries, thyme, radicchio, chinese celery), 
o quercetin (such as capers, lovage leaves, elderberry juice, dock leaves, raddish 
leaves, arugula, dill weed, coriander, and fennel, cilantro, banana peppers, juniper 
berries, oregano, onions, carob flour, radicchio, red leaf lettuce, onions, watercress, 
raw, asparagus, kale, okra, cocoa powder, chia seeds)  
o sulforaphane (such as broccoli sprouts, broccoli, cauliflower, kale, brussels sprouts, 
cabbage, collards, arugula, turnips) 
o resveratrol (such as red wine, red grapes, peanut butter, pistachios, cocoa powder, 
dark chocolate, strawberries, blueberries, bilberries, cranberries) 




Caveats on diet: 
• Many toxic/harmful substances enter the food supply during all phases of food growth, 
distribution, and processing.  While foods should be selected to maximize the amounts 
of healing nutrients identified above, care must be taken to minimize the level of toxic 
additions to the food in parallel. 
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• Low-temperature cooking should be used to minimize production of AGEs and other 
harmful products (nitrosamines, polycyclic aromatic hydrocarbons, and acrylamides) 
during the cooking process. 
• Only low-mercury wild-caught fish should be used; these tend to be smaller fish, lower on 
the food chain. 
• Grass-fed animals with no exogenous growth hormones or antibiotics should be used, if 
possible, since these harmful products could be passed through to the consumer.  
• For fruits and vegetables normally eaten with skin, those that have not been sprayed with 
harmful pesticides and other toxic chemicals should be used. 
• Heavy metals are a contributing factor for many diseases, especially neurodegenerative 
diseases.  One source of heavy metal bioaccumulation in the body is through the food 
supply.  Heavy metals can occur naturally in the soil in which food is grown, they can 
concentrate abnormally in soils from nearby industrial pollution or from precipitation of 
air pollution, they can preferentially absorb in different types of food, and, depending on 
the type of food, can be absorbed from the food processing and manufacturing process.  
Any of the above foods selected for chronic disease prevention or treatment/reversal 
purposes should have heavy metal concentrations as low as possible. 
(return to TOC) 
2C. Mandates 
 I’m treating this section separate from the results, even though it flows from the results.  The 
central thesis of our treatment protocol for chronic diseases is that contributing factor elimination is a 
prime requirement for the possibility of preventing and reversing chronic disease.  However, the inverse 
is also true.  Contributing factor enhancement is a prime requirement for developing and exacerbating 
chronic disease. 
 Unfortunately, there are myriad ways in which contributing factors to disease are imposed on 
the population by government mandates, loose regulations, and other means.  Effectively, government 
is promoting and, in some sense, mandating the expansion of chronic disease among its population. 
 Consider the example of non-ionizing radiation technology.  This technology has become 
ubiquitous in modern life (cell phones, WiFi, smart meters, etc.).  Research has shown that non-ionizing 
radiation in the cell phone radiofrequency part of the spectrum contributes to oxidative stress and 
inflammation of the brain [Kostoff and Lau, 2017; Chauhan, Verma, Sisodia et al, 2017; Kesari, Siddiqui, 
Meena, 2013], among many other adverse effects.  As our chronic disease study results show, oxidative 
stress and inflammation are key chronic disease characteristics.  Chronic exposure to non-ionizing 
radiation would be a factor contributing to increase the incidence of those many chronic diseases in 
which these two characteristics are important. 
 Non-ionizing radiation technology requires an infrastructure.  For cell phones, the major 
infrastructure is cell towers.  The Telecommunications Act of 1996 effectively mandates the construction 
of cell towers with no opposition allowed based on environmental considerations.  For example, the 
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Telecommunications Act of 1996, in Section 704, contains the statement “No State or local government 
or instrumentality thereof may regulate the placement, construction, and modification of personal 
wireless service facilities on the basis of the environmental effects of radio frequency emissions to the 
extent that such facilities comply with the Commission's regulations concerning such emissions” 
[Telecommunications Act, 1996].   
The Spectrum Act of 2012 “facilitates the telecommunications industry’s rapid deployment of 
wireless infrastructure by requiring local governments to approve any application by a carrier that asks 
to modify and existing cellular communication structure that does not “substantially change” the 
existing facility.   Section 6409 states cities ““may not deny, and shall approve any eligible facilities 
request for a modification of an existing wireless tower or base station that does not substantially 
change the physical dimensions of such tower or base station.” (47 U.S.C. § 1455(a)(1).) Section 6409 
defines “eligible facilities request” as “any request for modification of an existing wireless tower or base 
station that involves – 
(a) collocation of new transmission equipment; 
(b) removal of transmission equipment; or 
(c) replacement of transmission equipment [Spectrum, 2012].” 
Thus, “The U.S. Telecommunications Act of 1996 and the Spectrum Act of 2012 limit local 
government’s ability to place infrastructure for cellular communications and simultaneously facilitates 
industry deployment [Spectrum, 2012].”  For all practical purposes, this means that citizens opposed to 
cell tower construction cannot use adverse health effects in their arguments.   
As of this writing, the FCC is attempting to implement similar effective mandates for the next 
generation of mobile wireless technology, known as 5G.  A million or more 'short' cell towers (in the USA 
alone) would be required for 5G implementation, since the propagation of radiation energy at the high 
frequencies characteristic of 5G is poor, and the distance between 'short' cell towers is relatively small 
by necessity.   
 This means that populated areas will be blanketed (around the clock) with 3GHz-30GHz (or 
higher) radiofrequency radiation.  This is a range of the frequency spectrum essentially untested for 
adverse health effects, especially over the long-term in humans, and especially in combination with 
other toxic stimuli [Kostoff and Lau, 2017].  It is no different in principle from a contractor proposing to 
spray the populated areas of the USA with Agent Orange around the clock, and the relevant government 
regulatory agency stating that no opposition to the spraying is allowed based on health considerations.   
 Thus, we have a dichotomy in the relevant USA Federal policy.  On the one hand, the Federal 
government is investing heavily in biomedical research to treat and reverse many chronic diseases.  On 
the other hand, the Federal government is allowing essentially unrestricted and inadequately regulated 
expansion of technologies that are important contributing factors to these chronic diseases.  
Metaphorically, the Federal government is drilling holes in the floor of the boat at the same time they 
are pumping water out of the boat!  These policies are diametrically opposed, and will limit the 
effectiveness of any chronic disease treatment protocol, no matter how strictly followed. 
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Effectively, the Federal government is promoting/mandating non-ionizing radiation exposure on 
its citizens, and our chronic disease studies have shown that non-ionizing radiation is a contributing 
factor to myriad diseases.  For all practical purposes, the USA Federal government is 
promoting/mandating an increase in rates of these chronic diseases, with the potential of this increase 
being very large. 
Another example.  I did a study in 2018 examining OSHA’s Permissible Exposure Limits (PELs) 
[Kostoff, 2018].  They are the workplace limits legally enforceable by the Federal government.  For the 
chemicals I selected, I found that the PELs were one to four orders of magnitude higher than those 
exposures shown in the biomedical literature to cause health damage.  For all practical purposes, this 
functions as a mandate.  The government is effectively sanctioning excess exposures that have been 
shown to cause harm. 
The non-ionizing radiation, workplace chemicals, and many other examples where the 
enforceable exposure limits are orders of magnitude beyond those shown to cause damage are 
extremely difficult to avoid.  For most of these toxic stimuli that have enforceable exposure limits, the 
public will have no idea whether they are being exposed or not, and what levels of exposure they are 
experiencing.  Thus, a fraction (perhaps substantial) of the contributing factors identified for major 
chronic diseases cannot be eliminated, for all practical purposes, in today’s world.  While we now have 
the knowledge and capability to prevent and reverse many of these chronic diseases with information 
available today, we are blocked from doing so by a government that is actively promoting those factors 
that contribute to the development and exacerbation of chronic diseases. 
(return to TOC) 
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APPENDIX 1 – CKD CONTRIBUTING FACTOR AND TREATMENT IDENTIFICATION METHODOLOGY 
This appendix is divided into four sections.  The first section (1A) describes the query used to 
retrieve the total CKD core literature.  The second section (1B) describes the queries used to retrieve the 
foundational causes from the CKD core literature and non-CKD core literature.  The third section (1C) 
describes the queries used to retrieve the treatments from the CKD core literature and non-CKD core 
literature.  The fourth section (1D) describes the queries used to retrieve the symptoms from the CKD 
core literature. 
1A. Overall CKD Core Literature Retrieval Query 
The CKD core literature was generated using an iterative process.  The term "chronic kidney disease" 
was inserted into the Topic field in the Thomson version of Medline, and the MeSH terms of the 
retrieved records were examined for relevancy to the theme of the present study.  The most relevant 
MeSH terms (e.g., Kidney Failure, Chronic; Renal Insufficiency, Chronic; etc) were added to the initial 
query, and the process repeated.  Many retrieved records focused on treatments for the final stages of 
CKD (dialysis, transplantation, etc), were not matched to the goals of this study (which were essentially 
to avoid reaching these final stages), and negation terms were added to the query to exclude these 
dialysis and transplantation records.  The final query used to retrieve the CKD core literature was: 
"chronic kidney disease" - Text fields 
OR  
("kidney failure, chronic" OR "renal insufficiency, chronic" OR "Diabetic Nephropathies" OR 
Nephrosclerosis OR Nephrosis OR Nephritis OR "Nephritis, Interstitial") - MeSH Heading Field 
NOT (Renal Dialysis OR Kidney Transplantation OR Peritoneal Dialysis OR Peritoneal Dialysis, Continuous 
Ambulatory OR Nephrectomy OR Transplantation, Homologous OR Graft Rejection OR Graft Survival OR 
Dialysis Solutions OR Dialysis OR Hemodialysis, Home OR Hemodialysis Solutions OR Hemodialysis Units, 
Hospital OR Microdialysis OR Transplantation, Autologous OR Transplantation Immunology OR 
Transplantation Conditioning OR Transplantation, Heterologous OR Delayed Graft Function OR Kidney 
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1B. CKD Causes Query 
At the study's initiation, it was unclear whether more than a CKD core literature analysis would be 
pursued.  The approach used to define causes, treatments, and symptoms from the retrieved CKD core 
literature consisted of the labor-intensive visual inspection and analysis of MeSH terms and text phrases.  
When the decision was made to search for cause and treatment discovery beyond the CKD core 
literature, then queries were developed for causes and treatments (and, to a lesser extent, symptoms 
only in the CKD core literature).  These queries were initially applied to the core CKD literature to 
identify any causes, treatments, and symptoms overlooked by the manually-intensive approach, and the 
causes and treatments queries were then applied to the non-CKD literature to search for potential 
discovery.  The development of these queries, especially the comprehensive foundational 'causes' 
identification queries, constitutes the main information technology advance of this study. 
1B1. Non-query approaches to CKD core literature causes 
The first step in identifying foundational causes from the CKD core literature was a manually intensive 
approach.  The higher frequency MeSH terms associated with the CKD core literature records were 
examined, and those that appeared to relate to foundational causes were evaluated for relevance.  
Nominally, ten records that contained each candidate causes MeSH term were examined, and if 
relevance was about 70% or beyond, the MeSH term was selected.  In borderline cases, more MeSH 
terms were sampled until definitive conclusions could be drawn.  Relevant does not mean unanimity or 
consensus was achieved for either causes or treatments.  For causes especially, non-agreement with the 
majority could have been attributable to poor research, research with a pre-determined agenda (e.g., 
[14]), or selection of a 'window' in parameter space different from where the cause was operable.  But, 
if cause was found operable in a few of the sampled papers for a given MeSH term, the term was 
deemed sufficiently important to select. 
These higher frequency MeSH terms were then matrixed with all MeSH terms in the retrieval, lower 
frequency MeSH term candidates were identified through strong co-occurrence, and subsequently 
validated.  Then, a separate database was generated consisting of all the records that included these 
high and low frequency selected MeSH terms.  In this new database, the higher frequency Abstract 
phrases were examined, and those that appeared to relate to causes were evaluated for relevance.  A 
similar procedure to that used for causes MeSH term selection was followed.  The higher frequency 
Abstract phrases, and some generic Abstract phrases related to causes (e.g., expos*, induc*, etc), were 
matrixed with all Abstract phrases to identify lower frequency phrase candidates through strong co-
occurrence. 
Eventually, all the MeSH terms were read and examined, and a few low frequency terms that were 
missed with the co-occurrence procedure were added to the list.  The same was not possible with the 
Abstract phrases.  While there was a total of about 10,000 MeSH terms (readable, although visually 
intensive), there were millions of Abstract phrases.  When the 'causes' queries were developed for the 
non-CKD literature, they were initially applied to the CKD core literature, and further causes were 
identified that had been missed with the MeSH and Abstract phrase procedures.  Because of the 
proximity nature of the 'causes' queries, and the inability of Pubmed to accept proximity queries, these 
queries were applied to Thomson Medline to identify the additional causes. 
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As stated in the Introduction, only foundational causes were evaluated in this study.  There were five 
main types of foundational causes: genetics, iatrogenic, biotoxic, environmental exposure, and lifestyle.  
Since the purpose of this study is to identify specific causes to eliminate and treatments to pursue to 
prevent/halt/reverse CKD, and since relatively little can be done at this time to alter the genetics 
foundational causes, the genetics causes were not included in the final queries. 
1B2. Initial CKD core literature causes query 
Query=#1 AND (#2 OR #3) 
(terms defined below) 
After the CKD core literature causes MeSH terms and phrases had been identified through the manual 
processes, an initial causes query, applicable only to the CKD core literature, was developed.  It had two 
purposes: identify causes overlooked by the manual procedures, and serve as a precursor to a more 
complex query applicable to all literatures, CKD and non-CKD alike. 
The overall query structure was of the generic form [Cause][Produces][Symptom].  Two of the three 
would be specified in the query, directly or implicitly, and the retrieval would provide the third.  
Examples from causes query: 
a. Cause near Produces: steroid-induc* or diet-induc* OR antibiotic near/1 cause*.  These are generic or 
specific members of classes of potential causes in proximity to Produces-type terms.  The classes tend to 
be drugs, diets, etc.  The Produces-type terms are necessary since drugs, diets, etc can be either 
beneficial or harmful, depending on circumstances. 
b. Produces near Symptom: cause* near/5 "renal damage" NOT "renal damage cause*" 
c. Cause near Symptom: *Bacterium or pentachloro* in title, with either Symptom in title or in MeSH.  If 
we go to Abstracts, we need stronger proximity condition; e.g., *Bacterium near/5 Symptom.  Unlike 
case 1, in this case the causes are specific members of classes of potential causes that usually don't have 
beneficial effects, and therefore don't require proximity to causes-like terms; the causative nature is 
implied by the substance. 
Note on the above.  We have used [cause-produce-symptom] as the model, but a somewhat broader 
form could be: [cause-produce-adverse effects], of which Symptom is one way of describing an adverse 
effect.  Thus, 'toxic*' or 'adverse effect*', or 'harm*' in the title by itself, along with the Symptom in the 
title or MeSH tends to be accompanied by the cause and the effect it has.  
Additionally, many research articles addressing causes (and treatments) use the language 
[cause/treatment-activates/inhibits/blocks-signaling pathway(s)] (e.g., "Houttuynia cordata Thunb 
inhibits the production of pro‑inflammatory cytokines through inhibition of the NFkappaB signaling 
pathway in HMC‑1 human mast cells."; "Vitexin protects against cardiac hypertrophy via inhibiting 
calcineurin and CaMKII signaling pathways"; "MicroRNA-222 promotes tumorigenesis via targeting DKK2 
and activating the Wnt/beta-catenin signaling pathway").  The signaling pathways were not used as part 
of the queries in this study, but a future more comprehensive and well-resourced study could include 
the signaling pathways in the queries; their incorporation would be straight-forward.  Many research 
papers, especially at the more fundamental biological level, may not mention diseases or symptoms, but 
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are written in the language of effects on signaling pathways, and these papers could be accessed by the 
appropriately-written queries. 
The query below has three main components: #1 is the overall CKD retrieval, #2 is the MeSH component 
and #3 is the text (phrases) component.  Components #2 and #3 are intersected with component #1.  
While #2 and #3 contain genetics retrieval terms, these parts of the retrieval were not used for the 
analysis.  The causes identified from the prior manual procedures were used as negation terms in the 
query, to minimize extraneous retrieval. 
1.  OVERALL CKD CORE LITERATURE RETRIEVAL 
("kidney failure, chronic" OR "renal insufficiency, chronic" OR "Diabetic Nephropathies" OR 
Nephrosclerosis OR Nephrosis OR Nephritis OR "Nephritis, Interstitial") - MeSH Heading Field in 
Thomson Reuters 
OR "chronic kidney disease" - Topic Field 
NOT 
(Renal Dialysis OR Kidney Transplantation OR Peritoneal Dialysis OR Peritoneal Dialysis, Continuous 
Ambulatory OR Nephrectomy OR Transplantation, Homologous OR Graft Rejection OR Graft Survival OR 
Dialysis Solutions OR Dialysis OR Hemodialysis, Home OR Hemodialysis Solutions OR Hemodialysis Units, 
Hospital OR Microdialysis OR Transplantation, Autologous OR Transplantation Immunology OR 
Transplantation Conditioning OR Transplantation, Heterologous OR Delayed Graft Function OR Kidney 
Neoplasms OR Renal Replacement Therapy OR  Pancreas Transplant OR Neoplasms) - MeSH Heading 
Field 
AND 
2.  MESH COMPONENT 
("/chemically induced" OR /toxicity OR /poisoning OR /congenital OR "kidney failure, chronic/genetics" 
OR "renal insufficiency, chronic/genetics") - MeSH Heading field 
OR 
("Genetic Predisposition to Disease" OR "Smoking" OR "Polymorphism, Single Nucleotide" OR "Gene 
Frequency" OR "Alleles" OR "Aluminum" OR "Diphosphonates" OR "Gadolinium DTPA" OR "Sodium, 
Dietary" OR "Heterozygote" OR "Genetic Linkage" OR "Disease Susceptibility" OR "Haplotypes" OR 
"Sodium Chloride, Dietary" OR "Collagen Type IV" OR "Mutation, Missense" OR "Familial Mediterranean 
Fever" OR "Environmental Exposure" OR "Food Habits" OR "Aristolochic Acids" OR "Alcohol Drinking" OR 
"Substance-Related Disorders" OR "Lead" OR "Linkage Disequilibrium" OR "Amino Acid Substitution" OR 
"Occupational Exposure" OR "Infant, Low Birth Weight")  
OR  
("Occupational Diseases" OR "Cadmium" OR "Alcoholism" OR "Birth Weight" OR "Dehydration" OR 
"Fruit" OR "Lead Poisoning" OR "Carcinogens" OR "Genetic Association Studies" OR "Prenatal Exposure 
Delayed Effects" OR "Environmental Pollutants" OR "Nicotine" OR "Environmental Monitoring" OR 
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"Solvents" OR "Phenacetin" OR "Cocaine" OR "Silicon Dioxide" OR "Arsenic" OR "Metals, Heavy" OR 
"Hydrocarbons" OR "Mycotoxins" OR "Pesticides" OR "Cadmium Poisoning" OR "Silicosis" OR 
"Amphetamines" OR "Hallucinogens" OR "Inhalation Exposure" OR "Insecticides" OR "Organic 
Chemicals" OR "Aflatoxins" OR "Arsenic Poisoning" OR "Phenylenediamines") - MeSH Heading no 
Explode field 
2. TEXT COMPONENT 
(gene OR genes OR genetic* OR Polymorphism* near/5 "Single Nucleotide*" OR Allele* OR 
Heterozygote* OR "Collagen Type IV" OR Mutation* OR "Linkage Disequilibrium" OR "Amino Acid" 
near/5 Substitut* OR congenital OR Low* near/5 "Birth Weight*" OR familial OR hereditary OR 
heritable) OR (nephrotoxi* OR poison*) OR ((toxi* near/25 (drug* OR aluminum OR expos* OR "contrast 
agent*" OR nephropathy OR cisplatin OR antibiotic* OR anesthetic* OR occupation*)) NOT (uremic* OR 
uraemic)) 
OR 
("renal injury" OR "renal damage" OR "renal failure" OR "renal insufficiency" OR "renal disease" OR 
"kidney injury" OR "kidney damage" OR "kidney failure" OR "kidney disease" OR nephropath*) near/75 
(expos* near/15 (contrast OR nephropath* OR occupation* OR nephrogen* OR drug* OR aluminum OR 
environment* OR intoxication OR gadodiamide OR gadolinium OR cadmium OR solvent* OR herb* OR 
hydrocarbon* OR industr* OR silicosis OR tenofovir OR silica OR antiretroviral* OR statin* OR 
(angiotensin near/3 (inhibitor* OR blocker*)) OR cadmium OR fluoride* OR "heavy metal*" OR 
chloroform OR copper OR chromium OR mercury OR prenatal OR inhal* OR chemical*))  
OR  
(analges* OR acetaminophen OR nsaid* near/50 (necrosis OR nephritis OR nephropath*)  OR 
Phenacetin* OR Diphosphonate* OR adenine OR adriamycin OR doxorubicin OR "contrast agent*" OR 
"contrast medium" OR "Aristolochic Acid*" OR arsenic OR "Lead exposure" OR "blood lead" OR "lead 
burden" OR "environmental lead" OR Occupation* near/50 (silica OR solvent* OR hydrocarbon* OR 
fiberglass OR herbalist* OR "heavy metal*" OR poison*) OR Dehydrat* OR "star Fruit" OR Environment* 
near/50  Pollut* OR Solvent* OR Hydrocarbon* OR "Ethylene glycol")  
OR  
(lithium near/5 (nephrogen* OR intoxicat* OR induc* OR nephropath*) OR puromycin OR rapamycin OR 
acyclovir OR Pesticide* OR Insecticide* OR Chemical* near/5 induc* OR Aflatoxin* OR 
Phenylenediamine* OR Smok* OR high-Sodium OR high-salt or "sodium intake" OR "dietary sodium" OR 
"dietary salt" OR "dietary phosphorous" OR "protein intake" OR "dietary acid*" OR Cocaine OR heroin 
OR Amphetamine* OR Hallucinogen* OR Alcoholi* OR Nicotine OR Alcohol near/5 (consumption OR 
abuse* OR intake OR Drink* OR expos*) OR Substance near/5 abuse* OR "advanced glycation") - Topic 
1B3. Final CKD core literature causes query  
The following is the final all-literature causes query applied specifically to the CKD core literature.  The 
overall retrieval term was treated differently, to be consistent with the overall CKD retrieval term 
defined for the study. 
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Query=#1 AND (#2 OR #3 OR #4), where these numbers are defined below. 
Element #1 is the retrieval for overall CKD, and was defined in the previous section. 
The three query components that follow (all of which are intersected with Element #1) are designed to 
extract/filter only those records that identify foundational causes from the retrieval generated by 
Element #1.  The design of these query components was based on the assumption that foundational 
causes will have the following form: [Cause][Produces][Symptom].  Various combinations of 
Cause/Produces/Symptom may be used (e.g., Cause near Symptom, Produces near Symptom, Cause 
near Produces, etc), and all will provide complementary retrievals, with some degree of overlap.   
Element #2 can be interpreted as having two text (phrases) components: a specific high-Precision 
component and a generic high Recall component.  The two components complement each other.  The 
specific component consists of names of drugs, chemicals, viruses, bacteria, etc.  The specific drug and 
chemical terms used for the query were selected from lists of highly toxic drugs and chemicals.  
Numerous experiments showed that when these types of terms appeared in the title, they were usually 
there as causes.  The addition of many more such terms is possible, subject only to query length 
limitations.  Most of these terms could be viewed as being in the 'environmental exposures' category.  
This is an example of the Causes near Symptom combination mentioned above.  There were also some 
moderately generic terms like steroid-induc* or diet-induc*, which were examples of the Causes near 
Produces combination mentioned above. 
The generic component consists of proximity condition terms like cause* near/5 "renal damage", 
accompanied by negation terms of the form NOT "renal damage cause*".  Thus, this component 
retrieves unrestricted causes of renal damage, and the negation terms eliminate those cases where 
'renal damage' is the cause.  Initially, only phrases like "cause renal damage" were used, but the 
flexibility allowed by the proximity condition combined with the negation terms expanded the retrieval 
Recall substantially, with only a modest drop-off in Precision.  The causes identified here are examples 
of the Produces near Symptom combination mentioned above. 
Element #2 could have ranged from title to full text, but stricter proximity conditions would have had to 
be employed beyond title to insure high Precision.  In its present form, Element #2 was applied to title 
phrases only, but in a 'production run', could easily be expanded to other text fields using more 
stringent proximity conditions. 
Element #3 consisted of MeSH Qualifiers focused on causes.  If high Recall were desired, other 
Qualifiers, such as Adverse Effects or Pathogenicity, could be used, albeit with possibly reduced 
Precision.  Combinations of Qualifiers were not examined extensively, although in a 'production run', 
combinations would undoubtedly provide additional Recall with reasonable Precision.  Qualifiers like 
Etiology  might be more effective in combination. 
Element #4 consisted of relatively generic causes MeSH terms.  They tended to be examples of Causes 
near Symptoms combinations described above.  Initially, much broader and higher level MeSH terms 
were used for this component, in the MeSH Heading Explode Medline mode.  The retrieval would 'time 
out' when these broader terms were used.  The final list of MeSH terms shown in query Element #4 was 
a sub-set of the MeSH terms that had been generated by visual inspection of all the MeSH phrases in the 
Prevention and Reversal of Chronic Disease                           Copyright © 2019 RN Kostoff 
33 
 
core CKD retrieval, augmented by a few related MeSH terms from the Medline taxonomy tree.  Since 
these MeSH terms were obtained initially from the MeSH Headings in their No Explode configuration, it 
was decided to access this field only.  Restricting these terms to the MeSH Heading No Explode field 
eliminated the 'time out' problem, and provided the highest Precision/relevance, albeit at the expense 
of Recall. 
In a 'production run', if higher Recall is desired, and sufficient computer power is available along with an 
in-house version of Medline, the higher level MeSH terms could be employed along with the Explode 
option. 
In summary, many query options are available, depending on the objectives of the study, the degree of 
Precision/Recall desired, and the resources available for data retrieval and analysis.  We have described 
only a few above; other experiments were performed using intersections of Elements #2, #3, and #4, as 
well as with the higher level MeSH terms.  These combinations again yield high Precision at the expense 
of Recall.  Finally, the causes identified from the manual procedures initially, and the additional causes 
identified with the initial CKD core literature causes query, were used as negation terms to minimize 
extraneous retrieval for the final CKD core literature causes query. 
Query Elements 
1. TITLE PLUS MESH 
 ("kidney failure, chronic" OR "renal insufficiency, chronic" OR "Diabetic Nephropathies" OR 
Nephrosclerosis OR Nephrosis OR Nephritis OR "Nephritis, Interstitial") - MeSH Heading Field in 
Thomson Reuters 
OR "chronic kidney disease" - Topic Field 
NOT 
(Renal Dialysis OR Kidney Transplantation OR Peritoneal Dialysis OR Peritoneal Dialysis, Continuous 
Ambulatory OR Nephrectomy OR Transplantation, Homologous OR Graft Rejection OR Graft Survival OR 
Dialysis Solutions OR Dialysis OR Hemodialysis, Home OR Hemodialysis Solutions OR Hemodialysis Units, 
Hospital OR Microdialysis OR Transplantation, Autologous OR Transplantation Immunology OR 
Transplantation Conditioning OR Transplantation, Heterologous OR Delayed Graft Function OR Kidney 
Neoplasms OR Renal Replacement Therapy OR  Pancreas Transplant OR Neoplasms) - MeSH Heading 
Field 
AND  
2. TITLE PHRASES 
((Amiodarone OR Antipsychotic* OR "anti-infective*" OR antiadrenergic OR antiandrogen* OR 
antianginal OR antiarrhythmic OR antiasthmatic OR antibiotic* OR antineoplastic* OR antiemetic* OR 
anticholinergic* OR antispasmodic* OR anticoagulant* OR anticonvulsant* OR antidepressant*  OR 
antidiarrheal* OR antiemetic OR antivertigo OR antifungal* OR antigonadotropic OR antigout OR 
antihistamine* OR antimalarial OR antimetabolite* OR antimigraine OR antiparkinson OR antiplatelet 
OR antipseudomonal OR antipsoriatic* OR antirheumatic* OR antiseptic OR germicide* OR antitoxin* 
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OR antivenin* OR antituberculosis OR antitussive* OR antiviral OR Azole* OR Barbiturate* OR Bleomycin 
OR "Calcium Channel Blocker" OR Chloramphenicol OR Chlorpromazine OR Digitalis OR Haloperidol OR 
Halothane OR Ketoconazole OR Metronidazole OR Niacin OR Nitroglycerin OR Primaquine OR 
Sulfonamide* OR Tamoxifen OR Thioridazine OR Tricyclics OR "Valproic Acid") near/1 (caus* OR induc*)) 
OR ("*toxic" OR "*toxici*" OR "toxicologic*" OR "toxica*" OR "poison*" OR contamina* OR "adverse* 
effect*" OR "side effect*" OR "deleterious effect*" OR "negative effect*" OR "detrimental effect*" OR 
diet* near/1 effect* OR "ecotoxologic* effect*" OR particulate* near/1 effect* OR "adverse reaction*" 
OR "adverse food" OR "adverse drug" OR "adverse health" OR "expos*" OR "additives" OR "chemicals" 
OR "abuse*" OR "harm" OR "harms" OR "harmful" OR "aggravate*" OR "occupation*" OR "intoxicat*" 
OR pollut* OR "*virus*" OR antibiotic* OR environmental OR drug*-induc* OR chemotherapy-induc* OR 
treat*-induc* OR stress-induc* OR chemical*-induc* OR cytokine*-induc* OR exercise-induc* OR surg*-
induc* OR diet*-induc* OR radiation-induc* OR steroid-induc* OR mechanically-induc* OR "damage-
induc*" OR "damage-caus*" OR drug*-caus* OR chemotherapy-caus* OR treat*-caus* OR stress-caus* 
OR chemical*-caus* OR cytokine*-caus* OR exercise-caus* OR surg*-caus* OR diet*-caus* OR radiation-
caus* OR steroid-caus* OR mechanically-caus* OR *OBACTER OR Chlamydia OR Chlamydophila OR 
Clostridium OR *Bacterium OR *Chia OR *Ococcus OR Haemophilus OR Mycoplasma OR Neisseria OR 
*Omonas OR Rickettsia OR Rochalimaea OR marcescens OR Treponema OR Vibrio OR Yersinia OR 
*benzene OR trichloro* OR hexachloro* OR dichloro* OR tetrachloro* OR parachloro* OR dinitro* OR 
pentachloro* OR polychlor* OR *phthalate OR *ethane OR *toluene OR  *nitrophenol* OR perfluor* OR 
polyfluor* OR polybrom* OR hexabrom* OR decabrom* OR tetrabrom* OR waterborne OR "water-
borne" OR dietborne OR "sediment-associated" OR "particle-associated" OR "traffic-related" OR "work-
related") OR ((caus* near/5 ("renal injury" OR "renal damage" OR "renal failure" OR "renal insufficiency" 
OR "renal disease" OR "kidney injury" OR "kidney damage" OR "kidney failure" OR "kidney disease" OR 
nephropath*) OR induc* near/5 ("renal injury" OR "renal damage" OR "renal failure" OR "renal 
insufficiency" OR "renal disease" OR "kidney injury" OR "kidney damage" OR "kidney failure" OR "kidney 
disease" OR nephropath*) OR produc* near/5 ("renal injury" OR "renal damage" OR "renal failure" OR 
"renal insufficiency" OR "renal disease" OR "kidney injury" OR "kidney damage" OR "kidney failure" OR 
"kidney disease" OR nephropath*)) NOT ("renal injury caus*" OR "renal damage caus*" OR "renal failure 
caus*" OR "renal insufficiency caus*" OR "renal disease caus*" OR "kidney injury caus*" OR "kidney 
damage caus*" OR "kidney failure caus*" OR "kidney disease caus*" OR "nephropath* cause*" OR 
"caused by renal injury" OR "caused by renal damage" OR "caused by renal failure" OR "caused by renal 
insufficiency" OR "caused by renal disease" OR "caused by kidney injury" OR "caused by kidney damage" 
OR "caused by kidney failure" OR "caused by kidney disease" OR "caused by nephropath*" OR "renal 
injury induc*" OR "renal damage induc*" OR "renal failure induc*" OR "renal insufficiency induc*" OR 
"renal disease induc*" OR "kidney injury induc*" OR "kidney damage induc*" OR "kidney failure induc*" 
OR "kidney disease induc*" OR "nephropath* induc*" OR "induced by renal injury" OR "induced by renal 
damage" OR "induced by renal failure" OR "induced by renal insufficiency" OR "induced by renal 
disease" OR "induced by kidney injury" OR "induced by kidney damage" OR "induced by kidney failure" 
OR "induced by kidney disease" OR "induced by nephropath*" OR "renal injury produc*" OR "renal 
damage produc*" OR "renal failure produc*" OR "renal insufficiency produc*" OR "renal disease 
produc*" OR "kidney injury produc*" OR "kidney damage produc*" OR "kidney failure produc*" OR 
"kidney disease produc*" OR "nephropath* produc*")) 
3. MESH QUALIFIERS - MESH HEADING 
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(/"chemically induced" OR /toxicity OR /poisoning)  
OR 
4. MESH GENERIC TERMS - MESH HEADING NO EXPLODE 
Abnormalities, Drug-Induced OR Air Pollutants, Occupational OR Anti-Allergic Agents/adverse effects OR 
Anti-Asthmatic Agents/adverse effects OR Antibiotics, Antitubercular/adverse effects OR 
Anticonvulsants/adverse effects OR Antidepressive Agents/adverse effects OR Anti-Infective 
Agents/adverse effects OR Anti-Infective Agents, Urinary/adverse effects OR Antimanic Agents/adverse 
effects OR Antineoplastic Agents/adverse effects OR Antipsychotic Agents/adverse effects OR 
Antipyretics/adverse effects OR Antirheumatic Agents/adverse effects OR Antithyroid Agents/adverse 
effects OR Antitubercular Agents/adverse effects OR Anti-Ulcer Agents/toxicity OR Anti-Allergic 
Agents/toxicity OR Anti-Asthmatic Agents/toxicity OR Antibiotics, Antitubercular/toxicity OR 
Anticonvulsants/toxicity OR Antidepressive Agents/toxicity OR Anti-Infective Agents/toxicity OR Anti-
Infective Agents, Urinary/toxicity OR Antimanic Agents/toxicity OR Antineoplastic Agents/toxicity OR 
Antipsychotic Agents/toxicity OR Antipyretics/toxicity OR Antirheumatic Agents/toxicity OR Antithyroid 
Agents/toxicity OR Antitubercular Agents/toxicity OR Anti-Ulcer Agents/toxicity OR Congenital 
Abnormalities OR Congenital Disorders of Glycosylation OR Dermatitis, Occupational OR Drug Eruptions 
OR Drug Hypersensitivity OR Drug Toxicity OR Environmental Exposure OR Environmental Illness OR 
Environmental Monitoring OR Environmental Pollutants OR Fast Foods OR Food Additives OR Food 
Contamination OR Food Habits OR Food Preservatives OR Fossil Fuels OR Glycosylation End Products, 
Advanced OR Hallucinogens OR Hazardous Substances OR Herbicides OR Household Products OR 
Hydrocarbons OR Hydrocarbons, Alicyclic OR Hydrocarbons, Aromatic OR Hydrocarbons, Chlorinated OR 
Hydrocarbons, Fluorinated OR Hydrocarbons, Halogenated OR Iatrogenic Disease OR Inhalation 
Exposure OR Insecticides OR Leisure Activities OR Marine Toxins OR Maternal Exposure OR Mutagens 
OR Mycotoxins OR Neurotoxins OR Nonprescription Drugs OR Occupational Diseases OR Occupational 
Exposure OR Occupations OR Organic Chemicals OR Paternal Exposure OR Pesticides OR Plant Poisoning 
OR Plants, Toxic OR Poisoning OR Poisons OR Prenatal Exposure Delayed Effects OR Soil Pollutants OR 
Solvents OR Substance-Related Disorders OR Sweetening Agents OR Vehicle Emissions OR Water 
Pollutants, Chemical OR Welding 
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1B4. Non-CKD Core Literature Causes 
The causes from the non-CKD literature were generated with use of the final causes query alone.  The 
final query variant used was a tradeoff between Precision, Recall, and sufficient streamlining not to 
'time-out' the Web interface with Thomson Medline.  Specifically, more comprehensive queries that 
employed large numbers of Exploded MeSH terms (all MeSH sub-categories are examined when 
Exploded MeSH terms are used) would 'time out' the retrieval, and could not be used.  To reduce the 
volume of retrieval, both the records from the CKD core retrieval and the causes phrases identified in 
the CKD core literature causes analysis were subtracted from the retrieval. 
The final non-CKD core literature causes query is similar to the final CKD core literature causes query, 
with the exception that more negation terms are used in the non-CKD case, and a few extra generic 
terms were added at the end of Element #2.  The highlighted terms in 1A (below) are the additional core 
CKD causes identified in the process of validating discovery.  The query is as follows (hypertension used 
for illustrative purposes): 
Query=(#1 NOT (#1a OR #1b OR #1c)) AND (#2 OR #3 OR #4) 
1. TITLE PLUS MESH 
(hypertension)  
NOT 
1a. TITLE PHRASES 
("1-methyl-4-phenylpyridinium ion" OR "2,4,6-trinitrobenzene sulfonic acid" OR "3,4-dideoxyglucosone-
3-ene" OR "4-HNE" OR "5-fluorouracil" OR "7-Ketocholesterol" OR "9-hydroxy-2-methylellipticinium" OR 
"12-O-tetradecanoylphorbol-13-acetate" OR "ablation-induc*" OR "acarbose" OR "ACE inhibitor*" OR 
"Acetaldehyde" OR "acetaminophen" OR "acetazolamide" OR "acetylcholinesterase-inhibiting 
pesticide*" OR "acetylsalicylic acid" OR "acidogenic diet*" OR "acrolein" OR "activity restriction" OR 
"acyclovir" OR "adalimumab" OR "adefovir" OR "adenine" OR "Adenovirus*" OR "adriamycin" OR "adr-
induc*" OR "advanced glycation end product*" OR "advanced glycation end product*-oral" OR 
"Advanced glycosylation end product*" OR "aflatoxin*" OR "Aipysurus laevis venom" OR "air pollutants" 
OR "alclofenac" OR "alcohol abuse*" OR "alcohol consum*" OR "alcohol intake" OR "alcoholic*" OR 
"alcohol-induc*" OR "alcoholism" OR "aldrin" OR "alfacidol" OR "aliskiren" OR "allopurinol" OR "alloxan" 
OR "all-trans-retinoic acid" OR "alpha3-IV collagen" OR "alpha3(IV)-NC1-induced" OR "alpha-
mercaptopropionylglycine" OR "aluminium" OR "aluminum" OR "Amanita phalloides" OR "amikacin" OR 
"aminoglycoside " OR "amiodarone" OR "Amitriptyline" OR "amlodipine" OR "ammonium perchlorate" 
OR "Amoxicillin" OR "amphetamine*" OR "amphotericin b" OR "Ampicillin" OR "ampiroxicam" OR 
"anabolic steroid*" OR "ANCA" OR "ang ii-induc*" OR "angiotensin ii-induc*" OR "angiotensin-induc*" 
OR "anthracycline" OR "antiangiogenesis agents" OR "antibody-induced" OR "anti-DNA antibodies" OR 
"anti-mouse-GBM sera" OR "antineutrophil cytoplasmic autoantibody" OR "antiretroviral therapy" OR 
"anti-thymocyte serum" OR "anti-trinitrophenol switch variant mAbs" OR "AOPP-modified rat serum 
albumin" OR "apoferritin" OR "Aprotinin" OR "arachidonic acid" OR "areca nut chewing" OR 
"aristoloch*" OR "arsenic" OR "arsine gas" OR "Artemisia herba-alba" OR "asbestos" OR "Aspergillus" OR 
"aspirin" OR "asphalt" OR "AT1 receptor antagonist*" OR "atazanavir" OR "Atorvastatin" OR "ATRA" OR 
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"axitinib" OR "ayurvedic treatment*" OR "azathioprine" OR "azithromycin" OR "azobenzenearsonate" 
OR "bardoxolone methyl" OR "Barmah Forest virus" OR "Bartonella henselae" OR "bcl-induc*" OR 
"benoxaprofen" OR "beryllium" OR "beta-hemolysin/cytolysin" OR "beta-lactam" OR "betel nut 
chewing" OR "bevacizumab" OR "bezafibrate" OR "bile duct ligation" OR "binge eating-childhood" OR 
"bisacodyl" OR "bismuth" OR "bisphosphonate*" OR "bitumen" OR "bk-virus-induc*" OR "bleomycin" 
OR "blood lead" OR "bortezomib" OR "bovine serum albumin" OR "bromodichloromethane" OR 
"Bromocriptine mesylate" OR "bromoform" OR "bronchitis virus Cal99" OR "Brucella" OR "bucillamine" 
OR "bupivacaine" OR "Burkholderia pseudomallei" OR "burn injury" OR "Buspirone" OR "C1q" OR 
"Ca(2+)" OR "cadmium" OR "caffeine" OR "calcineurin inhibitor-induc*" OR "calcitriol-induced" OR 
"Campylobacter jejuni" OR "Candida albicans" OR "Candida tropicalis" OR "Candidemia" OR 
"cantharidin" OR "Capecitabine" OR "captopril" OR "carbon dioxide" OR "carrageenin" OR 
"carbamazepine" OR "Carbenoxolone" OR "carbon monoxide" OR "carbon tetrachloride" OR 
"carboplatin" OR "carmustine" OR "C-arylsuccinimides" OR "cecal ligation" OR "cediranib" OR "cefdinir" 
OR "Cefoxitin" OR "ceftriaxone" OR "Cefuroxime" OR "celecoxib" OR "cephaloridine" OR 
"cephalosporin*" OR "Ceramide" OR "cereal grains" OR "cetuximab" OR "childhood adversity" OR 
"chinese herb*" OR "chironomid larvae" OR "chitin" OR "Chlamydia pneumoniae" OR "chlorambucil" OR 
"chlorine" OR "chloroform" OR "chloroquine" OR "chlorpromazine" OR "chlorprothixene" OR 
"Chlorthalidone" OR "chlorpyrifos" OR "cholesterol-induced" OR "chromium" OR "ciclosporin" OR 
"cidofovir" OR "cigarette*" OR "cimetidine" OR "ciprofibrate" OR "ciprofloxacin" OR "cisplatin" OR 
"Citrobacter rodentium" OR "Clarithromycin" OR "classic heat stroke" OR "clometacin" OR 
"clomipramine" OR "clopidogrel" OR "Clostridium difficile toxin" OR "Cloxacillin" OR  "Clozapine" OR 
"cm-induc*" OR "cni exposure" OR "cni-induced" OR "cocaine" OR "cola" OR "colchicine" OR "colistin" 
OR "complete adjuvant" OR "concanavalin A" OR "connective tissue growth factor*" OR "contrast-
induced" OR "contrast medium-induced" OR "copper" OR "copper sulfate" OR "coronary artery bypass" 
OR "corosolic acid" OR "corticosteroid" OR "cortinarius" OR "Corynebacterium renale" OR "cow milk 
processing" OR "Coxsackie B4 virus" OR "Coxsackie B virus*" OR "coxsackie virus" OR "crf induced" OR 
"crude nephritogenoside" OR "csa-induced" OR "CTGF" OR "Cupressus funebris Endl" OR "cya-induced" 
OR "cyclic* stretch*" OR "cyclophosphamide" OR "Cycloserine" OR "cyclosporine" OR 
"Cylindrospermopsin" OR "Cytomegalovirus" OR "Cytosine arabinoside" OR "Dampness and moulds in 
workplace buildings" OR "daunomycin" OR "daunorubicin" OR "Deferasirox" OR "deferoxamine" OR 
"DEHP" OR "dehydration" OR "Demeclocycline" OR "Dengue fever" OR "dengue hemorrhagic fever" OR 
"deoxycorticosterone acetate-induced" OR "deoxycytidine" OR "deoxynivalenol" OR "depression" OR 
"desipramine" OR "dexamethasone" OR "dexfenfluramine" OR "Dextran" OR "dextrose-TPN" OR "di-2-
ethylhexyl-phthalate" OR "diacetylbenzidine" OR "dibromochloromethane" OR "diclofenac" OR 
"diethylacetylurea" OR  "diethylene glycol" OR "Diflunisal" OR "Digoxin" OR "diltiazem" OR 
"dimeglumine" OR "dimethylnitrosamine" OR "dinitrochlorobenzene" OR "dioxane" OR "dioxin*" OR 
"diphenylhydantoin" OR "diphosphonate*" OR "diphtheria toxin" OR "dipyrone" OR "Dirofilaria immitis" 
OR "Disopyramide" OR "doca-induced" OR "doca-salt" OR "domestic gas" OR "don expos*" OR "don-
induced" OR "doxepin" OR "dox-induced" OR "doxorubicin" OR "doxycycline" OR "d-penicillamine" OR 
"dRK6" OR "dxr-induced" OR "Echinococcus" OR "e. coli-induc*" OR "Efavirenz" OR "effort-reward 
imbalance" OR "Ehrlichia canis" OR "elastase" OR "emc virus-induc*" OR "emotional abuse" OR 
"enoldopam" OR "enoxaparin" OR "Enterococcus faecalis" OR "epoetin-induced" OR "epo-induced" OR 
"epoxy compound*" OR "epstein-barr-virus-induc*" OR "Erythromycin" OR "erythropoietin-alpha" OR 
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"erythropoietin-induced"  OR "escherichia coli-induc*" OR "esomeprazole" OR "etanercept" OR 
"Ethambutol" OR "ethanol" OR "ethionine" OR "Ethosuximide" OR "ethylene glycol" OR "Excessive 
endurance exercise training" OR "Exercise-induced" OR "expos* to lead" OR "exertional heat stroke" OR 
"exosome-like vesicles" OR "falciparum malaria" OR "Famotidine" OR "fangchi" OR "fenbufen" OR 
"Fenclofenac" OR "fenfluramine" OR "fenoldopam-induc*" OR "fenofibrate" OR "Fenoprofen" OR 
"Fentanyl citrate" OR "fiberglass" OR "fibrate therapy" OR "fibreglass" OR "firefighting activities" OR 
"flubiprofen" OR "flucloxacillin" OR "fluindione" OR "fluoro-10-methyl-1-2-benzanthracene" OR 
"fluoroquinolone*" OR "Fluoxetine" OR "fluphenazine" OR  "flurbiprofen" OR "Flurithromycin" OR "folic 
acid-induc*" OR "formaldehyde" OR "formic acid" OR "Foscarnet" OR "free-fatty-acid-induced" OR 
"friend leukemia virus-induc*" OR "fructose" OR "fumonisin B1" OR "furantoin" OR "furosemide" OR 
"Fusarium graminearum" OR "fusidic acid" OR "gabapentin" OR "gadodiamide" OR "gadolinium" OR 
"gadopentetate dimeglumine" OR "Gemella haemolysans" OR "gasoline" OR "Gatifloxacin" OR "gbca 
exposure" OR "gcca exposure" OR "gd exposure" OR "gefitinib" OR "gemcitabine" OR "gemfibrozil" OR 
"gentamicin" OR "germanium" OR "germ-free" OR "Glucocorticoid" OR "glucosamine" OR "glucose-
induc*" OR "glucose-peaks-short-term" OR "gluten" OR "glycerin" OR "glycerol-induc*" OR "gold" OR 
"grain dust" OR "GVHD" OR "haloperidol" OR "Hantaan virus" OR "Hantavirus" OR "hcy-induced" OR 
"heat stroke" OR "Helicobacter pylori" OR "heparin-induced" OR "hepatitis b-induced" OR "hepatitis b 
virus" OR "hepatitis c-induced" OR "hepatitis c virus" OR "hepatitis e-induced" OR "Hepatitis E virus" OR 
"hepatitis g-induced" OR "Hepatitis G virus" OR "heroin" OR "herpes simplex virus" OR "hetastarch" OR 
"hgcl2" OR "hg-induced" OR "high-fat-diet*" OR "high-glucose-induc*" OR High-glycemic-load diet*" OR 
"high home temperature" OR "high insulin" OR "high meat" OR "high-phosphate" OR "high-
phosphorous-diet*" OR "high-protein-diet*" OR "high-protein-intake*" OR "high-protein-induc*" OR 
"high-salt-diet*" OR "high-salt-intake*" OR "high-saturated-fat diet*" OR "high selenium diet" OR "high-
sodium-intake*" OR "high-sodium-diet*" OR "high-soybean oil" OR "high-sucrose-diet*" OR "high-
tryptophan-diet*" OR "hiv-induced" OR "house dust mite" OR "human immunodeficiency virus" OR 
"human rhinovirus" OR "hyaluronidase" OR "hydralazine" OR "hydrocarbon*" OR "hydroxychloroquine" 
OR "hydrochlorothiazide" OR "hydroxyethylstarch" OR "hypothermia" OR "hypoxia-induc*" OR 
"ibuprofen" OR "ifosfamide" OR "IGF-1" OR "iloprost" OR "imipramine" OR "imiquimod" OR "Il-23" OR 
"Il-33" OR "indinavir" OR "Indomethacin" OR "indoxyl" OR "infliximab" OR "influenza A virus" OR 
"Influenza vaccination" OR "insulin-induced" OR "Insulin-like growth factor" OR "Interleukin-2" OR 
"interferon-alpha" OR "interferon-beta" OR "interferon-gamma" OR "interferon-induced" OR 
"Intracerebral hemorrhage" OR "intravenous immune globulin*" OR "intravenous immunoglobulin*" OR 
"iodin*" OR "iodixanol" OR "iohexol" OR "ionizing radiation" OR "iopamidol" OR "iron-induced" OR 
"iron-overload" OR "iron sucrose" OR "ischemia-induced" OR "isoniazid" OR "isoprenaline" OR 
"isopropyl alcohol" OR "Jatropha curcas phorbol ester*" OR "job strain" OR "jp4 gasoline" OR "Ketamine 
hydrochloride" OR "ketone*" OR "ketoprofen" OR "ketorolac" OR "Klebsiella pneumoniae" OR  
"lansoprazole" OR "lapatinib" OR "lassa virus" OR "laxative abuse" OR "lead burden" OR "lead exposure" 
OR "lead level*" OR "lead poisoning" OR "Leflunomide" OR "leprosy" OR "Leptospirosis" OR "levan" OR 
"levetiracetam" OR "Levofloxacin" OR "licorice" OR "lifetime psychological trauma exposure" OR 
"ligation of the renal parenchyma" OR "lilium" OR "lipid-induced" OR "lipopolysaccharide*" OR "lithium" 
OR "L-NAME-induced" OR "L-NNA" OR "long-term competitive strength exercise training" OR "lopinavir" 
OR "loratadine" OR "low fiber diet*" OR "low legumes intake" OR "low manganese intake" OR "low 
melatonin" OR "low potassium intake" OR "low pulses intake" OR "low shear stress" OR "low-Vitamin D 
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intake" OR "lps-induced" OR "lps-stimulated" OR "lymphocytic choriomeningitis virus" OR "maedi-visna 
virus" OR "magnolia officinalis" OR "malaria" OR "malathion" OR "maleic vinyl ether anhydride" OR 
"Maneb" OR  "mannitol" OR "maprotiline" OR "measles virus" OR "meat" OR "mechanical strain" OR 
"mechanical stretch" OR "mechanical ventilation" OR "Mefanamic acid" OR "melamine" OR "menadione 
sodium bisulfite" OR "mercuric chloride" OR "mercury" OR "meropenem" OR "mesalamine" OR 
"mesalazine" OR "metformin" OR "methicillin" OR "Methocarbomol" OR "methotrexate" OR 
"methotrimeprazine" OR  "methoxyflurane" OR "methyldopa" OR "methylene chloride" OR "methyl 
tertiary-butyl ether" OR "methylglyoxal" OR "Methylphenidate" OR "Methysergide" OR "metolazone" 
OR "Metoprolol" OR "mg-induced" OR "microRNA-induced" OR "midecamycin acetate" OR 
"minocycline" OR "mirtazapine" OR  "mitomycin" OR "monocrotaline" OR "monosodium urate crystal" 
OR "morphine" OR "mothball abuse" OR "moxifloxacin" OR "MPP" OR "mtbe" OR "M-tropic SIVmacR71-
17E" OR "mumps virus" OR "mushrooms" OR "mustard gas" OR "mu tong" OR "muzolimine" OR "N-3-5-
dichlorophenyl-succinimide" OR "Na(+)" OR "nafcillin" OR "naproxen" OR "N-arylsuccinimides" OR "nasal 
decongestant*" OR "nelfinavir" OR "nematode" OR "Neomycin" OR "nickel" OR "nicotine" OR 
"Nifedipine" OR "niflumic acid" OR "nimesulide" OR "nitrendipine" OR "nitrofurantoin" OR "nitrogen 
mustard" OR "nitrogen oxides" OR "nivalenol" OR "n-methyl-n 1-nitro-n-nitroso guanidine" OR "n-n-
diacetylbenzidine" OR "noise" OR "Nomifensine" OR "Non-esterified fatty acids" OR "nonsteroidal anti-
inflammatory drug*" OR "non-steroidal anti-inflammatory drug*" OR "nonylphenol" OR 
"norepinephrine" OR "Norfloxacin" OR "nortriptyline" OR "NSAID*" OR "NVP-BKM120" OR 
"ochratoxin*" OR "O-glycosylated IgA rheumatoid factor" OR "olanzapine" OR "oleic acid" OR 
"olsalazine" OR "omega-6" OR "omeprazole" OR "oral-poliovirus vaccine" OR "organic solvent*" OR 
"orlistat" OR "ovalbumin" OR "oxalate" OR "oxidant-induced" OR "oxaliplatin" OR "oxytetracycline" OR 
"palmitate" OR "palmitic acid" OR "pamidronate" OR "p-Aminophenol" OR "pan-induced" OR 
"panitumumab" OR "pantoprazole" OR "papaverine-induced" OR "paracetamol" OR 
"paraphenylenediamine" OR "paraquat" OR "parental hypertension" OR "parental sucrose" OR 
"paroxetine" OR "particulate matter/ozone" OR "Parvovirus B19" OR "p-Cresyl sulfate" OR "pcr-rflp" OR 
"PDGF-BB" OR "pefloxacin" OR "penicillamine" OR "Penicillin*" OR "Penicillium aurantiogriseum" OR 
"pentachlorophenol" OR "Pentamidine" OR "pentazocine" OR "perchloroethylene" OR "perfluoroalkyl" 
OR "perfluorooctanoic acid" OR "pesticide*" OR "phenacetin" OR "Phenindione" OR "Phenobarbital" OR 
"phenol" OR "phenytoin" OR "Phenylbutazone" OR "phenylenediamine*" OR "Phenylephrine" OR 
"phenylpropanolamine" OR "phosphate*" OR "phosphatidylinositol-3-kinase inhibitor*" OR 
"phosphorus additive*" OR "physical inactivity" OR "Physostigmine" OR "pimozide" OR "Piperacillin" OR 
"piroxicam" OR "pirprofen" OR "Plasmodium brasilianum" OR  "platinum" OR "Pleural Tuberculosis" OR 
"poliomyelitis vaccine" OR "polymyxin B" OR "polymethyl methacrylate" OR "Polyomavirus*" OR 
"porcine circovirus*" OR "porcine parvovirus*" OR "portosystemic shunt surgery" OR "pranlukast" OR 
"prednisolone" OR "prenatal hypoxia" OR "pressure-induced" OR "pressure overload" OR "pristane" OR 
"procainamide" OR "Prochlorperazine" OR "Propionibacterium acnes" OR "propoxyphene" OR 
"propylthiouracil" OR "Proton pump inhibitor*" OR "Probenecid" OR "protamine" OR "Proteus mirabilis" 
OR "prulifloxacin" OR "Pseudoephedrine hydrochloride" OR "Pseudomonas aeruginosa" OR 
"psychogenic polydipsia" OR "ptu-induc*" OR "pufferfish" OR "puromycin" OR "puumala virus*" OR "p-
xylene" OR "Quercus calliprinos" OR "quetiapine" OR  "Quinacrine" OR "Quinidine" OR "quinine" OR 
"quinolone" OR "rabeprazol" OR "radiation-induc*" OR "radiocontrast-induced" OR "Ranitidine" OR 
"rapamycin" OR "refined cereals" OR "reperfusion-induced" OR "residential remoteness" OR 
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"respiratory syncytial virus" OR "Respiratory tract virus*" OR "retinoic acid-induced" OR "rhuepo-
induced" OR "rifampicin" OR "rifampin" OR "risperidone" OR  "Ritodrine hydrochloride" OR "ritonavir" 
OR "rofecoxib" OR "Ross River virus*" OR  "Rubella virus*" OR  "salt-induced" OR "salmonella" OR 
"scarlet pimpernel" OR  "Schistosoma haematobium" OR "Schistosoma mansoni" OR "Scopolamine" OR 
"sedentary" OR "Selegiline" OR "Selenium deficiency soil" OR "Sendai virus" OR "Serratia marcescens" 
OR "serotonin" OR "short sleep duration" OR "silane" OR "silica" OR "silicon dioxide" OR "silicosis" OR 
"silver" OR "sitting time" OR "sleep deprivation" OR "smoking" OR "snakebite*" OR "snake venom" OR 
"social environment" OR "sodium additives" OR "sodium barbital" OR  "sodium valproate" OR 
"sorafenib" OR "soybean oil heated repeatedly" OR "soy-rich diet" OR "spirapril" OR "spironolactone" 
OR "Staphylococcus aureus"OR "star fruit" OR "statins" OR "St. John's Wort" OR "steroid-induced" OR 
"streptococcal pyrogenic exotoxin B" OR "Streptococcus agalactiae" OR  "Streptococcus mutans" OR 
"streptomycin" OR "streptozocin-induced" OR "streptozotocin-induced" OR "stress-induced" OR 
"styrene" OR "stz-induced" OR "stz-treated" OR "sulfadiazine" OR "Sulfasalazine" OR "sulindac" OR 
"sulfonylurea*" OR "sulfur dioxide" OR "Sulindac" OR "sulphasalazine" OR "Sulphinpyrazone" OR 
"sulpiride" OR "sunflower oil" OR "sunitinib" OR "superdrol" OR "surgically-induced" OR "swine fever 
virus*" OR "tacrolimus" OR "Tamm-Horsfall protein" OR "tazobactam" OR "TcdA" OR "TcdB" OR "TCDD" 
OR "Telazol" OR "Telithromycin" OR "tenofovir" OR "testosterone" OR "tetrachlorodibenzo-p-dioxin" OR 
"tetrachloroethylene" OR  "Tetracycline*" OR "tetrandrine" OR "tetramethylbenzidine" OR 
"tetrodotoxin" OR "TGF-beta" OR "Thiazides" OR "Thioridazine hydrochloride" OR "thrombolytic 
therapy" OR "Thy-1.1 monoclonal antibody" OR "ticlopidine" OR "tiletamine" OR "tiopronin" OR "tissue 
kallikrein antibody" OR "titanium dioxide nanoparticles" OR "tobacco" OR "Tobramicin" OR "Tolmetin" 
OR "toluene" OR "total parenteral nutrition-overfeeding infants" OR "Toxocara canis" OR "TPA" OR 
"transmitted transfusion virus*" OR "traumatic brain injury" OR "Triamterene" OR "trichloroethane" OR 
"trichloroethylene" OR "trihalomethane" OR "triiodobenzoic acid*" OR "trimethadione" OR  
"trimethoprim-sulfamethoxazole" OR "trimethylpentane" OR "trimipramine" OR "tripelennamine" OR 
"Trypanosoma brucei" OR "U1-70-kd small nuclear ribonucleoprotein" OR "ureteropelvic junction 
stenosis" OR "ureteral obstruction" OR "uranium" OR "uranyl nitrate" OR "UVB" OR "vacor" OR 
"valdecoxib" OR "valproic acid" OR "valpromide" OR "varicella-zoster virus" OR "vancomycin" OR "vegf-
inhibit*" OR "Venlafaxine" OR "ventilator-induced" OR "verapamil" OR "verbesina encelioides" OR 
"verteporfin" OR  "vinyl isolator breeding" OR "vomitoxin" OR "vt-induced" OR "warfarin" OR "west nile 
virus" OR "wheat" OR "whole-body irradiation" OR "wortmannin" OR "Yersinia pseudotuberculosis" OR 
"Yohimbine hydrochloride" OR "zinc-deficient diet-maternal" OR "zinc-phosphide" OR "zolendronate" 
OR "Zopiclone") 
OR 
1b. MESH HEADINGS 
("kidney failure, chronic" OR "renal insufficiency, chronic" OR "Diabetic Nephropathies" OR 
Nephrosclerosis OR Nephrosis OR Nephritis OR "Nephritis, Interstitial") 
OR 
1c. TOPIC PHRASES 
"Chronic Kidney Disease" 




2. TITLE PHRASES 
((Amiodarone OR Antipsychotic* OR "anti-infective*" OR antiadrenergic OR antiandrogen* OR 
antianginal OR antiarrhythmic OR antiasthmatic OR antibiotic* OR antineoplastic* OR antiemetic* OR 
anticholinergic* OR antispasmodic* OR anticoagulant* OR anticonvulsant* OR antidepressant*  OR 
antidiarrheal* OR antiemetic OR antivertigo OR antifungal* OR antigonadotropic OR antigout OR 
antihistamine* OR antimalarial OR antimetabolite* OR antimigraine OR antiparkinson OR antiplatelet 
OR antipseudomonal OR antipsoriatic* OR antirheumatic* OR antiseptic OR germicide* OR antitoxin* 
OR antivenin* OR antituberculosis OR antitussive* OR antiviral OR Azole* OR Barbiturate* OR Bleomycin 
OR "Calcium Channel Blocker" OR Chloramphenicol OR Chlorpromazine OR Digitalis OR Haloperidol OR 
Halothane OR Ketoconazole OR Metronidazole OR Niacin OR Nitroglycerin OR Primaquine OR 
Sulfonamide* OR Tamoxifen OR Thioridazine OR Tricyclics OR "Valproic Acid") near/1 (caus* OR induc*)) 
OR ("*toxic" OR "*toxici*" OR "toxicologic*" OR "toxica*" OR "poison*" OR contamina* OR "adverse* 
effect*" OR "side effect*" OR "deleterious effect*" OR "negative effect*" OR "detrimental effect*" OR 
diet* near/1 effect* OR "ecotoxologic* effect*" OR particulate* near/1 effect* OR "adverse reaction*" 
OR "adverse food" OR "adverse drug" OR "adverse health" OR "expos*" OR "additives" OR "chemicals" 
OR "abuse*" OR "harm" OR "harms" OR "harmful" OR "aggravate*" OR "occupation*" OR "intoxicat*" 
OR pollut* OR "*virus*" OR antibiotic* OR environmental OR drug*-induc* OR chemotherapy-induc* OR 
treat*-induc* OR stress-induc* OR chemical*-induc* OR cytokine*-induc* OR exercise-induc* OR surg*-
induc* OR diet*-induc* OR radiation-induc* OR steroid-induc* OR mechanically-induc* OR "damage-
induc*" OR "damage-caus*" OR drug*-caus* OR chemotherapy-caus* OR treat*-caus* OR stress-caus* 
OR chemical*-caus* OR cytokine*-caus* OR exercise-caus* OR surg*-caus* OR diet*-caus* OR radiation-
caus* OR steroid-caus* OR mechanically-caus* OR *OBACTER OR Chlamydia OR Chlamydophila OR 
Clostridium OR *Bacterium OR *Chia OR *Ococcus OR Haemophilus OR Mycoplasma OR Neisseria OR 
*Omonas OR Rickettsia OR Rochalimaea OR marcescens OR Treponema OR Vibrio OR Yersinia OR 
*benzene OR trichloro* OR hexachloro* OR dichloro* OR tetrachloro* OR parachloro* OR dinitro* OR 
pentachloro* OR polychlor* OR *phthalate OR *ethane OR *toluene OR  *nitrophenol* OR perfluor* OR 
polyfluor* OR polybrom* OR hexabrom* OR decabrom* OR tetrabrom* OR waterborne OR "water-
borne" OR dietborne OR "sediment-associated" OR "particle-associated" OR "traffic-related" OR "work-
related") OR (((caus* OR induc*) near/5 (hypertension)) NOT ("hypertension caus*" OR "caused by 
hypertension" OR "hypertension induc*" OR "induced by hypertension")) OR ("hypertension was due to" 
OR "hypertension due to" OR "lead* to hypertension" OR "result* in hypertension" OR "role in 
hypertension" OR "hypertension was produced by" OR "hypertension produced by" OR "associated with 
hypertension" OR "hypertension was associated with" OR "association of hypertension" OR "association 
between hypertension" OR "mediate* hypertension" OR "hypertension mediated by" OR "hypertension 
was mediated by" OR "role in hypertension" OR "hypertension provoked by" OR "hypertension was 
provoked by" OR "provoked hypertension" OR "produce* hypertension" OR "hypertension was 
produced by" OR "risk* of hypertension" OR "risk* for hypertension" OR "hypertension risk factor*" OR 
"involvement in hypertension" OR "incidence of hypertension" OR "incident hypertension" OR "getting 
hypertension" OR "prevalence of hypertension" OR "susceptib* to hypertension" OR "contribut* to 
hypertension" OR "related to hypertension" OR "relationship between hypertension" OR "relationship 
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with hypertension" OR "development of hypertension" OR "develop* hypertension" OR "aggravat* 
hypertension" OR "resulted in hypertension") 
3. MESH QUALIFIERS - MESH HEADING 
(/"chemically induced" OR /toxicity OR /poisoning)  
OR 
4. MESH GENERIC TERMS - MESH HEADING NO EXPLODE 
Abnormalities, Drug-Induced OR Air Pollutants, Occupational OR Anti-Allergic Agents/adverse effects OR 
Anti-Asthmatic Agents/adverse effects OR Antibiotics, Antitubercular/adverse effects OR 
Anticonvulsants/adverse effects OR Antidepressive Agents/adverse effects OR Anti-Infective 
Agents/adverse effects OR Anti-Infective Agents, Urinary/adverse effects OR Antimanic Agents/adverse 
effects OR Antineoplastic Agents/adverse effects OR Antipsychotic Agents/adverse effects OR 
Antipyretics/adverse effects OR Antirheumatic Agents/adverse effects OR Antithyroid Agents/adverse 
effects OR Antitubercular Agents/adverse effects OR Anti-Ulcer Agents/toxicity OR Anti-Allergic 
Agents/toxicity OR Anti-Asthmatic Agents/toxicity OR Antibiotics, Antitubercular/toxicity OR 
Anticonvulsants/toxicity OR Antidepressive Agents/toxicity OR Anti-Infective Agents/toxicity OR Anti-
Infective Agents, Urinary/toxicity OR Antimanic Agents/toxicity OR Antineoplastic Agents/toxicity OR 
Antipsychotic Agents/toxicity OR Antipyretics/toxicity OR Antirheumatic Agents/toxicity OR Antithyroid 
Agents/toxicity OR Antitubercular Agents/toxicity OR Anti-Ulcer Agents/toxicity OR Congenital 
Abnormalities OR Congenital Disorders of Glycosylation OR Dermatitis, Occupational OR Drug Eruptions 
OR Drug Hypersensitivity OR Drug Toxicity OR Environmental Exposure OR Environmental Illness OR 
Environmental Monitoring OR Environmental Pollutants OR Fast Foods OR Food Additives OR Food 
Contamination OR Food Habits OR Food Preservatives OR Fossil Fuels OR Glycosylation End Products, 
Advanced OR Hallucinogens OR Hazardous Substances OR Herbicides OR Household Products OR 
Hydrocarbons OR Hydrocarbons, Alicyclic OR Hydrocarbons, Aromatic OR Hydrocarbons, Chlorinated OR 
Hydrocarbons, Fluorinated OR Hydrocarbons, Halogenated OR Iatrogenic Disease OR Inhalation 
Exposure OR Insecticides OR Leisure Activities OR Marine Toxins OR Maternal Exposure OR Mutagens 
OR Mycotoxins OR Neurotoxins OR Nonprescription Drugs OR Occupational Diseases OR Occupational 
Exposure OR Occupations OR Organic Chemicals OR Paternal Exposure OR Pesticides OR Plant Poisoning 
OR Plants, Toxic OR Poisoning OR Poisons OR Prenatal Exposure Delayed Effects OR Soil Pollutants OR 
Solvents OR Substance-Related Disorders OR Sweetening Agents OR Vehicle Emissions OR Water 
Pollutants, Chemical OR Welding 
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1C. CKD Treatments 
In parallel to the causes query structure ([Cause][Produces][Symptom]), we will define a treatments 
query structure.  An initial candidate is: ([Treatment][Eliminates][Symptom]).  Various combinations of 
Treatment/Eliminates/Symptom may be used (e.g., Treatment near Symptom, Eliminates near 
Symptom, Treatment near Eliminates, etc), and all will provide complementary retrievals, with some 
degree of overlap.    
Treatment query examples. 
1. Treatment near Eliminates: sulforaphane near/5 eliminated; steroid near/5 reduced; diet near/5 
improved: antibiotic near/1 reduced.   
2. Eliminates near Symptom: reduce* near/5 hypertension NOT hypertension reduce* 
3. Treatment near Symptom: sulforaphane in title, with either Symptom in title or MeSH.  If we go to 
Abstracts, we need stronger proximity condition; i.e., sulforaphane near/5 hypertension.  Unlike case 1, 
in this case the treatments are specific members of classes of potential treatments that usually have 
beneficial effects, and therefore don't require proximity to treatment-like terms; the treatment nature is 
implied by the substance.  Adding a proximity condition gives higher Precision at the expense of Recall. 
1C1.  CKD core literature treatments 
Query=(#1 NOT (#1a OR #1b OR #1c OR #1d)) AND ((2a NOT 2b) OR 2c OR 3a OR (4b AND 4c)) 
1.  TOTAL CKD RETRIEVAL 
1a.  ("kidney failure, chronic" OR "renal insufficiency, chronic" OR "Diabetic Nephropathies" OR 
Nephrosclerosis OR Nephrosis OR Nephritis OR "Nephritis, Interstitial") - MeSH Heading  
OR  
1b.  "chronic kidney disease" - topic 
NOT  
1c.  (Renal Dialysis OR Kidney Transplantation OR Peritoneal Dialysis OR Peritoneal Dialysis, Continuous 
Ambulatory OR Nephrectomy OR Transplantation, Homologous OR Graft Rejection OR Graft Survival OR 
Dialysis Solutions OR Dialysis OR Hemodialysis, Home OR Hemodialysis Solutions OR Hemodialysis Units, 
Hospital OR Microdialysis OR Transplantation, Autologous OR Transplantation Immunology OR 
Transplantation Conditioning OR Transplantation, Heterologous OR Delayed Graft Function OR Kidney 
Neoplasms OR Renal Replacement Therapy OR  Pancreas Transplant OR Neoplasms) - MeSH Heading 
Field 
(NEGATION TERMS FROM INITIAL CKD CORE TREATMENTS IDENTIFICATION) 
NOT  
1d.  ("22-oxacalcitriol" OR "acetaminophen" OR "acetylcysteine" OR "Acetylsalicylic Acid" OR 
"theophylline" OR "ADP P2Y(12) antagonist*" OR "aerobic exercise" OR "aldosterone antagonist*" OR 
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"aldosterone receptor antagonist*" OR "alfacalcidol" OR "aliskiren" OR "alkylating agent*" OR 
"allogeneic" OR "Allopurinol" OR "alpha-galactosidase" OR "alpha-glucosidase inhibitor*" OR 
"aluminum" OR "amlodipine" OR "amphotericin" OR "analgesic" OR "androgen" OR "angiotensin II 
antagonist*" OR "angiotensin II receptor antagonist*" OR "angiotensin-converting-enzyme-inhibitor*" 
OR "angiotensin-receptor blocker*" OR "antiplatelet therapy" OR "apocynin two inhibitor*" OR 
"aranesp" OR "artery bypass" OR "artery revascularization" OR "artery stenting" OR "ascorbic acid" OR 
"Aspirin" OR "AST-120" OR "Astragalus" OR "asymmetric dimethylarginine" OR "AT1 receptor 
antagonist*" OR "atenolol" OR "Atorvastatin" OR "AVE7688" OR "Azathioprine" OR "azelnidipine" OR 
"balloon angioplasty" OR "benazepril" OR "benidipine" OR "beta-adrenergic receptor antagonist*" OR 
"beta-blocker*" OR "Bifidobacteri*" OR "bisphosphonate*" OR "Bivalirudin" OR "blood transfusions" OR 
"BMP-7" OR "bone marrow transplantation" OR "bone morphogenetic protein-7" OR "bosentan" OR 
"BQ-123" OR "B-type natriuretic peptide*" OR "calcification inhibitor*" OR "calcineurin inhibitor*" OR 
"calcitonin" OR "calcitriol" OR "calcium acetate" OR "calcium antagonist*" OR "calcium carbonate" OR 
"calcium channel blocker*" OR "calcium supplementation" OR "candesartan" OR "captopril" OR 
"carnitine" OR "carvedilol" OR "Cell therapy" OR "cephalosporin*" OR "cereal" OR "charcoal" OR 
"chemotherap*" OR "Chinese herbs" OR "Chlorthalidone" OR "cholecalciferol" OR "cilazapril" OR 
"cinacalcet" OR "Clarithromycin" OR "clonidine" OR "clopidogrel" OR "coenzyme A reductase inhibitor*" 
OR "competitive methyltransferase inhibitor*" OR "coronary revascularization" OR "corticosteroid*" OR 
"COX-2 inhibitor*" OR "CS-866" OR "curcumin" OR "Cyclophosphamide" OR "cyclosporine" OR "CYP24A1 
inhibitor*" OR "CYP3A4 inhibitor*" OR "dairy product*" OR "darbepoetin" OR "darbepoetin alfa" OR 
"darbepoetin alpha" OR "DES implantation" OR "dexamethasone" OR "dietary fiber" OR "dietary 
phosphate restriction" OR "dietary soy" OR "digoxin" OR "dihydropyridine" OR "diltiazem" OR 
"dipeptidyl peptidase-4 inhibitor*" OR "diphenylene iodinium" OR "diphosphate ADP P2Y(12) 
antagonist*" OR "direct renin inhibitor*" OR "direct thrombin inhibitor*" OR "dobutamine" OR 
"dopamine" OR "doxercalciferol" OR "doxorubicin" OR "Doxycycline" OR "DPP-4 inhibitor*" OR 
"enalapril" OR "endothelin A receptor antagonist*" OR "endothelin receptor antagonist*" OR 
"endovascular therapy" OR "enoxaparin" OR "epinephrine" OR "eplerenone" OR "epoetin" OR "epoetin 
alfa" OR "epoetin beta" OR "Eprex" OR "ergocalciferol" OR "erythropoiesis-stimulating agent*" OR 
"Erythropoietic agent*" OR "erythropoietin" OR "essential amino acid*" OR "estradiol" OR "estrogen" 
OR "ET(A) receptor antagonist*" OR "ethanol" OR "everolimus" OR "ezetimibe" OR "factor-alpha 
plasminogen activator inhibitor-1" OR "felodipine" OR "Fenofibrate" OR "ferric carboxymaltose" OR 
"ferric gluconate" OR "Ferumoxytol" OR "fetuin-A" OR "FISH" OR "fish oil" OR "flaxseed" OR "fluvastatin" 
OR "folic acid" OR "fondaparinux" OR "furosemide" OR "garlic" OR "GBCA" OR "gene therapy" OR "gene 
transfer" OR "Ghrelin" OR "glucocorticoid" OR "glycoprotein IIb/IIIa inhibitor*" OR "growth hormone" 
OR "GW9662" OR "H2-blocker*" OR "H2-receptor antagonist*" OR "Hematide" OR "heparin*" OR 
"hepatocyte growth factor" OR "hepcidin" OR "herb" OR "herbal medicine" OR "HMG-CoA reductase 
inhibitor*" OR "HOE 140" OR "hormone replacement therapy" OR "human growth hormone" OR 
"hydralazine" OR "hydration" OR "hydrochlorothiazide" OR "hydroxymethylglutaryl-CoA reductase 
inhibitor*" OR "hypoglycemic agent*" OR "IGF-1" OR "IL-1Ra" OR "imatinib" OR "immunosuppression" 
OR "immunosuppressive agent*" OR "indinavir" OR "inhibitor of metalloproteinase-1" OR "Inhibitors of 
NADPH oxidase" OR "insulin therapy" OR "insulin-like growth factor*" OR "interferon" OR "Interleukin-1 
receptor antagonist*" OR "intravenous iron" OR "Irbesartan" OR "Irbesartan" OR "iron dextran" OR "iron 
sucrose" OR "iron supplementation" OR "iron therapy" OR "isoflavone" OR "ketoacids" OR "kinase 
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inhibitor p21" OR "Kremezin" OR "lanthanum" OR "l-arginine" OR "lercanidipine" OR "linezolid" OR 
"lipid-lowering agent*" OR "lipid-lowering drug*" OR "lisinopril" OR "lisinopril" OR "loop diuretics" OR 
"losartan" OR "low molecular weight heparin" OR "low-protein diet" OR "LU 135252" OR "Magnesium" 
OR "maxacalcitol" OR "medoxomil" OR "melanocortin-4 receptor antagonist*" OR "mesenchymal stem 
cell*" OR "Metformin" OR "methylprednisolone" OR "Metoprolol" OR "MG132" OR "mineralocorticoid 
receptor antagonist*" OR "Mineralocorticoid receptor block*" OR  "mycophenolate mofetil" OR 
"myostatin inhibition" OR "N-acetylcysteine" OR "Nebivolol" OR "NESP" OR "nifedipine" OR "nitric oxide 
synthase inhibitor*" OR "non-dihydropyridine calcium antagonist*" OR "non-dihydropyridine calcium 
channel blocker*" OR "Nonsteroidal anti-inflammatory drugs" OR "Non-steroidal anti-inflammatory 
drugs" OR "Nutritional therapy" OR "Olmesartan" OR "omega-3 fatty" OR "omeprazole" OR "opioid 
antagonist*" OR "opioid receptor antagonist*" OR "Opioids" OR "P2Y(12) receptor antagonist*" OR 
"pamidronate" OR "paracetamol" OR "paricalcitol" OR "pentoxifylline" OR "peptidase-4 inhibitor*" OR 
"percutaneous ethanol injection" OR "percutaneous transluminal renal angioplasty" OR "perindopril" OR 
"Peroxisome proliferator-activated receptor" OR "phenacetin" OR "phosphate binder*" OR 
"phosphodiesterase inhibitor*" OR "phosphodiesterase-5 inhibitor*" OR "phosphorus binder*" OR 
"phosphorus restriction*" OR "phototherapy" OR "physical exercise" OR "phytochemical*" OR 
"Phytoestrogens" OR "phyto-oestrogens" OR "pioglitazone" OR "Pitavastatin" OR "plasminogen 
activator inhibitor*" OR "polymerase inhibitor*" OR "polyunsaturated fatty acid*" OR "PPAR-gamma 
antagonist*" OR "pravastatin" OR "prednisolone" OR "prednisone" OR "protease inhibitor*" OR "protein 
restriction" OR "proton pump inhibitor*" OR "PTRA" OR "Ptx" OR "pulse therapy" OR "Pyrophosphate" 
OR "pyrrolidine-dithiocarbamate" OR "pyrrolidine-dithiocarbamate" OR "quinapril" OR "R-568" OR 
"ramipril" OR "Rapamycin" OR "Recombinant human erythropoietin" OR "reductase inhibitor*" OR 
"renal revascularization" OR "renin inhibitor*" OR "renin-angiotensin system block*" OR "restenosis" OR 
"reverse transcriptase inhibitor*" OR "rhEPO" OR "rHuEPO" OR "ribavirin" OR "ritanserin" OR 
"rituximab" OR "rosiglitazone" OR "rosuvastatin" OR "rottlerin" OR "ruboxistaurin" OR "salt restriction" 
OR "selective serotonin reuptake inhibitor*" OR "sevelamer" OR "sildenafil" OR "sildenafil" OR 
"simvastatin" OR "smoking cessation" OR "SMP-534" OR "sodium bicarbonate" OR "sodium restriction" 
OR "sodium thiosulfate" OR "somatostatin" OR "Soy protein*" OR "spironolactone" OR "src inhibitor*" 
OR "statin therapy" OR "statin treatment" OR "stent implantation" OR "surgical revascularization" OR 
"telmisartan" OR "temocapril" OR "Tempol" OR "Tenofovir" OR "Testosterone" OR "TFPI" OR "thiazide" 
OR "Thiazolidinediones" OR "thrombin inhibitor*" OR "thrombomodulin" OR "tissue engineering" OR 
"tolvaptan" OR "TRAM-34" OR "Trandolapril" OR "transluminal angioplasty" OR "type 1 receptor 
blocker*" OR "tyrosine kinase inhibitor*" OR "U-0126" OR "unfractionated heparin" OR "uricosuric 
agent*" OR "V2 receptor antagonist*" OR "valsartan" OR "vascular endothelial growth factor" OR 
"vasopeptidase inhibitor*" OR "vasopressin receptor antagonist*" OR "vasopressin V2 receptor 
antagonist*" OR "VDR activator*" OR "VDRA" OR "vegetable protein*" OR "VEGF" OR "verapamil" OR 
"vessel revascularization" OR "vitamin B12" OR "vitamin C" OR "vitamin D" OR "vitamin D receptor 
activator*" OR "vitamin E" OR "Vitamin K" OR "vitamin K antagonists" OR "VKA"  OR "anticoagulation 
therapy" OR "warfarin" OR "xanthine oxidase inhibitor*" OR "Zinc") - title 
AND  
2. TITLE PHRASES - (excludes dialysis or transplants) 
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2a. ((*treat* OR *therap* OR cure* OR intervention* OR rehabilitat* OR medication* OR drug* OR 
stimulant* OR pharmacological* OR diet* OR supplementation OR renoprotect* OR nephroprotect* OR 
"prevent* progressi*" OR "retard* the progressi*" OR "delay* the progressi*" OR "reduc* the 
progressi*" OR "attenuat* the progressi*" OR "halt* the progressi*" OR "inhibit* the progressi*" OR 
"suppress* the progressi*" OR "alleviat* the progressi" OR "oppos* the progressi" OR "imped* the 
progressi*" OR "limit* the progressi*" OR "ameliorat* the progressi*" OR protect* OR alleviate* OR 
ameliorate* OR improv* OR benefit*) OR ((reduc* OR inhibit* OR decreas* OR prevent* OR suppress* 
OR lessen* OR lower* OR mitigat*) near/1 (glycat* OR "peripheral vascular disease" OR arteriosclerosis 
OR vasoconstriction OR glycosylat* OR endothelin-1 OR inflammation OR hypertension OR "insulin 
resistance" OR fibrosis OR "metabolic syndrome" OR hyperglycemia OR nephropathy OR fibrogenesis OR 
"arterial stiffness" OR "renal injury" OR "renal damage" OR "renal failure" OR "renal insufficiency" OR 
"renal disease" OR "kidney injury" OR "kidney damage" OR "kidney failure" OR "kidney disease"))) - title 
(the above is the 'reduce' option, where reduction of effects is desired.  If an increase is desired, the 
appropriate 'increase' terminology is substituted for the 'reduce' terminology above) 
NOT  
2b. (glycat*-reduc* OR glycat*-inhibit* OR glycat*-decreas* OR glycat*-prevent* OR glycat*-suppress* 
OR glycat*-lessen* OR glycat*-lower* OR glycat*-mitigat* OR "glycat* caus*" OR "caused by glycat*" OR 
"glycat* induc*" OR "induced by glycat*" OR "glycat* was due to" OR "glycat* due to" OR "lead* to 
glycat*" OR "result* in glycat*" OR "role in glycat*" OR "glycat* was produced by" OR "glycat* produced 
by" OR "role in glycat*" OR "glycat* provoked by" OR "glycat* was provoked by" OR "provoked glycat*" 
OR "produce* glycat*" OR "glycat* was produced by" OR "incidence of glycat*" OR "incident glycat*" OR 
"getting glycat*" OR "prevalence of glycat*" OR "susceptib* to glycat*" OR "contribut* to glycat*" OR 
"development of glycat*" OR "develop* glycat*" OR "aggravat* glycat*" OR "resulted in glycat*") OR 
("peripheral vascular disease reduc*" OR "peripheral vascular disease inhibit*" OR "peripheral vascular 
disease decreas*" OR "peripheral vascular disease prevent*" OR "peripheral vascular disease suppress*" 
OR "peripheral vascular disease lessen*" OR "peripheral vascular disease lower*" OR "peripheral 
vascular disease mitigat*" OR "peripheral vascular disease caus*" OR "caused by peripheral vascular 
disease" OR "peripheral vascular disease induc*" OR "induced by peripheral vascular disease" OR 
"peripheral vascular disease was due to" OR "peripheral vascular disease due to" OR "lead* to 
peripheral vascular disease" OR "result* in peripheral vascular disease" OR "role in peripheral vascular 
disease" OR "peripheral vascular disease was produced by" OR "peripheral vascular disease produced 
by" OR "role in peripheral vascular disease" OR "peripheral vascular disease provoked by" OR 
"peripheral vascular disease was provoked by" OR "provoked peripheral vascular disease" OR "produce* 
peripheral vascular disease" OR "peripheral vascular disease was produced by" OR "incidence of 
peripheral vascular disease" OR "incident peripheral vascular disease" OR "getting peripheral vascular 
disease" OR "prevalence of peripheral vascular disease" OR "susceptib* to peripheral vascular disease" 
OR "contribut* to peripheral vascular disease" OR "development of peripheral vascular disease" OR 
"develop* peripheral vascular disease" OR "aggravat* peripheral vascular disease" OR "resulted in 
peripheral vascular disease") OR (arteriosclerosis-reduc* OR arteriosclerosis-inhibit* OR arteriosclerosis-
decreas* OR arteriosclerosis-prevent* OR arteriosclerosis-suppress* OR arteriosclerosis-lessen* OR 
arteriosclerosis-lower* OR arteriosclerosis-mitigat* OR "arteriosclerosis caus*" OR "caused by 
arteriosclerosis" OR "arteriosclerosis induc*" OR "induced by arteriosclerosis" OR "arteriosclerosis was 
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due to" OR "arteriosclerosis due to" OR "lead* to arteriosclerosis" OR "result* in arteriosclerosis" OR 
"role in arteriosclerosis" OR "arteriosclerosis was produced by" OR "arteriosclerosis produced by" OR 
"role in arteriosclerosis" OR "arteriosclerosis provoked by" OR "arteriosclerosis was provoked by" OR 
"provoked arteriosclerosis" OR "produce* arteriosclerosis" OR "arteriosclerosis was produced by" OR 
"incidence of arteriosclerosis" OR "incident arteriosclerosis" OR "getting arteriosclerosis" OR 
"prevalence of arteriosclerosis" OR "susceptib* to arteriosclerosis" OR "contribut* to arteriosclerosis" 
OR "development of arteriosclerosis" OR "develop* arteriosclerosis" OR "aggravat* arteriosclerosis" OR 
"resulted in arteriosclerosis") 
OR 
(vasoconstriction-reduc* OR vasoconstriction-inhibit* OR vasoconstriction-decreas* OR 
vasoconstriction-prevent* OR vasoconstriction-suppress* OR vasoconstriction-lessen* OR 
vasoconstriction-lower* OR vasoconstriction-mitigat* OR "vasoconstriction caus*" OR "caused by 
vasoconstriction" OR "vasoconstriction induc*" OR "induced by vasoconstriction" OR "vasoconstriction 
was due to" OR "vasoconstriction due to" OR "lead* to vasoconstriction" OR "result* in 
vasoconstriction" OR "role in vasoconstriction" OR "vasoconstriction was produced by" OR 
"vasoconstriction produced by" OR "role in vasoconstriction" OR "vasoconstriction provoked by" OR 
"vasoconstriction was provoked by" OR "provoked vasoconstriction" OR "produce* vasoconstriction" OR 
"vasoconstriction was produced by" OR "incidence of vasoconstriction" OR "incident vasoconstriction" 
OR "getting vasoconstriction" OR "prevalence of vasoconstriction" OR "susceptib* to vasoconstriction" 
OR "contribut* to vasoconstriction" OR "development of vasoconstriction" OR "develop* 
vasoconstriction" OR "aggravat* vasoconstriction" OR "resulted in vasoconstriction") OR (glycosylat*-
reduc* OR glycosylat*-inhibit* OR glycosylat*-decreas* OR glycosylat*-prevent* OR glycosylat*-
suppress* OR glycosylat*-lessen* OR glycosylat*-lower* OR glycosylat*-mitigat* OR "glycosylat* caus*" 
OR "caused by glycosylat*" OR "glycosylat* induc*" OR "induced by glycosylat*" OR "glycosylat* was 
due to" OR "glycosylat* due to" OR "lead* to glycosylat*" OR "result* in glycosylat*" OR "role in 
glycosylat*" OR "glycosylat* was produced by" OR "glycosylat* produced by" OR "role in glycosylat*" OR 
"glycosylat* provoked by" OR "glycosylat* was provoked by" OR "provoked glycosylat*" OR "produce* 
glycosylat*" OR "glycosylat* was produced by" OR "incidence of glycosylat*" OR "incident glycosylat*" 
OR "getting glycosylat*" OR "prevalence of glycosylat*" OR "susceptib* to glycosylat*" OR "contribut* to 
glycosylat*" OR "development of glycosylat*" OR "develop* glycosylat*" OR "aggravat* glycosylat*" OR 
"resulted in glycosylat*") OR (endothelin-1-reduc* OR endothelin-1-inhibit* OR endothelin-1-decreas* 
OR endothelin-1-prevent* OR endothelin-1-suppress* OR endothelin-1-lessen* OR endothelin-1-lower* 
OR endothelin-1-mitigat* OR "endothelin-1 caus*" OR "caused by endothelin-1" OR "endothelin-1 
induc*" OR "induced by endothelin-1" OR "endothelin-1 was due to" OR "endothelin-1 due to" OR 
"lead* to endothelin-1" OR "result* in endothelin-1" OR "role in endothelin-1" OR "endothelin-1 was 
produced by" OR "endothelin-1 produced by" OR "role in endothelin-1" OR "endothelin-1 provoked by" 
OR "endothelin-1 was provoked by" OR "provoked endothelin-1" OR "produce* endothelin-1" OR 
"endothelin-1 was produced by" OR "incidence of endothelin-1" OR "incident endothelin-1" OR "getting 
endothelin-1" OR "prevalence of endothelin-1" OR "susceptib* to endothelin-1" OR "contribut* to 
endothelin-1" OR "development of endothelin-1" OR "develop* endothelin-1" OR "aggravat* 
endothelin-1" OR "resulted in endothelin-1") 
OR 
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(inflammation-reduc* OR inflammation-inhibit* OR inflammation-decreas* OR inflammation-prevent* 
OR inflammation-suppress* OR inflammation-lessen* OR inflammation-lower* OR inflammation-
mitigat* OR "inflammation caus*" OR "caused by inflammation" OR "inflammation induc*" OR "induced 
by inflammation" OR "inflammation was due to" OR "inflammation due to" OR "lead* to inflammation" 
OR "result* in inflammation" OR "role in inflammation" OR "inflammation was produced by" OR 
"inflammation produced by" OR "role in inflammation" OR "inflammation provoked by" OR 
"inflammation was provoked by" OR "provoked inflammation" OR "produce* inflammation" OR 
"inflammation was produced by" OR "incidence of inflammation" OR "incident inflammation" OR 
"getting inflammation" OR "prevalence of inflammation" OR "susceptib* to inflammation" OR 
"contribut* to inflammation" OR "development of inflammation" OR "develop* inflammation" OR 
"aggravat* inflammation" OR "resulted in inflammation") OR (hypertension-reduc* OR hypertension-
inhibit* OR hypertension-decreas* OR hypertension-prevent* OR hypertension-suppress* OR 
hypertension-lessen* OR hypertension-lower* OR hypertension-mitigat* OR "hypertension caus*" OR 
"caused by hypertension" OR "hypertension induc*" OR "induced by hypertension" OR "hypertension 
was due to" OR "hypertension due to" OR "lead* to hypertension" OR "result* in hypertension" OR "role 
in hypertension" OR "hypertension was produced by" OR "hypertension produced by" OR "role in 
hypertension" OR "hypertension provoked by" OR "hypertension was provoked by" OR "provoked 
hypertension" OR "produce* hypertension" OR "hypertension was produced by" OR "incidence of 
hypertension" OR "incident hypertension" OR "getting hypertension" OR "prevalence of hypertension" 
OR "susceptib* to hypertension" OR "contribut* to hypertension" OR "development of hypertension" 
OR "develop* hypertension" OR "aggravat* hypertension" OR "resulted in hypertension") OR ("insulin 
resistance reduc*" OR "insulin resistance inhibit*" OR "insulin resistance decreas*" OR "insulin 
resistance prevent*" OR "insulin resistance suppress*" OR "insulin resistance lessen*" OR "insulin 
resistance lower*" OR "insulin resistance mitigat*" OR "insulin resistance caus*" OR "caused by insulin 
resistance" OR "insulin resistance induc*" OR "induced by insulin resistance" OR "insulin resistance was 
due to" OR "insulin resistance due to" OR "lead* to insulin resistance" OR "result* in insulin resistance" 
OR "role in insulin resistance" OR "insulin resistance was produced by" OR "insulin resistance produced 
by" OR "role in insulin resistance" OR "insulin resistance provoked by" OR "insulin resistance was 
provoked by" OR "provoked insulin resistance" OR "produce* insulin resistance" OR "insulin resistance 
was produced by" OR "incidence of insulin resistance" OR "incident insulin resistance" OR "getting 
insulin resistance" OR "prevalence of insulin resistance" OR "susceptib* to insulin resistance" OR 
"contribut* to insulin resistance" OR "development of insulin resistance" OR "develop* insulin 
resistance" OR "aggravat* insulin resistance" OR "resulted in insulin resistance") 
OR 
(fibrosis-reduc* OR fibrosis-inhibit* OR fibrosis-decreas* OR fibrosis-prevent* OR fibrosis-suppress* OR 
fibrosis-lessen* OR fibrosis-lower* OR fibrosis-mitigat* OR "fibrosis caus*" OR "caused by fibrosis" OR 
"fibrosis induc*" OR "induced by fibrosis" OR "fibrosis was due to" OR "fibrosis due to" OR "lead* to 
fibrosis" OR "result* in fibrosis" OR "role in fibrosis" OR "fibrosis was produced by" OR "fibrosis 
produced by" OR "role in fibrosis" OR "fibrosis provoked by" OR "fibrosis was provoked by" OR 
"provoked fibrosis" OR "produce* fibrosis" OR "fibrosis was produced by" OR "incidence of fibrosis" OR 
"incident fibrosis" OR "getting fibrosis" OR "prevalence of fibrosis" OR "susceptib* to fibrosis" OR 
"contribut* to fibrosis" OR "development of fibrosis" OR "develop* fibrosis" OR "aggravat* fibrosis" OR 
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"resulted in fibrosis") OR ("metabolic syndrome reduc*" OR "metabolic syndrome inhibit*" OR 
"metabolic syndrome decreas*" OR "metabolic syndrome prevent*" OR "metabolic syndrome 
suppress*" OR "metabolic syndrome lessen*" OR "metabolic syndrome lower*" OR "metabolic 
syndrome mitigat*" OR "metabolic syndrome caus*" OR "caused by metabolic syndrome" OR 
"metabolic syndrome induc*" OR "induced by metabolic syndrome" OR "metabolic syndrome was due 
to" OR "metabolic syndrome due to" OR "lead* to metabolic syndrome" OR "result* in metabolic 
syndrome" OR "role in metabolic syndrome" OR "metabolic syndrome was produced by" OR "metabolic 
syndrome produced by" OR "role in metabolic syndrome" OR "metabolic syndrome provoked by" OR 
"metabolic syndrome was provoked by" OR "provoked metabolic syndrome" OR "produce* metabolic 
syndrome" OR "metabolic syndrome was produced by" OR "incidence of metabolic syndrome" OR 
"incident metabolic syndrome" OR "getting metabolic syndrome" OR "prevalence of metabolic 
syndrome" OR "susceptib* to metabolic syndrome" OR "contribut* to metabolic syndrome" OR 
"development of metabolic syndrome" OR "develop* metabolic syndrome" OR "aggravat* metabolic 
syndrome" OR "resulted in metabolic syndrome") OR (hyperglycemia-reduc* OR hyperglycemia-inhibit* 
OR hyperglycemia-decreas* OR hyperglycemia-prevent* OR hyperglycemia-suppress* OR 
hyperglycemia-lessen* OR hyperglycemia-lower* OR hyperglycemia-mitigat* OR "hyperglycemia caus*" 
OR "caused by hyperglycemia" OR "hyperglycemia induc*" OR "induced by hyperglycemia" OR 
"hyperglycemia was due to" OR "hyperglycemia due to" OR "lead* to hyperglycemia" OR "result* in 
hyperglycemia" OR "role in hyperglycemia" OR "hyperglycemia was produced by" OR "hyperglycemia 
produced by" OR "role in hyperglycemia" OR "hyperglycemia provoked by" OR "hyperglycemia was 
provoked by" OR "provoked hyperglycemia" OR "produce* hyperglycemia" OR "hyperglycemia was 
produced by" OR "incidence of hyperglycemia" OR "incident hyperglycemia" OR "getting hyperglycemia" 
OR "prevalence of hyperglycemia" OR "susceptib* to hyperglycemia" OR "contribut* to hyperglycemia" 
OR "development of hyperglycemia" OR "develop* hyperglycemia" OR "aggravat* hyperglycemia" OR 
"resulted in hyperglycemia") 
OR 
(nephropathy-reduc* OR nephropathy-inhibit* OR nephropathy-decreas* OR nephropathy-prevent* OR 
nephropathy-suppress* OR nephropathy-lessen* OR nephropathy-lower* OR nephropathy-mitigat* OR 
"nephropathy caus*" OR "caused by nephropathy" OR "nephropathy induc*" OR "induced by 
nephropathy" OR "nephropathy was due to" OR "nephropathy due to" OR "lead* to nephropathy" OR 
"result* in nephropathy" OR "role in nephropathy" OR "nephropathy was produced by" OR 
"nephropathy produced by" OR "role in nephropathy" OR "nephropathy provoked by" OR "nephropathy 
was provoked by" OR "provoked nephropathy" OR "produce* nephropathy" OR "nephropathy was 
produced by" OR "incidence of nephropathy" OR "incident nephropathy" OR "getting nephropathy" OR 
"prevalence of nephropathy" OR "susceptib* to nephropathy" OR "contribut* to nephropathy" OR 
"development of nephropathy" OR "develop* nephropathy" OR "aggravat* nephropathy" OR "resulted 
in nephropathy") OR (fibrogenesis-reduc* OR fibrogenesis-inhibit* OR fibrogenesis-decreas* OR 
fibrogenesis-prevent* OR fibrogenesis-suppress* OR fibrogenesis-lessen* OR fibrogenesis-lower* OR 
fibrogenesis-mitigat* OR "fibrogenesis caus*" OR "caused by fibrogenesis" OR "fibrogenesis induc*" OR 
"induced by fibrogenesis" OR "fibrogenesis was due to" OR "fibrogenesis due to" OR "lead* to 
fibrogenesis" OR "result* in fibrogenesis" OR "role in fibrogenesis" OR "fibrogenesis was produced by" 
OR "fibrogenesis produced by" OR "role in fibrogenesis" OR "fibrogenesis provoked by" OR "fibrogenesis 
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was provoked by" OR "provoked fibrogenesis" OR "produce* fibrogenesis" OR "fibrogenesis was 
produced by" OR "incidence of fibrogenesis" OR "incident fibrogenesis" OR "getting fibrogenesis" OR 
"prevalence of fibrogenesis" OR "susceptib* to fibrogenesis" OR "contribut* to fibrogenesis" OR 
"development of fibrogenesis" OR "develop* fibrogenesis" OR "aggravat* fibrogenesis" OR "resulted in 
fibrogenesis") OR ("arterial stiffness reduc*" OR "arterial stiffness inhibit*" OR "arterial stiffness 
decreas*" OR "arterial stiffness prevent*" OR "arterial stiffness suppress*" OR "arterial stiffness 
lessen*" OR "arterial stiffness lower*" OR "arterial stiffness mitigat*" OR "arterial stiffness caus*" OR 
"caused by arterial stiffness" OR "arterial stiffness induc*" OR "induced by arterial stiffness" OR "arterial 
stiffness was due to" OR "arterial stiffness due to" OR "lead* to arterial stiffness" OR "result* in arterial 
stiffness" OR "role in arterial stiffness" OR "arterial stiffness was produced by" OR "arterial stiffness 
produced by" OR "role in arterial stiffness" OR "arterial stiffness provoked by" OR "arterial stiffness was 
provoked by" OR "provoked arterial stiffness" OR "produce* arterial stiffness" OR "arterial stiffness was 
produced by" OR "incidence of arterial stiffness" OR "incident arterial stiffness" OR "getting arterial 
stiffness" OR "prevalence of arterial stiffness" OR "susceptib* to arterial stiffness" OR "contribut* to 
arterial stiffness" OR "development of arterial stiffness" OR "develop* arterial stiffness" OR "aggravat* 
arterial stiffness" OR "resulted in arterial stiffness") - title 
OR (based on treatment MeSH terms) 
2c.  ("Adrenergic alpha-1 Receptor Antagonist*" OR "Adrenergic beta-Agonist*" OR "Adrenergic beta-
Antagonist*"  OR "Aldosterone Antagonist*" OR "Essential Amino Acid*" OR "Anabolic Agent*" OR 
"Androgen*" OR "Angiotensin II Type 1 Receptor Blockers*" OR "Angiotensin II Type 2 Receptor 
Blockers*" OR "Angiotensin Receptor Antagonist*" OR "Angiotensin-Converting Enzyme Inhibitor*" OR 
"Anti-Arrhythmia Agent*" OR "Monoclonal Antibodies" OR "Anticholesteremic Agent*" OR 
"Anticoagulant*" OR "Antifibrinolytic Agent*" OR "Antihypertensive*" OR "Anti-Inflammatory Agent*" 
OR "Antioxidant*" OR "Antithrombin*" OR "Antitubercular Agent*" OR "Anti-Ulcer Agent*" OR 
"Biological Availability" OR "Biosimilar Pharmaceutical*" OR "Blood Substitute*" OR "Bone Density 
Conservation Agent*" OR "Bone Morphogenetic Protein*" OR "Calcimimetic Agent*" OR "Calcium 
Channel Agonist*" OR "Calcium Channel Blocker*" OR "Caloric Restriction" OR "Cardiotonic Agent*" OR 
"Cardiovascular Agent*" OR "Chelating Agent*" OR "Colony-Stimulating Factor*" OR "Combined 
Modality Therapy" OR "Complement Inactivating Agent*" OR "Complement Inactivator Protein*" OR 
"Complementary Therap*" OR "Condiment*" OR "Cyclooxygenase Inhibitor*" OR "Cytoprotection" OR 
"Diabetic Diet*" OR "Diet Therap*" OR "Carbohydrate-Restricted diet*" OR "Fat-Restricted Diet*" OR 
"Mediterranean Diet*" OR "Protein-Restricted Diet*" OR "Sodium-Restricted Diet*" OR "Vegetarian 
Diet*" OR "Dietary Carbohydrates" OR "Dietary Fat*" OR "Dietary Fiber" OR "Dietary Protein*" OR 
"Dietary Supplement*" OR "Dietetics" OR "Dipeptidyl-Peptidase IV Inhibitor*" OR "Dose-Response 
Relationship*" OR "Drug Combination*" OR "Drug Discovery" OR "Drug Evaluation" OR "Drug 
Synergism" OR "Drug Therapy" OR "Drug Therapy" OR "Drug Utilization" OR "Investigational Drugs" OR 
"Embryonic Stem Cell*" OR "Energy Intake" OR "Enzyme Inhibitor*" OR "Estrogen*" OR "Exercise 
Therapy" OR "Fermentation" OR "Fetal Stem Cell*" OR "Fibrinolytic Agent*" OR "Flavonoid*" OR "Food 
Handling" OR "Formulated Food" OR "Free Radical Scavenger*" OR "Fruit*" OR "Gastrointestinal 
Agent*" OR "Gene Expression Regulation" OR "Gene Therapy" OR "Genetic Vector*" OR 
"Glycosaminoglycan*" OR "Health Food*" OR "Hematopoietic Stem Cell*" OR "Hirudin Therapy" OR  
"Horme*" OR "Human Growth Hormone*" OR "Hydroxymethylglutaryl-CoA Reductase Inhibitor*" OR 
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"Hypoglycemic Agent*" OR "Hypolipidemic Agent*" OR "Inflammation Mediator*" OR "Integrative 
Medicine" OR "Isoflavone*" OR "Leukotriene Antagonist*" OR "Chinese Traditional Medicine" OR 
"Traditional Medicine" OR "Mesenchymal Stem Cell*" OR "Micronutrient*" OR "Motor Activity" OR 
"Multipotent Stem Cell*" OR "Neuroprotective Agent*" OR "Nonprescription Drug*" OR "Nutrition 
Policy" OR "Nutrition Therapy" OR "Nutritional Physiological Phenomena" OR "Nutritional 
Requirement*" OR "Nutritional Science*" OR "Nutritional Support" OR "Parenteral Nutrition" OR 
"Peripheral Blood Stem Cell*" OR "Pharmaceutical Preparation*" OR "Pharmacokinetic*" OR "Phenol*" 
OR "Phosphodiesterase 5 Inhibitor*" OR "Phosphodiesterase Inhibitor*" OR "Phytoestrogen*" OR 
"Phytotherapy" OR "Plant Extract*" OR "Plant Leaves" OR "Plant Oil*" OR "Plant Preparation*" OR 
"Plant Protein*" OR "Plant Root*" OR "Medicinal Plant*" OR "Platelet Aggregation Inhibitor*" OR 
"Pluripotent Stem Cell*" OR "Polyphenol*" OR "Prebiotic*" OR "Prescription Drug*" OR "Primary 
Prevention" OR "Probiotic*" OR "Protease Inhibitor*" OR "Protective Agent*" OR "Protein Kinase 
Inhibitor*" OR "Recombinant Protein*" OR "Regeneration" OR "Seed*" OR "Selective Estrogen Receptor 
Modulator*" OR "Sodium Chloride Symporter Inhibitor*" OR "Sodium Potassium Chloride Symporter 
Inhibitor*" OR "Stem Cell Transplantation" OR "Stem Cell*" OR "Steroid*" OR "Stromal Cell*" OR 
"Synbiotic*" OR "Thrombolytic Therapy" OR "Tissue Therapy" OR "Treatment Outcome" OR "Vasodilator 
Agent*" OR "Vegetable Protein*" OR "Vegetable*") near/5  (glycat* OR "peripheral vascular disease" OR 
arteriosclerosis OR vasoconstriction OR glycosylat* OR endothelin-1 OR inflammation OR hypertension 
OR "insulin resistance" OR fibrosis OR "metabolic syndrome" OR hyperglycemia OR nephropathy OR 
fibrogenesis OR "arterial stiffness") - title 
3. MESH QUALIFIERS - MESH HEADING 
3a.  ("kidney failure, chronic/diet therapy" OR "renal insufficiency, chronic/diet therapy" OR "Diabetic 
Nephropathies/diet therapy" OR Nephrosclerosis/diet therapy OR Nephrosis/diet therapy OR 
Nephritis/diet therapy OR "Nephritis, Interstitial/diet therapy") OR ("kidney failure, chronic/drug 
therapy" OR "renal insufficiency, chronic/drug therapy" OR "Diabetic Nephropathies/drug therapy" OR 
Nephrosclerosis/drug therapy OR Nephrosis/drug therapy OR Nephritis/drug therapy OR "Nephritis, 
Interstitial/drug therapy") OR ("kidney failure, chronic/prevention & control" OR "renal insufficiency, 
chronic/prevention & control" OR "Diabetic Nephropathies/prevention & control" OR 
Nephrosclerosis/prevention & control OR Nephrosis/prevention & control OR Nephritis/prevention & 
control OR "Nephritis, Interstitial/prevention & control") OR ("kidney failure, chronic/pharmacology" OR 
"renal insufficiency, chronic/pharmacology" OR "Diabetic Nephropathies/pharmacology" OR 
Nephrosclerosis/pharmacology OR Nephrosis/pharmacology OR Nephritis/pharmacology OR "Nephritis, 
Interstitial/pharmacology") 
4. MESH GENERIC TERMS - MESH HEADING NO EXPLODE 
(Extracted from 441 Treatment MeSH terms of CKD core analysis, with some related additions) 
4a. (Adrenergic alpha-1 Receptor Antagonists OR Adrenergic beta-Agonists OR Adrenergic beta-
Antagonists  OR Aldosterone Antagonists OR Amino Acids OR Amino Acids, Essential OR Anabolic Agents 
OR Androgens OR Angiotensin II Type 1 Receptor Blockers OR Angiotensin II Type 2 Receptor Blockers 
OR Angiotensin Receptor Antagonists OR Angiotensin-Converting Enzyme Inhibitors OR Anti-Arrhythmia 
Agents OR Antibodies, Monoclonal OR Anticholesteremic Agents OR Anticoagulants OR Antifibrinolytic 
Agents OR Antihypertensive Agents OR Anti-Inflammatory Agents OR Anti-Inflammatory Agents, Non-
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Steroidal OR Antioxidants OR Antithrombins OR Antitubercular Agents OR Anti-Ulcer Agents OR 
Biological Availability OR Biosimilar Pharmaceuticals OR Blood Substitutes OR Bone Density Conservation 
Agents OR Bone Morphogenetic Proteins OR Calcimimetic Agents OR Calcium Channel Agonists OR 
Calcium Channel Blockers OR Caloric Restriction OR Cardiotonic Agents OR Cardiovascular Agents OR 
Chelating Agents OR Colony-Stimulating Factors OR Combined Modality Therapy OR Complement 
Inactivating Agents OR Complement Inactivator Proteins OR Complementary Therapies OR Condiments 
OR Cyclooxygenase Inhibitors OR Cytoprotection OR Diabetic Diet OR Diet OR Diet Therapy OR Diet, 
Carbohydrate-Restricted OR Diet, Fat-Restricted OR Diet, Mediterranean OR Diet, Protein-Restricted OR 
Diet, Sodium-Restricted OR Diet, Vegetarian OR Dietary Carbohydrates OR Dietary Fats OR Dietary Fats, 
Unsaturated OR Dietary Fiber OR Dietary Proteins OR Dietary Supplements OR Dietetics OR Dipeptidyl-
Peptidase IV Inhibitors OR Dose-Response Relationship, Drug OR Drug Combinations OR Drug Discovery 
OR Drug Evaluation, Preclinical OR Drug Synergism OR Drug Therapy OR Drug Therapy, Combination OR 
Drug Utilization OR Drugs, Investigational OR Embryonic Stem Cells OR Energy Intake OR Enzyme 
Inhibitors OR Estrogens OR Estrogens, Conjugated (USP) OR Estrogens, Non-Steroidal OR Exercise OR 
Exercise Therapy OR Fermentation OR Fetal Stem Cells OR Fibrinolytic Agents OR Flavonoids OR Food OR 
Food Handling OR Food, Formulated OR Free Radical Scavengers OR Fruit OR Gastrointestinal Agents OR 
Gene Expression Regulation OR Gene Therapy OR Genetic Vectors OR Glycosaminoglycans OR Health 
Food OR Hematopoietic Stem Cell Transplantation OR Hematopoietic Stem Cells OR Hirudin Therapy OR 
Hirudins OR Hormesis OR Human Growth Hormone OR Hydroxymethylglutaryl-CoA Reductase Inhibitors 
OR Hypoglycemic Agents OR Hypolipidemic Agents OR Inflammation Mediators OR Integrative Medicine 
OR Isoflavones OR Leukotriene Antagonists OR Medicine, Chinese Traditional OR Medicine, Traditional 
OR Mesenchymal Stem Cell Transplantation OR Micronutrients OR Motor Activity OR Multipotent Stem 
Cells OR Neuroprotective Agents OR Nonprescription Drugs OR Nutrition Policy OR Nutrition Therapy OR 
Nutritional Physiological Phenomena OR Nutritional Requirements OR Nutritional Sciences OR 
Nutritional Support OR Parenteral Nutrition OR Peripheral Blood Stem Cell Transplantation OR 
Pharmaceutical Preparations OR Pharmacokinetics OR Phenols OR Phosphodiesterase 5 Inhibitors OR 
Phosphodiesterase Inhibitors OR Phytoestrogens OR Phytotherapy OR Plant Extracts OR Plant Leaves OR 
Plant Oils OR Plant Preparations OR Plant Proteins OR Plant Roots OR Plants, Medicinal OR Platelet 
Aggregation Inhibitors OR Pluripotent Stem Cells OR Polyphenols OR Prebiotics OR Prescription Drugs 
OR Primary Prevention OR Probiotics OR Protease Inhibitors OR Protective Agents OR Protein Kinase 
Inhibitors OR Recombinant Proteins OR Regeneration OR Seeds OR Selective Estrogen Receptor 
Modulators OR Sodium Chloride Symporter Inhibitors OR Sodium Potassium Chloride Symporter 
Inhibitors OR Stem Cell Transplantation OR Stem Cells OR Steroids OR Stromal Cells OR Synbiotics OR 
Thrombolytic Therapy OR Tissue Therapy OR Treatment Outcome OR Vasodilator Agents OR Vegetable 
Proteins OR Vegetables) - MeSH Hdg No Expl 
(The following is a reduced version of MeSH terms [terms highlighted above] that was necessary to 
avoid the timeout problem)  
4b. (Antioxidants OR Caloric Restriction OR Complementary Therapies OR Condiments OR Diet Therapy 
OR Dietary Fiber OR Dietary Supplements OR Embryonic Stem Cells OR Energy Intake OR Exercise OR 
Exercise Therapy OR Fermentation OR Fetal Stem Cells OR Fibrinolytic Agents OR Flavonoids OR Health 
Food OR Hematopoietic Stem Cell Transplantation OR Hematopoietic Stem Cells OR Hormesis OR 
Inflammation Mediators OR Integrative Medicine OR Isoflavones OR Mesenchymal Stem Cell 
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Transplantation OR Multipotent Stem Cells OR Nutrition Therapy OR Peripheral Blood Stem Cell 
Transplantation OR Phenols OR Phytoestrogens OR Phytotherapy OR Plant Extracts OR Plant Leaves OR 
Plant Oils OR Plant Preparations OR Plant Proteins OR Plant Roots OR Plants, Medicinal OR Pluripotent 
Stem Cells OR Polyphenols OR Prebiotics OR Primary Prevention OR Probiotics OR Protective Agents OR 
Regeneration OR Seeds OR Stem Cell Transplantation OR Stem Cells OR Stromal Cells OR Synbiotics OR 
Vegetable Proteins OR Vegetables) 
4c. (treat* OR therap* OR cure* OR intervention* OR rehabilitat* OR monotherap* OR pretreat* OR 
psychotherap* OR pharmacotherap* OR medication* OR drug* OR stimulant* OR pharmacological* OR 
diet* OR supplementation OR renoprotect* OR nephroprotect* OR "prevent* progressi*" OR "retard* 
the progressi*" OR "delay* the progressi*" OR "reduc* the progressi*" OR "attenuat* the progressi*" 
OR "halt* the progressi*" OR "inhibit* the progressi*" OR "suppress* the progressi*" OR "alleviat* the 
progressi" OR "oppos* the progressi" OR "imped* the progressi*" OR "limit* the progressi*" OR 
"ameliorat* the progressi*" OR protect* OR alleviate* OR ameliorate* OR improv* OR benefit*) 
AND 
USE NEGATION TERMS FROM #2 
NOT (hypertension-reduc* OR hypertension-inhibit* OR hypertension-decreas* OR hypertension-
prevent* OR hypertension-suppress* OR hypertension-lessen* OR hypertension-lower* OR 
hypertension-mitigat* OR "hypertension caus*" OR "caused by hypertension" OR "hypertension induc*" 
OR "induced by hypertension" OR "hypertension was due to" OR "hypertension due to" OR "lead* to 
hypertension" OR "result* in hypertension" OR "role in hypertension" OR "hypertension was produced 
by" OR "hypertension produced by" OR "role in hypertension" OR "hypertension provoked by" OR 
"hypertension was provoked by" OR "provoked hypertension" OR "produce* hypertension" OR 
"hypertension was produced by" OR "incidence of hypertension" OR "incident hypertension" OR 
"getting hypertension" OR "prevalence of hypertension" OR "susceptib* to hypertension" OR 
"contribut* to hypertension" OR "development of hypertension" OR "develop* hypertension" OR 




Prevention and Reversal of Chronic Disease                           Copyright © 2019 RN Kostoff 
54 
 
1C2. Non-CKD Literature Treatments 
(to reduce retrieval volume, fifteen symptoms were selected, and all combinations of two symptoms 
were generated for title): (glycat* OR "peripheral vascular disease" OR arteriosclerosis OR 
vasoconstriction OR glycosylat* OR endothelin-1 OR inflammation OR hypertension OR "insulin 
resistance" OR fibrosis OR "metabolic syndrome" OR hyperglycemia OR nephropathy OR fibrogenesis OR 
"arterial stiffness") 
Query=#(1a NOT (#1b OR #1c OR #1d OR 2b)) AND ((2a OR 2c OR (3a AND 3b) OR (4a AND 4b)) 
1a. TITLE PLUS MESH (use title only for demonstration) 
(glycat* AND "peripheral vascular disease") OR (glycat* AND arteriosclerosis) OR (glycat* AND 
vasoconstriction) OR (glycat* AND glycosylat*) OR (glycat* AND endothelin-1) OR (glycat* AND 
Inflammation) OR (glycat* AND hypertension) OR (glycat* AND "insulin resistance") OR (glycat* AND 
fibrosis) OR (glycat* AND "metabolic syndrome") OR (glycat* AND hyperglycemia) OR (glycat* AND 
Nephropathy) OR (glycat* AND fibrogenesis) OR (glycat* AND "arterial stiffness") OR ("peripheral 
vascular disease" AND arteriosclerosis) OR ("peripheral vascular disease" AND vasoconstriction) OR 
("peripheral vascular disease" AND glycosylat*) OR ("peripheral vascular disease" AND endothelin-1) OR 
("peripheral vascular disease" AND Inflammation) OR ("peripheral vascular disease" AND hypertension) 
OR ("peripheral vascular disease" AND "insulin resistance") OR ("peripheral vascular disease" AND 
fibrosis) OR ("peripheral vascular disease" AND "metabolic syndrome") OR ("peripheral vascular disease" 
AND hyperglycemia) OR ("peripheral vascular disease" AND Nephropathy) OR ("peripheral vascular 
disease" AND fibrogenesis) OR ("peripheral vascular disease" AND "arterial stiffness") OR 
(arteriosclerosis AND vasoconstriction) OR (arteriosclerosis AND glycosylat*) OR (arteriosclerosis AND 
endothelin-1) OR (arteriosclerosis AND Inflammation) OR (arteriosclerosis AND hypertension) OR 
(arteriosclerosis AND "insulin resistance") OR (arteriosclerosis AND fibrosis) OR (arteriosclerosis AND 
"metabolic syndrome") OR (arteriosclerosis AND hyperglycemia) OR (arteriosclerosis AND Nephropathy) 
OR (arteriosclerosis AND fibrogenesis) OR (arteriosclerosis AND "arterial stiffness") OR (vasoconstriction 
AND glycosylat*) OR (vasoconstriction AND endothelin-1) OR (vasoconstriction AND Inflammation) OR 
(vasoconstriction AND hypertension) OR (vasoconstriction AND "insulin resistance") OR 
(vasoconstriction AND fibrosis) OR (vasoconstriction AND "metabolic syndrome") OR (vasoconstriction 
AND hyperglycemia) OR (vasoconstriction AND Nephropathy) OR (vasoconstriction AND fibrogenesis) OR 
(vasoconstriction AND "arterial stiffness") OR (glycosylat* AND endothelin-1) OR (glycosylat* AND 
Inflammation) OR (glycosylat* AND hypertension) OR (glycosylat* AND "insulin resistance") OR 
(glycosylat* AND fibrosis) OR (glycosylat* AND "metabolic syndrome") OR (glycosylat* AND 
hyperglycemia) OR (glycosylat* AND Nephropathy) OR (glycosylat* AND fibrogenesis) OR (glycosylat* 
AND "arterial stiffness") OR (endothelin-1 AND Inflammation) OR (endothelin-1 AND hypertension) OR 
(endothelin-1 AND "insulin resistance") OR (endothelin-1 AND fibrosis) OR (endothelin-1 AND 
"metabolic syndrome") OR (endothelin-1 AND hyperglycemia) OR (endothelin-1 AND Nephropathy) OR 
(endothelin-1 AND fibrogenesis) OR (endothelin-1 AND "arterial stiffness") OR (Inflammation AND 
hypertension) OR (Inflammation AND "insulin resistance") OR (Inflammation AND fibrosis) OR 
(Inflammation AND "metabolic syndrome") OR (Inflammation AND hyperglycemia) OR (Inflammation 
AND Nephropathy) OR (Inflammation AND fibrogenesis) OR (Inflammation AND "arterial stiffness") OR 
(hypertension AND "insulin resistance") OR (hypertension AND fibrosis) OR (hypertension AND 
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"metabolic syndrome") OR (hypertension AND hyperglycemia) OR (hypertension AND Nephropathy) OR 
(hypertension AND fibrogenesis) OR (hypertension AND "arterial stiffness") OR ("insulin resistance" AND 
fibrosis) OR ("insulin resistance" AND "metabolic syndrome") OR ("insulin resistance" AND 
hyperglycemia) OR ("insulin resistance" AND Nephropathy) OR ("insulin resistance" AND fibrogenesis) 
OR ("insulin resistance" AND "arterial stiffness") OR (fibrosis AND "metabolic syndrome") OR (fibrosis 
AND hyperglycemia) OR (fibrosis AND Nephropathy) OR (fibrosis AND fibrogenesis) OR (fibrosis AND 
"arterial stiffness") OR ("metabolic syndrome" AND hyperglycemia) OR ("metabolic syndrome" AND 
Nephropathy) OR ("metabolic syndrome" AND fibrogenesis) OR ("metabolic syndrome" AND "arterial 
stiffness") OR (hyperglycemia AND Nephropathy) OR (hyperglycemia AND fibrogenesis) OR 
(hyperglycemia AND "arterial stiffness") OR (Nephropathy AND fibrogenesis) OR (Nephropathy AND 
"arterial stiffness") OR (fibrogenesis AND "arterial stiffness") 
NOT 
1b. ("kidney failure, chronic" OR "renal insufficiency, chronic" OR "Diabetic Nephropathies" OR 
Nephrosclerosis OR Nephrosis OR Nephritis OR "Nephritis, Interstitial") - MeSH Heading  
OR  
1c.  "chronic kidney disease" OR "cystic fibrosis" - topic 
OR 
(treatments from CKD core literature analysis) 
1d. "15(R/S)-methyl- lipoxin A(4)" OR "15-deoxyspergualin" OR "2-(8-hydroxy-6-methoxy-1-oxo-1h-2-
benzopyran-3-yl) propionic acid" OR "22-oxacalcitriol" OR "3-hydroxy-3-methylglutaryl" OR "3-hydroxy-
DL-kynurenine" OR "3-methoxy-4-propargyloxycinnamoyl anthranilate" OR "4-phenylbutyric acid" OR 
"5-aminosalicylic acid" OR "5-HT(2A) receptor C-terminus" OR "5-methyltetrahydrofolate" OR "7-O-
galloyl-D-sedoheptulose" OR "Abatacept" OR "abciximab" OR "Abelmoschus manihot" OR "Abetimus 
sodium" OR "ABT-627" OR "Acacia gum" OR "Acacia nilotica pods extract" OR "acarbose" OR 
"acetaminophen" OR "acetazolamide" OR "acetylcysteine" OR "Acetylsalicylic Acid" OR "ACTH" OR 
"acupuncture" OR "adalimumab" OR "Adaptive servo-ventilation" OR "Adenosine 3', 5' cyclic 
monophosphate" OR "adrenocorticotropic hormone*" OR "adrenocorticotropin" OR "adrenomedullin" 
OR "adriamycin" OR "aerobic exercise" OR "AG490" OR "agalsidase alfa" OR "Agmatine" OR 
"alagebrium" OR "albendazole" OR "albumin" OR "alendronate" OR "alfacalcidol" OR "aliskiren" OR 
"Allopurinol" OR "All-trans-retinoic acid" OR "alpha3(IV)NC1" OR "alphacalcidiol" OR "alpha-
galactosidase" OR "alpha-galactosylceramide" OR "alpha-lipoic-acid" OR "alpha-spinasterol" OR "alpha-
tocopherol" OR "alprostadil" OR "ALT-946" OR "aluminum" OR "ambrisentan" OR "amikacin" OR 
"amiloride" OR "aminoguanidine" OR "aminopenicillins" OR "amitriptyline" OR "amlodipine" OR 
"amoxicillin" OR "amphotericin" OR "ampicillin" OR "ampicillin-sulbactam" OR "Anakinra" OR 
"anastrozole" OR "androgen*" OR "Andrographolide" OR "Angiostatin*" OR "angiotensin-(1-7)" OR 
"Anthranilic acid" OR "antisense oligodeoxynucleotide near/3 CK2alpha" OR "Antroquinonol" OR 
"Apelin" OR "apheresis near/1 therapy" OR "Apocynin" OR "aprotinin" OR "Arabic gum" OR "aranesp" 
OR "arginine" OR "artemisinin" OR "artery bypass" OR "artery revascularization" OR "artery stent*" OR 
"Artesunate" OR "Artocarpus communis" OR "artonin E" OR "AS101" OR "ascorbic acid" OR "a-series 
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gangliosides" OR "Aspirin" OR "AST-120" OR "astaxanthin" OR "astilbin" OR "Astragali" OR 
"Astragaloside IV" OR "Astragalus" OR "asymmetric dimethylarginine" OR "atenolol" OR "Atorvastatin" 
OR "atra" OR "atrasentan" OR "AVE7688" OR "Avosentan" OR "Azathioprine" OR "azelnidipine" OR 
"azuki bean*" OR "B12" OR "Bacillus Calmette-Guerin vaccine" OR "balloon angioplasty" OR 
"balneotherapy" OR "baoyuan dahuang" OR "bardoxolone methyl" OR "bare metal stent*" OR "bariatric 
surgery" OR "batroxobin" OR "belatacept" OR "belimumab" OR "benazepril" OR "benfotiamine" OR 
"benidipine" OR "benzbromarone" OR "benzodiazepine" OR "Beraprost sodium" OR "Berberine" OR 
"beta-carotene" OR "beta-D-mannuronic acid" OR "Beta-galactosylceramide" OR "betaine" OR "beta-
Lactams" OR "Bezafibrate" OR "BG9588" OR "bicarbonate" OR "Bifidobacterium" OR "bilirubin" OR 
"biliverdin" OR "bindarit" OR "bisoprolol" OR "bisphosphonate" OR "bitter gourd" OR "Bivalirudin" OR 
"blood stem cell transplantation" OR "blood transfusions" OR "BMP-7" OR "BMS" OR "bone marrow 
transplantation" OR "Bone morphogenic protein-7" OR "bortezomib" OR "bosentan" OR "Boswellia" OR 
"BQ-123" OR "bright-light phototherapy" OR "B-type natriuretic peptide" OR "Bupleurum falcatum" OR 
"Bupleurum polysaccharides" OR "Bupleurum scorzoneraefolium" OR "Bushen Huoxue" OR "Bushen 
Jianpi Huoxue Paidu" OR "Butein" OR "Caffeic acid phenethyl ester" OR "calcidiol" OR "calcitonin" OR 
"calcitriol" OR "calcium acetate" OR "calcium carbonate" OR "calcium dobesilate" OR "calcium 
hydroxyapatite" OR "calcium supplement*" OR "Calori* restrict*" OR "camostat mesilate" OR 
"candesartan" OR "cannabinoid*" OR "Capoten" OR "capsaicin" OR "captopril" OR "carbapenems" OR 
"carnitine" OR "Carnosine" OR "carvedilol" OR "casein" OR "catechin*" OR "CD37" OR "cefadroxil" OR 
"cefazolin" OR "cefepime" OR "cefixime" OR "cefotaxime" OR "cefotiam" OR "ceftazidime" OR 
"ceftibuten" OR "ceftriaxone" OR "Cefuroxime" OR "CEP-33779" OR "cephalexin" OR "cephalosporin" OR 
"cephoxitin" OR "cerivastatin" OR "Chailing" OR "charcoal" OR "chelat* therapy" OR "Chembridge-
5861528" OR "chenodeoxycholic acid" OR "cherries" OR "chitosan" OR "chitosan-coated dialdehyde 
cellulose" OR "chlorambucil" OR "Chlorella pyrenoidosa" OR "chloroquine" OR "Chlorthalidone" OR 
"cholecalciferol" OR "Chromium" OR "chronotherapy" OR "ciclosporin" OR "Ciglitazone" OR "cilazapril" 
OR "cilnidipine" OR "Cilostazol" OR "cinacalcet" OR "cinnamic aldehyde" OR "cinnamon oil" OR 
"cinnamoyl anthranilates" OR "ciprofloxacin" OR "cladribine" OR "Clarithromycin" OR "clarithromycin" 
OR "clavulanic acid" OR "clodronate" OR "clofibrate" OR "clofibric acid" OR "Clonazepam" OR 
"clonidine" OR "clopidogrel" OR "Cnidium officinale Makino" OR "cobalt" OR "Coenzyme Q10" OR 
"colchicine" OR "colforsin daropate hydrochloride" OR "Colistin" OR "colquhounia root" OR "Cordyceps 
sinensis" OR "Corni Fructus" OR "Cornus officinalis" OR "coronary revascularization" OR "cotrimoxazole" 
OR "co-trimoxazole" OR "CR2-Crry" OR "CR2-fH" OR "cranberry extract near/3 Zuravit" OR "C-reactive 
protein" OR "Cryoapheresis" OR "Cryptococcus neoformans" OR "CS-866" OR "CTLA4 immunoglobulin" 
OR "curantil" OR "curcumin" OR "CYC202" OR "cycloferon" OR "Cyclophosphamide" OR "cyclosporin" OR 
"cyclosporine" OR "cyprophloxacin" OR "cysteamine" OR "Cytapheresis" OR "Daflon" OR "dalfopristin" 
OR "D-alpha-tocopherol" OR "damp-heat" OR "Dan Shao Tang" OR "Danggui buxue tang" OR 
"Daptomycin" OR "darbepoetin" OR "darusentan" OR "decorin gene transfection" OR "Defibrase" OR 
"Deflazacort" OR "Deflux" OR "dehydroepiandrosterone " OR "delapril" OR "denosumab" OR "Dermatan 
sulfate" OR "DES implantation" OR "desmopressin" OR "dexamethasone" OR "dextranomer" OR "DHEA" 
OR "dialysis" OR "diclofenac" OR "dietary fiber" OR "diet* near/3 n-3 lipids" OR "diet* near/3 n-6 lipids" 
OR "diet* near/3 phosphate restrict*" OR "diet* near/3 protein restrict*" OR "dietary soy" OR "digoxin" 
OR "Dihuang" OR "dihydropyridine" OR "dihydrotestosterone" OR "dilazep" OR "diltiazem" OR 
"diphenylene iodinium" OR "dipyridamole" OR "diuretic" OR "DNA vaccination" OR "dobutamine" OR 
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"docosahexaenoic acid" OR "Dolabi " OR "dopamine" OR "doripenem" OR "doxazosin" OR "doxepin" OR 
"doxercalciferol" OR "doxorubicin" OR "Doxycycline" OR "D-penicillamine" OR "drug-eluting stent*" OR 
"duloxetine" OR "E4177" OR "ebselen" OR "eculizumab" OR "edaravone" OR "Efonidipine" OR 
"eicosapentaenoic acid" OR "electroporation" OR "emodin" OR "enalapril" OR "endoglycosidase S" OR 
"EndoS" OR "enoxaparin" OR "entecavir" OR "epigallocatechin-3-gallate" OR "epinephrine" OR 
"eplerenone" OR "EPO" OR "epoetin" OR "Epoxyeicosatrienoic acid*" OR "Epratuzumab" OR "Eprex" OR 
"Eprodisate" OR "eprosartan" OR "epsilon-aminocaproic acid" OR "ergocalciferol" OR "ergone" OR 
"Eritrichium sericeum" OR "ertapenem" OR "erythromycin" OR "erythropoietin" OR "ESA" OR "essential 
amino acid*" OR "estradiol" OR "estrogen" OR "ESWL" OR "etanercept" OR "ethanol" OR "ethanolic" OR 
"ethyl-icosapentate" OR "etidronate" OR "etodolac" OR "Euonymus alatus" OR "everolimus" OR 
"exendin-4" OR "extracorporeal shock-wave lithotripsy" OR "ezetimibe" OR "falecalcitriol" OR "fasudil" 
OR "Fc fusion protein" OR "Febuxostat" OR "felodipine" OR "fengbei huayu" OR "Fenofibrate" OR 
"fenoldopam" OR "ferric carboxymaltose" OR "ferric gluconate" OR "ferulic acid" OR "Ferumoxytol" OR 
"fetuin-A" OR "FG-3019" OR "fish oil" OR "FK506" OR "flaxseed" OR "fluconazole" OR "fludarabine" OR 
"fluoroquinolone*" OR "fluvastatin" OR "folate" OR "folic acid" OR "fondaparinux" OR "fosfomycin" OR 
"fosinopril" OR "FR167653" OR "frusemide" OR "fucoidan" OR "Fufang Xueshuantong Capsule" OR 
"furosemide" OR "Fuzheng Huayu recipe" OR "G. inflata" OR "gabapentin" OR "gabexate mesylate" OR 
"Gamma linolenic acid" OR "gammaglobulin" OR "gangleron-electrophoresis with sinusoidal modulated 
currents" OR "Ganoderma lucidum" OR "garlic" OR "gatifloxacin" OR "GBCA" OR "gentamicin" OR 
"Ghrelin" OR "Ginger" OR "Ginkgo biloba" OR "Ginseng" OR "ginsenoside Rg1" OR "glabridin" OR 
"glibenclamide" OR "gliclazide" OR "glimepiride" OR "gliotoxin" OR "Glitazones" OR "glutamine" OR 
"gluten-free diet*" OR "Glycyrrhiza uralensis" OR "grape seed extract" OR "Green tea" OR "Growth 
Hormone*" OR "guava fruit" OR "GW501516" OR "GW9662" OR "gymnemic acid" OR "Hachimi-jio-gan" 
OR "Hatha yoga" OR "heat-producing needling" OR "Hematide" OR "hemin" OR "heparan sulfate" OR 
"heparin" OR "hepatocyte growth factor" OR "hepcidin" OR "Hibiscus sabdariffa Linnaeus" OR "hirudin*" 
OR "HOE 140" OR "Honokiol" OR "Hormonal adjuvants" OR "hormone replacement therapy" OR 
"Huang" OR "Huangqi" OR "Huayu" OR "human erythropoietin" OR "human growth hormone*" OR 
"Huoxue" OR "hyaluronic acid" OR "hyaluronic acid copolymer" OR "hydralazine" OR "hydration" OR 
"hydrochlorothiazide" OR "hydrocortisone" OR "Hydroxiapatite" OR "Hydroxychloroquine" OR 
"hydroxyurea" OR "Hyperbaric oxygen" OR "hypoproteic diet*" OR "hypotonic intravenous fluid" OR 
"Ichnocarpus frutescens" OR "IDEC-131" OR "IdeS" OR "IGF-1" OR "IgG glycan hydrolysis" OR "IgG-
degrading enzyme of S.pyogenes" OR "IL-10" OR "IL-11" OR "IL-1Ra" OR "Iloprost" OR "imatinib" OR 
"imidapril" OR "Imipenem" OR "immunoglobulin G" OR "incretin" OR "indapamide" OR "indinavir" OR 
"Indole-3-carbinol" OR "indomethacin" OR "infliximab" OR "Insulin" OR "insulin-like growth factor*" OR 
"intelligent near/3 nanoparticle*" OR "interference therapy" OR "interferon*" OR "interleukin-10" OR 
"Interleukin-11" OR "Interleukin-4" OR "iododoxorubicin" OR "Irbesartan" OR "irinotecan" OR "iron 
dextran" OR "iron sucrose" OR "iron supplementation" OR "iron therapy" OR "Irradiation" OR "islet cell 
transplantation" OR "isoflavone" OR "Isotretinoin" OR "isradipine" OR "itraconazole" OR "Jianpi 
Qinghua" OR "ju-ling-tang" OR "keto acids" OR "ketoacids" OR "keto-analogues" OR "ketoconazole" OR 
"KF24345" OR "kidney transplant*" OR "Kremezin" OR "labetalol" OR "lacidipine" OR "Lactobacillus 
reuteri GMNL-263" OR "LAF237" OR "Laminaria japonica" OR "lamivudine" OR "lansoprazole" OR 
"lanthanum carbonate" OR "l-arginine" OR "laser radiation" OR "laser therapy" OR "lasix" OR "lazaroid" 
OR "leflunomide" OR "Lei Gong Teng Radix et Rhizoma Tripterygii" OR "lenalidomide" OR "lercanidipine" 
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OR "Lespedeza michx" OR "leukocytapheresis" OR "leupeptin" OR "levamisole" OR "levofloxacin" OR 
"licochalcone A" OR "licorisoflavan A" OR "Ligustrazine" OR "linagliptin" OR "linezolid" OR "linoleic acid" 
OR "LIPIN" OR "lipoic acid" OR "lisinopril" OR "lithotripsy" OR "Liuwei Dihuang" OR "LJP 394" OR 
"loganin" OR "losartan" OR "lovastatin" OR "low-casein diet*" OR "Low-dose radiation" OR "low-fat 
dairy products" OR "low-phosphorous" OR "low-protein diet*" OR "low-salt diet*" OR "low-sodium" OR 
"LR-74" OR "LR-9" OR "LR-90" OR "LSKL" OR "LU 135252" OR "lumbrukinase" OR "LY333531" OR 
"Lysozyme" OR "M2000" OR "Magnesium" OR "magnetolaserotherapy" OR "Magnolia biondii" OR 
"Magnolia officinalis" OR "magnolol" OR "mai-luo-tong" OR "manidipine" OR "mannitol" OR "man-shen-
ling" OR "maxacalcitol" OR "mecillinam" OR "Mediterranean diet" OR "medoxomil" OR "Megestrol 
acetate" OR "melanocortin" OR "melatonin" OR "meloxicam" OR "melphalan" OR "meprinbeta" OR 
"mesenchymal stem cells" OR "Mesenchymal stromal cells" OR "metanephric mesenchymal cells" OR 
"Metformin" OR "methionine" OR "methotrexate" OR "methoxy polyethylene glycol-epoetin beta" OR 
"methyl prednisolone" OR "Methyldopa" OR "methylene blue" OR "methylprednisolone" OR 
"Metoprolol" OR "metronidazole" OR "MG132" OR "microwave resonance therapy" OR "microwaves" 
OR "miglitol" OR "Milk thistle extract" OR "miltiorrhiza" OR "mineral water" OR "mirtazapine" OR 
"misoprostol" OR "mitochondria-targeted ubiquinone" OR "MitoQ " OR "mizoribine" OR "MMF" OR 
"mNOX-E36" OR "molecular adsorbent recirculating system" OR "molsidomine" OR "Monascus 
purpureus Went rice" OR "monoclonal antibodies to B-cell markers" OR "monoclonal antibody (mAb) for 
ICOS" OR "Monoclonal immunoglobulin G1" OR "monopril" OR "montelukast" OR "morphine sulphate" 
OR "Morroniside" OR "Morus alba" OR "morusin" OR "moxonidine" OR "mycophenolate mofetil" OR 
"mycophenolate sodium" OR "mycophenolic acid" OR "myo-inositol" OR "myricetin" OR "MZR 
treatment" OR "N-acetylcysteine" OR "N-acetyl-seryl-aspartyl-lysyl-proline" OR "Nandrolone decanoate" 
OR "nanocarrier complex*" OR "Nateglinide" OR "natural Indigo" OR "NCTD" OR "Nebivolol" OR 
"nelfinavir" OR "nephrolithiasis" OR "nephrolitholapaxy" OR "nephrolithotomy" OR "NESP" OR 
"netilmicin" OR "Neu5Ac" OR "neuraminidase" OR "Niacin" OR "Niaoduqing" OR "niceritrol" OR 
"nicorandil" OR "nifedipine" OR "nilvadipine" OR "Nitrendipine" OR "nitrofurantoin" OR "nitroglycerin" 
OR "nitro-oleic acid" OR "Norcantharidin" OR "norepinephrine" OR "norfloxacin" OR "Notoginseng" OR 
"novel erythropoiesis stimulating protein" OR "NOX-A12" OR "NPS R-568" OR "Octreotide" OR 
"ofloxacin" OR "oleanolic acid" OR "Olmesartan" OR "omapatrilat" OR "omega-3" OR "omeprazole" OR 
"ondansetron" OR "ONO-1301" OR "ophloxacin" OR "Opioids" OR "orlistat" OR "oseltamivir" OR 
"osteoprotegerin" OR "Oxalobacter formigenes" OR "oxycodone" OR "p21" OR "paclitaxel" OR "paeony" 
OR "paidu baoshen" OR "palm-oil near/3 Tocotrienol-rich-fraction" OR "pamidronate" OR "Panax 
ginseng" OR "Panax notoginseng" OR "pancreas transplantation" OR "paracetamol" OR "paricalcitol" OR 
"paroxetine" OR "parthenolide" OR "PD123319" OR "PDL-1" OR "pectin" OR "PEDF" OR "pefloxacin" OR 
"Peginesatide" OR "penicillin" OR "pentosan polysulfate" OR "pentoxifylline" OR "pephloxacin" OR 
"Perilla frutescens" OR "perindopril" OR "persantine" OR "Phellodendri Cortex" OR "phenacetin" OR 
"Phlorizin" OR "phosphorus restriction" OR "photopheresis" OR "phycocyanin" OR "phycocyanobilin" OR 
"Phytoestrogens" OR "Phytolacca americana" OR "picrorhiza" OR "pimagedine" OR "pioglitazone" OR 
"piperacillin" OR "pirfenidone" OR "Pitavastatin" OR "pivmecillinam" OR "plasma exchange therapy" OR 
"plasmapheresis" OR "plastoquinone" OR "policosanol" OR "polydimethylsiloxane" OR "polyethylene 
glycol" OR "Polygonum capitatum" OR "polymyxin B" OR "polyoxidonium" OR "polyunsaturated fatty 
acids" OR "Poria cocos" OR "positive airway pressure" OR "pravastatin" OR "prednisolone" OR 
"prednisone" OR "prenylflavonoid*" OR "prestarium A" OR "Probenecid" OR "probucol" OR "Prohibitin" 
Prevention and Reversal of Chronic Disease                           Copyright © 2019 RN Kostoff 
59 
 
OR "Prolit" OR "propolis" OR "prostaglandin E1" OR "protein restrict*" OR "protocatechuic acid" OR 
"Psidium guajava" OR "PTRA" OR "Ptx" OR "pulse therapy" OR "Purple corn anthocyanins" OR 
"pyelolithotomy" OR "pyridoxal" OR "pyridoxamine" OR "pyridoxine" OR "Pyrophosphate" OR 
"pyrrolidine-dithiocarbamate" OR "Qidi Yiqi Yangyin Huoxue" OR "qingre huoxue" OR "qingshen 
granule" OR "quercetin" OR "Qufeng Tongluo" OR "quinapril" OR "quinupristin" OR "R-568" OR 
"rabdosiin" OR "radiation" OR "Radix Astragali" OR "radon therapy" OR "radon water" OR "raloxifene" 
OR "ramipril" OR "Rapamycin" OR "rasburicase" OR "red wine" OR "reduced glutathione" OR "relaxin" 
OR "renal angioplasty" OR "renal revascularization" OR "renal transplant" OR "renoureteral catheter" OR 
"repaglinide" OR "reserpine" OR "Reserpinum Triamterene" OR "resveratrol" OR "retinoic acid" OR 
"revascularization" OR "rhein" OR "rhEPO" OR "Rheum officinale" OR "Rheum palmatum" OR "Rhizoma 
Ligustici chuanxiong" OR "rhodamine derivative*" OR "rhubarb" OR "rHuEPO" OR "ribavirin" OR "rice-
bran-oil near/3 Tocotrienol-rich-fraction" OR "rifampicin" OR "rifampin" OR "rimonabant" OR 
"Risedronate" OR "ritanserin" OR "rituximab" OR "RNA interference" OR "rolipram" OR "Rosa laevigata 
Michx" OR "rosiglitazone" OR "rosmarinic acid" OR "rosuvastatin" OR "rottlerin" OR "R-roscovitine" OR 
"RS504393" OR "ruboxistaurin" OR "rutin" OR "Saccharomyces boulardii" OR "safflower-seed oil" OR 
"saikosaponin a" OR "saikosaponin c" OR "saikosaponin d" OR "Saikosaponin-d" OR "Sairei-to" OR 
"salacia chinensis" OR "salbutamol" OR "salt restrict*" OR "Salvia miltiorrhiza" OR "salvianolate" OR 
"sandimmun" OR "Sarpogrelate" OR "SAT05f" OR "saxagliptin" OR "SB203580" OR "Schisandra 
chinensis" OR "selenium" OR "selenomethionine" OR "seliciclib" OR "sevelamer" OR "Shao" OR "Shao 
Tang" OR "Shathavaryadi Yoga" OR "Shen Yan Ling" OR "Shenkang" OR "Shenkangwan" OR "shenle 
capsule" OR "shenqi fuzheng" OR "Shenqi Jiedu" OR "shenshuaining" OR "Short interfering RNAs" OR 
"sialic acid" OR "sildenafil" OR "silymarin" OR "simvastatin" OR "sinusoidal modulated currents" OR 
"siRNA" OR "sirolimus" OR "sitagliptin" OR "sitaxsentan" OR "Skimmin" OR "skin grafting" OR "SM934" 
OR "smoking cessation" OR "SMP-534" OR "sodium bicarbonate" OR "sodium chloride bath*" OR 
"sodium ferulate" OR "sodium polystyrene sulf*" OR "sodium restrict*" OR "sodium selenite" OR 
"sodium thiosulfate" OR "somatostatin" OR "soy isoflavones" OR "soy protein" OR "sparflo" OR 
"sparfloxacin" OR "spirapril" OR "spironolactone" OR "Spirulina platensis" OR "SR141716" OR 
"stanniocalcin-1" OR "stavudine" OR "stent implantation" OR "Sulfasalazine" OR "sulfonylurea" OR 
"sulforaphane" OR "sulfur amino acid" OR "sulodexide" OR "sulphated hyaluronic acid" OR "suramin" OR 
"surgical revascularization" OR "T-1095" OR "TA606" OR "Tabanus fulvus Meigan" OR "tacrolimus" OR 
"tamoxifen" OR "Tang" OR "Tangshenning" OR "Tangshenqing" OR "Tanshinone IIA" OR "taurine" OR 
"TCM-WM" OR "teicoplanin" OR "telmisartan" OR "temocapril" OR "Tempol" OR "Tenofovir" OR 
"Terazosin Hydrochloride" OR "terlipressin" OR "Testosterone" OR "TETA" OR "Tetrahydrocurcumin" OR 
"Tetrahydroxystilbene glucoside" OR "tetramethylpyrazine" OR "TFPI" OR "thalidomide" OR 
"theophylline" OR "thiamine" OR "thiazide" OR "Thiazolidinedione" OR "thienam" OR "threonine" OR 
"thrombomodulin" OR "thymoquinone" OR "thymosin" OR "Thyrotropin" OR "TIAOJINING" OR "tissue 
engineering" OR "TJN-331 " OR "TJN-598" OR "Tocilizumab" OR "tolvaptan" OR "Tongluo" OR 
"torasemide" OR "TRAM-34" OR "tramadol" OR "Trandolapril" OR "Tranexamic acid" OR "Tranilast" OR 
"transfer factor" OR "transluminal angioplasty" OR "Triamcinolone acetonide" OR "trichostatin A" OR 
"triethylenetetramine" OR "trimethoprim-sulfamethoxazole" OR "Tripterygium wilfordii Hook" OR 
"triptolide" OR "troglitazone" OR "turmeric" OR "U-0126" OR "ultrasound" OR "ultraviolet B" OR 
"Ultravist" OR "unfractionated heparin" OR "Urate oxidase" OR "urinary alkalinization" OR "uroguanylin" 
OR "urokinase" OR "Uroprofit" OR "Ursodeoxycholic acid" OR "UVB" OR "valproate" OR "valproic acid" 
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OR "valsartan" OR "vanadium-lazaroid" OR "Vancomycin" OR "vascular endothelial growth factor" OR 
"VDRA" OR "vegan diet*" OR "vegetable proteins" OR "vegetarian" OR "VEGF" OR "Venlafaxine" OR 
"venom" OR "verapamil" OR "vessel revascularization" OR "vildagliptin" OR "Vincristine" OR "vitamin 
B6" OR "vitamin C" OR "vitamin D" OR "vitamin D3" OR "vitamin E" OR "Vitamin K" OR "VKA" OR 
"voriconazole" OR "walking" OR "Wang Kentang's Bai Fu Ling Wan" OR "warfarin" OR "wen-pi-tang" OR 
"Wenshen Huatan" OR "wenshen xiezhuo" OR "xiaochalhu" OR "Xiezhuo" OR "Xueshuantong" OR "Y-
27632" OR "yiqi zishen" OR "Yishen Huoxue" OR "yishen jianpi huayu" OR "Zinc" OR "Zingiber officinale 
Roscoe" OR "zishen huayu fang" 
(core literature-derived CKD treatments that were too general and might have eliminated specific 
discoveries in the same class were subtracted from this negation term: "corticoid*" OR "dairy" OR 
"exercise" OR "fatty acid*" OR "fish" OR "fruit*" OR "iron" OR "lanthanum" OR "phototherapy" OR 
"phytochemicals" OR "seeds" OR "soy" OR "tea" OR "tocopherols" OR "vegetables") 
AND  
2. TITLE PHRASES - (excludes dialysis and transplantation) 
2a. (treat* OR therap* OR cure* OR intervention* OR rehabilitat* OR monotherap* OR pretreat* OR 
psychotherap* OR pharmacotherap* OR medication* OR drug* OR stimulant* OR pharmacological* OR 
diet* OR supplementation OR protect* OR alleviate* OR ameliorate* OR improv* OR benefit* OR 
reduc* OR inhibit* OR decreas* OR prevent* OR suppress* OR lessen* OR lower* OR mitigat*) near/5 
(glycat* OR "peripheral vascular disease" OR arteriosclerosis OR vasoconstriction OR glycosylat* OR 
endothelin-1 OR inflammation OR hypertension OR "insulin resistance" OR fibrosis OR "metabolic 
syndrome" OR hyperglycemia OR nephropathy OR fibrogenesis OR "arterial stiffness") 
NOT  
2b. (glycat*-reduc* OR glycat*-inhibit* OR glycat*-decreas* OR glycat*-prevent* OR glycat*-suppress* 
OR glycat*-lessen* OR glycat*-lower* OR glycat*-mitigat* OR "glycat* caus*" OR "caused by glycat*" OR 
"glycat* induc*" OR "induced by glycat*" OR "glycat* was due to" OR "glycat* due to" OR "lead* to 
glycat*" OR "result* in glycat*" OR "role in glycat*" OR "glycat* was produced by" OR "glycat* produced 
by" OR "role in glycat*" OR "glycat* provoked by" OR "glycat* was provoked by" OR "provoked glycat*" 
OR "produce* glycat*" OR "glycat* was produced by" OR "incidence of glycat*" OR "incident glycat*" OR 
"getting glycat*" OR "prevalence of glycat*" OR "susceptib* to glycat*" OR "contribut* to glycat*" OR 
"development of glycat*" OR "develop* glycat*" OR "aggravat* glycat*" OR "resulted in glycat*") OR 
("peripheral vascular disease reduc*" OR "peripheral vascular disease inhibit*" OR "peripheral vascular 
disease decreas*" OR "peripheral vascular disease prevent*" OR "peripheral vascular disease suppress*" 
OR "peripheral vascular disease lessen*" OR "peripheral vascular disease lower*" OR "peripheral 
vascular disease mitigat*" OR "peripheral vascular disease caus*" OR "caused by peripheral vascular 
disease" OR "peripheral vascular disease induc*" OR "induced by peripheral vascular disease" OR 
"peripheral vascular disease was due to" OR "peripheral vascular disease due to" OR "lead* to 
peripheral vascular disease" OR "result* in peripheral vascular disease" OR "role in peripheral vascular 
disease" OR "peripheral vascular disease was produced by" OR "peripheral vascular disease produced 
by" OR "role in peripheral vascular disease" OR "peripheral vascular disease provoked by" OR 
"peripheral vascular disease was provoked by" OR "provoked peripheral vascular disease" OR "produce* 
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peripheral vascular disease" OR "peripheral vascular disease was produced by" OR "incidence of 
peripheral vascular disease" OR "incident peripheral vascular disease" OR "getting peripheral vascular 
disease" OR "prevalence of peripheral vascular disease" OR "susceptib* to peripheral vascular disease" 
OR "contribut* to peripheral vascular disease" OR "development of peripheral vascular disease" OR 
"develop* peripheral vascular disease" OR "aggravat* peripheral vascular disease" OR "resulted in 
peripheral vascular disease") OR (arteriosclerosis-reduc* OR arteriosclerosis-inhibit* OR arteriosclerosis-
decreas* OR arteriosclerosis-prevent* OR arteriosclerosis-suppress* OR arteriosclerosis-lessen* OR 
arteriosclerosis-lower* OR arteriosclerosis-mitigat* OR "arteriosclerosis caus*" OR "caused by 
arteriosclerosis" OR "arteriosclerosis induc*" OR "induced by arteriosclerosis" OR "arteriosclerosis was 
due to" OR "arteriosclerosis due to" OR "lead* to arteriosclerosis" OR "result* in arteriosclerosis" OR 
"role in arteriosclerosis" OR "arteriosclerosis was produced by" OR "arteriosclerosis produced by" OR 
"role in arteriosclerosis" OR "arteriosclerosis provoked by" OR "arteriosclerosis was provoked by" OR 
"provoked arteriosclerosis" OR "produce* arteriosclerosis" OR "arteriosclerosis was produced by" OR 
"incidence of arteriosclerosis" OR "incident arteriosclerosis" OR "getting arteriosclerosis" OR 
"prevalence of arteriosclerosis" OR "susceptib* to arteriosclerosis" OR "contribut* to arteriosclerosis" 
OR "development of arteriosclerosis" OR "develop* arteriosclerosis" OR "aggravat* arteriosclerosis" OR 
"resulted in arteriosclerosis") 
OR 
(vasoconstriction-reduc* OR vasoconstriction-inhibit* OR vasoconstriction-decreas* OR 
vasoconstriction-prevent* OR vasoconstriction-suppress* OR vasoconstriction-lessen* OR 
vasoconstriction-lower* OR vasoconstriction-mitigat* OR "vasoconstriction caus*" OR "caused by 
vasoconstriction" OR "vasoconstriction induc*" OR "induced by vasoconstriction" OR "vasoconstriction 
was due to" OR "vasoconstriction due to" OR "lead* to vasoconstriction" OR "result* in 
vasoconstriction" OR "role in vasoconstriction" OR "vasoconstriction was produced by" OR 
"vasoconstriction produced by" OR "role in vasoconstriction" OR "vasoconstriction provoked by" OR 
"vasoconstriction was provoked by" OR "provoked vasoconstriction" OR "produce* vasoconstriction" OR 
"vasoconstriction was produced by" OR "incidence of vasoconstriction" OR "incident vasoconstriction" 
OR "getting vasoconstriction" OR "prevalence of vasoconstriction" OR "susceptib* to vasoconstriction" 
OR "contribut* to vasoconstriction" OR "development of vasoconstriction" OR "develop* 
vasoconstriction" OR "aggravat* vasoconstriction" OR "resulted in vasoconstriction") OR (glycosylat*-
reduc* OR glycosylat*-inhibit* OR glycosylat*-decreas* OR glycosylat*-prevent* OR glycosylat*-
suppress* OR glycosylat*-lessen* OR glycosylat*-lower* OR glycosylat*-mitigat* OR "glycosylat* caus*" 
OR "caused by glycosylat*" OR "glycosylat* induc*" OR "induced by glycosylat*" OR "glycosylat* was 
due to" OR "glycosylat* due to" OR "lead* to glycosylat*" OR "result* in glycosylat*" OR "role in 
glycosylat*" OR "glycosylat* was produced by" OR "glycosylat* produced by" OR "role in glycosylat*" OR 
"glycosylat* provoked by" OR "glycosylat* was provoked by" OR "provoked glycosylat*" OR "produce* 
glycosylat*" OR "glycosylat* was produced by" OR "incidence of glycosylat*" OR "incident glycosylat*" 
OR "getting glycosylat*" OR "prevalence of glycosylat*" OR "susceptib* to glycosylat*" OR "contribut* to 
glycosylat*" OR "development of glycosylat*" OR "develop* glycosylat*" OR "aggravat* glycosylat*" OR 
"resulted in glycosylat*") OR (endothelin-1-reduc* OR endothelin-1-inhibit* OR endothelin-1-decreas* 
OR endothelin-1-prevent* OR endothelin-1-suppress* OR endothelin-1-lessen* OR endothelin-1-lower* 
OR endothelin-1-mitigat* OR "endothelin-1 caus*" OR "caused by endothelin-1" OR "endothelin-1 
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induc*" OR "induced by endothelin-1" OR "endothelin-1 was due to" OR "endothelin-1 due to" OR 
"lead* to endothelin-1" OR "result* in endothelin-1" OR "role in endothelin-1" OR "endothelin-1 was 
produced by" OR "endothelin-1 produced by" OR "role in endothelin-1" OR "endothelin-1 provoked by" 
OR "endothelin-1 was provoked by" OR "provoked endothelin-1" OR "produce* endothelin-1" OR 
"endothelin-1 was produced by" OR "incidence of endothelin-1" OR "incident endothelin-1" OR "getting 
endothelin-1" OR "prevalence of endothelin-1" OR "susceptib* to endothelin-1" OR "contribut* to 
endothelin-1" OR "development of endothelin-1" OR "develop* endothelin-1" OR "aggravat* 
endothelin-1" OR "resulted in endothelin-1") 
OR 
(inflammation-reduc* OR inflammation-inhibit* OR inflammation-decreas* OR inflammation-prevent* 
OR inflammation-suppress* OR inflammation-lessen* OR inflammation-lower* OR inflammation-
mitigat* OR "inflammation caus*" OR "caused by inflammation" OR "inflammation induc*" OR "induced 
by inflammation" OR "inflammation was due to" OR "inflammation due to" OR "lead* to inflammation" 
OR "result* in inflammation" OR "role in inflammation" OR "inflammation was produced by" OR 
"inflammation produced by" OR "role in inflammation" OR "inflammation provoked by" OR 
"inflammation was provoked by" OR "provoked inflammation" OR "produce* inflammation" OR 
"inflammation was produced by" OR "incidence of inflammation" OR "incident inflammation" OR 
"getting inflammation" OR "prevalence of inflammation" OR "susceptib* to inflammation" OR 
"contribut* to inflammation" OR "development of inflammation" OR "develop* inflammation" OR 
"aggravat* inflammation" OR "resulted in inflammation") OR (hypertension-reduc* OR hypertension-
inhibit* OR hypertension-decreas* OR hypertension-prevent* OR hypertension-suppress* OR 
hypertension-lessen* OR hypertension-lower* OR hypertension-mitigat* OR "hypertension caus*" OR 
"caused by hypertension" OR "hypertension induc*" OR "induced by hypertension" OR "hypertension 
was due to" OR "hypertension due to" OR "lead* to hypertension" OR "result* in hypertension" OR "role 
in hypertension" OR "hypertension was produced by" OR "hypertension produced by" OR "role in 
hypertension" OR "hypertension provoked by" OR "hypertension was provoked by" OR "provoked 
hypertension" OR "produce* hypertension" OR "hypertension was produced by" OR "incidence of 
hypertension" OR "incident hypertension" OR "getting hypertension" OR "prevalence of hypertension" 
OR "susceptib* to hypertension" OR "contribut* to hypertension" OR "development of hypertension" 
OR "develop* hypertension" OR "aggravat* hypertension" OR "resulted in hypertension") OR ("insulin 
resistance reduc*" OR "insulin resistance inhibit*" OR "insulin resistance decreas*" OR "insulin 
resistance prevent*" OR "insulin resistance suppress*" OR "insulin resistance lessen*" OR "insulin 
resistance lower*" OR "insulin resistance mitigat*" OR "insulin resistance caus*" OR "caused by insulin 
resistance" OR "insulin resistance induc*" OR "induced by insulin resistance" OR "insulin resistance was 
due to" OR "insulin resistance due to" OR "lead* to insulin resistance" OR "result* in insulin resistance" 
OR "role in insulin resistance" OR "insulin resistance was produced by" OR "insulin resistance produced 
by" OR "role in insulin resistance" OR "insulin resistance provoked by" OR "insulin resistance was 
provoked by" OR "provoked insulin resistance" OR "produce* insulin resistance" OR "insulin resistance 
was produced by" OR "incidence of insulin resistance" OR "incident insulin resistance" OR "getting 
insulin resistance" OR "prevalence of insulin resistance" OR "susceptib* to insulin resistance" OR 
"contribut* to insulin resistance" OR "development of insulin resistance" OR "develop* insulin 
resistance" OR "aggravat* insulin resistance" OR "resulted in insulin resistance") 




(fibrosis-reduc* OR fibrosis-inhibit* OR fibrosis-decreas* OR fibrosis-prevent* OR fibrosis-suppress* OR 
fibrosis-lessen* OR fibrosis-lower* OR fibrosis-mitigat* OR "fibrosis caus*" OR "caused by fibrosis" OR 
"fibrosis induc*" OR "induced by fibrosis" OR "fibrosis was due to" OR "fibrosis due to" OR "lead* to 
fibrosis" OR "result* in fibrosis" OR "role in fibrosis" OR "fibrosis was produced by" OR "fibrosis 
produced by" OR "role in fibrosis" OR "fibrosis provoked by" OR "fibrosis was provoked by" OR 
"provoked fibrosis" OR "produce* fibrosis" OR "fibrosis was produced by" OR "incidence of fibrosis" OR 
"incident fibrosis" OR "getting fibrosis" OR "prevalence of fibrosis" OR "susceptib* to fibrosis" OR 
"contribut* to fibrosis" OR "development of fibrosis" OR "develop* fibrosis" OR "aggravat* fibrosis" OR 
"resulted in fibrosis") OR ("metabolic syndrome reduc*" OR "metabolic syndrome inhibit*" OR 
"metabolic syndrome decreas*" OR "metabolic syndrome prevent*" OR "metabolic syndrome 
suppress*" OR "metabolic syndrome lessen*" OR "metabolic syndrome lower*" OR "metabolic 
syndrome mitigat*" OR "metabolic syndrome caus*" OR "caused by metabolic syndrome" OR 
"metabolic syndrome induc*" OR "induced by metabolic syndrome" OR "metabolic syndrome was due 
to" OR "metabolic syndrome due to" OR "lead* to metabolic syndrome" OR "result* in metabolic 
syndrome" OR "role in metabolic syndrome" OR "metabolic syndrome was produced by" OR "metabolic 
syndrome produced by" OR "role in metabolic syndrome" OR "metabolic syndrome provoked by" OR 
"metabolic syndrome was provoked by" OR "provoked metabolic syndrome" OR "produce* metabolic 
syndrome" OR "metabolic syndrome was produced by" OR "incidence of metabolic syndrome" OR 
"incident metabolic syndrome" OR "getting metabolic syndrome" OR "prevalence of metabolic 
syndrome" OR "susceptib* to metabolic syndrome" OR "contribut* to metabolic syndrome" OR 
"development of metabolic syndrome" OR "develop* metabolic syndrome" OR "aggravat* metabolic 
syndrome" OR "resulted in metabolic syndrome") OR (hyperglycemia-reduc* OR hyperglycemia-inhibit* 
OR hyperglycemia-decreas* OR hyperglycemia-prevent* OR hyperglycemia-suppress* OR 
hyperglycemia-lessen* OR hyperglycemia-lower* OR hyperglycemia-mitigat* OR "hyperglycemia caus*" 
OR "caused by hyperglycemia" OR "hyperglycemia induc*" OR "induced by hyperglycemia" OR 
"hyperglycemia was due to" OR "hyperglycemia due to" OR "lead* to hyperglycemia" OR "result* in 
hyperglycemia" OR "role in hyperglycemia" OR "hyperglycemia was produced by" OR "hyperglycemia 
produced by" OR "role in hyperglycemia" OR "hyperglycemia provoked by" OR "hyperglycemia was 
provoked by" OR "provoked hyperglycemia" OR "produce* hyperglycemia" OR "hyperglycemia was 
produced by" OR "incidence of hyperglycemia" OR "incident hyperglycemia" OR "getting hyperglycemia" 
OR "prevalence of hyperglycemia" OR "susceptib* to hyperglycemia" OR "contribut* to hyperglycemia" 
OR "development of hyperglycemia" OR "develop* hyperglycemia" OR "aggravat* hyperglycemia" OR 
"resulted in hyperglycemia") 
OR 
(nephropathy-reduc* OR nephropathy-inhibit* OR nephropathy-decreas* OR nephropathy-prevent* OR 
nephropathy-suppress* OR nephropathy-lessen* OR nephropathy-lower* OR nephropathy-mitigat* OR 
"nephropathy caus*" OR "caused by nephropathy" OR "nephropathy induc*" OR "induced by 
nephropathy" OR "nephropathy was due to" OR "nephropathy due to" OR "lead* to nephropathy" OR 
"result* in nephropathy" OR "role in nephropathy" OR "nephropathy was produced by" OR 
"nephropathy produced by" OR "role in nephropathy" OR "nephropathy provoked by" OR "nephropathy 
was provoked by" OR "provoked nephropathy" OR "produce* nephropathy" OR "nephropathy was 
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produced by" OR "incidence of nephropathy" OR "incident nephropathy" OR "getting nephropathy" OR 
"prevalence of nephropathy" OR "susceptib* to nephropathy" OR "contribut* to nephropathy" OR 
"development of nephropathy" OR "develop* nephropathy" OR "aggravat* nephropathy" OR "resulted 
in nephropathy") OR (fibrogenesis-reduc* OR fibrogenesis-inhibit* OR fibrogenesis-decreas* OR 
fibrogenesis-prevent* OR fibrogenesis-suppress* OR fibrogenesis-lessen* OR fibrogenesis-lower* OR 
fibrogenesis-mitigat* OR "fibrogenesis caus*" OR "caused by fibrogenesis" OR "fibrogenesis induc*" OR 
"induced by fibrogenesis" OR "fibrogenesis was due to" OR "fibrogenesis due to" OR "lead* to 
fibrogenesis" OR "result* in fibrogenesis" OR "role in fibrogenesis" OR "fibrogenesis was produced by" 
OR "fibrogenesis produced by" OR "role in fibrogenesis" OR "fibrogenesis provoked by" OR "fibrogenesis 
was provoked by" OR "provoked fibrogenesis" OR "produce* fibrogenesis" OR "fibrogenesis was 
produced by" OR "incidence of fibrogenesis" OR "incident fibrogenesis" OR "getting fibrogenesis" OR 
"prevalence of fibrogenesis" OR "susceptib* to fibrogenesis" OR "contribut* to fibrogenesis" OR 
"development of fibrogenesis" OR "develop* fibrogenesis" OR "aggravat* fibrogenesis" OR "resulted in 
fibrogenesis") OR ("arterial stiffness reduc*" OR "arterial stiffness inhibit*" OR "arterial stiffness 
decreas*" OR "arterial stiffness prevent*" OR "arterial stiffness suppress*" OR "arterial stiffness 
lessen*" OR "arterial stiffness lower*" OR "arterial stiffness mitigat*" OR "arterial stiffness caus*" OR 
"caused by arterial stiffness" OR "arterial stiffness induc*" OR "induced by arterial stiffness" OR "arterial 
stiffness was due to" OR "arterial stiffness due to" OR "lead* to arterial stiffness" OR "result* in arterial 
stiffness" OR "role in arterial stiffness" OR "arterial stiffness was produced by" OR "arterial stiffness 
produced by" OR "role in arterial stiffness" OR "arterial stiffness provoked by" OR "arterial stiffness was 
provoked by" OR "provoked arterial stiffness" OR "produce* arterial stiffness" OR "arterial stiffness was 
produced by" OR "incidence of arterial stiffness" OR "incident arterial stiffness" OR "getting arterial 
stiffness" OR "prevalence of arterial stiffness" OR "susceptib* to arterial stiffness" OR "contribut* to 
arterial stiffness" OR "development of arterial stiffness" OR "develop* arterial stiffness" OR "aggravat* 
arterial stiffness" OR "resulted in arterial stiffness") - title 
OR (based on treatment MeSH terms) 
2c. ("Adrenergic alpha-1 Receptor Antagonist*" OR "Adrenergic beta-Agonist*" OR "Adrenergic beta-
Antagonist*"  OR "Aldosterone Antagonist*" OR "Essential Amino Acid*" OR "Anabolic Agent*" OR 
"Androgen*" OR "Angiotensin II Type 1 Receptor Blockers*" OR "Angiotensin II Type 2 Receptor 
Blockers*" OR "Angiotensin Receptor Antagonist*" OR "Angiotensin-Converting Enzyme Inhibitor*" OR 
"Anti-Arrhythmia Agent*" OR "Monoclonal Antibodies" OR "Anticholesteremic Agent*" OR 
"Anticoagulant*" OR "Antifibrinolytic Agent*" OR "Antihypertensive*" OR "Anti-Inflammatory Agent*" 
OR "Antioxidant*" OR "Antithrombin*" OR "Antitubercular Agent*" OR "Anti-Ulcer Agent*" OR 
"Biological Availability" OR "Biosimilar Pharmaceutical*" OR "Blood Substitute*" OR "Bone Density 
Conservation Agent*" OR "Bone Morphogenetic Protein*" OR "Calcimimetic Agent*" OR "Calcium 
Channel Agonist*" OR "Calcium Channel Blocker*" OR "Caloric Restriction" OR "Cardiotonic Agent*" OR 
"Cardiovascular Agent*" OR "Chelating Agent*" OR "Colony-Stimulating Factor*" OR "Combined 
Modality Therapy" OR "Complement Inactivating Agent*" OR "Complement Inactivator Protein*" OR 
"Complementary Therap*" OR "Condiment*" OR "Cyclooxygenase Inhibitor*" OR "Cytoprotection" OR 
"Diabetic Diet*" OR "Diet Therap*" OR "Carbohydrate-Restricted diet*" OR "Fat-Restricted Diet*" OR 
"Mediterranean Diet*" OR "Protein-Restricted Diet*" OR "Sodium-Restricted Diet*" OR "Vegetarian 
Diet*" OR "Dietary Carbohydrates" OR "Dietary Fat*" OR "Dietary Fiber" OR "Dietary Protein*" OR 
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"Dietary Supplement*" OR "Dietetics" OR "Dipeptidyl-Peptidase IV Inhibitor*" OR "Dose-Response 
Relationship*" OR "Drug Combination*" OR "Drug Discovery" OR "Drug Evaluation" OR "Drug 
Synergism" OR "Drug Therapy" OR "Drug Therapy" OR "Drug Utilization" OR "Investigational Drugs" OR 
"Embryonic Stem Cell*" OR "Energy Intake" OR "Enzyme Inhibitor*" OR "Estrogen*" OR "Exercise 
Therapy" OR "Fermentation" OR "Fetal Stem Cell*" OR "Fibrinolytic Agent*" OR "Flavonoid*" OR "Food 
Handling" OR "Formulated Food" OR "Free Radical Scavenger*" OR "Fruit*" OR "Gastrointestinal 
Agent*" OR "Gene Expression Regulation" OR "Gene Therapy" OR "Genetic Vector*" OR 
"Glycosaminoglycan*" OR "Health Food*" OR "Hematopoietic Stem Cell*" OR "Hirudin Therapy" OR  
"Horme*" OR "Human Growth Hormone*" OR "Hydroxymethylglutaryl-CoA Reductase Inhibitor*" OR 
"Hypoglycemic Agent*" OR "Hypolipidemic Agent*" OR "Inflammation Mediator*" OR "Integrative 
Medicine" OR "Isoflavone*" OR "Leukotriene Antagonist*" OR "Chinese Traditional Medicine" OR 
"Traditional Medicine" OR "Mesenchymal Stem Cell*" OR "Micronutrient*" OR "Motor Activity" OR 
"Multipotent Stem Cell*" OR "Neuroprotective Agent*" OR "Nonprescription Drug*" OR "Nutrition 
Policy" OR "Nutrition Therapy" OR "Nutritional Physiological Phenomena" OR "Nutritional 
Requirement*" OR "Nutritional Science*" OR "Nutritional Support" OR "Parenteral Nutrition" OR 
"Peripheral Blood Stem Cell*" OR "Pharmaceutical Preparation*" OR "Pharmacokinetic*" OR "Phenol*" 
OR "Phosphodiesterase 5 Inhibitor*" OR "Phosphodiesterase Inhibitor*" OR "Phytoestrogen*" OR 
"Phytotherapy" OR "Plant Extract*" OR "Plant Leaves" OR "Plant Oil*" OR "Plant Preparation*" OR 
"Plant Protein*" OR "Plant Root*" OR "Medicinal Plant*" OR "Platelet Aggregation Inhibitor*" OR 
"Pluripotent Stem Cell*" OR "Polyphenol*" OR "Prebiotic*" OR "Prescription Drug*" OR "Primary 
Prevention" OR "Probiotic*" OR "Protease Inhibitor*" OR "Protective Agent*" OR "Protein Kinase 
Inhibitor*" OR "Recombinant Protein*" OR "Regeneration" OR "Seed*" OR "Selective Estrogen Receptor 
Modulator*" OR "Sodium Chloride Symporter Inhibitor*" OR "Sodium Potassium Chloride Symporter 
Inhibitor*" OR "Stem Cell Transplantation" OR "Stem Cell*" OR "Steroid*" OR "Stromal Cell*" OR 
"Synbiotic*" OR "Thrombolytic Therapy" OR "Tissue Therapy" OR "Treatment Outcome" OR "Vasodilator 
Agent*" OR "Vegetable Protein*" OR "Vegetable*") near/15  (glycat* OR "peripheral vascular disease" 
OR arteriosclerosis OR vasoconstriction OR glycosylat* OR endothelin-1 OR inflammation OR 
hypertension OR "insulin resistance" OR fibrosis OR "metabolic syndrome" OR hyperglycemia OR 
nephropathy OR fibrogenesis OR "arterial stiffness") - title 
3. MESH QUALIFIERS - MESH HEADING 
3a. (/diet therapy OR /drug therapy OR /prevention & control OR /radiotherapy OR /rehabilitation OR 
/therapeutic use OR /therapy OR /administration & dosage OR /pharmacology) - MeSH Heading 
AND 
3b. (treat* OR therap* OR cure* OR intervention* OR rehabilitat* OR monotherap* OR pretreat* OR 
psychotherap* OR pharmacotherap* OR medication* OR drug* OR stimulant* OR pharmacological* OR 
diet* OR supplementation OR protect* OR alleviate* OR ameliorate* OR improv* OR benefit* OR 
reduc* OR inhibit* OR decreas* OR prevent* OR suppress* OR lessen OR lower* OR mitigat*) - title 
OR 
4. MESH GENERIC TERMS - MESH HEADING NO EXPLODE 
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(Extracted from 441 Treatment MeSH terms of CKD core analysis, with some related additions) 
4a. (Adrenergic alpha-1 Receptor Antagonists OR Adrenergic beta-Agonists OR Adrenergic beta-
Antagonists  OR Aldosterone Antagonists OR Amino Acids OR Amino Acids, Essential OR Anabolic Agents 
OR Androgens OR Angiotensin II Type 1 Receptor Blockers OR Angiotensin II Type 2 Receptor Blockers 
OR Angiotensin Receptor Antagonists OR Angiotensin-Converting Enzyme Inhibitors OR Anti-Arrhythmia 
Agents OR Antibodies, Monoclonal OR Anticholesteremic Agents OR Anticoagulants OR Antifibrinolytic 
Agents OR Antihypertensive Agents OR Anti-Inflammatory Agents OR Anti-Inflammatory Agents, Non-
Steroidal OR Antioxidants OR Antithrombins OR Antitubercular Agents OR Anti-Ulcer Agents OR 
Biological Availability OR Biosimilar Pharmaceuticals OR Blood Substitutes OR Bone Density Conservation 
Agents OR Bone Morphogenetic Proteins OR Calcimimetic Agents OR Calcium Channel Agonists OR 
Calcium Channel Blockers OR Caloric Restriction OR Cardiotonic Agents OR Cardiovascular Agents OR 
Chelating Agents OR Colony-Stimulating Factors OR Combined Modality Therapy OR Complement 
Inactivating Agents OR Complement Inactivator Proteins OR Complementary Therapies OR Condiments 
OR Cyclooxygenase Inhibitors OR Cytoprotection OR Diabetic Diet OR Diet OR Diet Therapy OR Diet, 
Carbohydrate-Restricted OR Diet, Fat-Restricted OR Diet, Mediterranean OR Diet, Protein-Restricted OR 
Diet, Sodium-Restricted OR Diet, Vegetarian OR Dietary Carbohydrates OR Dietary Fats OR Dietary Fats, 
Unsaturated OR Dietary Fiber OR Dietary Proteins OR Dietary Supplements OR Dietetics OR Dipeptidyl-
Peptidase IV Inhibitors OR Dose-Response Relationship, Drug OR Drug Combinations OR Drug Discovery 
OR Drug Evaluation, Preclinical OR Drug Synergism OR Drug Therapy OR Drug Therapy, Combination OR 
Drug Utilization OR Drugs, Investigational OR Embryonic Stem Cells OR Energy Intake OR Enzyme 
Inhibitors OR Estrogens OR Estrogens, Conjugated (USP) OR Estrogens, Non-Steroidal OR Exercise OR 
Exercise Therapy OR Fermentation OR Fetal Stem Cells OR Fibrinolytic Agents OR Flavonoids OR Food OR 
Food Handling OR Food, Formulated OR Free Radical Scavengers OR Fruit OR Gastrointestinal Agents OR 
Gene Expression Regulation OR Gene Therapy OR Genetic Vectors OR Glycosaminoglycans OR Health 
Food OR Hematopoietic Stem Cell Transplantation OR Hematopoietic Stem Cells OR Hirudin Therapy OR 
Hirudins OR Hormesis OR Human Growth Hormone OR Hydroxymethylglutaryl-CoA Reductase Inhibitors 
OR Hypoglycemic Agents OR Hypolipidemic Agents OR Inflammation Mediators OR Integrative Medicine 
OR Isoflavones OR Leukotriene Antagonists OR Medicine, Chinese Traditional OR Medicine, Traditional 
OR Mesenchymal Stem Cell Transplantation OR Micronutrients OR Motor Activity OR Multipotent Stem 
Cells OR Neuroprotective Agents OR Nonprescription Drugs OR Nutrition Policy OR Nutrition Therapy OR 
Nutritional Physiological Phenomena OR Nutritional Requirements OR Nutritional Sciences OR 
Nutritional Support OR Parenteral Nutrition OR Peripheral Blood Stem Cell Transplantation OR 
Pharmaceutical Preparations OR Pharmacokinetics OR Phenols OR Phosphodiesterase 5 Inhibitors OR 
Phosphodiesterase Inhibitors OR Phytoestrogens OR Phytotherapy OR Plant Extracts OR Plant Leaves OR 
Plant Oils OR Plant Preparations OR Plant Proteins OR Plant Roots OR Plants, Medicinal OR Platelet 
Aggregation Inhibitors OR Pluripotent Stem Cells OR Polyphenols OR Prebiotics OR Prescription Drugs 
OR Primary Prevention OR Probiotics OR Protease Inhibitors OR Protective Agents OR Protein Kinase 
Inhibitors OR Recombinant Proteins OR Regeneration OR Seeds OR Selective Estrogen Receptor 
Modulators OR Sodium Chloride Symporter Inhibitors OR Sodium Potassium Chloride Symporter 
Inhibitors OR Stem Cell Transplantation OR Stem Cells OR Steroids OR Stromal Cells OR Synbiotics OR 
Thrombolytic Therapy OR Tissue Therapy OR Treatment Outcome OR Vasodilator Agents OR Vegetable 
Proteins OR Vegetables) - MeSH Hdg No Expl 




4b. ((treat* OR therap* OR cure* OR intervention* OR rehabilitat* OR monotherap* OR pretreat* OR 
psychotherap* OR pharmacotherap* OR medication* OR drug* OR stimulant* OR pharmacological* OR 
diet* OR supplementation OR protect* OR alleviate* OR ameliorate* OR improv* OR benefit* OR 
reduc* OR inhibit* OR decreas* OR prevent* OR suppress* OR lessen OR lower* OR mitigat*)  
About 55 potential Discovery candidates were identified (validated through Medline).  Another dozen or 
so were identified from examining the citation network around some of the 55 initial Discoveries.  The 
next step was validating the 65+ total Discovery candidates through the SCI.  A query derived from the 
MeSH-based query used for CKD was used for the SCI validation: 
("chronic kidney disease" OR "chronic kidney failure" OR "chronic renal insufficiency" OR "diabet* 
near/3 nephropath*" OR nephrosclerosis OR nephrosis OR nephritis)  
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1D. CKD SYMPTOMS 
1D1.  Manual generation 
The MeSH terms in the full CKD core literature retrieval were examined, and 271 terms related to 
symptoms were validated and selected.  A separate database was generated whose records contained 
at least one of the symptoms MeSH terms.  Tens of thousands of Abstract and title phrases were 
examined, and those describing a symptom were selected. 
1D2.  CKD core literature symptoms query 
Since the symptoms query was applied only to the CKD core literature to identify any symptoms not 
identified through the manual process, an abbreviated symptoms query was developed. 
Query=((#1a OR #1b) NOT (#1c OR #1d)) AND (#1e OR #1f OR #1g) 
1a.  ("kidney failure, chronic" OR "renal insufficiency, chronic" OR "Diabetic Nephropathies" OR 
Nephrosclerosis OR Nephrosis OR Nephritis OR "Nephritis, Interstitial") - MeSH Heading  
OR  
1b.  "chronic kidney disease" - topic 
NOT  
1c.  (Renal Dialysis OR Kidney Transplantation OR Peritoneal Dialysis OR Peritoneal Dialysis, Continuous 
Ambulatory OR Nephrectomy OR Transplantation, Homologous OR Graft Rejection OR Graft Survival OR 
Dialysis Solutions OR Dialysis OR Hemodialysis, Home OR Hemodialysis Solutions OR Hemodialysis Units, 
Hospital OR Microdialysis OR Transplantation, Autologous OR Transplantation Immunology OR 
Transplantation Conditioning OR Transplantation, Heterologous OR Delayed Graft Function OR Kidney 
Neoplasms OR Renal Replacement Therapy OR  Pancreas Transplant OR Neoplasms) - MeSH Heading 
Field 
OR 
(symptom phrases from manual procedure) 
1d. (1,25-dihydroxyvitamin D OR 25-hydroxyvitamin D OR 8-hydroxy-2'-deoxyguanosine OR abdominal 
fat OR adipocytokine* OR ADIPONECTIN OR adipose tissue OR adrenal insufficiency OR advanced 
glycosylation end products OR adynamic bone OR albumin/creatinine ratio OR albuminuria OR 
aldosterone OR alkaline phosphatase OR alpha-galactosidase OR alpha-galactosidase A. OR alpha-
smooth muscle actin OR amyloidosis OR anaemia OR androgen OR anemia OR angiogenesis OR 
angiotensin II receptor* OR angiotensin receptor* OR angiotensin-converting enzyme OR ankle-brachial 
index OR anti-inflamm* OR antioxidant defense OR antiphospholipid syndrome OR Aortic pulse wave 
velocity OR aplasia OR apolipoprotein* OR apoptosis OR arrhythmias OR arter* stenosis OR arterial stiff* 
OR arteriosclerosis OR asymmetric dimethylarginine OR atherosclerosis OR atherosclerotic plaques OR 
azotaemia OR azotemia OR B lymphocytes OR baroreflex OR beta 2-Microglobulin OR beta2-
microglobulin OR blood glucose OR blood hemoglobin OR blood pressure OR blood sugar OR blood urea 
nitrogen OR bone density OR bone mineral density OR cachexia OR calcidiol OR calcification OR 
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calcinosis OR Calciphylaxis OR calcitonin OR calcium deposition OR calcium oxalate OR calcium 
phosphate OR carbonyl stress OR carboxymethyllysine OR cardiac hypertrophy OR carnitine  OR catalase 
OR catecholamines OR CD31 OR cGMP OR collagen degradation OR connective tissue growth factor OR 
copper OR C-reactive protein OR creatine kinase OR dehydration OR dyslipidaemia OR dyslipidemia OR 
E-cadherin OR edema OR elastin degradation OR endothelin-1 OR erythropoie* OR erythropoietin OR 
estrogen  OR extracellular fluid volume OR extracellular matrix OR extracellular matrix degradation OR 
extracellular phosphoglycoprotein OR extracellular water OR F2-isoprostanes OR fatty acid synthase OR 
fatty acid-binding protein* OR FERRITIN OR fetuin-A OR FGF23 OR FGF-23 OR fibrin degradation OR 
fibrinogen OR fibrinolysis OR fibrinolysis OR fibroblast growth factor 23 OR fibroblast growth factor-23 
OR fibrogenesis OR fibrogenic OR fibronectin OR fibrosis OR folate deficiency OR folic acid OR free 
radicals OR gangrene OR glomerular hypertrophy OR glomerulosclerosis OR glutathione OR glycation OR 
GLYCATED OR glycemia OR glycosylated hemoglobin OR glycosylation OR glycoxidation OR growth 
hormone OR haematuria OR haemoglobin OR haploinsufficiency OR heart rate response OR heart rate 
variability OR hematuria OR hepcidin OR HIGH SERUM CALCIUM OR HIGH SERUM POTASSIUM OR HIGH-
DENSITY LIPOPROTEIN OR HDL  OR homocysteine OR hydration OR hydrolytic degradation OR 
hydronephrosis OR hyperaldosteronism OR hypercalcaemi* OR hypercalcemi* OR hypercalciuria OR 
hypercellularity OR hypercholesterolaemia OR hypercholesterolemi* OR hypercoagulability OR 
hypercoagulable OR hyperemia OR hyperfiltration OR hyperglycaemia OR hyperglycemi* OR 
hyperglycosylated OR Hyperhomocysteinaemia OR hyperhomocysteinemi* OR hyperinsulinaemia OR 
hyperinsulinemi* OR hyperkalaemia OR hyperkalemi* OR hyperleptinemia OR hyperlipid* OR 
hypermagnesemia OR hyperoxaluria OR hyperparathyroid* OR Hyperphosphataemia OR 
hyperphosphatemi* OR hyperplasia OR hypersecretion OR hypertens* OR hyperthyroid* OR 
hypertriglycerid* OR hyperuricaemia OR hyperuricem* OR Hypervolemia OR hypoalbumin* OR 
hypocalcaemia OR hypocalcemi* OR hypoglycaemia OR hypoglycemi* OR hypogonad* OR hypokalaemia 
OR hypokalemi* OR hypolipidemi* OR hypomagnesemia OR hypomethylation OR hyponatremia OR 
hypoparathyroidism OR hypoperfusion OR hypophosphatemi* OR hypoplasia OR hyporespons* OR 
hypotensi* OR hypothyroid* OR Hypovitaminosis D OR hypoxemia OR hypoxi* OR hypoxia-INDUC* OR 
hypozincemia OR IFN-gamma OR IL-1* OR IL-18 OR IL-4 OR IL-6 OR IL-8 OR indoxyl sulfate OR inflamm* 
OR insulin resistance OR insulin sensitivity OR insulin-like growth factor* OR intercellular adhesion 
molecule-1 OR interferon-gamma OR interleukin-1* OR interleukin-10 OR interleukin-18 OR interleukin-
6 OR intima-media thickness OR iron deficiency OR iron depletion OR iron-deficiency OR kallikrein OR 
Klotho OR lactate dehydrogenase OR lean body mass OR left ventricular ejection fraction OR left 
ventricular hypertrophy OR left ventricular mass index OR leptin OR leukocyte count OR lipid 
metabolism OR lipid peroxid* OR lipoperoxidation OR lipotoxicity OR lipoxidation OR LOW SERUM 
CALCIUM OR LOW SERUM POTASSIUM OR low-density lipoprotein OR LDL OR macroalbuminuria OR 
macrophage infiltration OR Magnesium OR MG OR Malnutrition OR malondialdehyde OR matrix 
accumulation OR matrix metalloproteinases OR MDA OR membrane protein DAMAGE OR metabolic 
acidosis OR metabolic syndrome OR methylenetetrahydrofolate reductase OR methylglyoxal OR 
methylmalonic OR microalbuminuria OR microinflammation OR mineral metabolism OR mitogen-
activated protein KINASE* OR monocyte chemoattractant protein-1 OR myeloperoxidase OR N(epsilon)-
(carboxymethyl)lysine OR N-acetyl-beta-D-glucosaminidase OR NADPH oxidase OR natriuretic peptide 
OR nephrin OR nephrocalcinosis OR nephrogenesis OR nephrogenic fibrosing OR nephron damage OR 
nephrosclerosis OR neuropeptide Y OR neutrophil gelatinase-associated lipocalin OR NF-kappaB OR 
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nitric oxide OR nitric oxide synthase OR nonesterified fatty acids OR norepinephrine OR nutrition OR 
obes* OR oedema OR osteitis fibrosa OR osteocalcin OR osteodystrophy OR osteomalacia OR 
osteopenia OR osteopontin OR osteoporosis OR osteoprotegerin OR overweight OR oxidation OR 
oxidative stress OR Oxidized low-density lipoprotein OR pancreatic insufficiency OR paraoxonase OR 
parathormone OR PARATHORMONE OR parathyroid hormone OR p-cresol OR pentosidine OR peripheral 
vascular disease OR peroxynitrite OR phospholipid* OR phosphorous OR plasma renin OR Plasmalogens 
OR plasminogen activator inhibitor OR plasminogen activator inhibitor-1 OR podocyte damage OR 
podocyte depletion OR profibrotic cytokines OR proinflamm* OR pro-inflamm* OR protein carbonyl* OR 
protein catabolism OR protein degradation OR protein depletion OR protein excretion OR protein 
metabolism OR proteinuri* OR pulse wave velocity OR pure red cell aplasia OR pyelonephritis OR 
reactive oxygen species OR red blood cell* OR renal circulation OR RENAL ISCHEMIA OR Renalase OR 
retinol-binding protein OR RNA degradation OR SERUM ALBUMIN OR serum amyloid OR serum calcitriol 
OR serum cholesterol OR serum cTnT OR serum EPO OR SERUM FERRITIN OR serum folate OR serum 
insulin OR serum lipid* OR serum OPG OR serum parathyroid hormone OR serum phosphate OR serum 
phosphorus OR serum prealbumin OR Serum sodium OR sleep apnea OR SOX markers Cu/Zn OR 
spermatogenesis OR superoxide dismutase OR superoxide production OR symmetric dimethylarginine 
OR sympathetic nerve activity OR Testosterone OR TGF-beta1 OR thyroxine OR TNFalpha OR TNF-alpha 
OR TRANSFERRIN OR transforming growth factor-beta* OR triglyceride* OR troponin OR tubular atrophy 
OR tubular necrosis OR tubulointerstitial injury OR tubulointerstitial lesions OR tubulointerstitial 
nephritis OR tumor necrosis factor* OR type I collagen OR type IV collagen OR tyrosine OR Uraemia OR 
uremic OR uric acid OR URIN* ALBUMIN OR urin* protein OR URINE albumin-creatinine ratio OR URINE 
albumin-to-creatinine ratio OR uromodulin OR vascular cell adhesion molecule-1 OR vascular endothelial 
growth factor OR vascular resistance OR vasculitis OR vasoconstriction OR vasodilatation OR VCAM-1 OR 
VEGF OR vesicoureteral reflux OR vimentin OR vitamin B12  OR Vitamin C OR vitamin D OR vitamin K OR 
wall thickness AND (RENAL OR KIDNEY OR ARTERIAL OR VENTRICULAR) OR White blood cell count OR 
Zinc) - Topic 
AND 
1e.  (Signs and Symptoms OR Glomerular Filtration Rate OR Creatinine OR Hypertension OR Biological 
Markers OR Anemia OR Blood Pressure OR Erythropoietin OR Proteinuria OR Uremia OR Parathyroid 
Hormone OR Hyperparathyroidism, Secondary OR Calcinosis OR Hemoglobins OR Inflammation OR 
Oxidative Stress OR C-Reactive Protein OR Albuminuria OR Body Mass Index OR Phosphates OR 
Phosphorus OR Nutritional Status OR Obesity OR Hypertrophy, Left Ventricular OR Fibrosis OR Urea OR 
Body Weight OR Arteriosclerosis OR Endothelium, Vascular OR Atherosclerosis OR Hypertension, Renal 
OR Homocysteine OR Blood Glucose OR Bone Density OR Interleukin-6 OR Blood Urea Nitrogen OR 
Anemia, Iron-Deficiency OR Cytokines OR Lipids OR Arginine OR Hyperparathyroidism OR Cholesterol OR 
Malnutrition OR Metabolic Syndrome X OR Insulin Resistance OR Tumor Necrosis Factor-alpha OR 
Cystatin C OR Hyperlipidemias OR Heart Rate OR Glucose OR Vitamin D Deficiency OR Insulin OR Nitric 
Oxide OR Hyperphosphatemia OR Body Composition OR Apoptosis OR Triglycerides OR Calciphylaxis OR 
Potassium OR Ischemia OR Glycosylation End Products, Advanced OR Fibroblast Growth Factors OR 
Natriuretic Peptide, Brain OR Transforming Growth Factor beta OR Protein-Energy Malnutrition OR 
Hyperhomocysteinemia OR Hemoglobin A, Glycosylated OR Peptide Fragments OR Dyslipidemias OR 
Metabolic Clearance Rate OR Hypotension OR Hypercalcemia OR beta 2-Microglobulin OR Stroke 
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Volume OR Renal Circulation OR Uric Acid OR Hyperkalemia OR Alkaline Phosphatase OR Cholesterol, 
LDL OR Erythropoiesis OR Transferrin OR Leptin OR Nutrition Disorders OR Acidosis OR Cholesterol, HDL 
OR Vascular Resistance OR Osteoporosis OR Lipid Peroxidation OR Reactive Oxygen Species OR 
Lipoproteins, LDL OR Troponin T OR Malondialdehyde OR Nitric Oxide Synthase OR Membrane Proteins 
OR Bone Remodeling OR Lipoproteins OR Hematuria OR Hypercholesterolemia OR Adiponectin OR 
Minerals OR Aldosterone OR Adipose Tissue OR Hyperuricemia OR Magnesium OR Superoxide 
Dismutase OR Albumins OR Cystatins OR Endothelin-1 OR Hyperplasia OR Sleep Disorders OR Cognition 
Disorders OR Hypocalcemia OR Phosphorus Metabolism Disorders OR Vasculitis OR Troponin I OR Nitric 
Oxide Synthase Type III OR Phosphorus, Dietary OR Sleep Apnea Syndromes OR Hypertension, 
Renovascular OR Lipid Metabolism OR Nephrosclerosis OR Fibrinogen OR Elasticity OR Glutathione OR 
Hyperglycemia OR Hyperoxaluria, Primary OR Edema OR Indican OR Lipoproteins, HDL OR Bone 
Resorption OR Leukocyte Count OR Extracellular Matrix OR Interleukin-10 OR Interleukin-1 OR Collagen 
Type I OR NF-kappa B OR Oxygen OR Lipocalins OR Lipoprotein(a) OR Osteoprotegerin OR Lymphocytes 
OR Norepinephrine OR Restless Legs Syndrome OR Atrial Natriuretic Factor OR Calcifediol OR 
Plasminogen Activator Inhibitor 1 OR Vascular Calcification OR Glycoproteins OR Testosterone OR 
Hypoalbuminemia OR Interferon-gamma OR Zinc OR Calcification, Physiologic OR Calcium Phosphates 
OR Muscular Atrophy OR Creatine Kinase OR Hypophosphatemia OR Hypothyroidism OR Glucose 
Tolerance Test OR Apolipoproteins OR Apolipoproteins B OR Cachexia OR Methylenetetrahydrofolate 
Reductase (NADPH2) OR Genetic Markers OR Sleep OR Apolipoproteins E OR Calcitonin OR 
Hypertension, Pulmonary OR Muscle Proteins OR Sleep Apnea, Obstructive OR Obesity, Morbid OR 
Nephrocalcinosis OR Uromodulin OR Ankle Brachial Index OR Hypertrophy OR Overweight OR 
Pulmonary Edema OR Rhabdomyolysis OR Genome-Wide Association Study OR Matrix 
Metalloproteinase 2 OR NADPH Oxidase OR Antiphospholipid Syndrome OR Anorexia OR Fibronectins 
OR Appetite OR B-Lymphocytes OR Hyperthyroidism OR Hypokalemia OR Vascular Stiffness OR Catalase 
OR Glycosylation OR Troponin OR Tyrosine OR Fatty Acid-Binding Proteins OR Hemostasis OR 
Hypertriglyceridemia OR Angiotensinogen OR Vasoconstriction OR Matrix Metalloproteinase 9 OR 
Nitrites OR Thyroxine OR Wasting Syndrome OR DNA Damage OR Blood Cell Count OR Calcium Oxalate 
OR Hyperoxaluria OR Cresols OR Hypoparathyroidism OR Superoxides OR Glucose Intolerance OR 
Interleukin-8 OR Methylmalonic Acid OR Sulfhydryl Compounds OR Fibrinolysis OR Copper OR 
Deoxyguanosine OR Phospholipids OR Erythrocyte Count OR Hyperinsulinism OR Hyponatremia OR 
Acetylglucosaminidase OR Anemia, Hypochromic OR Hyperaldosteronism OR Waist Circumference OR 
Intra-Abdominal Fat OR Azotemia OR Connective Tissue Growth Factor OR Interleukin-18 OR Lipid 
Peroxides OR Protein Carbonylation OR Neuropeptide Y OR Nitric Oxide Synthase Type I OR Retinol-
Binding Proteins OR F2-Isoprostanes OR Monoamine Oxidase) - MeSH Heading 
OR 
1f. /deficiency - MeSH Heading 
OR 
 1g. (biomarker* OR "biological marker*" OR disorder* OR deficien* OR deplet* OR associat* OR risk* 
OR "surrogate marker*" OR "metabolic profile*" OR profiling OR abnormal* OR insufficien* OR 
dysfunction* OR impair* OR poor OR hypo* OR degrad* OR dysregulat*OR deteriorat* OR deficit* OR 
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defect* OR disturb*  OR susceptib* OR instability OR (plasma OR serum OR blood OR hemoglobin) 
near/3 (level* OR concentration*) OR link* OR indicat* OR predict*) - Topic 
 
 
(return to TOC) 
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APPENDIX 2 – PERVASIVE CAUSES OF DISEASE CONTRIBUTING FACTOR IDENTIFICATION METHODOLOGY 
1B. Methodology used to Retrieve Causes-Related Articles 
1B1. Identification of Causes of Disease 
The present study focuses on identifying all direct and indirect foundational causes for all 
diseases and symptoms.  It extrapolates, and significantly advances, the techniques used in our recent 
study on causes (and treatments) of a single disease, chronic kidney disease (CKD), in which 
approximately 900 direct and indirect causes of CKD were identified [12].  The goal is to present a quasi-
streamlined methodology for identifying the full spectrum of potential causes, and relating them to the 
full spectrum of diseases and symptoms.  Expanding single-disease queries developed in past studies 
(such as [12]) to all diseases and symptoms is not practical because of the sheer magnitude of query 
terms required.   
Three approaches were used: one highly streamlined, and two far less streamlined.  The highly 
streamlined approach used MeSH Qualifiers only to retrieve the records for analysis.  The first of the less 
streamlined approaches used generic MeSH terms relatively unamibiguously related to causes to 
retrieve the records for analysis, and the second of the less streamlined approaches used text terms 
applied to the Title field to retrieve the records.  The results of all three approaches were integrated in 
the main body of the text; the details of the approaches follow. 
1B1a. MeSH Qualifiers Approach  
1B1a1. MeSH Format Causes 
An offshoot of the MeSH Qualifier concept was used for identifying causes.  There are 83 topical MeSH 
Qualifiers used for indexing and cataloging in conjunction with MeSH Heading descriptors.  All 83 were 
examined in more or less detail for applicability to identifying foundational causes of disease.  Four were 
selected as producing highly relevant results: adverse effects, toxicity, pathogenicity, poisoning.  A few 
limited combinations of the remaining Qualifiers were examined, but none were deemed to have 
sufficient relevance.  These four Qualifiers constituted the query. 
It was decided to use Pubmed as the source search engine for the Medline database rather than 
Thomson Medline, as was used in the CKD study [12].  Much larger retrievals were expected in the 
present study because of the numbers of causes and diseases expected.  In Pubmed, the full retrieval 
can be downloaded at once; in Thompson, only 500 records per download are allowed.  When 
downloading hundreds of thousands of records, download time becomes important.  Also, Pubmed 
introduces records at an earlier stage of processing.  For example, a search of Thomson for 'virus' in the 
Title for 2014 (performed on 19 May 2014) retrieved 3789 records, whereas a search of Pubmed with 
the same query retrieved 4951 records.  For the above reasons, and since the proximity search 
capability of Thomson would not be used for this study, Pubmed was used as the data source. 
This simplified query (consisting of four MeSH Qualifiers) was entered into Pubmed for the time interval 
2004-2014, 592,074 records (all with Abstracts) were retrieved and downloaded on 10 May 2014, and 
were imported into the Vantage Point software.  591,884 unique Abstracts were displayed by the 
software.  There were 595,730 MeSH terms (with Qualifiers) listed.  All MeSH terms that included at 
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least one of the above four Qualifiers were placed in a separate group, containing a total of 116,538 
MeSH terms with Qualifiers.  The software integrated over the MeSH Qualifiers to yield 9,038 MeSH 
Headings (no Qualifiers shown).   These were the foundational causes for all diseases expressed in MeSH 
terminology. 
It was desired to generate a causes-diseases and symptoms matrix.  Therefore, the diseases and 
symptoms needed to be identified and grouped.  A detailed examination of the remaining Qualifiers, 
and observation of Qualifier patterns in the records where causes Qualifiers appeared, showed that the 
following Qualifiers tended to be associated with diseases and symptoms: etiology, chemically induced, 
complications, pathology, diagnosis, immunology, microbiology, parasitology, physiopathology, virology, 
epidemiology, radiation effects, metabolism, drug effects, prevention and control.  All MeSH terms that 
included at least one of the above fifteen Qualifiers were placed in a separate group, containing a total 
of 353,383 MeSH terms with Qualifiers.  The software integrated over the MeSH Qualifiers to yield 
17,142 MeSH Headings (no Qualifiers shown). 
However, this initial list went beyond diseases and symptoms, and required further filtering.  NIH 
generates a Web site entitled MeSH Tree Structures (http://www.nlm.nih.gov/mesh/trees.html) that 
lists all the MeSH Headings in the different branches of the MeSH tree.  The MeSH Headings listed for all 
diseases and symptoms were downloaded and intersected with the above list of 17,142 MeSH Headings.  
A perusal of this filtered list, compared with the unfiltered list, showed a number of items that were not 
listed in the MeSH tree under one of the three categories, but, nevertheless, were impacted by the 
items listed as 'causes'.  For the most part, these additional items could be viewed as processes and 
mechanisms.  Therefore, the first 5,000 items in the list of 17,142 MeSH Headings were inspected 
visually, and all those that could be impacted by the 'causes' were added to the filtered list.  Substantial 
sampling was performed to validate any selections in question.  The resulting list of 5,870 diseases and 
symptoms was inspected visually, and any terms that were not diseases or symptoms (typically 
biomarkers) were removed.  There were 4,147 diseases in the final list. 
It became clear at this point that two different matrices would be preferable for identifying direct 
foundational causes and indirect foundational causes.  For identifying and tabulating direct causes, a 
causes-diseases and symptoms matrix would offer the most credibility.  For identifying indirect causes, a 
causes-diseases and symptoms matrix linked to a diseases and symptoms square matrix would be 
preferable, because causes could then be linked to the disease(s) of interest through other diseases and 
symptoms that were closely related to the disease(s) of interest. 
In the causes-diseases-only matrix, there were 8046 causes (MeSH terminology) and 4147 diseases 
(MeSH Headings No Explode).  Causes that could be viewed as quasi-universal were those that impacted 
more than a threshold number of diseases. 
For identifying indirect foundational causes, two matrices were plotted with this data sharing a common 
axis.  The upper matrix was a square symmetrical matrix of diseases and symptoms (hereafter 
abbreviated as Diseases) on each axis.  The lower matrix was a plot of causes vs Diseases.  The 
intersection of cause i with Disease j was defined as a direct cause of Disease j if the matrix cell 
contained an entry(s), and a possible indirect cause if the matrix cell did not contain an entry. 
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To identify potential indirect causes of Disease j, direct causes of Diseases strongly associated with 
Disease j were identified, and hypothesized to be indirect causes of Disease j.  Thus, for example, if 
Hypertension is shown to be strongly related to CKD, and substance X was a direct cause of 
Hypertension but not a direct cause of CKD, then substance X is hypothesized to be an indirect cause of 
CKD.  The stronger the relationship between the two Diseases, and the more strong pathways that exist 
linking other Diseases (for which substance X is a direct cause) to CKD, the stronger will be the basis for 
the assumption that substance X is a potential indirect cause of CKD, and is in fact a Discovery in the 
Swanson sense of discovery (heretofore applied only to potential treatments). 
What constitutes a strong relationship/association between two Diseases that would form a credible 
basis for hypothesizing potential discovery of indirect causes?  Two metrics were examined.  One metric 
was co-occurrence of two Disease MeSH terms well beyond that expected randomly.  Thus, if there are 
Nt total records in a database, the probability of MeSH term A occuring in any one record would be Na 
(the number of records that contain MeSH term A in the database) divided by Nt, the probability of 
MeSH term B occurring in any one record would be Nb/Nt, the probability of MeSH terms A and B co-
occurring in one record by chance would be Na/Nt*Nb/Nt, and the co-occurrence expected by chance 
would be Na/Nt*Nb/Nt*Nt, or (Na*Nb)/Nt.  Thus, if the actual co-occurrence Cab of two Disease MeSH 
terms A and B is substantially larger than (Na*Nb)/Nt, the linkage between Diseases A and B is assumed 
to be strong.  The higher the ratio of actual co-occurrence to expected co-occurrence, the stronger is the 
assumed relationship. 
The other metric examined was the Inclusion Index based on the smaller of the two frequencies of 
occurrence, defined as Cab/Min(Na,Nb).  Because of behavior at the limits, the latter metric was 
selected.  The Disease-Disease matrix was normalized using the Inclusion Index.  The combination of the 
causes-Diseases matrix and the normalized Diseases-Diseases matrix formed a causes-Diseases network, 
which allowed both direct causes to be identified from the causes-Diseases matrix and indirect causes to 
be identified by tracking potential causes through myriad pathways in the Diseases-Diseases component 
of the network. 
1B1a2. Chemical Registry Number Causes 
Pubmed contains two fields called Registry Number and Substance Name.  Registry Number contains 
identifiers representing the substances mentioned in the article when such identifiers are included in 
the MeSH record for the substance.  Substance Name may contain any of 3 types of supplementary 
concept record (SCR) data: 1) MeSH SCR chemical and drug terms (Class 1); 2) protocol terms (Class 2); 
and 3) non-MeSH rare disease terms (Class 3) from the NIH Office of Rare Diseases. The MeSH Database 
and MeSH Browser contain all of these terms. 
These two fields are combined into one field in the VP software (Chemical Registry Number), and may 
contain causes that are not shown in the Title or MeSH Heading. This field was examined for potential 
causes only in the MeSH Qualifiers-retrieved database.  There were no associated linking terms that 
would allow extraction of causes only, so the CRN terms had to be inspected manually.  These terms 
could be causes, treatments, and biomarkers mainly.  They were read to a cutoff frequency, and 
additional terms were identified at lower frequencies from intersection with lists of toxic materials.  All 
1,394 resulting CRN causes terms were validated by visual inspection. 
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1B1b. Generic MeSH Headings Approach 
Generic MeSH Headings unambiguously related to causes were identified two ways.  Results from past 
studies were examined, especially the CKD study [12], and generic relevant MeSH Headings were 
extracted.  Second, a few of the most unambiguous generic MeSH terms identified from past studies 
were entered into Pubmed as query terms, and all the MeSH terms in the resultant retrieval (i.e., those 
that co-occurred with the entry terms) were examined for relevance.  There were 145 terms judged to 
produce highly relevant results (shown later).  These 145 terms constituted the query.  Pubmed was also 
used as the source search engine for the Medline database, for the reasons presented above.    
This query was entered into Pubmed for the time interval 1994-2014, 693,450 records (most with 
Abstracts) were retrieved and downloaded on 18 October 2014, and were imported into the Vantage 
Point software.  690,486 unique Abstracts were displayed by the software.  There were 516,519 MeSH 
terms (with Qualifiers) listed.  All MeSH terms that included at least one of the four Qualifiers shown in 
the previous MeSH Qualifiers section were placed in a separate group, containing a total of 52,949 
MeSH terms with Qualifiers.  The software integrated over the MeSH Qualifiers to yield 6,543 MeSH 
Headings (no Qualifiers shown).  These 6,543 MeSH Headings, combined with the 9,038 MeSH Heading 
causes from the MeSH Qualifiers study in the previous MeSH Qualifiers section, with the 1,394 Chemical 
Registry Substances extracted in the MeSH Qualifiers study, and with the 13,762 raw text causes 
extracted from the results of the Title text retrieval study of the next section, were intersected with the 
24,231 Top Level MeSH Headings, to yield a total of 8,982 causes.  These were the foundational causes 
for all diseases expressed in MeSH terminology from the relatively unambiguous MeSH Headings 
retrieval. 
1B1c. Title Linking Phrases Approach 
Because of limitations from use of MeSH terms (not all records have MeSH descriptors, not all MeSH 
terms are included in those records that have MeSH, not all MeSH descriptors used have appropriate 
Qualifiers attached. etc), a text-based approach for identifying causes was added.  While the Abstract 
field would have been most informative and appropriate, computer storage and software limitations 
would not allow the parsed Abstract field phrases to be opened.  Therefore, the record Title field was 
selected for analysis.  A query consisting of two components was used to retrieve the records.  The first 
component consisted of terms that, when they appeared in the Title, were associated with causes in the 
Title relatively unambiguously.  These terms were validated a priori.  The second component consisted 
of terms that, when they co-occurred in the Title with disease names, were associated with causes in the 
Title relatively unambiguously.  The full query used to retrieve records is shown later.  This query was 
entered into Pubmed for the time interval 1989-2014, 616,300 records (many with Abstracts) were 
retrieved and downloaded on 28 September 2014, and were imported into the Vantage Point software.  
536,833 unique Abstracts were displayed by the software.  There were 5,452,563 Title phrases listed, 
which consisted of all single-word, double-word, triple-word, and quadruple-word phrases that did not 
start or end with stop-words.  
The causes in the retrieved records were identified three ways.  The parsed Title phrases were examined 
visually until a threshold frequency, and causes terms were extracted and validated.  Given the 
extremely large number of Title phrases, only a very small fraction could be examined visually.  For 
lower frequency phrases, the strongest linking terms were used to extract potential causes phrases (e.g., 
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-induced, -related, -associated, -exposed, caused by, induced by, exposure to, exposed to, etc).  The 
extracted terms were stripped of the linking phrases, combined to avoid duplication, and added to the 
causes identified visually in the first part.  Finally, causes from all other sources, including from past 
studies, government-approved lists of toxic substances, MeSH-derived causes, and CRN-derived causes, 
were intersected with the full list of Title phrases, and added to the causes identified in the first two 
parts. 
There were 13,762 validated causes that resulted from from the above extraction techniques.  However, 
many were similar concepts, and could be combined.  After a three-step combination approach, 6,480 
causes resulted.  Some were generic, but most were specific.  
 
1C. Queries used to Retrieve Causes-Related Articles 
1C1. MeSH Qualifier Query 
MeSH Headings have a number of Qualifiers associated with them to allow focus on items of interest.  
Thus, the MeSH term Cadmium/toxicity allows records to be retrieved related to the toxicity of 
Cadmium.  These Qualifiers may be perceived as linking terms to the MeSH Headings, allowing for 
'surgical' extraction of MeSH Headings that meed desired criteria.  Thus, if Qualifiers strongly related to 
causes can be identified, they can be used to identify MeSH Headings that are potential causes of 
disease.  As shown previously, the four MeSH Qualifiers listed below were selected as the query. 
Query 
adverse effects [sh] OR toxicity [sh] OR pathogenicity [sh] OR poisoning [sh] 
 
1C2. Title Text Term Query 
Because many Medline records do not contain MeSH terms, and because MeSH term assignment may 
not always be complete, it was decided to augment the MeSH queries with a text query.  This query 
consists of two parts: standalone terms, and terms that are intersected with diseases.  Most were 
derived by examining Titles of records that addressed causes of disease, and selecting those terms that 
tended to appear frequently with the causes.  The diseases used for the second group of terms were 
obtained by starting with Pubmed's list of all diseases (in MeSH terminology), converting them to text 
form, consolidating diseases to more generic descriptors, and adding some generic terms not in MeSH 
(such as cancer*). 
 
1C2a. Standalone Terms  
([ti] is the Pubmed tag for Title field) 
cardiotoxic* [ti] OR genotoxic* [ti] OR hepatotoxic* [ti] OR immunotoxic* [ti] OR intoxicat* [ti] OR 
nephrotoxic* [ti] OR neurotoxic* [ti] OR ototoxic* [ti] OR phototoxic* [ti] OR phytotoxic* [ti] OR toxic-
effect* [ti] OR toxic-potential* [ti] OR toxic-hazard* [ti] OR toxic-combin* [ti] OR toxicities [ti] OR toxicity 
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[ti] OR toxicological-effect* [ti] OR toxicological-evaluation* [ti] OR toxicological-impact* [ti] OR 
toxicological-hazard* [ti] OR toxicological-assessment* [ti] OR toxin-associated [ti] OR toxin-related [ti] 
OR toxin-injur* [ti] OR toxin-risk* [ti] OR lethal-toxin* [ti] OR (toxin* [ti] AND (fatal* [ti] OR adverse [ti] 
OR morbid* [ti] OR mortality [ti] or anaphyla* [ti] OR harm [ti] OR damag* [ti] OR deteriorat* [ti] OR 
exacerbat* [ti] OR trigger* [ti] OR aggravat* [ti])) OR injury-associated [ti] OR risk-associated [ti] OR 
virus-associated [ti] OR (Ionizing [ti] AND risk* [ti]) OR (risk-of [ti] AND adverse [ti]) OR (adverse-health-
effect* [ti] AND (effects-of [ti] OR effect-of [ti])) OR adverse-effect* [ti] OR injury-following [ti] OR 
related-consequences [ti] OR therapy-related [ti] OR traffic-related [ti] OR health-consequences [ti] OR 
long-term consequences [ti] OR anaphylactic-reaction* [ti] OR cutaneous-reaction* [ti] OR 
hypersensitivity-reaction* [ti] OR transfusion-reaction* [ti] OR skin-reaction* [ti] OR inflammation-
reaction* [ti] OR inflammatory-reaction* [ti] OR reaction-associated [ti] OR foreign-body-reaction* [ti] 
OR tissue-reaction* [ti] OR infusion-reaction* [ti] OR systemic-reaction* [ti] OR (allergic [ti] AND 
reaction-to [ti]) OR teratogenicity [ti] OR teratogenic-effect* [ti] OR advanced-glycation [ti] OR 
allergenicity [ti] OR bioaccumulation [ti] OR carcinogen [ti] OR Carcinogenic [ti] OR carcinogenicity [ti] 
OR contaminat* [ti] OR disrupting-chemical* [ti] OR ((effects [ti] OR effect [ti]) AND subchronic [ti]) OR 
((effects-of [ti] OR effect-of [ti]) AND prenatal [ti]) OR envenomation [ti] OR fatalities [ti] OR high-fat [ti] 
OR mutagenicity [ti] OR poisons [ti] OR poisoning [ti] OR precipitated-by [ti] OR precipitated-after [ti] OR 
precipitated-following [ti] OR side-effect* [ti] OR teratogenesis [ti] OR deleterious-effect* [ti] OR 
detrimental-effect* [ti] OR late-effect* [ti] OR adverse-metabolic-effect* [ti] OR adverse-renal-effect* 
[ti] OR respiratory-effect* [ti] OR negative-effect* [ti] OR adverse-reaction* [ti] OR (adversity [ti] AND 
(early [ti] OR child* [ti] OR life* [ti] OR social [ti] OR family [ti])) OR causative-agent [ti] OR caused-by [ti] 
OR exposure-to [ti] OR exposed-to [ti] OR exposures [ti] OR (damage-in [ti] AND mice [ti]) OR (damage-in 
[ti] AND rats [ti]) OR hepatic-damage [ti] OR liver-damage [ti] OR ((increased-risk* [ti] OR complications 
[ti] OR mutagenic [ti] OR adverse-outcome* [ti] OR life-threatening [ti] OR lung-injury [ti] OR renal-injury 
[ti] OR susceptibility [ti] OR adverse [ti] OR allergic-reaction* [ti] OR anaphyla* [ti] OR cognitive-
dysfunction [ti] OR cardiac-dysfunction [ti] OR (dysfunction [ti] AND in-rats [ti]) OR erectile-dysfunction 
[ti] OR renal-dysfunction [ti] OR mitochondrial-dysfunction [ti] OR endothelial-dysfunction [ti] OR sexual-
dysfunction [ti] OR ventricular-dysfunction [ti] OR allograft-dysfunction [ti] OR thyroid-dysfunction [ti] 
OR graft-dysfunction [ti] OR liver-dysfunction [ti] OR diastolic-dysfunction [ti] OR vascular-dysfunction 
[ti] OR organ-dysfunction [ti] OR barrier-dysfunction [ti] OR myocardial-dysfunction [ti] OR systolic-
dysfunction [ti] OR voiding-dysfunction [ti] OR hepatic-dysfunction [ti] OR bladder-dysfunction [ti] OR 
bowel-dysfunction [ti] OR urinary-dysfunction [ti] OR swallowing-dysfunction [ti] OR anorectal-
dysfunction [ti] OR cardiopulmonary-dysfunction [ti] OR fatal [ti] OR fibrosis [ti] OR high-incidence [ti] 
OR iatrogenic [ti] OR mortality [ti] OR morbidity [ti] OR risk* [ti]) AND (after [ti] OR following [ti] OR 
related-to [ti] OR resulting-from [ti] OR due-to [ti])) 
 
1C2b.  Intersect with Diseases 
(Expos* [ti] OR induce [ti] OR induced [ti] OR induces [ti] OR incarceration [ti] OR occupation* [ti] OR 
pathogen* [ti] OR pollut* [ti] OR poverty [ti] OR socioeconomic [ti] OR worker*) AND (Abdominal-
Pregnancy [ti] OR Aberrant-Crypt-Foci [ti] OR Abnormal-Karyotype [ti] OR Abnormal-Reflex [ti] OR 
Abnormalities [ti] OR Abnormality [ti] OR Abortion [ti] OR Abruptio-Placentae [ti] OR Abscess* [ti] OR 
Acalculous-Cholecystitis [ti] OR Acanthamoeba-Keratitis [ti] OR Acantholysis [ti] OR Acanthosis-Nigricans 
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[ti] OR Acatalasia [ti] OR Accelerated-Idioventricular-Rhythm [ti] OR Accessory-Atrioventricular-Bundle 
[ti] OR Achlorhydria [ti] OR Achondroplasia [ti] OR Acid-Base-Imbalance* [ti] OR Acidosis [ti] OR Acne-
Keloid [ti] OR Acne-Vulgaris [ti] OR Acrocephalosyndactylia [ti] OR Acrodermatitis [ti] OR Acrodynia [ti] 
OR Acromegaly [ti] OR Acro-Osteolysis [ti] OR Acrospiroma [ti] OR Actinomycosis [ti] OR Activated-
Protein-C-Resistance [ti] OR Acute-Abdomen [ti] OR Acute-Generalized-Exanthematous-Pustulosis [ti] 
OR Acute-Kidney-Injury [ti] OR Acute-Lung-Injury [ti] OR Acute-Phase-Reaction [ti] OR Adenocarcinoma* 
[ti] OR Adenofibroma [ti] OR Adenolymphoma [ti] OR Adenoma* [ti] OR Adenomyoma [ti] OR 
Adenomyosis [ti] OR Adenosarcoma [ti] OR Adiposis-Dolorosa [ti] OR Adrenal-Insufficiency [ti] OR 
Adrenocortical-Hyperfunction [ti] OR Adrenoleukodystrophy [ti] OR Aerophagy [ti] OR Afibrinogenemia 
[ti] OR African-Horse-Sickness [ti] OR Agammaglobulinemia [ti] OR Agenesis-of-Corpus-Callosum [ti] OR 
Ageusia [ti] OR Aggressive-Periodontitis [ti] OR Agnosia [ti] OR Agranulocytosis [ti] OR Agraphia [ti] OR 
AIDS-Arteritis [ti] OR AIDS-Dementia-Complex [ti] OR AIDS-Related-Complex [ti] OR Airway-Obstruction* 
[ti] OR Airway-Remodeling [ti] OR Akathisia [ti] OR Akinetic-Mutism [ti] OR Albinism [ti] OR Albuminuria 
[ti] OR Alcohol-Withdrawal-Delirium [ti] OR Alcohol-Withdrawal-Seizures [ti] OR Alcoholism [ti] OR 
Alexia [ti] OR Alkalosis [ti] OR Alkaptonuria [ti] OR Alopecia [ti] OR alpha-1-Antitrypsin-Deficiency [ti] OR 
alpha-Mannosidosis [ti] OR alpha-Thalassemia [ti] OR Alternariosis [ti] OR Altitude-Sickness [ti] OR 
Alveolar-Bone-Loss [ti] OR Alveolitis [ti] OR Amaurosis-Fugax [ti] OR Amblyopia [ti] OR Amebiasis [ti] OR 
Ameloblastoma [ti] OR Amelogenesis-Imperfecta [ti] OR Amenorrhea [ti] OR Amino-Acid-Metabolism [ti] 
OR Amnesia [ti] OR amyloid-Plaque [ti] OR Amyloidosis [ti] OR Anaemia [ti] OR Anaphylaxis [ti] OR 
Anaplasia [ti] OR Anaplasmosis [ti] OR Anastomotic-Leak [ti] OR Ancylostomiasis [ti] OR Anemia [ti] OR 
Anencephaly [ti] OR Anetoderma [ti] OR Aneurysm [ti] OR Angina [ti] OR Angiodysplasia [ti] OR 
Angioedema* [ti] OR Angiofibroma [ti] OR Angioid-Streaks [ti] OR Angiokeratoma [ti] OR Angiolipoma 
[ti] OR Angiomatosis [ti] OR Angiomyolipoma [ti] OR Anhedonia [ti] OR Aniridia [ti] OR Anisakiasis [ti] OR 
Aniseikonia [ti] OR Anisocoria [ti] OR Anisometropia [ti] OR Ankylosis [ti] OR Anodontia [ti] OR Anomia 
[ti] OR Anophthalmos [ti] OR Anorexia [ti] OR Anovulation [ti] OR Anoxia [ti] OR Anthracosilicosis [ti] OR 
Anthracosis [ti] OR Anthrax [ti] OR Antithrombin-III-Deficiency [ti] OR Anuria [ti] OR Aortic-Coarctation 
[ti] OR Aortic-Valve-Insufficiency [ti] OR Aortic-Valve-Prolapse [ti] OR Aortitis [ti] OR Aphakia [ti] OR 
Aphasia [ti] OR Aphonia [ti] OR Aplasia [ti] OR Apnea [ti] OR Apoptosis [ti] OR Appendicitis [ti] OR 
Apraxia [ti] OR Apraxias [ti] OR Arachnoid-Cyst* [ti] OR Arachnoiditis [ti] OR Arcus-Senilis [ti] OR 
Argininosuccinic-Aciduria [ti] OR Argyria [ti] OR Arnold-Chiari-Malformation [ti] OR Arrhythmia* [ti] OR 
Arterial-Stiffness [ti] OR Arterio-Arterial-Fistula [ti] OR Arteriolosclerosis [ti] OR Arteriosclerosis [ti] OR 
Arteriovenous-Fistula [ti] OR Arteriovenous-Malformations [ti] OR Arteritis [ti] OR Arthralgia [ti] OR 
Arthritis [ti] OR Arthrogryposis [ti] OR Arthropathy [ti] OR Arthus-Reaction [ti] OR Artificial-Lens-Implant-
Migration [ti] OR Asbestosis [ti] OR Ascariasis [ti] OR Ascaridiasis [ti] OR Ascites [ti] OR Ascorbic-Acid-
Deficiency [ti] OR Aspergillosis [ti] OR Asphyxia [ti] OR Asthenia [ti] OR Asthenopia [ti] OR 
Asthenozoospermia [ti] OR Asthma [ti] OR Astigmatism [ti] OR Astrocytoma [ti] OR Ataxia [ti] OR 
Atherosclerosis [ti] OR atherosclerotic-plaque [ti] OR Athetosis [ti] OR Atrial-Fibrillation [ti] OR Atrial-
Flutter [ti] OR Atrial-Premature-Complexes [ti] OR Atrial-Remodeling [ti] OR Atrioventricular-Block [ti] 
OR Atrophic-Vaginitis [ti] OR Atrophy [ti] OR Autolysis [ti] OR Autonomic-Dysreflexia [ti] OR Avian-
Leukosis [ti] OR Avitaminosis [ti] OR Azoospermia [ti] OR Azotemia [ti] OR Babesiosis [ti] OR babinski-
Reflex [ti] OR Bacteremia [ti] OR Bacteriuria [ti] OR Balanitis [ti] OR Balanitis-Xerotica-Obliterans [ti] OR 
Balantidiasis [ti] OR Barrett-Esophagus [ti] OR Bell-Palsy [ti] OR Bell's-Palsy [ti] OR Beriberi [ti] OR 
Berylliosis [ti] OR beta-Thalassemia [ti] OR Bile-Reflux [ti] OR Biliary-Atresia [ti] OR Biliary-Dyskinesia [ti] 
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OR Biliary-Fistula [ti] OR Binge-Drinking [ti] OR Biotinidase-Deficiency [ti] OR Bird-Fancier's-Lung [ti] OR 
Birth-Injuries [ti] OR Birth-Weight [ti] OR Bladder-Exstrophy [ti] OR Blast-Crisis [ti] OR Blastomycosis [ti] 
OR Blepharitis [ti] OR Blepharoptosis [ti] OR Blepharospasm [ti] OR Blindness [ti] OR Blister* [ti] OR 
Blood-Group-Incompatibility [ti] OR Blood-Loss [ti] OR Bluetongue [ti] OR Body-Weight [ti] OR Bone-
Anteversion [ti] OR Bone-Cysts [ti] OR Bone-Demineralization [ti] OR Bone-Malalignment [ti] OR Bone-
Resorption [ti] OR Bone-Retroversion [ti] OR Botulism [ti] OR Brachial-Plexus-Neuritis [ti] OR 
Brachydactyly [ti] OR Bradycardia [ti] OR Brain-Concussion [ti] OR Brain-Damage [ti] OR Brain-Death [ti] 
OR Brain-Injur* [ti] OR Brain-Ischemia [ti] OR Branchioma [ti] OR Breast-Cyst* [ti] OR Breech-
Presentation [ti] OR Brenner-Tumor* [ti] OR Bronchial-Fistula [ti] OR Bronchial-Hyperreactivity [ti] OR 
Bronchial-Spasm [ti] OR Bronchiectasis [ti] OR Bronchiolitis [ti] OR Bronchitis [ti] OR Bronchogenic-Cyst* 
[ti] OR Bronchomalacia [ti] OR Bronchopneumonia [ti] OR Bronchopulmonary-Sequestration [ti] OR 
Brucellosis [ti] OR Bruxism [ti] OR Bulbar-Palsy [ti] OR Bulbo-Spinal-Atrophy [ti] OR Bulimia [ti] OR 
Bundle-Branch-Block [ti] OR Burkitt-Lymphoma [ti] OR Bursitis [ti] OR Buschke-Lowenstein-Tumor* [ti] 
OR Byssinosis [ti] OR Cachexia [ti] OR CADASIL [ti] OR Cafe-au-Lait-Spots [ti] OR Calcification [ti] OR 
Calcinosis [ti] OR Calciphylaxis [ti] OR Calculi [ti] OR Callosities [ti] OR Cancer* [ti] OR Candidemia [ti] OR 
Candidiasis [ti] OR Capsule-Opacification [ti] OR Carbohydrate-Metabolism [ti] OR Carbonyl-Stress [ti] OR 
Carboxymethyllysine [ti] OR Carcinogenesis [ti] OR Carcinoid-Tumor* [ti] OR Carcinoma* [ti] OR 
Carcinosarcoma* [ti] OR Cardiac-Arrest [ti] OR Cardiac-Complexes [ti] OR Cardiac-Output [ti] OR Cardiac-
Tamponade [ti] OR Cardiogenic-Shock [ti] OR Cardiomegaly [ti] OR Cardiomyopath* [ti] OR 
cardiovascular-health [ti] OR cardiovascular-outcome* [ti] OR cardiovascular-risk [ti] OR Carney-Complex 
[ti] OR Carotid-Artery-Dissection [ti] OR Carotid-Artery-Injuries [ti] OR Carotid-Body-Tumor* [ti] OR 
Carotid-Cavernous-Sinus-Fistula [ti] OR Catalepsy [ti] OR Cataplexy [ti] OR Cataract* [ti] OR Catatonia [ti] 
OR Causalgia [ti] OR Cellulitis [ti] OR Central-Nervous-System-Cyst* [ti] OR Central-Nervous-System-
Helminthiasis [ti] OR Central-Nervous-System-Vascular-Malformation* [ti] OR Central-Serous-
Chorioretinopathy [ti] OR Cephalopelvic-Disproportion [ti] OR Cerebellar-Ataxia [ti] OR Cerebral-
Amyloid-Angiopathy [ti] OR Cerebral-Palsy [ti] OR Cerebral-Phaeohyphomycosis [ti] OR Cerebral-
Ventriculitis [ti] OR Cerebrospinal-Fluid-Otorrhea [ti] OR Cerebrospinal-Fluid-Rhinorrhea [ti] OR 
Cerebrovascular-Trauma [ti] OR Cervical-Intraepithelial-Neoplasia [ti] OR Chagas-Cardiomyopathy [ti] OR 
Chalazion [ti] OR Chancre [ti] OR Chancroid [ti] OR Channelopathies [ti] OR Cheilitis [ti] OR Cheyne-
Stokes-Respiration [ti] OR Chickenpox [ti] OR Chills [ti] OR Chloracne [ti] OR Choanal-Atresia [ti] OR 
Cholangiocarcinoma [ti] OR Cholangitis [ti] OR Cholecystitis [ti] OR Cholecystolithiasis [ti] OR 
Choledochal-Cyst* [ti] OR Choledocholithiasis [ti] OR Cholelithiasis [ti] OR Cholera [ti] OR Cholestasis [ti] 
OR Cholesteatoma [ti] OR Choline-Deficiency [ti] OR Chondroblastoma [ti] OR Chondrocalcinosis [ti] OR 
Chondrodysplasia-Punctata [ti] OR Chondroma [ti] OR Chondromalacia-Patellae [ti] OR Chondrosarcoma 
[ti] OR Chordoma [ti] OR Chorea [ti] OR Chorioamnionitis [ti] OR Choriocarcinoma [ti] OR Chorioretinitis 
[ti] OR Choristoma [ti] OR Choroidal-Neovascularization [ti] OR Choroiditis [ti] OR Chromoblastomycosis 
[ti] OR Chromosomal-Instability [ti] OR Chromosome-Aberration* [ti] OR Chromosome-Breakage [ti] OR 
Chromosome-Fragility [ti] OR Chromosome-Inversion [ti] OR Chylothorax [ti] OR Chylous-Ascites [ti] OR 
Cicatrix [ti] OR Citrullinemia [ti] OR Cleft-Lip [ti] OR Cleft-Palate [ti] OR Clonorchiasis [ti] OR Clubfoot [ti] 
OR Cluster-Headache* [ti] OR Coccidioidomycosis [ti] OR Coccidiosis [ti] OR Colic [ti] OR Colitis [ti] OR 
Collagenous-Sprue [ti] OR Colloid-Cysts [ti] OR Coloboma [ti] OR Colonic-Polyps [ti] OR Colonic-Pseudo-
Obstruction [ti] OR Color-Vision-Defects [ti] OR Coma [ti] OR Common-Cold [ti] OR Common-Variable-
Immunodeficiency [ti] OR Commotio-Cordis [ti] OR Complication* [ti] OR Condylomata-Acuminata [ti] 
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OR Confusion [ti] OR Congenital-Hyperinsulinism [ti] OR Congenital-Hypothyroidism [ti] OR Conjoined-
Twins [ti] OR Conjunctivitis [ti] OR Constipation [ti] OR Constriction [ti] OR Contracture [ti] OR 
Coproporphyria [ti] OR Cor-Triatriatum [ti] OR Corneal-Dystrophies [ti] OR Corneal-Endothelial-Cell-Loss 
[ti] OR Corneal-Neovascularization [ti] OR Corneal-Opacity [ti] OR Corneal-Perforation [ti] OR Corneal-
Wavefront-Aberration [ti] OR Coronary-Aneurysm* [ti] OR Coronary-Occlusion [ti] OR Coronary-
Vasospasm* [ti] OR Coronary-Vessel-Anomalies [ti] OR Cough [ti] OR Cowpox [ti] OR Coxa-Valga [ti] OR 
Coxa-Vara [ti] OR Craniocerebral-Trauma [ti] OR Craniofacial-Dysostosis [ti] OR Craniopharyngioma [ti] 
OR Craniosynostoses [ti] OR Croup [ti] OR Cryoglobulinemia [ti] OR Cryptococcosis [ti] OR Cryptogenic-
Organizing-Pneumonia [ti] OR Cryptorchidism [ti] OR Cryptosporidiosis [ti] OR Cutaneous-Fistula [ti] OR 
Cutis-Laxa [ti] OR Cyanosis [ti] OR Cyclosporiasis [ti] OR Cystadenocarcinoma [ti] OR Cystadenoma [ti] OR 
Cystic-Fibrosis [ti] OR Cysticercosis [ti] OR Cystinosis [ti] OR Cystinuria [ti] OR Cystitis [ti] OR Cystocele [ti] 
OR Cysts [ti] OR Cytochrome-c-Oxidase-Deficiency [ti] OR Cytomegalovirus-Retinitis [ti] OR Dacryocystitis 
[ti] OR Dandruff [ti] OR Deafness [ti] OR Decalcification [ti] OR Decerebrate-State [ti] OR Dehydration [ti] 
OR Delayed-Emergence-from-Anesthesia [ti] OR Delayed-Graft-Function [ti] OR Delayed-Puberty [ti] OR 
Delirium [ti] OR Delta-Thalassemia [ti] OR Dementia [ti] OR Dendritic-Cell-Sarcoma [ti] OR Dengue [ti] OR 
Dental-Calculus [ti] OR Dental-Caries [ti] OR Dental-Deposits [ti] OR Dental-Enamel-Hypoplasia [ti] OR 
Dental-Fissures [ti] OR Dental-Fistula [ti] OR Dental-Leakage [ti] OR Dental-Occlusion [ti] OR Dental-
Plaque [ti] OR Dental-Pulp-Calcification [ti] OR Dental-Pulp-Exposure [ti] OR Dental-Pulp-Necrosis [ti] OR 
Dentigerous-Cyst [ti] OR Dentin-Sensitivity [ti] OR Dentinogenesis-Imperfecta [ti] OR Dentofacial-
Deformities [ti] OR Depression [ti] OR Dermatitis [ti] OR Dermatofibrosarcoma [ti] OR Dermatomycoses 
[ti] OR Dermatomyositis [ti] OR Dermoid-Cyst [ti] OR Desmoplastic-Small-Round-Cell-Tumor* [ti] OR 
Dextrocardia [ti] OR Diabetes [ti] OR Diabetic [ti] OR Diaper-Rash [ti] OR Diaphragmatic-Eventration [ti] 
OR Diarrhea [ti] OR Diastema [ti] OR Dicrocoeliasis [ti] OR Dientamoebiasis [ti] OR Diffuse-Axonal-Injury 
[ti] OR Digestive-System-Fistula [ti] OR Dihydropyrimidine-Dehydrogenase-Deficiency [ti] OR Dilatation 
[ti] OR Diphtheria [ti] OR Diphyllobothriasis [ti] OR Diplopia [ti] OR Dirofilariasis [ti] OR Discitis [ti] OR 
Disease* [ti] OR  [ti] OR Disorder* [ti] OR Disseminated-Intravascular-Coagulation [ti] OR Distemper [ti] 
OR Diurnal-Enuresis [ti] OR Diverticulitis [ti] OR Diverticulosis [ti] OR Diverticulum [ti] OR Dizziness [ti] OR 
Double-Outlet-Right-Ventricle [ti] OR Dracunculiasis [ti] OR Drowning [ti] OR Drug-Hypersensitivity [ti] 
OR Drug-Overdose [ti] OR Drug-Induced-Liver-Injury [ti] OR Dry-Socket [ti] OR Ductus-Arteriosus [ti] OR 
Duodenal-Obstruction* [ti] OR Duodenitis [ti] OR Duodenogastric-Reflux [ti] OR Dupuytren-Contracture 
[ti] OR Dwarfism [ti] OR Dysarthria [ti] OR Dysautonomia [ti] OR Dysbiosis [ti] OR Dyscalculia [ti] OR 
Dysentery [ti] OR Dysfunction* [ti] OR Dysgammaglobulinemia [ti] OR Dysgerminoma [ti] OR Dysgeusia 
[ti] OR Dyskeratosis-Congenita [ti] OR Dyskinesia* [ti] OR Dyslexia [ti] OR Dyslipid* [ti] OR Dysmenorrhea 
[ti] OR Dysostoses [ti] OR Dyspareunia [ti] OR Dyspepsia [ti] OR Dysphonia [ti] OR Dysplasia [ti] OR 
Dyspnea [ti] OR Dyssomnias [ti] OR Dystocia [ti] OR Dystonia [ti] OR Dysuria [ti] OR Ear-Deformities [ti] 
OR Earache [ti] OR Ebstein-Anomaly [ti] OR Ecchymosis [ti] OR Eccrine-Porocarcinoma [ti] OR 
Echinococcosis [ti] OR Echinostomiasis [ti] OR Eclampsia [ti] OR Ecthyma [ti] OR Ectoparasitic-
Infestations [ti] OR Ectopia-Cordis [ti] OR Ectopia-Lentis [ti] OR ectopic-Pregnancy [ti] OR Ectromelia [ti] 
OR Ectropion [ti] OR Eczema [ti] OR Edema* [ti] OR edentulous-Mouth [ti] OR Egg-Hypersensitivity [ti] 
OR Ehrlichiosis [ti] OR Eisenmenger-Complex [ti] OR Elephantiasis [ti] OR Elliptocytosis [ti] OR Emaciation 
[ti] OR Embolism* [ti] OR Embryo-Loss [ti] OR Emergencies [ti] OR Emphysema [ti] OR Emphysematous-
Cholecystitis [ti] OR Empyema [ti] OR Encephalitis [ti] OR Encephalitozoonosis [ti] OR Encephalocele [ti] 
OR Encephalomalacia [ti] OR Encephalomyelitis [ti] OR Encephalopathy [ti] OR Enchondromatosis [ti] OR 
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Endarteritis [ti] OR Endocardial-Cushion-Defects [ti] OR Endocardial-Fibroelastosis [ti] OR Endocarditis 
[ti] OR Endodermal-Sinus-Tumor* [ti] OR Endoleak [ti] OR Endolymphatic-Hydrops [ti] OR Endometrial-
Stromal-Tumors* [ti] OR Endometriosis [ti] OR Endometritis [ti] OR Endophthalmitis [ti] OR Endotoxemia 
[ti] OR Enophthalmos [ti] OR Entamoebiasis [ti] OR Enteritis [ti] OR Enterobiasis [ti] OR Enterocolitis [ti] 
OR Enterotoxemia [ti] OR Entropion [ti] OR Enuresis [ti] OR Enzootic-Bovine-Leukosis [ti] OR Eosinophilia 
[ti] OR Eosinophilic-Granuloma [ti] OR Ependymoma [ti] OR Epidermal-Cyst* [ti] OR Epidermodysplasia-
Verruciformis [ti] OR Epidermolysis-Bullosa [ti] OR Epididymitis [ti] OR Epiglottitis [ti] OR Epilepsia-
Partialis-Continua [ti] OR Epilepsies [ti] OR Epilepsy [ti] OR Epiphyses [ti] OR Epiretinal-Membrane [ti] OR 
Epispadias [ti] OR Epistaxis [ti] OR Equinus-Deformity [ti] OR Erectile-Dysfunction [ti] OR Ergotism [ti] OR 
Eructation [ti] OR Eruption* [ti] OR Erysipelas [ti] OR Erysipeloid [ti] OR Erythema* [ti] OR 
Erythroblastosis [ti] OR Erythrokeratodermia-Variabilis [ti] OR Erythromelalgia [ti] OR Erythroplasia [ti] 
OR Esophageal-Achalasia [ti] OR Esophageal-and-Gastric-Varices [ti] OR Esophageal-Atresia [ti] OR 
Esophageal-Cyst* [ti] OR Esophageal-Fistula [ti] OR Esophageal-Perforation* [ti] OR Esophageal-Spasm* 
[ti] OR Esophagitis [ti] OR Esotropia [ti] OR Essential-Tremor* [ti] OR Esthesioneuroblastoma [ti] OR 
Ethmoid-Sinusitis [ti] OR Exanthema [ti] OR Exocrine-Pancreatic-Insufficiency [ti] OR Exophthalmos [ti] 
OR Exostoses [ti] OR Exotropia [ti] OR Exsanguination [ti] OR Eye-Injuries [ti] OR Facial-Asymmetry [ti] 
OR Facial-Dermatoses [ti] OR Facial-Hemiatrophy [ti] OR Facial-Neuralgia [ti] OR Facial-Paralysis [ti] OR 
Factor-V-Deficiency [ti] OR Factor-VII-Deficiency [ti] OR Factor-X-Deficiency [ti] OR Factor-XI-Deficiency 
[ti] OR Factor-XII-Deficiency [ti] OR Factor-XIII-Deficiency [ti] OR Failure-to-Thrive [ti] OR Familial-
Hypophosphatemic-Rickets [ti] OR Fanconi-Anemia [ti] OR Farmer's-Lung [ti] OR Fasciculation [ti] OR 
Fasciitis [ti] OR Fascioliasis [ti] OR Fascioloidiasis [ti] OR Fatigue [ti] OR Fatty-Liver [ti] OR Favism [ti] OR 
Febrile-Neutropenia [ti] OR Fecal-Impaction [ti] OR Fecal-Incontinence [ti] OR Feline-Panleukopenia [ti] 
OR Feminization [ti] OR Femoracetabular-Impingement [ti] OR Fetal-Death* [ti] OR Fetal-Distress [ti] OR 
Fetal-Growth-Retardation [ti] OR Fetal-Hypoxia [ti] OR Fetal-Macrosomia [ti] OR Fetal-Membranes [ti] 
OR Fetal-Resorption [ti] OR Fetal-Weight [ti] OR Fetofetal-Transfusion [ti] OR Fetomaternal-Transfusion 
[ti] OR Fever [ti] OR Fibroadenoma* [ti] OR Fibroma* [ti] OR Fibromatosis [ti] OR Fibromyalgia [ti] OR 
Fibrosarcoma [ti] OR Fibrosis [ti] OR Fibrous-Tumor* [ti] OR Filariasis [ti] OR Fissure-in-Ano [ti] OR 
Fissured-Tongue [ti] OR Fistula [ti] OR Flatfoot [ti] OR Flatulence [ti] OR Flea-Infestation* [ti] OR 
Fluorosis [ti] OR Flushing [ti] OR Focal-Dermal-Hypoplasia [ti] OR Folic-Acid-Deficiency [ti] OR Follicular-
Cyst* [ti] OR Folliculitis [ti] OR Food-Hypersensitivity [ti] OR Foot-Deformities [ti] OR Foot-Dermatoses 
[ti] OR Foramen-Ovale [ti] OR Foreign-Body-Reaction* [ti] OR Fournier-Gangrene [ti] OR Fowlpox [ti] OR 
Freemartinism [ti] OR Friedreich-Ataxia [ti] OR Frontal-Sinusitis [ti] OR Frontotemporal-Dementia [ti] OR 
Frontotemporal-Lobar-Degeneration [ti] OR Fructose-Intolerance [ti] OR Fructose-1,6-Diphosphatase-
Deficiency [ti] OR Fuchs'-Endothelial-Dystrophy [ti] OR Fucosidosis [ti] OR Fungemia [ti] OR Funnel-Chest 
[ti] OR Furcation-Defects [ti] OR Furunculosis [ti] OR Fusariosis) 
 
(Expos* [ti] OR induce [ti] OR induced [ti] OR induces [ti] OR incarceration [ti] OR occupation* [ti] OR 
pathogen* [ti] OR pollut* [ti] OR poverty [ti] OR socioeconomic [ti] OR worker*) AND (Gagging [ti] OR 
Gait-Apraxia [ti] OR Gait-Ataxia [ti] OR Galactorrhea [ti] OR Galactosemia* [ti] OR Gallstone* [ti] OR 
Ganglioglioma [ti] OR Ganglion-Cyst* [ti] OR Ganglioneuroblastoma [ti] OR Ganglioneuroma* [ti] OR 
Gangliosidosis [ti] OR Gangrene [ti] OR Gastric-Antral-Vascular-Ectasia [ti] OR Gastric-Dilatation [ti] OR 
Gastric-Fistula [ti] OR Gastric-Outlet-Obstruction* [ti] OR Gastrinoma [ti] OR Gastritis [ti] OR 
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Gastroenteritis [ti] OR Gastroesophageal-Reflux [ti] OR Gastrointestinal-Stromal-Tumor* [ti] OR 
Gastroparesis [ti] OR Gastroschisis [ti] OR Genomic-Instability [ti] OR Genu-Valgum [ti] OR Genu-Varum 
[ti] OR Geographic-Atrophy [ti] OR Geotrichosis [ti] OR Germinoma [ti] OR Giant-Cell-Arteritis [ti] OR 
Giant-Cell-Tumor-of-Bone [ti] OR Giant-Cell-Tumor* [ti] OR Giardiasis [ti] OR Gigantism [ti] OR Gingival-
Hypertrophy [ti] OR Gingival-Overgrowth [ti] OR Gingival-Pocket* [ti] OR Gingival-Recession [ti] OR 
Gingivitis [ti] OR Glanders [ti] OR Glaucoma [ti] OR Glioblastoma [ti] OR Glioma [ti] OR Gliosarcoma [ti] 
OR Gliosis [ti] OR Glomerulonephritis [ti] OR Glomerulosclerosis [ti] OR Glomus-Jugulare-Tumor* [ti] OR 
Glomus-Tumor* [ti] OR Glomus-Tympanicum-Tumor* [ti] OR Glossalgia [ti] OR Glossitis [ti] OR 
Glucagonoma [ti] OR Glucose-Intolerance [ti] OR Glucosephosphate-Dehydrogenase-Deficiency [ti] OR 
Glycat* [ti] OR Glycemia [ti] OR Glycosuria [ti] OR Glycosylat* [ti] OR Glycoxidation [ti] OR 
Gnathostomiasis [ti] OR Goiter [ti] OR Gonadal-Dysgenesis [ti] OR Gonorrhea [ti] OR Gout [ti] OR Graft-
Occlusion* [ti] OR Granular-Cell-Tumor* [ti] OR Granuloma* [ti] OR Granulomatosis [ti] OR 
Granulomatous-Mastitis [ti] OR Granulosa-Cell-Tumor* [ti] OR Graves-Ophthalmopathy [ti] OR 
Gynatresia [ti] OR Gynecomastia [ti] OR Gyrate-Atrophy [ti] OR Haematuria [ti] OR Haemonchiasis [ti] OR 
Hairy-Tongue [ti] OR Halitosis [ti] OR Hallucination* [ti] OR Hallux-Rigidus [ti] OR Hallux-Valgus [ti] OR 
Hallux-Varus [ti] OR Hamartoma [ti] OR Hand-Deformities [ti] OR Hand-Dermatoses [ti] OR 
Haploinsufficiency [ti] OR Hazard* [ti] OR Head-Injur* [ti] OR Headache* [ti] OR Hearing-Loss [ti] OR 
Heart-Aneurysm* [ti] OR Heart-Arrest [ti] OR Heart-Block* [ti] OR Heart-Defect* [ti] OR Heart-Failure [ti] 
OR Heart-Murmur* [ti] OR Heart-Septal-Defect* [ti] OR Heartburn [ti] OR Heel-Spur* [ti] OR 
Helminthiasis [ti] OR Hemangioblastoma [ti] OR Hemangioendothelioma [ti] OR Hemangioma* [ti] OR 
Hemangiopericytoma [ti] OR Hemangiosarcoma [ti] OR Hemarthrosis [ti] OR Hematemesis [ti] OR 
Hematocele [ti] OR Hematocolpos [ti] OR Hematoma* [ti] OR Hematometra [ti] OR Hematuria [ti] OR 
Hemianopsia [ti] OR Hemifacial-Spasm* [ti] OR Hemiplegia [ti] OR Hemobilia [ti] OR Hemochromatosis 
[ti] OR Hemoglobinopathies [ti] OR Hemoglobinuria [ti] OR Hemolysis [ti] OR Hemoperitoneum [ti] OR 
Hemophilia [ti] OR Hemopneumothorax [ti] OR Hemoptysis [ti] OR Hemorrhag* [ti] OR Hemorrhoids [ti] 
OR Hemosiderosis [ti] OR Hemospermia [ti] OR Hemothorax [ti] OR Hepatic-Encephalopathy [ti] OR 
Hepatic-Insufficiency [ti] OR Hepatitis [ti] OR Hepatoblastoma [ti] OR Hepatolenticular-Degeneration [ti] 
OR Hepatomegaly [ti] OR Hereditary-Angioedema [ti] OR Hernia* [ti] OR Heroin-Dependence [ti] OR 
Herpangina [ti] OR Herpes-Genitalis [ti] OR Herpes-Labialis [ti] OR Herpes-Simplex [ti] OR Herpes-Zoster 
[ti] OR Heterotopic-Pregnancy [ti] OR Hiccup* [ti] OR Hidradenitis [ti] OR Hidrocystoma [ti] OR Hip-
Contracture [ti] OR Hip-Dislocation* [ti] OR Hirsutism [ti] OR Histiocytic-Necrotizing-Lymphadenitis [ti] 
OR Histiocytic-Sarcoma [ti] OR Histiocytoma [ti] OR Histiocytosis [ti] OR Histoplasmosis [ti] OR HIV-
Enteropathy [ti] OR HIV-Seropositivity [ti] OR HIV/AIDS [ti] OR Hoarseness [ti] OR Holoprosencephaly [ti] 
OR Homocystinuria [ti] OR Hot-Flashes [ti] OR Hutchinson's-Melanotic-Freckle [ti] OR 
Hyalohyphomycosis [ti] OR Hydatidiform-Mole [ti] OR Hydranencephaly [ti] OR Hydroa-Vacciniforme [ti] 
OR Hydrocephalus [ti] OR Hydronephrosis [ti] OR Hydrophthalmos [ti] OR Hydropneumothorax [ti] OR 
Hydrops-Fetalis [ti] OR Hydrothorax [ti] OR Hymenolepiasis [ti] OR Hyperacusis [ti] OR 
Hyperaldosteronism [ti] OR Hyperalgesia [ti] OR Hyperammonemia [ti] OR Hyperamylasemia [ti] OR 
Hyperandrogenism [ti] OR Hyperargininemia [ti] OR Hyperbilirubinemia [ti] OR Hypercalcemi* [ti] OR 
Hypercalciuria [ti] OR Hypercapnia [ti] OR Hypercellularity [ti] OR Hypercementosis [ti] OR 
Hypercholesterol* [ti] OR Hypercoagul* [ti] OR Hyperemesis-Gravidarum [ti] OR Hyperemi* [ti] OR 
Hyperesthesia [ti] OR Hypergammaglobulinemia [ti] OR Hyperglyc* [ti] OR Hyperhidrosis [ti] OR 
Hyperhomocystein* [ti] OR Hyperinsulin* [ti] OR Hyperkal* [ti] OR Hyperkeratosis [ti] OR Hyperkinesi* 
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[ti] OR Hyperleptinemia* [ti] OR Hyperlipid* [ti] OR Hyperlipoproteinemia* [ti] OR Hyperlysinemias [ti] 
OR Hypermagnesemi* [ti] OR Hypernatremia [ti] OR Hyperopia [ti] OR Hyperostosis [ti] OR 
Hyperoxaluria [ti] OR Hyperoxia [ti] OR Hyperparathyroid* [ti] OR Hyperphagia [ti] OR Hyperphosphat* 
[ti] OR Hyperpigmentation [ti] OR Hyperpituitarism [ti] OR Hyperplasia [ti] OR Hyperprolactinemia [ti] OR 
Hypersecretion [ti] OR Hypersensitivity [ti] OR Hypersomnolence [ti] OR Hypersplenism [ti] OR 
Hypertelorism [ti] OR Hypertension [ti] OR Hypertensive-Encephalopathy [ti] OR Hypertensive-
Retinopathy [ti] OR Hyperthyroidism [ti] OR Hyperthyroxinemia [ti] OR Hypertrichosis [ti] OR 
Hypertriglycerid* [ti] OR Hypertrophy [ti] OR Hyperuric* [ti] OR Hyperventilation [ti] OR 
Hypervitaminosis [ti] OR Hypervolemia [ti] OR Hypesthesia [ti] OR Hyphema [ti] OR Hypoalbuminemia 
[ti] OR Hypoaldosteronism [ti] OR Hypoalphalipoproteinemia* [ti] OR Hypobetalipoproteinemia* [ti] OR 
Hypocalcemi* [ti] OR Hypocapnia [ti] OR Hypodermyiasis [ti] OR Hypoglyc* [ti] OR Hypogonadism [ti] OR 
Hypohidrosis [ti] OR Hypokalemi* [ti] OR Hypokinesi* [ti] OR Hypolipid* [ti] OR Hypolipoproteinemias 
[ti] OR Hypomagnesemi* [ti] OR Hypomethylation [ti] OR Hyponatremi* [ti] OR Hypoparathyroidism [ti] 
OR Hypoperfusion [ti] OR Hypophosphat* [ti] OR Hypopigmentation [ti] OR Hypopituitarism [ti] OR 
Hypoplasia [ti] OR Hypoprothrombinemia* [ti] OR Hypospadias [ti] OR Hypotension [ti] OR Hypothermia 
[ti] OR Hypothyroid* [ti] OR Hypotrichosis [ti] OR Hypoventilation [ti] OR Hypovolemia [ti] OR 
Hypoxemia [ti] OR Hypoxia [ti] OR Ichthyosis [ti] OR IgA-Deficiency [ti] OR IgG-Deficiency [ti] OR Ileitis [ti] 
OR Ileus [ti] OR Iliac-Aneurysm [ti] OR Illness [ti] OR Illusions [ti] OR Immersion-Foot [ti] OR 
Immunoblastic-Lymphadenopathy [ti] OR Impacted-Tooth [ti] OR Imperforate-Anus [ti] OR Impetigo [ti] 
OR Implant-Capsular-Contracture [ti] OR Impotence [ti] OR Incontinentia-Pigmenti [ti] OR Inert-Gas-
Narcosis [ti] OR Infarction* [ti] OR Infect* [ti] OR Infertility [ti] OR Inflammation [ti] OR Inflammatory [ti] 
OR Influenza [ti] OR Ingrown-Nails [ti] OR Inhalant-Abuse* [ti] OR (Injury-in [ti] AND Mice [ti]) OR (injury-
in [ti] AND rats [ti]) OR Insect-Bite* [ti] OR Insect-Sting* [ti] OR Insomnia* [ti] OR Insulin-Coma [ti] OR 
Insulin-Resistance [ti] OR Insulinoma [ti] OR Intellectual-Disability [ti] OR Intermittent-Claudication [ti] 
OR Interstitial-Pneumonias [ti] OR Intertrigo [ti] OR Intervertebral-Disc-Degeneration [ti] OR 
Intervertebral-Disc-Displacement [ti] OR Intestinal-Atresia [ti] OR Intestinal-Fistula* [ti] OR Intestinal-
Obstruction* [ti] OR Intestinal-Perforation* [ti] OR Intestinal-Polyposis [ti] OR Intestinal-Polyps [ti] OR 
Intestinal-Pseudo-Obstruction [ti] OR Intestinal-Volvulus [ti] OR Intracranial-Arteriosclerosis [ti] OR 
Intracranial-Arteriovenous-Malformations [ti] OR Intracranial-Embolism* [ti] OR Intracranial-
Hypotension [ti] OR Intraoperative-Awareness [ti] OR Intraoperative-Complications [ti] OR 
Intussusception [ti] OR Iridocyclitis [ti] OR Iritis [ti] OR Iron-Overload [ti] OR Ischemia [ti] OR Ischemic-
Attack [ti] OR Ischemic-Contracture [ti] OR Isolated-Noncompaction-of-the-Ventricular-Myocardium [ti] 
OR Isosporiasis [ti] OR Jaundice [ti] OR Jaw-Cyst* [ti] OR Joint-Deformities [ti] OR Joint-Instability [ti] OR 
Joint-Loose-Bodies [ti] OR Keloid [ti] OR Keratitis [ti] OR Keratoacanthoma [ti] OR Keratoconjunctivitis [ti] 
OR Keratoconus [ti] OR Keratoderma [ti] OR Keratosis [ti] OR Kernicterus [ti] OR Ketosis [ti] OR Kidney-
Calculi [ti] OR Kidney-Failure [ti] OR Klatskin's-Tumor [ti] OR Krukenberg-Tumor [ti] OR Kuru [ti] OR 
Kwashiorkor [ti] OR Kyphosis [ti] OR Labyrinthitis [ti] OR Lacrimal-Duct-Obstruction* [ti] OR Lactose-
Intolerance [ti] OR Larva-Migrans [ti] OR Laryngismus [ti] OR Laryngitis [ti] OR Laryngomalacia [ti] OR 
Laryngopharyngeal-Reflux [ti] OR Laryngostenosis [ti] OR Latex-Hypersensitivity [ti] OR Lathyrism [ti] OR 
Leber-Congenital-Amaurosis [ti] OR Lecithin-Acyltransferase-Deficiency [ti] OR Leg-Dermatoses [ti] OR 
Leg-Length-Inequality [ti] OR Legionellosis [ti] OR Leiomyoma [ti] OR Leiomyomatosis [ti] OR 
Leiomyosarcoma [ti] OR Leishmania* [ti] OR Lens-Subluxation [ti] OR Lentigo [ti] OR Leprosy [ti] OR 
Leptospirosis [ti] OR Lethargy [ti] OR Leukemia [ti] OR Leukemic-Infiltration [ti] OR Leukemoid-Reaction 
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[ti] OR Leukoaraiosis [ti] OR Leukocytosis [ti] OR Leukodystrophy [ti] OR Leukoedema [ti] OR 
Leukoencephalitis [ti] OR Leukoencephalopath* [ti] OR Leukokeratosis [ti] OR Leukomalacia [ti] OR 
Leukopenia [ti] OR Leukoplakia [ti] OR Leukorrhea [ti] OR Leukostasis [ti] OR Leydig-Cell-Tumor [ti] OR 
Lice-Infestation* [ti] OR Lichen-Nitidus [ti] OR Lichen-Planus [ti] OR Lichen-Sclerosus-et-Atrophicus [ti] 
OR Limb-Deformit* [ti] OR Linear-IgA-Bullous-Dermatosis [ti] OR Lingual-Thyroid [ti] OR Linitis-Plastica 
[ti] OR Lipid-Metabolism [ti] OR Lipidoses [ti] OR Lipid-Peroxid* [ti] OR Lipodystrophy [ti] OR Lipoma [ti] 
OR Lipomatosis [ti] OR Lipoperoxidation [ti] OR Liposarcoma [ti] OR Lipoxidation [ti] OR Lissencephalies 
[ti] OR Lissencephaly [ti] OR Listeriosis [ti] OR Lithiasis [ti] OR Livedo-Reticularis [ti] OR Liver-Cirrhosis [ti] 
OR Liver-Failure [ti] OR Liver-Injury [ti] OR Loiasis [ti] OR Lordosis [ti] OR Low-Tension-Glaucoma [ti] OR 
Lower-Extremity-Deformit* [ti] OR Lower-Urinary-Tract-Symptom* [ti] OR Ludwig's-Angina [ti] OR Lung-
Injury [ti] OR Lupus-Erythematosus [ti] OR Lupus-Nephritis [ti] OR Lupus-Vulgaris [ti] OR Lyme-
Neuroborreliosis [ti] OR Lymphadenitis [ti] OR Lymphangiectasis [ti] OR Lymphangioleiomyomatosis [ti] 
OR Lymphangioma [ti] OR Lymphangiomyoma [ti] OR Lymphangiosarcoma [ti] OR Lymphangitis [ti] OR 
Lymphatic-Metastas* [ti] OR Lymphedema [ti] OR Lymphocele [ti] OR Lymphocytic-Choriomeningitis [ti] 
OR Lymphocytosis [ti] OR Lymphogranuloma-Venereum [ti] OR Lymphohistiocytosis [ti] OR Lymphoma 
[ti] OR Lymphomatoid-Granulomatosis [ti] OR Lymphomatoid-Papulosis [ti] OR Lymphopenia) 
 
(Expos* [ti] OR induce [ti] OR induced [ti] OR induces [ti] OR incarceration [ti] OR occupation* [ti] OR 
pathogen* [ti] OR pollut* [ti] OR poverty [ti] OR socioeconomic [ti] OR worker*) AND (Macroalbuminuria 
[ti] OR Macrocephaly [ti] OR Macroglossia [ti] OR Macular-Degeneration [ti] OR Magnesium-Deficiency 
[ti] OR Malacoplakia [ti] OR Malaria [ti] OR Malformations-of-Cortical-Development [ti] OR Malformed-
Nails [ti] OR Malignant-Catarrh [ti] OR Malignant-Hyperthermia [ti] OR Malnutrition [ti] OR Malocclusion 
[ti] OR Mandibulofacial-Dysostosis [ti] OR Mansonelliasis [ti] OR Marijuana-Abuse [ti] OR Mast-Cell-
Sarcoma [ti] OR Mastitis [ti] OR Mastocytoma [ti] OR Mastocytosis [ti] OR Mastodynia [ti] OR Mastoiditis 
[ti] OR Maternal-Death [ti] OR Maxillary-Sinusitis [ti] OR Measles [ti] OR Meckel-Diverticulum [ti] OR 
Mediastinal-Cyst [ti] OR Mediastinal-Emphysema [ti] OR Mediastinitis [ti] OR Medullary-Sponge-Kidney 
[ti] OR Medulloblastoma [ti] OR Megacolon [ti] OR Melanoma* [ti] OR Melanosis [ti] OR Melena [ti] OR 
Melioidosis [ti] OR Meningeal-Carcinomatosis [ti] OR Meningioma* [ti] OR Meningism [ti] OR Meningitis 
[ti] OR Meningocele [ti] OR Meningoencephalitis [ti] OR Meningomyelocele [ti] OR Menopause [ti] OR 
Menorrhagia [ti] OR Menstruation-Disturbances [ti] OR Mental-Fatigue [ti] OR Mental-Retardation [ti] 
OR Mesenchymoma [ti] OR Mesenteric-Cyst* [ti] OR Mesenteric-Lymphadenitis [ti] OR Mesenteric-
Vascular-Occlusion [ti] OR Mesial-Movement-of-Teeth [ti] OR Mesothelioma [ti] OR Metabolic-Acidosis 
[ti] OR Metabolic-Syndrome [ti] OR Metabolism [ti] OR Metal-Metabolism [ti] OR Metaplasia [ti] OR 
Metatarsalgia [ti] OR Methemoglobinemia [ti] OR Metrorrhagia [ti] OR Mevalonate-Kinase-Deficiency [ti] 
OR Microalbuminuria [ti] OR Microcephaly [ti] OR Micrognathism [ti] OR Microinflammation [ti] OR 
Micronuclei [ti] OR Microphthalmos [ti] OR Microsatellite-Instability [ti] OR Microscopic-Polyangiitis [ti] 
OR Microsporidiosis [ti] OR Microstomia [ti] OR Microvascular-Angina [ti] OR Migraine* [ti] OR Miliaria 
[ti] OR Milk-Hypersensitivity [ti] OR Milk-Sickness [ti] OR Mink-Viral-Enteritis [ti] OR Miosis [ti] OR Mite-
Infestation* [ti] OR Mitochondrial-Encephalomyopath* [ti] OR Mitochondrial-Myopath* [ti] OR Mitral-
Valve-Insufficiency [ti] OR Mitral-Valve-Prolapse [ti] OR Mixed-Tumor* [ti] OR Molluscum-Contagiosum 
[ti] OR Monieziasis [ti] OR Monilethrix [ti] OR Monkeypox [ti] OR Monoclonal-Gammopathy [ti] OR 
Mononeuropath* [ti] OR Morning-Sickness [ti] OR Morphine-Dependence [ti] OR Motion-Sickness [ti] 
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OR Mouth-Breathing [ti] OR Mucinoses [ti] OR Mucinosis [ti] OR Mucocele [ti] OR Mucolipidoses [ti] OR 
Mucopolysaccharidoses [ti] OR Mucopolysaccharidosis [ti] OR Mucormycosis [ti] OR Mucositis [ti] OR 
Multicystic-Dysplastic-Kidney [ti] OR Multiple-Acyl-Coenzyme-A-Dehydrogenase-Deficiency [ti] OR 
Multiple-Carboxylase-Deficiency [ti] OR Multiple-Chemical-Sensitivity [ti] OR Multiple-Myeloma [ti] OR 
Multiple-Organ-Failure* [ti] OR Multiple-Pulmonary-Nodules [ti] OR Multiple-System-Atrophy [ti] OR 
Mumps [ti] OR Muscle-Cramp* [ti] OR Muscle-Hypertonia [ti] OR Muscle-Hypotonia [ti] OR Muscle-
Rigidity [ti] OR Muscle-Spasticity [ti] OR Muscle-Weakness [ti] OR Muscular-Atrophy [ti] OR Muscular-
Dystroph* [ti] OR Mutism [ti] OR Myalgia [ti] OR Myasthenia-Gravis [ti] OR Mycetoma [ti] OR Mycoses 
[ti] OR Mycosis-Fungoides [ti] OR Mycotoxicosis [ti] OR Mydriasis [ti] OR Myelinolysis [ti] OR Myelitis [ti] 
OR Myelolipoma [ti] OR Myiasis [ti] OR Myocardial-Bridging [ti] OR Myocardial-Ischemia [ti] OR 
Myocardial-Reperfusion-Injury [ti] OR Myocardial-Stunning [ti] OR Myocarditis [ti] OR Myoclonic-
Cerebellar-Dyssynergia [ti] OR Myoclonic-Epileps* [ti] OR Myoclonus [ti] OR Myoepithelioma [ti] OR 
Myoglobinuria [ti] OR Myokymia [ti] OR Myoma [ti] OR Myopath* [ti] OR Myopia [ti] OR Myositis [ti] OR 
Myotonia [ti] OR Myotonic-Dystrophy [ti] OR Myringosclerosis [ti] OR Myxedema [ti] OR Myxoma [ti] OR 
Myxomatosis [ti] OR Myxosarcoma [ti] OR Narcolepsy [ti] OR Nasal-Obstruction* [ti] OR Nasal-Polyp* [ti] 
OR Nasal-Septal-Perforation [ti] OR Nasopharyngitis [ti] OR Nausea [ti] OR Necatoriasis [ti] OR 
Necrobiosis-Lipoidica [ti] OR Necrobiotic-Xanthogranuloma [ti] OR Necrolytic-Migratory-Erythema [ti] 
OR Necrosis [ti] OR Neointima [ti] OR Neoplasia [ti] OR Neoplasm* [ti] OR Neoplastic-Cell* [ti] OR 
Neovascularization [ti] OR Nephritis [ti] OR Nephrocalcinosis [ti] OR Nephrogenic-Fibrosing-Dermopathy 
[ti] OR Nephrolithiasis [ti] OR Nephroma [ti] OR Nephropath* [ti] OR Nephrosclerosis [ti] OR Nephrosis 
[ti] OR Nerve-Degeneration [ti] OR Nerve-Injur* [ti] OR Nervous-System-Malformation* [ti] OR 
Nesidioblastosis [ti] OR Neural-Tube-Defect* [ti] OR Neuralgia [ti] OR Neurilemmoma [ti] OR Neuritis [ti] 
OR Neuroacanthocytosis [ti] OR Neuroaspergillosis [ti] OR Neuroaxonal-Dystroph* [ti] OR 
Neuroblastoma [ti] OR Neurocysticercosis [ti] OR Neurocytoma [ti] OR Neuroectodermal-Tumor* [ti] OR 
Neuroendocrine-Tumor* [ti] OR Neurofibroma [ti] OR Neurofibromatos* [ti] OR Neurofibrosarcoma [ti] 
OR Neurogenic-Bowel [ti] OR Neurogenic-Inflammation [ti] OR Neurogenic-Urinary-Bladder [ti] OR 
Neuroma [ti] OR Neuromyelitis-Optica [ti] OR Neuronal-Ceroid-Lipofuscinoses [ti] OR Neuropath* [ti] OR 
Neuroschistosomiasis [ti] OR Neurosyphilis [ti] OR Neurothekeoma [ti] OR Neutropenia [ti] OR Nevus [ti] 
OR Night-Blindness [ti] OR Night-Terror* [ti] OR Nocturia [ti] OR Nocturnal-Enuresis [ti] OR Nocturnal-
Paroxysmal-Dystonia [ti] OR Noma [ti] OR Nondisjunction [ti] OR Nonodontogenic-Cysts [ti] OR Nonvital-
Tooth [ti] OR No-Reflow-Phenomenon [ti] OR Nose-Deformities [ti] OR Nut-Hypersensitivity [ti] OR 
Nystagmus [ti] OR Obesity [ti] OR Obstetric-Labor-Complications [ti] OR Ochronosis [ti] OR Ocular-
Hypotension [ti] OR Odontogenic-Cyst* [ti] OR Odontogenic-Tumor* [ti] OR Odontoma [ti] OR Oedema 
[ti] OR Oligodendroglioma [ti] OR Oligohydramnios [ti] OR Oligomenorrhea [ti] OR Oligospermia [ti] OR 
Oliguria [ti] OR Olivopontocerebellar-Atrophies [ti] OR Onchocerciasis [ti] OR Onycholysis [ti] OR 
Onychomycosis [ti] OR Oophoritis [ti] OR Open-Bite [ti] OR Ophthalmia [ti] OR Ophthalmoplegia [ti] OR 
Opisthorchiasis [ti] OR Optic-Atrophy [ti] OR Optic-Disk-Drusen [ti] OR Optic-Nerve-Glioma [ti] OR Optic-
Neuritis [ti] OR Oral-Fistula* [ti] OR Orbital-Cellulitis [ti] OR Orbital-Myositis [ti] OR Orbital-
Pseudotumor* [ti] OR Orchitis [ti] OR Oroantral-Fistula* [ti] OR Orthostatic-Intolerance [ti] OR 
Ossification [ti] OR Osteitis [ti] OR Osteoarthritis [ti] OR Osteoarthropath* [ti] OR Osteoblastoma [ti] OR 
Osteochondritis [ti] OR Osteochondrodysplasias [ti] OR Osteochondroma [ti] OR Osteochondrosis [ti] OR 
Osteodystrophy [ti] OR Osteogenesis-Imperfecta [ti] OR Osteolysis [ti] OR Osteoma [ti] OR Osteomalacia 
[ti] OR Osteomyelitis [ti] OR Osteonecrosis [ti] OR Osteopenia [ti] OR Osteopetrosis [ti] OR Osteophyte 
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[ti] OR Osteoporosis [ti] OR Osteosarcoma [ti] OR Osteosclerosis [ti] OR Ostertagiasis [ti] OR Otitis [ti] OR 
Otomycosis [ti] OR Otosclerosis [ti] OR Ovarian-Cyst* [ti] OR Overactive-Urinary-Bladder [ti] OR Overbite 
[ti] OR Overnutrition [ti] OR Overweight [ti] OR Oxidative-Stress [ti] OR Oxyuriasis [ti] OR Pachyonychia-
Congenita [ti] OR Pain [ti] OR Pallor [ti] OR Pancreatic-Cyst* [ti] OR Pancreatic-Fistula* [ti] OR 
Pancreatic-Insufficiency [ti] OR Pancreatic-Pseudocyst [ti] OR Pancreatitis [ti] OR Pancytopenia [ti] OR 
Panniculitis [ti] OR Panuveitis [ti] OR Papilledema [ti] OR Papilloma [ti] OR Paracoccidioidomycosis [ti] 
OR Paraganglioma [ti] OR Paragonimiasis [ti] OR Parakeratosis [ti] OR Paralyses [ti] OR Paralysis [ti] OR 
Paraneoplastic [ti] OR Paraparesis [ti] OR Paraphimosis [ti] OR Paraplegia [ti] OR Paraproteinemias [ti] 
OR Parapsoriasis [ti] OR Parasitemia [ti] OR Parasomnias [ti] OR Parasystole [ti] OR Paratuberculosis [ti] 
OR Paresis [ti] OR Paresthesia [ti] OR Paronychia [ti] OR Parotitis [ti] OR Paroxysmal-Hemicrania [ti] OR 
Pars-Planitis [ti] OR Pasteurellosis [ti] OR Peanut-Hypersensitivity [ti] OR Pediatric-Obesity [ti] OR Pelger-
Huet-Anomaly [ti] OR Peliosis-Hepatis [ti] OR Pellagra [ti] OR Pelvic-Organ-Prolapse [ti] OR Pemphigoid 
[ti] OR Pemphigus [ti] OR Penile-Induration [ti] OR Periapical-Granuloma* [ti] OR Periarthritis [ti] OR 
Pericardial-Effusion [ti] OR Pericarditis [ti] OR Pericoronitis [ti] OR Peri-Implantitis [ti] OR Perinephritis 
[ti] OR Periodontal-Atrophy [ti] OR Periodontal-Attachment-Loss [ti] OR Periodontal-Cyst* [ti] OR 
Periodontal-Pocket [ti] OR Periodontitis [ti] OR Periostitis [ti] OR Peritonitis [ti] OR Periventricular-
Nodular-Heterotopia [ti] OR Persistent-Hyperplastic-Primary-Vitreous [ti] OR Persistent-Vegetative-State 
[ti] OR Peste-des-Petits-Ruminants [ti] OR Phaeohyphomycosis [ti] OR Phantom-Limb [ti] OR Pharyngitis 
[ti] OR Phencyclidine-Abuse* [ti] OR Phenylketonuria* [ti] OR Pheochromocytoma [ti] OR Phimosis [ti] 
OR Phlebitis [ti] OR Photophobia [ti] OR Phyllodes-Tumor [ti] OR Piebaldism [ti] OR Piedra [ti] OR 
Pilomatrixoma [ti] OR Pilonidal-Sinus [ti] OR Pinealoma [ti] OR Pinguecula [ti] OR Pituitary-ACTH-
Hypersecretion [ti] OR Pituitary-Apoplexy [ti] OR Pityriasis [ti] OR Placenta [ti] OR Placental-Insufficiency 
[ti] OR Plagiocephaly [ti] OR Plague [ti] OR Plasma-Cell-Granuloma* [ti] OR Plasmacytoma [ti] OR 
Platelet-Storage-Pool-Deficiency [ti] OR Platybasia [ti] OR Pleural-Effusion [ti] OR Pleurisy [ti] OR 
Pleurodynia [ti] OR Pleuropneumonia [ti] OR Pneumatosis-Cystoides-Intestinalis [ti] OR Pneumocephalus 
[ti] OR Pneumoconiosis [ti] OR Pneumonia [ti] OR Pneumopericardium [ti] OR Pneumoperitoneum [ti] 
OR Pneumorrhachis [ti] OR Pneumothorax [ti] OR Poliomyelitis [ti] OR Polyarteritis-Nodosa [ti] OR 
Polychondritis [ti] OR Polycystic-Kidney [ti] OR Polycythemia [ti] OR Polydactyly [ti] OR Polydipsia [ti] OR 
Polyendocrinopathies [ti] OR Polyhydramnios [ti] OR Polymyalgia-Rheumatica [ti] OR Polymyositis [ti] OR 
Polyneuropathies [ti] OR Polyps [ti] OR Polyradiculopathy [ti] OR Polyuria [ti] OR Popliteal-Cyst* [ti] OR 
Porokeratosis [ti] OR Poroma [ti] OR Porphyria* [ti] OR Port-Wine-Stain [ti] OR Positive-Pressure-
Respiration [ti] OR Posterior-Tibial-Tendon-Dysfunction [ti] OR Post-Exercise-Hypotension [ti] OR 
Postoperative-Complications [ti] OR Postoperative-Nausea [ti] OR postoperative-vomiting [ti] OR 
Postpartum-Thyroiditis [ti] OR Potassium-Deficiency [ti] OR Pouchitis [ti] OR Precancerous [ti] OR 
Precocious-Puberty [ti] OR Prediabetic-State [ti] OR Pre-Eclampsia [ti] OR Pre-Excitation [ti] OR 
Pregnancy-Complications [ti] OR Pregnancy-in-Diabetics [ti] OR Prehypertension [ti] OR Preleukemia [ti] 
OR Premature-Aging [ti] OR Premature-Birth [ti] OR Premature-Ejaculation [ti] OR Premature-Obstetric-
Labor [ti] OR Prenatal-Injur* [ti] OR Presbycusis [ti] OR Presbyopia [ti] OR Priapism [ti] OR Primary-
Dysautonomias [ti] OR Primary-Graft-Dysfunction* [ti] OR Primary-Myelofibrosis [ti] OR Primary-
Ovarian-Insufficiency [ti] OR Proctitis [ti] OR Proctocolitis [ti] OR Progeria [ti] OR Prognathism [ti] OR 
Prolactinoma [ti] OR Prolonged-Pregnancy [ti] OR Propionic-Acidemia [ti] OR Prosopagnosia [ti] OR 
Prostatism [ti] OR Prostatitis [ti] OR Prosthesis-Failure* [ti] OR Protein-C-Deficiency [ti] OR Protein-
Deficiency [ti] OR Protein-S-Deficiency [ti] OR Protein-Energy-Malnutrition [ti] OR Protein-Losing-
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Enteropathies [ti] OR Proteinuria [ti] OR Proteostasis-Deficiencies [ti] OR Protoporphyria [ti] OR Prurigo 
[ti] OR Pruritus [ti] OR Pseudobulbar-Palsy [ti] OR Pseudohypoaldosteronism [ti] OR 
Pseudohypoparathyroidism [ti] OR Pseudolymphoma [ti] OR Pseudomyxoma-Peritonei [ti] OR 
Pseudophakia [ti] OR Pseudorabies [ti] OR Pseudotumor-Cerebri [ti] OR Pseudoxanthoma-Elasticum [ti] 
OR Psittacosis [ti] OR Psoriasis [ti] OR Psychomotor-Agitation [ti] OR Psychoses [ti] OR Pterygium [ti] OR 
Pubic-Symphysis-Diastasis [ti] OR Pudendal-Neuralgia [ti] OR Pulmonary-Alveolar-Proteinosis [ti] OR 
Pulmonary-Aspergillosis [ti] OR Pulmonary-Atelectasis [ti] OR Pulmonary-Atresia [ti] OR Pulmonary-
Blastoma [ti] OR Pulmonary-Embolism [ti] OR Pulmonary-Emphysema [ti] OR Pulmonary-Eosinophilia [ti] 
OR Pulmonary-Nodule* [ti] OR Pulmonary-Sclerosing-Hemangioma [ti] OR Pulmonary-Valve-
Insufficiency [ti] OR Pulpitis [ti] OR Pure-Autonomic-Failure [ti] OR Purine-Pyrimidine-Metabolism [ti] OR 
Purpura [ti] OR Pyelitis [ti] OR Pyelonephritis [ti] OR Pyoderma [ti] OR Pyometra [ti] OR Pyomyositis [ti] 
OR Pyonephrosis [ti] OR Pythiosis [ti] OR Pyuria [ti] OR Quadriplegia [ti] OR Rabies [ti] OR Radiation-
Pneumonitis [ti] OR Radicular-Cyst* [ti] OR Radiculopathy [ti] OR Ranula [ti] OR Reactive-Oxygen-Species 
[ti] OR Rectal-Fistula [ti] OR Rectal-Prolapse [ti] OR Rectocele [ti] OR Rectovaginal-Fistula [ti] OR 
Recurrence [ti] OR Red-Cell-Aplasia [ti] OR Reflex-Sympathetic-Dystrophy [ti] OR Refractive-Errors [ti] OR 
Renal-Aminoacidurias [ti] OR Renal-Artery-Obstruction [ti] OR Renal-Colic [ti] OR Renal-Injury [ti] OR 
Renal-Insufficiency [ti] OR Renal-Osteodystrophy [ti] OR Renal-Tubular-Transport [ti] OR Reperfusion-
Injury [ti] OR Respiratory-Aspiration [ti] OR Respiratory-Hypersensitivity [ti] OR Respiratory-Insufficiency 
[ti] OR Respiratory-Paralysis [ti] OR Respiratory-Sounds [ti] OR Respiratory-Tract-Fistula [ti] OR 
Restenosis [ti] OR Reticulocytosis [ti] OR Retinal-Artery-Occlusion [ti] OR Retinal-Degeneration [ti] OR 
Retinal-Detachment [ti] OR Retinal-Drusen [ti] OR Retinal-Neovascularization [ti] OR Retinal-Perforations 
[ti] OR Retinal-Telangiectasis [ti] OR Retinal-Vein-Occlusion [ti] OR Retinitis [ti] OR Retinoblastoma [ti] 
OR Retinopathy [ti] OR Retinoschisis [ti] OR Retrognathia [ti] OR Retrograde-Degeneration [ti] OR 
Retropneumoperitoneum [ti] OR Rh-Isoimmunization [ti] OR Rhabdoid-Tumor* [ti] OR Rhabdomyolysis 
[ti] OR Rhabdomyoma [ti] OR Rhabdomyosarcoma [ti] OR Rheumatic-Nodule* [ti] OR Rheumatoid-
Nodule* [ti] OR Rhinitis [ti] OR Rhinophyma [ti] OR Rhinoscleroma [ti] OR Rhinosporidiosis [ti] OR 
Riboflavin-Deficiency [ti] OR Rickets [ti] OR Rigor-Mortis [ti] OR Rinderpest [ti] OR Root-Caries [ti] OR 
Root-Resorption [ti] OR Rosacea [ti] OR Rubella [ti] OR Rupture) 
 
 
(Expos* [ti] OR induce [ti] OR induced [ti] OR induces [ti] OR incarceration [ti] OR occupation* [ti] OR 
pathogen* [ti] OR pollut* [ti] OR poverty [ti] OR socioeconomic [ti] OR worker*) AND (Sacroiliitis [ti] OR 
Salivary-Duct-Calculi [ti] OR Salivary-Gland-Calculi [ti] OR Salivary-Gland-Fistula [ti] OR Salpingitis [ti] OR 
Sarcocystosis [ti] OR Sarcoidosis [ti] OR Sarcoma [ti] OR Sarcopenia [ti] OR Scabies [ti] OR Scalp-
Dermatoses [ti] OR Schistosomiasis [ti] OR Sciatica [ti] OR Scleredema-Adultorum [ti] OR Sclerema-
Neonatorum [ti] OR Scleritis [ti] OR Scleroderma [ti] OR Scleromyxedema [ti] OR Sclerosis [ti] OR 
Scoliosis [ti] OR Scorpion-Sting* [ti] OR Scotoma [ti] OR Scrapie [ti] OR Scrub-Typhus [ti] OR Scurvy [ti] 
OR Seizures [ti] OR Seminoma [ti] OR Sepsis [ti] OR Septic-Shock [ti] OR Seroma [ti] OR Serositis [ti] OR 
Sertoli-Cell-Tumor* [ti] OR Sertoli-Leydig-Cell-Tumor [ti] OR Serum-Sickness [ti] OR Severe-Combined-
Immunodeficiency [ti] OR Severe-Dengue [ti] OR Sex-Chromosome-Aberrations [ti] OR Sex-Cord-
Gonadal-Stromal-Tumor* [ti] OR Sexual-Dysfunction [ti] OR Shwartzman-Phenomenon [ti] OR 
Sialadenitis [ti] OR Sialometaplasia [ti] OR Sialorrhea [ti] OR Sickle-Cell-Trait [ti] OR Siderosis [ti] OR 
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Silicosis [ti] OR Silicotuberculosis [ti] OR Single-Umbilical-Artery [ti] OR Sinoatrial-Block [ti] OR Sinus-
Arrest [ti] OR Sinus-Pericranii [ti] OR Sinusitis [ti] OR Situs-Inversus [ti] OR Skull-Fracture* [ti] OR Sleep-
Apnea [ti] OR Sleep-Bruxism [ti] OR Sleep-Deprivation [ti] OR Sleep-Paralysis [ti] OR Slipped-Capital-
Femoral-Epiphyses [ti] OR Smallpox [ti] OR Smooth-Muscle-Tumor* [ti] OR Snake-Bite* [ti] OR Sneezing 
[ti] OR Snoring [ti] OR Somatostatinoma [ti] OR Somnambulism [ti] OR Space-Motion-Sickness [ti] OR 
Sparganosis [ti] OR Spasm [ti] OR Spasms [ti] OR Spastic-Paraplegia [ti] OR Spermatic-Cord-Torsion [ti] 
OR Spermatocele [ti] OR Sphenoid-Sinusitis [ti] OR Spherocytosis [ti] OR Sphincter-of-Oddi-Dysfunction 
[ti] OR Sphingolipidoses [ti] OR Spider-Bite* [ti] OR Spina-Bifida [ti] OR Spinal-Cord-Compression [ti] OR 
Spinal-Cord-Injur* [ti] OR Spinal-Cord-Ischemia [ti] OR Spinal-Curvature* [ti] OR Spinal-Dysraphism [ti] 
OR Spinal-Muscular-Atrophies-of-Childhood [ti] OR Spinal-Osteophytosis [ti] OR Spinocerebellar-Ataxias 
[ti] OR Spinocerebellar-Degeneration* [ti] OR Splenomegaly [ti] OR Splenosis [ti] OR Spondylarthritis [ti] 
OR Spondylarthropathies [ti] OR Spondylitis [ti] OR Spondylolisthesis [ti] OR Spondylolysis [ti] OR 
Spondylosis [ti] OR Sporotrichosis [ti] OR Sprue [ti] OR Starvation [ti] OR Status-Asthmaticus [ti] OR 
Status-Epilepticus [ti] OR Steatitis [ti] OR Steatorrhea [ti] OR Stenosis [ti] OR Steroid-Metabolism [ti] OR 
Stings [ti] OR Stomach-Volvulus [ti] OR Stomatitis [ti] OR Strabismus [ti] OR Striae-Distensae [ti] OR 
Striatonigral-Degeneration [ti] OR Stricture* [ti] OR Stroke [ti] OR Strongyloidiasis [ti] OR Stupor [ti] OR 
Stuttering [ti] OR Subacute-Combined-Degeneration [ti] OR Subacute-Sclerosing-Panencephalitis [ti] OR 
Subcutaneous-Emphysema [ti] OR Subdural-Effusion [ti] OR Substance-Abuse* [ti] OR Sudden-Death [ti] 
OR Sudden-Infant-Death* [ti] OR Sulfhemoglobinemia [ti] OR Sunburn [ti] OR Supernumerary-Tooth [ti] 
OR Suppuration [ti] OR Supranuclear-Palsy [ti] OR Surgical-Shock [ti] OR Surgical-Wound-Dehiscence [ti] 
OR Sweating [ti] OR Swine-Erysipelas [ti] OR Syncope [ti] OR Syndactyly [ti] OR Syndrome* [ti] OR 
Synkinesis [ti] OR Synostosis [ti] OR Synovial-Cyst* [ti] OR Synovitis [ti] OR Syphilis [ti] OR Syringoma [ti] 
OR Syringomyelia [ti] OR Systolic-Murmurs [ti] OR Tabes-Dorsalis [ti] OR Tachycardia [ti] OR Tachypnea 
[ti] OR Taeniasis [ti] OR Takayasu-Arteritis [ti] OR Takotsubo-Cardiomyopathy [ti] OR Tarlov-Cysts [ti] OR 
Tauopathies [ti] OR Tauopathy [ti] OR TDP-43-Proteinopathies [ti] OR Telangiectasia [ti] OR 
Telangiectasis [ti] OR Tendinopath* [ti] OR Tendon-Entrapment [ti] OR Tennis-Elbow [ti] OR 
Tenosynovitis [ti] OR Teratocarcinoma* [ti] OR Teratogenesis [ti] OR Teratoma [ti] OR Testicular-
Hydrocele* [ti] OR Tetanus [ti] OR Tetany [ti] OR Tetralogy-of-Fallot [ti] OR Thalassemia [ti] OR Thecoma 
[ti] OR Theileriasis [ti] OR Thiamine-Deficiency [ti] OR Thinness [ti] OR Thrombasthenia [ti] OR 
Thromboangiitis-Obliterans [ti] OR Thrombocythemia [ti] OR Thrombocytopenia [ti] OR Thrombocytosis 
[ti] OR Thromboembolism [ti] OR Thrombophilia [ti] OR Thrombophlebitis [ti] OR Thrombosis [ti] OR 
Thrombotic-Microangiopathies [ti] OR Thymoma [ti] OR Thyroglossal-Cyst* [ti] OR Thyroid-Crisis [ti] OR 
Thyroid-Dysgenesis [ti] OR Thyroid-Nodule* [ti] OR Thyroiditis [ti] OR Thyrotoxicosis [ti] OR Tick-Bite* [ti] 
OR Tick-Infestation* [ti] OR Tick-Paralysis [ti] OR Tick-Toxicoses [ti] OR Tics [ti] OR Tinea [ti] OR Tinnitus 
[ti] OR Tissue-Adhesions [ti] OR T-Lymphocytopenia [ti] OR Tonic-Pupil [ti] OR Tonsillitis [ti] OR Tooth-
Abrasion [ti] OR Tooth-Ankylosis [ti] OR Tooth-Attrition [ti] OR Tooth-Avulsion [ti] OR Tooth-
Demineralization [ti] OR Tooth-Discoloration* [ti] OR Tooth-Erosion [ti] OR Tooth-Fracture* [ti] OR 
Tooth-Injur* [ti] OR Tooth-Loss [ti] OR Tooth-Migration [ti] OR Tooth-Mobility [ti] OR Tooth-Resorption 
[ti] OR Tooth-Wear [ti] OR Toothache* [ti] OR Torsades-de-Pointes [ti] OR Torticollis [ti] OR Toxascariasis 
[ti] OR Toxemia [ti] OR Toxic-Shock [ti] OR Toxocariasis [ti] OR Toxoplasmosis [ti] OR Tracheitis [ti] OR 
Tracheobronchomalacia [ti] OR Tracheobronchomegaly [ti] OR Tracheoesophageal-Fistula [ti] OR 
Tracheomalacia [ti] OR Trachoma [ti] OR Transient-Tachypnea [ti] OR Translocation [ti] OR 
Transposition-of-Great-Vessels [ti] OR Trauma [ti] OR Traumatic-Shock [ti] OR Tremor* [ti] OR Trichiasis 
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[ti] OR Trichinellosis [ti] OR Trichomonas-Vaginitis [ti] OR Trichosporonosis [ti] OR Trichostrongyloidiasis 
[ti] OR Trichostrongylosis [ti] OR Trichuriasis [ti] OR Tricuspid-Atresia [ti] OR Tricuspid-Valve-Insufficiency 
[ti] OR Trigeminal-Autonomic-Cephalalgias [ti] OR Trigeminal-Neuralgia [ti] OR Trilogy-of-Fallot [ti] OR 
Trismus [ti] OR Trisomy [ti] OR Trombiculiasis [ti] OR Trophoblastic-Tumor* [ti] OR Trypanosomiasis [ti] 
OR Tubal-Pregnancy [ti] OR Tuberculoma [ti] OR Tuberculosis [ti] OR Tularemia [ti] OR Tungiasis [ti] OR 
Tympanic-Membrane-Perforation [ti] OR Typhlitis [ti] OR Typhus [ti] OR Tyrosinemias [ti] OR Ulcer* [ti] 
OR Unconsciousness [ti] OR Uniparental-Disomy [ti] OR Upper-Extremity-Deformities [ti] OR Urachal-
Cyst* [ti] OR Uraemia [ti] OR Uremia [ti] OR Ureteral-Calculi [ti] OR Ureteral-Obstruction* [ti] OR 
Ureterocele [ti] OR Ureterolithiasis [ti] OR Urethral-Obstruction* [ti] OR Urethritis [ti] OR Urinary-
Bladder-Calculi [ti] OR Urinary-Bladder-Fistula* [ti] OR Urinary-Bladder-Neck-Obstruction* [ti] OR 
Urinary-Calculi [ti] OR Urinary-Fistula [ti] OR Urinary-Incontinence [ti] OR Urinary-Retention [ti] OR 
Urinoma [ti] OR Urolithiasis [ti] OR Urticaria [ti] OR Urticaria-Pigmentosa [ti] OR Uterine-Cervical-Erosion 
[ti] OR Uterine-Cervical-Incompetence [ti] OR Uterine-Cervicitis [ti] OR Uterine-Inertia [ti] OR Uterine-
Inversion [ti] OR Uterine-Perforation* [ti] OR Uterine-Prolapse [ti] OR Uterine-Retroversion [ti] OR 
Uveitis [ti] OR Vaccinia [ti] OR Vaginal-Discharge* [ti] OR Vaginal-Fistula* [ti] OR Vaginismus [ti] OR 
Vaginitis [ti] OR Vaginosis [ti] OR Varicocele [ti] OR Varicose-Veins [ti] OR Vasa-Previa [ti] OR Vascular-
Calcification [ti] OR Vascular-Fistula [ti] OR Vascular-Malformations [ti] OR Vascular-Resistance [ti] OR 
Vascular-Stiffness [ti] OR Vascular-System-Injur* [ti] OR Vasculitis [ti] OR Vasoconstriction [ti] OR 
Vasoplegia [ti] OR Vasospasm [ti] OR Vein-of-Galen-Malformations [ti] OR Velopharyngeal-Insufficiency 
[ti] OR Venous-Insufficiency [ti] OR Venous-Thromboembolism* [ti] OR Ventilator-Induced-Lung-Injury 
[ti] OR Ventricular-Dysfunction* [ti] OR Ventricular-Fibrillation* [ti] OR Ventricular-Outflow-Obstruction* 
[ti] OR Ventricular-Premature-Complexes [ti] OR Ventricular-Remodeling [ti] OR Vertebral-Artery-
Dissection [ti] OR Vertebrobasilar-Insufficiency [ti] OR Vertigo [ti] OR Vesico-Ureteral-Reflux [ti] OR 
Vesicovaginal-Fistula* [ti] OR Vesicular-Stomatitis [ti] OR Vestibular-Neuronitis [ti] OR VIRAL-Cell-
Transformation [ti] OR Viremia [ti] OR Virilism [ti] OR Visceral-Prolapse [ti] OR Visna [ti] OR Vitamin-A-
Deficiency [ti] OR Vitamin-B-12-Deficiency [ti] OR Vitamin-B-6-Deficiency [ti] OR Vitamin-B-Deficiency [ti] 
OR Vitamin-D-Deficiency [ti] OR Vitamin-E-Deficiency [ti] OR Vitamin-K-Deficiency [ti] OR Vitiligo [ti] OR 
Vitreoretinopathy [ti] OR Vitreous-Detachment [ti] OR Vocal-Cord-Dysfunction [ti] OR Vocal-Cord-
Paralysis [ti] OR Vomiting [ti] OR Vulvar-Lichen-Sclerosus [ti] OR Vulvar-Vestibulitis [ti] OR Vulvitis [ti] OR 
Vulvodynia [ti] OR Vulvovaginitis [ti] OR Waldenstrom-Macroglobulinemia [ti] OR Wallerian-
Degeneration [ti] OR Wandering-Spleen [ti] OR Warts [ti] OR Water-Electrolyte-Imbalance [ti] OR 
Wegener-Granulomatosis [ti] OR Wernicke-Encephalopathy [ti] OR Wet-Macular-Degeneration [ti] OR 
Wheat-Hypersensitivity [ti] OR Whooping-Cough [ti] OR Wilms-Tumor [ti] OR Xanthogranuloma* [ti] OR 
Xanthomatosis [ti] OR Xeroderma-Pigmentosum [ti] OR Xerophthalmia [ti] OR Xerostomia [ti] OR Yang-
Deficiency [ti] OR Yaws [ti] OR Yin-Deficiency [ti] OR Zenker-Diverticulum [ti] OR Zoonoses [ti] OR Zoster-
Sine-Herpete [ti] OR Zygomycosis [ti]) 
 
1C3. Linking Terms Used to Extract Causes from Titles 
There were millions of Title phrases that had to be evaluated for potential causes.  Only the highest 
frequency phrases could be inspected visually.  To access the lower frequency terms, a number of linking 
terms were identified. 
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The linking terms were obtained through visual inspection of many records containing causes in the 
Titles, and identifying those that appeared frequently with the causes.  These linking terms included: -
induced; caused by; induced by; -contaminated; exposure to; exposure(s) [at end of phrase]; exposed to; 
poisoning [at end]; workers [at end]; -exposed [at end]; -related; -associated; -infected; abuse*; toxicity.  
The inclusion of the term 'workers' was to identify industries that were noticeable contributors to 
disease.  The phrases that included the linking terms had to be separated from the linking terms to 
identify the specific causes and include them in the software matrices.  Other linking terms were virus* 
and generic bacterial headings, but these did not have to be separated from the phrases.  
 
1C4. Linking Terms Used to Extract Diseases from Titles 
The linking terms were obtained through visual inspection of many records containing diseases in the 
Titles, and identifying those that appeared frequently with the diseases.  These linking terms included: 
disease; syndrome; infection; cancer; *toxicity; *opathy.  Since specific diseases did not always appear in 
record Titles when the causes appeared, terms that implied damage or adverse effects were used, such 
as *toxicity.  So, for example, with a phrase like 'cadmium toxicity', 'cadmium' would be extracted as a 
cause, and 'toxicity' would be listed as a 'disease'. 
 
1C5. Generic MeSH Terms Strongly Related to Potential Causes 
A number of records with MeSH term assignments either had no Qualifiers listed or insufficient 
Qualifiers.  In addition, while the Qualifiers used for the all-Qualifier query captured a large number of 
causes, they were incomplete.  Therefore, the high and mid-frequency MeSH terms in the MeSH tree 
were inspected visually, and those that appeared to be generic and cause-focused were selected as a 
query.  The MeSH Headings that resulted in the retrieval consisted of causes, and other.  Because there 
were no linking terms that could be used to extract only the causes MeSH Headings, the output had to 
be inspected visually, and those terms that appeared to be causes had to be extracted manually and 
validated.  Mainly, the high frequency output terms were the only ones evaluated. 
The following query was used to retrieve the records from Pubmed, where the first set consists of all 
diseases and symptoms from the MeSH tree, and the second set is the MeSH terms strongly related to 
causes: 
([MH] is the Pubmed tag for MeSH Heading; [MH:NOEXP] is the Pubmed tag for MeSH Heading No 
Explode) 
(Bacterial Infections and Mycoses [MH] OR Cardiovascular Diseases [MH] OR Chemically-Induced 
Disorders [MH] OR Congenital, Hereditary, and Neonatal Diseases and Abnormalities [MH] OR Digestive 
System Diseases [MH] OR Disorders of Environmental Origin [MH] OR Endocrine System Diseases [MH] 
OR Eye Diseases [MH] OR Female Urogenital Diseases and Pregnancy Complications [MH] OR Hemic and 
Lymphatic Diseases [MH] OR Immune System Diseases [MH] OR Male Urogenital Diseases [MH] OR 
Musculoskeletal Diseases [MH] OR Neoplasms [MH] OR Nervous System Diseases [MH] OR Nutritional 
and Metabolic Diseases [MH] OR Occupational Diseases [MH] OR Otorhinolaryngologic Diseases [MH] 
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OR Parasitic Diseases [MH] OR Pathological Conditions, Signs and Symptoms [MH] OR Respiratory Tract 
Diseases [MH] OR Skin and Connective Tissue Diseases [MH] OR Stomatognathic Diseases [MH] OR Virus 
Diseases [MH]) 
AND  
("DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS" [MH:NOEXP] OR ABNORMALITIES, DRUG 
INDUCED [MH:NOEXP] OR ABNORMALITIES, RADIATION-INDUCED [MH:NOEXP] OR AGRICULTURAL 
WORKERS DISEASES [MH:NOEXP] OR AIDS RELATED OPPORTUNISTIC INFECTIONS [MH:NOEXP] OR AIR 
POLLUTANTS [MH:NOEXP] OR AIR POLLUTANTS, OCCUPATIONAL [MH:NOEXP] OR AIR POLLUTANTS, 
RADIOACTIVE [MH:NOEXP] OR AIR POLLUTION [MH:NOEXP] OR AIR POLLUTION, INDOOR [MH:NOEXP] 
OR AIR POLLUTION, RADIOACTIVE [MH:NOEXP] OR ALCOHOL DRINKING [MH:NOEXP] OR ALCOHOL 
RELATED DISORDERS [MH:NOEXP] OR ALCOHOLIC BEVERAGES [MH:NOEXP] OR ALCOHOLIC 
INTOXICATION [MH:NOEXP] OR ALCOHOLISM [MH:NOEXP] OR AMPHETAMINE RELATED DISORDERS 
[MH:NOEXP] OR AMPHETAMINES [MH:NOEXP] OR ARSENIC POISONING [MH:NOEXP] OR ASTHMA, 
ASPIRIN-INDUCED [MH:NOEXP] OR ASTHMA, EXERCISE-INDUCED [MH:NOEXP] OR ASTHMA, 
OCCUPATIONAL [MH:NOEXP] OR BEHAVIOR, ADDICTIVE [MH:NOEXP] OR BULLYING [MH:NOEXP] OR 
CADMIUM POISONING [MH:NOEXP] OR CARBON MONOXIDE POISONING [MH:NOEXP] OR CARBON 
TETRACHLORIDE POISONING [MH:NOEXP] OR CARCINOGENICITY TESTS [MH:NOEXP] OR CARCINOGENS 
[MH:NOEXP] OR CARCINOGENS, ENVIRONMENTAL [MH:NOEXP] OR CAUSALITY [MH:NOEXP] OR 
CARDIOMEGALY, EXERCISE-INDUCED [MH:NOEXP] OR CHEMICAL WARFARE AGENTS [MH:NOEXP] OR 
CHEMICALLY-INDUCED DISORDERS [MH:NOEXP] OR CHILD ABUSE [MH:NOEXP] OR CHILD ABUSE, 
SEXUAL [MH:NOEXP] OR CHOLESTEROL, DIETARY [MH:NOEXP] OR CIGUATERA POISONING [MH:NOEXP] 
OR COCAINE RELATED DISORDERS [MH:NOEXP] OR CYTOMEGALOVIRUS INFECTIONS [MH:NOEXP] OR 
DERMATITIS, OCCUPATIONAL [MH:NOEXP] OR DIET, ATHEROGENIC [MH:NOEXP] OR DIET, HIGH FAT 
[MH:NOEXP] OR DIETARY CARBOHYDRATES [MH:NOEXP] OR DIETARY FATS [MH:NOEXP] OR DIETARY 
FATS, UNSATURATED [MH:NOEXP] OR DIETARY FIBER [MH:NOEXP] OR DIETARY SUCROSE [MH:NOEXP] 
OR DOMESTIC VIOLENCE [MH:NOEXP] OR DRUG CONTAMINATION [MH:NOEXP] OR DRUG ERUPTIONS 
[MH:NOEXP] OR DRUG HYPERSENSITIVITY [MH:NOEXP] OR DRUG OVERDOSE [MH:NOEXP] OR DRUG-
INDUCED LIVER INJURY [MH:NOEXP] OR DYSKINESIA, DRUG INDUCED [MH:NOEXP] OR EATING 
DISORDERS [MH:NOEXP] OR ENVIRONMENTAL EXPOSURE [MH:NOEXP] OR ENVIRONMENTAL ILLNESS 
[MH:NOEXP] OR ENVIRONMENTAL POLLUTANTS [MH:NOEXP] OR ENVIRONMENTAL POLLUTION 
[MH:NOEXP] OR ENVIRONMENTAL POLLUTION [MH:NOEXP] OR ESCHERICHIA COLI INFECTIONS 
[MH:NOEXP] OR FAST FOODS [MH:NOEXP] OR FLUORIDE POISONING [MH:NOEXP] OR FOOD ADDITIVES 
[MH:NOEXP] OR FOOD CONTAMINATION [MH:NOEXP] OR FOOD HYPERSENSITIVITY [MH:NOEXP] OR 
FOODBORNE DISEASES [MH:NOEXP] OR GAS POISONING [MH:NOEXP] OR HAZARDOUS SUBSTANCES 
[MH:NOEXP] OR HAZARDOUS WASTE [MH:NOEXP] OR HEARING LOSS, NOISE INDUCED [MH:NOEXP] OR 
HEAVY METAL POISONING, NERVOUS SYSTEM [MH:NOEXP] OR HEPATITIS A, CHRONIC [MH:NOEXP] OR 
HEPATITIS B, CHRONIC [MH:NOEXP] OR HEPATITIS C, CHRONIC [MH:NOEXP] OR HEROIN DEPENDENCE 
[MH:NOEXP] OR HERPESVIRIDAE INFECTIONS [MH:NOEXP] OR HTLV I INFECTIONS [MH:NOEXP] OR 
HYPERSENSITIVITY [MH:NOEXP] OR HYPERSENSITIVITY, DELAYED [MH:NOEXP] OR HYPERSENSITIVITY, 
IMMEDIATE [MH:NOEXP] OR IATROGENIC DISEASE [MH:NOEXP] OR INHALATION EXPOSURE 
[MH:NOEXP] OR IRON OVERLOAD [MH:NOEXP] OR LEAD POISONING [MH:NOEXP] OR LEAD POISONING, 
NERVOUS SYSTEM [MH:NOEXP] OR LEAD POISONING, NERVOUS SYSTEM, ADULT [MH:NOEXP] OR LEAD 
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POISONING, NERVOUS SYSTEM, CHILDHOOD [MH:NOEXP] OR LEUKEMIA, RADIATION INDUCED 
[MH:NOEXP] OR MANGANESE POISONING [MH:NOEXP] OR MARIJUANA ABUSE [MH:NOEXP] OR 
MATERNAL EXPOSURE [MH:NOEXP] OR MERCURY POISONING [MH:NOEXP] OR MERCURY POISONING, 
NERVOUS SYSTEM [MH:NOEXP] OR MORPHINE DEPENDENCE [MH:NOEXP] OR MPTP POISONING 
[MH:NOEXP] OR MUSHROOM POISONING [MH:NOEXP] OR MUTAGENICITY TESTS [MH:NOEXP] OR 
MUTAGENS [MH:NOEXP] OR NEOPLASMS, RADIATION INDUCED [MH:NOEXP] OR NEUROTOXICITY 
SYNDROMES [MH:NOEXP] OR OCCUPATIONAL DISEASES [MH:NOEXP] OR OCCUPATIONAL EXPOSURE 
[MH:NOEXP] OR OPIOID RELATED DISORDERS [MH:NOEXP] OR OPPORTUNISTIC INFECTIONS 
[MH:NOEXP] OR ORGANOPHOSPHATE POISONING [MH:NOEXP] OR PATERNAL EXPOSURE [MH:NOEXP] 
OR PLANT POISONING [MH:NOEXP] OR PNEUMONIA, VENTILATOR-ASSOCIATED [MH:NOEXP] OR 
POISONING [MH:NOEXP] OR POISONS [MH:NOEXP] OR PRENATAL EXPOSURE DELAYED EFFECTS 
[MH:NOEXP] OR PSYCHOSES, SUBSTANCE INDUCED [MH:NOEXP] OR RADIATION EFFECTS [MH:NOEXP] 
OR RADIATION INJURIES [MH:NOEXP] OR RADIOACTIVE HAZARD RELEASE [MH:NOEXP] OR RADIOACTIVE 
POLLUTANTS [MH:NOEXP] OR RESPIRATORY HYPERSENSITIVITY [MH:NOEXP] OR SALMONELLA FOOD 
POISONING [MH:NOEXP] OR SEDENTARY LIFESTYLE [MH:NOEXP] OR SHELLFISH POISONING [MH:NOEXP] 
OR SLEEP DEPRIVATION [MH:NOEXP] OR SLEEP DISORDERS [MH:NOEXP] OR SODIUM CHLORIDE, 
DIETARY [MH:NOEXP] OR SODIUM, DIETARY [MH:NOEXP] OR SOIL POLLUTANTS [MH:NOEXP] OR SOIL 
POLLUTANTS, RADIOACTIVE [MH:NOEXP] OR SPOUSE ABUSE [MH:NOEXP] OR STAPHYLOCOCCAL FOOD 
POISONING [MH:NOEXP] OR STAPHYLOCOCCAL INFECTIONS [MH:NOEXP] OR STREPTOCOCCAL 
INFECTIONS [MH:NOEXP] OR SUBSTANCE ABUSE, INTRAVENOUS [MH:NOEXP] OR SUBSTANCE 
WITHDRAWAL SYNDROME [MH:NOEXP] OR SUBSTANCE-RELATED DISORDERS [MH:NOEXP] OR 
TERATOGENS [MH:NOEXP] OR TOBACCO SMOKE POLLUTION [MH:NOEXP] OR TOBACCO USE DISORDER 
[MH:NOEXP] OR TOXICITY TESTS, CHRONIC [MH:NOEXP] OR VIRUS DISEASES [MH:NOEXP] OR VITAMIN D 
DEFICIENCY [MH:NOEXP] OR WATER POLLUTANTS [MH:NOEXP] OR WATER POLLUTANTS, CHEMICAL 
[MH:NOEXP] OR WATER POLLUTANTS, RADIOACTIVE [MH:NOEXP] OR WATER POLLUTION [MH:NOEXP] 
OR WATER POLLUTION, CHEMICAL [MH:NOEXP]) 
 
 
(return to TOC) 
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APPENDIX 3 – AD CONTRIBUTING FACTOR AND TREATMENT IDENTIFICATION METHODOLOGY 
SDM-2.  Detailed Methodology 
SDM-2A. Identification of Foundational Causes of AD 
SDM-2A1. Overview 
 This study focuses on identifying Direct (and some Indirect) AD foundational causes.  It 
extrapolates and extends the identification techniques used in the chronic kidney disease (CKD) study 
(Kostoff and Patel, 2015) and in the eBook on identifying foundational causes for 'all' diseases (Kostoff, 
2015). In the CKD study, approximately 900 direct and indirect potential foundational causes of CKD 
were identified (as well as direct and indirect treatments), and in the eBook, approximately 800 
potential pervasive foundational causes of disease were identified ('pervasive' meant that the 
foundational cause listed contributed to some threshold number of different diseases). 
 The present study had two main components, with a different approach and different search 
engine for each component.  The earlier component involved 1) using a novel targeted query to retrieve 
records with high probability of containing AD foundational causes, and then 2) performing a visual 
inspection (reading) of the retrieved records.  The later component involved retrieving all the records in 
the AD core literature, then using advanced text mining techniques to extract phrases from text fields 
(and MeSH terms from the MeSH field) that had high probability of being foundational causes. 
SDM-2A2. Database/ Search Engine Selection 
 The first step in designing and developing a specific query for retrieving records is identifying the 
databases(s) and search engine(s) that will be used in the retrieval process, since the query format has 
to be tailored to the database and search engine characteristics. Medline was selected as the database 
to be used, since it is the main repository of records from the premier biomedical journals. The Thomson 
Reuters version of the Medline search engine was used for the initial visual inspection component of the 
AD study, since the Thomson search engine had the proximity search capability compatible with query 
terms.  The Pubmed version of the Medline search engine was used for the later 'streamlined' 
component of the AD study, since the phrase extraction approach did not require proximity searching.  
SDM-2A3. Visual Inspection Component 
 To define candidate query terms, an AD core literature consisting of about 100,000 Medline 
records was downloaded and examined.  The higher frequency MeSH terms associated with the AD core 
literature records were examined manually, and those MeSH terms that appeared to relate to 
foundational causes were evaluated for relevance. Nominally, ten records that contained each 
candidate causes MeSH term were examined, and if relevance was about 70% or beyond, the MeSH 
term was selected. In borderline cases, more MeSH terms were sampled until definitive conclusions 
could be drawn. Relevant does not mean unanimity or consensus was achieved for causes. Non-
agreement with the majority could have been attributable to poor research, research with a pre-
determined agenda (e.g., Kostoff, 2015, 2016), or selection of a 'window' in parameter space different 
from where the cause was operable. But, if cause was found operable in a few of the sampled papers for 
a given MeSH term, the term was deemed sufficiently important to select for the query. 
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 These higher frequency MeSH terms were then matrixed with all MeSH terms in the retrieval.  
Lower frequency MeSH term candidates were identified through strong co-occurrence with the higher 
frequency terms, and the lower frequency terms were subsequently validated. Then, a separate 
database was generated consisting of all the records that included these high and low frequency 
selected MeSH terms. In this new database, the higher frequency Abstract phrases were examined, and 
those that appeared to relate to potential causes were evaluated for relevance. A similar procedure to 
that used for causes MeSH term selection was followed. The higher frequency Abstract phrases, and 
some generic Abstract phrases related to causes (e.g., expos*, induc*, etc), were matrixed with all 
Abstract phrases to identify lower frequency phrase candidates through strong co-occurrence. 
 Eventually, all the MeSH terms were read and examined, and a few low frequency terms that 
were missed with the co-occurrence procedure were added to the list. The same was not possible with 
the Abstract phrases. While there were thousands of MeSH terms (readable, although visually 
intensive), there were millions of Abstract phrases.  
 As stated in the Introduction, only foundational causes were evaluated in this study. There were 
six main types of foundational causes: Lifestyle, Iatrogenic, Biotoxic, Occupational/Environmental, 
Psychosocial/Socioeconomic, and Genetics. Since the purpose of this study is to identify specific causes 
to eliminate in order to prevent/halt/reverse AD, and since relatively little can be done at this time to 
alter the genetics foundational causes, the genetics causes were not included in the final queries. 
 The overall query structure was of the generic form [Cause][Produces][Symptom]. Two of the 
three would be specified in the query, directly or implicitly, and the retrieval would provide the third. 
Examples from causes query: 
a. Cause near Produces: steroid-induc* or diet-induc* OR antibiotic near/1 cause*. These are generic or 
specific members of classes of potential causes in proximity to Produces-type terms. The classes tend to 
be drugs, diets, chemicals, radiation sources, etc. The Produces-type terms are necessary since drugs, 
diets, etc can be either beneficial or harmful, depending on circumstances (e.g., a chemotherapeutic 
drug can be helpful for treating cancer, but may also produce cognitive decline). 
b. Produces near Symptom: cause* near/5 "cognitive decline" NOT "cognitive decline cause*" 
c. Cause near Symptom: *Bacterium or pentachloro* in title, with either Symptom in title or in MeSH. If 
Abstracts are searched, stronger proximity conditions are required; e.g., *Bacterium near/5 Symptom. 
Unlike case a) above, in this case the causes are specific members of classes of potential causes that 
usually don't have beneficial effects, and therefore don't require proximity to causes-like terms; the 
causative nature is implied by the substance. 
 Note on the above. The model used was [cause-produce-symptom], but a somewhat broader 
form could be: [cause-produce-adverse effects], of which Symptom is one way of describing an adverse 
effect. Thus, 'toxic*' or 'adverse effect*', or 'harm*' in the Title by itself, along with the Symptom in the 
Title or MeSH tends to be accompanied by the cause and the effect it has. 
 Additionally, many research articles addressing causes use the language [cause-
activates/inhibits/blocks-signaling pathway(s)] (e.g., "MicroRNA-222 promotes tumorigenesis via 
targeting DKK2 and activating the Wnt/beta-catenin signaling pathway"). The signaling pathways were 
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not used as part of the queries in this study, but a future more comprehensive and well-resourced study 
could include the signaling pathways in the queries; their incorporation would be straight-forward. 
Many research papers, especially at the more fundamental biological level, may not mention diseases or 
symptoms, but are written in the language of effects on signaling pathways, and these papers could be 
accessed by the appropriately-written queries.  To close the loop in this case, the link between altered 
signalling pathway and either AD or its surrogate endpoints would have to be established. 
 The final query used is shown in SDM-2A - Appendix 1.  The Thomson Medline AD core literature 
(from 1994-2014) consisted of 76663 records, and intersection of the query terms with this literature 
yielded 10,733 records.  The most recent 5,000 were inspected visually, and the relevant foundational 
causes were extracted. 
SDM-2A4. Streamlined Component 
SDM-2A4a. Overview  
 An AD core literature consisting of 99,610 records was downloaded from Pubmed on 25 April 
2015.  Three streamlined sub-components were applied to this downloaded literature to extract AD 
foundational causes.   
 The first sub-component used only MeSH Qualifiers to filter downloaded records and extract 
potential foundational causes.  The second sub-component used  MeSH terms (relatively unambiguously 
related to foundational causes) to filter downloaded records and extract potential foundational causes.  
The third sub-component used text terms (applied to the Title and Abstract fields) to filter downloaded 
records and extract potential foundational causes. The results of the Visual Inspection component and 
the Streamlined component were integrated to produce the final AD foundational causes, as shown in 
the taxonomy of SDM-3.   
SDM-2A4b. MeSH-Based Approach 
SDM-2A4b1.  MeSH Qualifiers Approach 
 An offshoot of the MeSH Qualifier concept was used for identifying foundational causes. MeSH 
Headings have a number of Qualifiers associated with them to allow focus on items of interest. Thus, the 
MeSH term Cadmium/ toxicity allows records to be retrieved related to the toxicity of Cadmium. These 
MeSH Qualifiers may be perceived as linking terms to the MeSH Headings, allowing for 'surgical' 
extraction of MeSH Headings that meet desired criteria. Thus, if MeSH Qualifiers strongly related to 
foundational causes can be identified, they can be used to identify MeSH Headings that are potential 
foundational causes of disease. 
 There are 83 topical MeSH Qualifiers used for indexing and cataloging in conjunction with MeSH 
Heading descriptors in Pubmed (as of 2015). All 83 were examined in more or less detail for applicability 
to identifying foundational causes of disease. For the initial Visual Inspection approach query, three 
were selected as producing  relevant results when used in isolation: chemically induced, toxicity, 
poisoning.   
 The Streamlined approach was performed one year after the Visual Inspection approach, with 
one year's experience working with the selected MeSH qualifiers.  The MeSH qualifiers were re-
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examined for the Streamlined approach, and four were selected (after extensive validation) as 
producing highly relevant results when used in isolation: adverse effects, toxicity, pathogenicity, 
poisoning. A few limited combinations of the remaining MeSH Qualifiers were examined for the 
Streamlined approach, but none were deemed to have sufficient relevance.  
 All MeSH terms that contained at least one of these qualifiers were extracted, and the related 
records examined for potential foundational causes.  While this MeSH Qualifier linking approach was 
developed for, and applied to, potential foundational causes, it can be easily modified for identifying 
potential treatments, identifying potential biomarkers, identifying potential mechanisms, etc. 
SDM-2A4b2. MeSH Headings Approach 
 MeSH Headings related relatively unambiguously to foundational causes were identified two 
ways. First, results from past studies were examined, especially (Kostoff and Patel, 2015; Kostoff, 2015), 
and relevant MeSH Headings were extracted. Second, a few of the most unambiguous MeSH terms 
identified from past studies were entered into Pubmed as query terms, and all the MeSH terms in the 
resultant retrieval (i.e., those that co-occurred with the entry MeSH terms) were examined for 
relevance.  The final list of relevant MeSH terms (SDM-2A - Appendix 2) was intersected with the total 
list of MeSH terms in the retrieved database, and the resulting records were examined for potential AD 
foundational causes.  Again, while this focused MeSH Heading approach was developed for identifying 
potential foundational causes, it could (with some work) be adapted to identifying potential treatments, 
potential biomarkers, potential mechanisms, etc. 
SDM-2A4c. Text-Based Approach 
SDM-2A4c1. Title Linking Phrases Approach 
 Because of MeSH terms' limitations (not all Medline records have MeSH descriptors, not all 
MeSH terms are included in those records that have MeSH terms, not all MeSH descriptors used have 
appropriate Qualifiers attached. etc), a text-based approach for identifying causes was added. Because 
of 1) the large number of phrases in a record's Abstract compared to the Title, and 2) computer storage 
and software limitations, the bulk of the analysis was performed on the Title phrases.  A more limited 
analysis was performed on the Abstract phrases, and is shown in Section SDM-2A4c3 - Abstract Linking 
Phrases Approach. 
 There were millions of Title phrases that had to be evaluated for potential causes. Only the 
highest frequency phrases could be inspected visually. To access the lower frequency terms, a number 
of linking terms were identified. 
 The linking terms were generated through visually inspecting many records containing 
foundational causes in the Titles, and identifying those terms that appeared frequently with the 
foundational causes. These linking terms include: -induced; caused by; induced by; -contaminated; 
exposure to; exposure(s) [at end of phrase]; exposed to; poisoning [at end]; -exposed [at end]; -related; -
associated; -infected; abuse*; toxicity. The phrases that included the linking terms eventually had to be 
separated from the linking terms to identify the specific foundational causes. Other linking terms were 
virus* and generic bacterial headings, but these did not have to be separated from the phrases. 
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SDM-2A4c2. Title Dot Product Approach 
 Finally, potential foundational causes from myriad other sources (including past foundational 
causes studies, government-approved lists of toxic substances, MeSH-derived causes, etc) were 
intersected with the full list of Title phrases, and added to the potential foundational causes identified in 
the Linking Phrases approach. 
 While the Title phrase linking terms were developed specifically for identifying causes, a similar 
approach could be used to develop linking terms for identifying potential treatments, potential 
biomarkers, or potential mechanisms. Moreover, there could be substantial benefits gained by using 
Abstracts for phrase generation rather than Titles, and even full-text rather than Abstracts. While use of 
proximity queries with the linking terms in the Title were not required, they would be required for use in 
Abstracts or full-text. Adding proximity capability would be a minor modification to the form of the 
query developed below. The major issue would be switching to a database search engine that had the 
capability of proximity searching. 
SDM-2A4c3 - Abstract Linking Phrases Approach 
 Given the size and breadth of Abstracts relative to Titles, most of the linking terms used to 
extract causes from the Title were relatively inefficient in extracting foundational causes from the 
Abstract.  Variants of induc* and expos* were used to link to potential foundational causes in Abstract 
records, and these extracted terms received the same treatment as those from the Title. 
 The myriad potential foundational causes from the Visual Inspection component and the 
Streamlined component were combined. 
SDM-2A5 - Validation of Potential Foundational Causes 
 There were 9427 potential foundational causes that resulted from combination of the above 
sources.  Each of these terms had to be validated before inclusion in the final AD potential foundational 
causes taxonomy.  The validation process was as follows. 
 The Thomson Medline search engine was the main vehicle used for validation, although in some 
cases Thomson Science Citation Index Expanded (SCI) had to be used, and in a very few cases, Pubmed 
was used.  A query consisting of two components was entered into the search engine.  The first 
component covered the core AD literature: Alzheimer* OR dementia in Title or MeSH.  The second 
component was the potential foundational cause to be validated (e.g., smoking).  The two components 
were intersected (e.g., (alzheimer* OR dementia) AND smoking), and some/all of the records retrieved 
were read.  The evidence for linkages between the potential foundational cause and Alzheimer's Disease 
directly or surrogate endpoints was evaluated critically.  This was a difficult process, compounded by the 
fact that adverse effects of toxic stimuli may be under-reported/mis-reported (Kostoff, 2016). 
 Because of the presence of duplicate terms and concepts, not all the 9427 potential 
foundational cause terms had to be read with the same level of certainty.  Many could be eliminated by 
inspection, as long as the duplication was perceived. 
SDM-2A - Appendix 1 - Alzheimer's Disease Causes Query - Visual Inspection Approach  
Prevention and Reversal of Chronic Disease                           Copyright © 2019 RN Kostoff 
99 
 








(streptozotocin OR scopolamine OR colchicine OR LPS-induc* OR polymorphism* OR abeta-induc* OR 
"beta-amyloid-induc*" OR "amyloid-beta-induc*" OR "beta-amyloid peptide-induc*" OR "abeta25-35-
induc*" OR "abeta25-35 peptide-induc*" OR abeta40-induc* OR nontoxic OR non-toxic)  
AND 
Remainder of Query Intersected with Core Literature 
2. TEXT FIELD TERMS 
2A. NON-LIFESTYLE-SPECIFIC COMPONENT - TOPIC 
 ("2,4,6- triiodobenzoic acid" OR "3-deazaneplanocin A" OR "5AZA" OR "5-aza-deoxycytidine" OR "5-
fluorouracil" OR "9-alpha fluorocortisol" OR "9-alpha fluoroprednisolone" OR "9-hydroxy-2-
methylellipticinium" OR "acarbose" OR "ACE inhibitor*" OR "acetaminophen" OR "acetazolamide" OR 
"acetylsalicylic acid" OR "acyclovir" OR "adalimumab" OR "adefovir" OR "adriamycin" OR "alclofenac" OR 
"aliskiren" OR "alizapride" OR "allopurinol" OR "all-trans-retinoic acid" OR "alpha-
mercaptopropionylglycine" OR "amikacin" OR "Aminoglycoside*" OR "Amiodarone" OR "amitriptyline" 
OR "amlodipine" OR "amoxicillin" OR "amphetamine*" OR "amphotericin b" OR "ampicillin" OR 
"ampiroxicam" OR "anabolic steroid*" OR "Anaesthetic*" OR "Analgesic*" OR "anasthesia" OR 
"androgen deprivation therapy" OR "anesthetic*" OR "anthracycline" OR "antiadrenergic agent*" OR 
"anti-adrenergic agent*" OR "antiadrenergic drug*" OR "anti-adrenergic drug*" OR "antiallergic agent*" 
OR "Anti-Allergic agent*" OR "antiallergic drug*" OR "Anti-Allergic drug*" OR "antiandrogen* agent*" 
OR "anti-androgen* agent*" OR "antiandrogen* drug*" OR "anti-androgen* drug*" OR "antianginal 
agent*" OR "anti-anginal agent*" OR "antianginal drug*" OR "anti-anginal drug*" OR "antiangiogenesis 
agent*" OR "anti-angiogenesis agent*" OR "antiangiogenesis drug*" OR "anti-angiogenesis drug*" OR 
"antiarrhythmic agent*" OR "antiarrhythmic drug*" OR "anti-arrythmatic agent*" OR "anti-arrythmatic 
drug*" OR "antiasthmatic agent*" OR "anti-asthmatic agent*" OR "antiasthmatic drug*" OR "anti-
asthmatic drug*" OR "antibacterial agent*" OR "Anti-bacterial agent*" OR "antibacterial drug*" OR 
"Anti-bacterial drug*" OR "antibiotic*" OR "antibone-loss agent*" OR "Anti-Bone-Loss agent*" OR 
"antibone-loss drug*" OR "Anti-Bone-Loss drug*" OR "anticholinergic agent*" OR "anti-cholinergic 
agent*" OR "anti-cholinergic drug*" OR "anticholinergic* drug*" OR "anticoagulant*" OR "Anti-
coagulant*" OR "anticonvulsant*" OR "anti-convulsant*" OR "antidepressant*" OR "anti-depressant*" 
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OR "Antidiabetic agent*" OR "anti-diabetic agent*" OR "Antidiabetic drug*" OR "anti-diabetic drug*" OR 
"antidiarrheal agent*" OR "anti-diarrheal agent*" OR "antidiarrheal drug*" OR "anti-diarrheal drug*" OR 
"anti-emetic" OR "antiemetic*" OR "antifungal agent*" OR "anti-fungal agent*" OR "antifungal drug*" 
OR "anti-fungal drug*" OR "antigonadotropic agent*" OR "anti-gonadotropic agent*" OR 
"antigonadotropic drug*" OR "anti-gonadotropic drug*" OR "antigout agent*" OR "anti-gout agent*" OR 
"antigout drug*" OR "anti-gout drug*" OR "antihistamine agent*" OR "anti-histamine agent*" OR 
"antihistamine drug*" OR "anti-histamine drug*" OR "Antihypertensive agent*" OR "anti-hypertensive 
agent*" OR "Antihypertensive drug*" OR "anti-hypertensive drug*" OR "antiinfective agent*" OR "Anti-
Infective agent*" OR "antiinfective drug*" OR "Anti-Infective drug*" OR "anti-infective*" OR 
"antiinflammatory agent*" OR "Anti-Inflammatory agent*" OR "antiinflammatory drug*" OR "Anti-
Inflammatory drug*" OR "antimalarial agent*" OR "anti-malarial agent*" OR "antimalarial drug*" OR 
"anti-malarial drug*" OR "antimetabolite agent*" OR "anti-metabolite agent*" OR "antimetabolite 
drug*" OR "anti-metabolite drug*" OR "antimigraine agent*" OR "anti-migraine agent*" OR 
"antimigraine drug*" OR "anti-migraine drug*" OR "Antineoplastic Agent*" OR "anti-neoplastic agent*" 
OR "Antineoplastic drug*" OR "anti-neoplastic drug*" OR "antiparkinson agent*" OR "anti-parkinson 
agent*" OR "antiparkinson drug*" OR "anti-parkinson drug*" OR "antiplatelet agent*" OR "anti-platelet 
agent*" OR "antiplatelet drug*" OR "anti-platelet drug*" OR "antipseudomonal agent*" OR "anti-
pseudomonal agent*" OR "antipseudomonal drug*" OR "anti-pseudomonal drug*" OR "antipsoriatic 
agent*" OR "anti-psoriatic agent*" OR "antipsoriatic drug*" OR "anti-psoriatic drug*" OR "Antipsychotic 
Agent*" OR "Anti-psychotic agent*" OR "Antipsychotic drug*" OR "Anti-psychotic drug*" OR 
"Antiretroviral Agent*" OR "Anti-retroviral Agent*" OR "Antiretroviral drug*" OR "Antiretroviral drug*" 
OR "antiretroviral therapy" OR "Antirheumatic Agent*" OR "anti-rheumatic agent*" OR "Antirheumatic 
drug*" OR "anti-rheumatic drug*" OR "antiseptic agent*" OR "anti-septic agent*" OR "antiseptic drug*" 
OR "anti-septic drug*" OR "antispasmodic agent*" OR "anti-spasmodic agent*" OR "antispasmodic 
drug*" OR "anti-spasmodic drug*" OR "anti-thymocyte serum" OR "Antithyroid Agent*" OR "Anti-
thyroid Agent*" OR "Antithyroid drug*" OR "Anti-thyroid drug*" OR "antitoxin*" OR "anti-toxin*" OR 
"antituberculosis agent*" OR "anti-tuberculosis agent*" OR "antituberculosis drug*" OR "anti-
tuberculosis drug*" OR "antitussive agent*" OR "anti-tussive agent*" OR "antitussive drug*" OR "anti-
tussive drug*" OR "antivenin*" OR "antivertigo agent*" OR "anti-vertigo agent*" OR "antivertigo drug*" 
OR "anti-vertigo drug*" OR "Antiviral agent*" OR "Anti-viral agent*" OR "Antiviral drug*" OR "Anti-viral 
drug*" OR "aprotinin" OR "aspirin" OR "AT1 receptor antagonists" OR "atazanavir" OR "atorvastatin" OR 
"axitinib" OR "azacitadine" OR "azathioprine" OR "azithromycin" OR "Azole*" OR "Barbiturate*" OR 
"bardoxolone methyl" OR "benfluorex" OR "benoxaprofen" OR "beta-lactam" OR "bevacizumab" OR 
"bezafibrate" OR "bisacodyl" OR "Bisphosphonate*" OR "Bleomycin" OR "bortezomib" OR "bucillamine" 
OR "bupivacaine" OR "buspirone" OR "caffeine" OR "calcineurin inhibitor*" OR "calcitriol" OR "Calcium 
Channel Blocker" OR "Calcium channel blocker*" OR "capecitabine" OR "captopril" OR "carbamazepine" 
OR "carbenoxolone" OR "carbimazole" OR "carboplatin" OR "Cardiovascular Agent*" OR "carmustine" 
OR "C-arylsuccinimides" OR "cediranib" OR "cefdinir" OR "cefoxitin" OR "ceftriaxone" OR "cefuroxime" 
OR "celecoxib" OR "Central Nervous System Agent*" OR "cephaloridine" OR "cephalosporins" OR 
"Cephems" OR "cetuximab" OR "chlorambucil" OR "Chloramphenicol" OR "chlormezanone" OR 
"chloroquine" OR "Chlorpromazine" OR "chlorprothixene" OR "chlorthalidone" OR "cidofovir" OR 
"cimetidine" OR "ciprofibrate" OR "ciprofloxacin" OR "cisplatin" OR "clarithromycin" OR "clometacin" OR 
"clomipramine" OR "clopentixol" OR "clopidogrel" OR "cloxacillin" OR "clozapine" OR "colchicine" OR 
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"colistin" OR "contrast medium" OR "coronary artery bypass" OR "corosolic acid" OR "Corticosteroid*" 
OR "cyclophosphamide" OR "cycloserine" OR "cyclosporine" OR "cytarabine" OR "cytosine arabinoside" 
OR "dasatinib" OR "daunomycin" OR "daunorubicin" OR "decitabine" OR "deferasirox" OR 
"deferoxamine" OR "demeclocycline" OR "deoxycorticosterone acetate" OR "desipramine" OR 
"dexamethasone" OR "dexfenfluramine" OR "dexmethylphenidate" OR "dextran" OR "diaziquone" OR 
"diclofenac" OR "didecyldimethylammonium chloride" OR "diethyacetylurea" OR "diflunisal" OR 
"Digitalis" OR "diltiazem" OR "diphenylhydantoin" OR "diphosphonates" OR "dipivalyl adrenaline 
hydrochloride" OR "dipyrone" OR "disopyramide" OR "Diuretic*" OR "doxepin" OR "doxorubicin" OR 
"doxycycline" OR "d-penicillamine" OR "dRK6" OR "efavirenz" OR "enoxaparin" OR "epoetin" OR 
"erythromycin" OR "erythropoietin" OR "esomeprazole" OR "etanercept" OR "ethambutol" OR 
"ethosuximide" OR "famotidine" OR "fenbufen" OR "fenclofenac" OR "fenfluramine" OR "fenofibrate" 
OR "fenoldopam" OR "fenoprofen" OR "Fibrate therapy" OR "flubiprofen" OR "flucloxacillin" OR 
"fluindione" OR "Fluoroquinolones" OR "flupenthixol" OR "fluphenazine" OR "flurbiprofen" OR 
"flurithromycin" OR "fondaparinux sodium" OR "foscarnet" OR "furantoin" OR "furosemide" OR "fusidic 
acid" OR "FYX-051" OR "gabapentin" OR "gadodiamide" OR "Gadolinium" OR "gadopentetate 
dimeglumine" OR "Gastrointestinal Agent*" OR "gatifloxacin" OR "GBCA" OR "GCCA" OR "gefitinib" OR 
"gemcitabine" OR "gemfibrozil" OR "gentamicin" OR "germicide*" OR "Glucocorticoid*" OR 
"glycyrrhizinic acid" OR "Haloperidol" OR "Halothane" OR "Hematologic Agent*" OR "heparin" OR 
"hetastarch" OR "high insulin" OR "hydralazine" OR "hydrochlorothiazide" OR "hydroxychloroquine" OR 
"hydroxyethylstarch" OR "hydroxymethylglutaryl-CoA reductase inhibitor*" OR "hylan G-F 20" OR 
"Hypnotic Agent*" OR "iatrogenic" OR "ibuprofen" OR "ifosfamide" OR "IGF-1" OR "iloprost" OR 
"imatinib" OR "imipramine" OR "imiquimod" OR "Immunosuppressive Agent*" OR "indinavir" OR 
"indomethacin" OR "infliximab" OR "Interferon*" OR "intravenous immunoglobulin*" OR "Iodine" OR 
"iodixanol" OR "iohexol" OR "ionizing radiation" OR "iopamidol" OR "ioxilan" OR "iron sucrose" OR "iron-
induced" OR "iron-overload" OR "isocarboxazid" OR "isoniazid" OR "isoprenaline" OR "ketamine" OR 
"Ketoconazole" OR "ketoprofen" OR "ketorolac" OR "lansoprazole" OR "lapatinib" OR "leflunomide" OR 
"levetiracetam" OR "levofloxacin" OR "Lipid Regulating Agent*" OR "lithium" OR "lopinavir" OR 
"loratadine" OR "loxapine" OR "mannitol" OR "maprotiline" OR "mefanamic acid" OR "meropenem" OR 
"mesalamine" OR "mesalazine" OR "mesoridazine" OR "metamizole" OR "metformin" OR "methicillin" 
OR "methimazole" OR "methocarbamol" OR "methotrexate" OR "methotrimeprazine" OR 
"methoxyflurance" OR "methyldopa" OR "methylphenidate" OR "methysergide" OR "metolazone" OR 
"metoprolol" OR "Metronidazole" OR "midecamycin acetate" OR "Mineralcorticoid*" OR "minocycline" 
OR "mirtazapine" OR "mitomycin" OR "Mood Stabilizer*" OR "morphine" OR "Movement Stabilizer*" OR 
"moxifloxacin" OR "Muscle Relaxant*" OR "Mustard gas" OR "muzolimine" OR "nafcillin" OR 
"naphazoline hydrochloride" OR "naproxen" OR "N-arylsuccinimides" OR "Nasal decongestant*" OR 
"nelfinavir" OR "neomycin" OR "Niacin" OR "nifedipine" OR "niflumic acid" OR "nimesulide" OR 
"nitrendipine" OR "nitrofurantoin" OR "nitrogen mustard" OR "Nitroglycerin" OR "nitrosureas" OR 
"nomifensine" OR "Nonsteroidal anti-inflammatory drug*" OR "norepinephrine" OR "norfloxacin" OR 
"nortriptyline" OR "NSAID*" OR "NVP-BKM120" OR "ofloxasin" OR "olanzapine" OR "olmetin" OR 
"olsalazine" OR "omeprazole" OR "orlistat" OR "oxaliplatin" OR "oxymetazoline hydrochloride" OR 
"oxytetracycline" OR "ozurdex" OR "paliperidone" OR "pamidronate" OR "panitumumab" OR 
"pantoprazole" OR "papaverine" OR "paracetamol" OR "paroxetine" OR "pazopanib" OR "pefloxacin" OR 
"Penams" OR "penicillamine" OR "penicillin" OR "pentamidine" OR "pentazocine" OR "pericyazine" OR 
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"perphenazine" OR "phenacetin" OR "phenindione" OR "phenobarbital" OR "phenylbutazone" OR 
"phenylephrine" OR "phenylpropanolamine" OR "phenytoin" OR "phosphatidylinositol-3-kinase 
inhibitor*" OR "physostigmine" OR "pimozide" OR "piperacillin" OR "piroxicam" OR "pirprofen" OR 
"platalet aggregation inhibitor*" OR "polymyxin B" OR "pranlukast" OR "prednisolone" OR "Primaquine" 
OR "probenecid" OR "procainamide" OR "prochlorperazine" OR "propoxyphene" OR "propylthiouracil" 
OR "protamine" OR "Proton pump inhibitor*" OR "prulifloxacin" OR "pseudoephedrine hydrochloride" 
OR "ptu-induced" OR "puromycin" OR "quetiapine" OR "quinacrine" OR "quinidine" OR "quinine" OR 
"quinolone" OR "rabeprazole" OR "radiofrequency-induced cosmetic volume reduction" OR "ranitidine" 
OR "rapamycin" OR "rhuepo-induced" OR "rifampicin" OR "rifampin" OR "risperidone" OR "Ritalin" OR 
"ritodrine hydrochloride" OR "ritonavir" OR "rofecoxib" OR "rosuvastatin" OR "scopolamine" OR 
"selegiline" OR "sibutramine" OR "simvastatin" OR "sodium barbital" OR "sodium valproate" OR 
"sorafenib" OR "spirapril" OR "spironolactone" OR "Statin*" OR "Steroid*" OR "Stimulant*" OR 
"streptomycin" OR "streptozocin" OR "streptozotocin" OR "Succinimide derivative*" OR "sulfadiazine" 
OR "sulfamethoxazole" OR "sulfasalazine" OR "Sulfonamide*" OR "sulfonylureas" OR "sulfur mustard" 
OR "sulindac" OR "sulphinpyrazone" OR "sulpiride" OR "sunitinib" OR "superdrol" OR "tacrolimus" OR 
"Tamoxifen" OR "tazobactam" OR "telazol" OR "telithromycin" OR "tenofovir" OR "testosterone" OR 
"tetrabenazine" OR "Tetracycline*" OR "tetrahydrozoline hydrochloride" OR "tetrandrine" OR 
"thiazides" OR "thiopropazate" OR "thioproperazine" OR "Thioridazine" OR "thiothixene" OR 
"thrombolytic therapy" OR "ticlopidine" OR "tiletamine" OR "tiopronin" OR "tobramicin" OR 
"triamterene" OR "trichostatin A" OR "Tricyclics" OR "trimethadione" OR "trimethoprim" OR 
"trimipramine" OR "tripelennamine" OR "valdecoxib" OR "Valproic Acid" OR "valpromide" OR 
"vancomycin" OR "venlafaxine" OR "verapamil" OR "verteporfin" OR "warfarin" OR "whole-body 
irradiation" OR "wortmannin" OR "yohimbine" OR "zoledronate" OR "zopiclone" OR "zotepine" OR 
"zuclopenthixol" OR "4-HNE" OR "7-Ketocholesterol" OR "aflatoxin" OR "Aipysurus laevis venom" OR 
"amorimia exotropica" OR "anti-mouse-GBM sera" OR "AOPP-modified rat serum albumin" OR 
"apoferritin" OR "bee sting*" OR "beta-conglycinin" OR "bovine serum albumin" OR "cantharidin" OR 
"ceramide" OR "citrinin" OR "concanavalin A" OR "connective tissue growth factor" OR "cow milk 
processing" OR "CTGF" OR "cylindrospermopsin" OR "deoxynivalenol" OR "D-fructofuranosyl" OR 
"Endotoxin*" OR "Exotoxin*" OR "fumonisin B1" OR "homopolysaccharide" OR "indican" OR "indoxyl 
sulfate" OR "levan" OR "lipopolysaccharide" OR "lipopolysaccharide-induced" OR "L-NAME" OR "L-NNA" 
OR "lps-induced" OR "monocrotaline" OR "monosodium urate crystal" OR "mycobacterial infection*" OR 
"Mycotoxin*" OR "nephritogenoside" OR "NG-nitro-L-arginine methyl ester" OR "Nitroarginine" OR 
"nivalenol" OR "Nω-nitro-L-arginine" OR "oak toxicosis" OR "ochratoxin A" OR "Ochratoxin*" OR "O-
glycosylated IgA rheumatoid factor" OR "p-Cresyl sulfate" OR "PDGF-BB" OR "penicillic acid" OR 
"Platelet-derived growth factor-BB" OR "pufferfish tetrodotoxin" OR "quercus calliprinos" OR "scorpion 
sting*" OR "sea anemone Phyllodiscus semoni" OR "sea snake venom" OR "snake bite" OR "stinging 
insect venom" OR "tetrodotoxin" OR "Tityus serrulatus scorpion venom" OR "Tricothecene*" OR "U1-70-
kDa small nuclear ribonucleoprotein/snRPN70" OR "viper snake venom" OR "vomitoxin" OR "wasp 
sting*" OR "yew" OR "*Bacteri*" OR "*Chia" OR "*Ococcus" OR "*Omonas" OR "adenine" OR 
"Aspergillus " OR "Bartonella henselae" OR "beta-hemolysin " OR "Brucella" OR "Burkholderia 
pseudomallei" OR "C. difficile toxin A" OR "C. difficile toxin B" OR "Campylobacter jejuni" OR 
"Campylobacter jejuni" OR "Candida albicans" OR "Candida tropicalis" OR "Candidemia" OR "Capillaria 
hepatica" OR "Chlamydia pneumoniae" OR "Chlamydia" OR "Chlamydophila" OR "Citrobacter 
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rodentium" OR "Clostridium" OR "Corynebacterium diphtheriae" OR "diphtheria toxin" OR 
"Corynebacterium renale" OR "Dirofilaria immitis" OR "Echinococcus" OR "Ehrlichia canis" OR 
"Enterococcus faecalis" OR "Escherichia coli" OR "e. coli" OR "falciparum malaria" OR "malaria" OR 
"Fusarium graminearum" OR "Gemella haemolysans" OR "Haemophilus" OR "Helicobacter pylori" OR 
"Klebsiella pneumoniae" OR "leprosy" OR "Mycobacterium leprae" OR "Mycobacterium lepromatosis" 
OR "Leptospirosis" OR "leptospira" OR "marcescens" OR "Mycoplasma" OR "Neisseria" OR "Nematode*" 
OR "Parasite*" OR "Penicillium aurantiogriseum" OR "Penicillium aurantiogriseum" OR "Plasmodium 
brasilianum" OR "Propionibacterium acnes" OR "Proteus mirabilis" OR "Pseudomonas aeruginosa" OR 
"Rickettsia" OR "Rochalimaea" OR "salmonella" OR "Schistosoma haematobium" OR "Schistosoma 
mansoni" OR "Serratia marcescens" OR "staphylococcal infection*" OR "Staphylococcus aureus" OR 
"Streptococcus agalactiae" OR "Streptococcus mutans" OR "Streptococcus pyogenes" OR "streptococcal 
pyrogenic exotoxin B" OR "Thy-1.1 monoclonal antibody" OR "Toxocara canis" OR "Treponema" OR 
"Trichinella spiralis" OR "Trypanosoma brucei" OR "Tyrophagus putrescentiae" OR "Vibrio" OR "Yersinia" 
OR "*OBACTER" OR "*nitrophenol*" OR "*benzene" OR "*ethane" OR "*phthalate" OR "*toluene" OR 
"1,1,1-trichloroethane" OR "12-O-tetradecanoylphorbol-13-acetate " OR "1-methyl-4-phenylpyridinium" 
OR "2,3,5-triiodobenzoic acid" OR "2,3,7,8-tetrachlorodibenzo-p-dioxin" OR "2-Amino-4-
(ethylthio)butyric acid) " OR "acetaldehyde" OR "acrolein" OR "Air pollutant*" OR "air pollution" OR 
"aldrin" OR "alloxan" OR "alpha-Naphthylisothiocyanate" OR "aluminium" OR "aluminum" OR 
"ammonium perchlorate" OR "anti-trinitrophenol switch variant mAbs" OR "arsenic" OR "asbestos" OR 
"asphalt" OR "atrazine" OR "beryllium" OR "Bis(2-ethylhexyl) phthalate" OR "bismuth" OR "bitumen" OR 
"bromodichloromethane" OR "bromoform" OR "cadmium" OR "carbon tetrachloride" OR "cedar dust" 
OR "cerium oxide nanoparticles" OR "chloroform" OR "chlorpyrifos" OR "chromic acid " OR "chromium" 
OR "copper sulphate " OR "copper" OR "cotton pellets" OR "cyromazine" OR "decabrom*" OR "DEHP" 
OR "diazinon" OR "dibromochloromethane" OR "dichloro*" OR "diesel" OR "diethylene glycol" OR 
"dimethylnitrosamine " OR "dinitro*" OR "dinitrochlorobenzene" OR "dioxane" OR "dioxin " OR 
"domestic gas" OR "ethionine " OR "ethylene dibromide " OR "ethylene glycol" OR "fiberglass" OR 
"fibreglass" OR "fluoro-10-methyl-1-2-benzanthracene " OR "formaldehyde" OR "gasoline" OR 
"germanium" OR "glycerol" OR "grain dust" OR "halomethane* " OR "hcy-induced " OR "Heavy metal*" 
OR "Herbicide*" OR "hexabrom*" OR "hexachloro*" OR "hgcl2" OR "homocysteine" OR "house dust 
mite" OR "Hydrocarbons" OR "Insecticide*" OR "isopropyl alcohol" OR "jatropha curcas phorbol ester" 
OR "ketones" OR "malathion" OR "maleic vinyl ether anhydride " OR "Maneb" OR "melamine" OR 
"menadione sodium bisulfite" OR "mercuric chloride" OR "Mercury" OR "methyl tertiary-butyl ether " 
OR "methylene chloride" OR "methylglyoxal" OR "multiwalled carbon nanotube*" OR "N,N′-dimethyl-
4,4′-bipyridinium dichloride" OR "N,N'-diacetylbenzidine " OR "N-3-5-dichlorophenyl-succinimide" OR 
"nanocopper" OR "n-methyl-n 1-nitro-n-nitroso guanidine " OR "nonylphenol" OR "octylphenol" OR 
"oxalates" OR "oxidant-induced" OR "p-Aminophenol" OR "parachloro*" OR "paraphenylenediamine" 
OR "paraquat " OR "Particulates" OR "pb" OR "pentachloro*" OR "pentachlorophenol" OR 
"perchloroethylene" OR "perfluor*" OR "perfluoroalkyl chemicals" OR "perfluorooctane sulfonate" OR 
"perfluorooctanoic acid" OR "Pesticide*" OR "Phenols" OR "phenylenediamine " OR "picric acid" OR 
"plant growth regulator* " OR "polybrom*" OR "polychlor*" OR "polychlorinated organic compound* " 
OR "polyfluor*" OR "polymethyl methacrylate " OR "potassium bichromate " OR "pristane" OR "p-
xylene" OR "pyrinuron" OR "pyruvaldehyde " OR "silane " OR "silica" OR "silicon dioxide" OR "single wall 
carbon nanotube*" OR "styrene" OR "tetrabrom*" OR "tetrachloro*" OR "tetrachloroethylene" OR 
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"thioacetamide " OR "titanium dioxide nanoparticles" OR "toluene" OR "trichloro*" OR 
"trichloroethylene" OR "trimethylpentane" OR "trinitrobenzenesulfonic acid " OR "Trinitrophenol" OR 
"uranium" OR "uranyl nitrate" OR "vacor" OR "wood dust" OR "wood preservatives" OR "xylene" OR 
"zinc phosphide" OR "sediment-associated" OR "particle-associated" OR "traffic-related" OR "work-
related" OR EMF) near/20 ("poison*" OR "ecotoxologic* effect*" OR "occupation*" OR pollut* OR 
"*virus*" OR environmental OR "induc*" OR "damage-caus*" OR "drug*-caus*" OR "infect*-caus*" OR 
"chemotherapy-caus*" OR "treat*-caus*" OR "anesthesia-caus*" OR "chemical*-caus*" OR "cytokine*-
caus*" OR "surg*-caus*" OR "radiation-caus*" OR "steroid-caus*" OR "mechanically-caus*" OR 
"promot* progression" OR "caus* accumulation" OR "caus* * accumulation" OR "progression of" OR 
expos* OR contamina* OR chemicals OR abuse* OR induc* OR "long-term effect*" OR "inhibit* 
*protection" OR dysfunction* OR aggregation OR accumulation OR "disease link* to" OR "chemical 
initiator*" OR "stimulat* microglia" OR "activat* microglia" OR "increas* risk*" OR "increas* the risk*" 
OR "adverse event*" OR "adverse reaction*" OR "adverse * event*" OR "adverse * reaction" OR 
"adverse effect*" OR "adverse * effect*" OR hypersensitivity OR aggravat* OR exacerbat* OR 
detriment* OR "caus* *toxi*" OR "increas* *toxi" OR "produc* *toxi*" OR "enhanc* *toxi*" OR 
"stimulat* *toxi*" OR "accelerat* *toxi*" OR "caus* degrad*" OR "increas* degrad*" OR "caus* 
damag*" OR "increas* damag*" OR "caus* * *toxi*" OR "increas* * *toxi" OR "produc* * *toxi*" OR 
"enhanc* * *toxi*" OR "stimulat* * *toxi*" OR "accelerat* * *toxi*" OR "caus* * degrad*" OR "increas* 
* degrad*" OR "caus* * damag*" OR "increas* * damag*" OR "*toxi* caus* by" OR "*toxi* increas* by" 
OR "*toxi* produc* by" OR "*toxi* enhanc* by" OR "*toxi* stimulat* by" OR "*toxi* accelerat* by" OR 
"damag* caus* by" OR "*damag* increas* by" OR deleterious OR deteriorat* OR trigger* OR  worsen* 
OR harm* OR hazard* OR "side-effect*" OR dangerous OR destructive OR injurious OR unsafe OR 
"increas* amyloid-beta" OR "increas* beta-amyloid" OR "increas* abeta" OR "increas* senile plaque*" 
OR "increas* tau aggregat*" OR "increas* T-tau" OR "increas* P-tau" OR "increas*total tau" OR 
"increas* phospho-tau" OR "increas* tau protein*" OR "increas* hyperphosphorylated tau" OR 
"increas* neurofibrillary tangle*" OR "enhanc* amyloid-beta" OR "enhanc* beta-amyloid" OR "enhanc* 
abeta" OR "enhanc* senile plaque*" OR "enhanc* tau aggregat*" OR "enhanc* T-tau" OR "enhanc* P-
tau" OR "enhanc*total tau" OR "enhanc* phospho-tau" OR "enhanc* tau protein*" OR "enhanc* 
hyperphosphorylated tau" OR "enhanc* neurofibrillary tangle*" OR "stimulat* amyloid-beta" OR 
"stimulat* beta-amyloid" OR "stimulat* abeta" OR "stimulat* senile plaque*" OR "stimulat* tau 
aggregat*" OR "stimulat* T-tau" OR "stimulat* P-tau" OR "stimulat*total tau" OR "stimulat* phospho-
tau" OR "stimulat* tau protein*" OR "stimulat* hyperphosphorylated tau" OR "stimulat* neurofibrillary 
tangle*" OR "elevat* amyloid-beta" OR "elevat* beta-amyloid" OR "elevat* abeta" OR "elevat* senile 
plaque*" OR "elevat* tau aggregat*" OR "elevat* T-tau" OR "elevat* P-tau" OR "elevat*total tau" OR 
"elevat* phospho-tau" OR "elevat* tau protein*" OR "elevat* hyperphosphorylated tau" OR "elevat* 
neurofibrillary tangle*" OR "induc* amyloid-beta" OR "induc* beta-amyloid" OR "induc* abeta" OR 
"induc* senile plaque*" OR "induc* tau aggregat*" OR "induc* T-tau" OR "induc* P-tau" OR "induc*total 
tau" OR "induc* phospho-tau" OR "induc* tau protein*" OR "induc* hyperphosphorylated tau" OR 
"induc* neurofibrillary tangle*" OR "produc* amyloid-beta" OR "produc* beta-amyloid" OR "produc* 
abeta" OR "produc* senile plaque*" OR "produc* tau aggregat*" OR "produc* T-tau" OR "produc* P-
tau" OR "produc*total tau" OR "produc* phospho-tau" OR "produc* tau protein*" OR "produc* 
hyperphosphorylated tau" OR "produc* neurofibrillary tangle*" OR "accelerat* amyloid-beta" OR 
"accelerat* beta-amyloid" OR "accelerat* abeta" OR "accelerat* senile plaque*" OR "accelerat* tau 
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aggregat*" OR "accelerat* T-tau" OR "accelerat* P-tau" OR "accelerat*total tau" OR "accelerat* 
phospho-tau" OR "accelerat* tau protein*" OR "accelerat* hyperphosphorylated tau" OR "accelerat* 
neurofibrillary tangle*" OR "amyloid-beta induc* by" OR "beta-amyloid induc* by" OR "abeta induc* by" 
OR "senile plaque* induc* by" OR "tau aggregat* induc* by" OR "T-tau induc* by" OR "P-tau induc* by" 
OR "total tau induc* by" OR "phospho-tau induc* by" OR "tau protein* induc* by" OR 
"hyperphosphorylated tau induc* by" OR "neurofibrillary tangle* induc* by" OR "amyloid-beta produc* 
by" OR "beta-amyloid produc* by" OR "abeta produc* by" OR "senile plaque* produc* by" OR "tau 
aggregat* produc* by" OR "T-tau produc* by" OR "P-tau produc* by" OR "total tau produc* by" OR 
"phospho-tau produc* by" OR "tau protein* produc* by" OR "hyperphosphorylated tau produc* by" OR 
"neurofibrillary tangle* produc* by" OR "caus* Alzheimer*" OR "caus* dementia" OR "caus* cognitive 
decline" OR "caus* brain* decline" OR "caus* functional decline" OR "caus* memory decline" OR "caus* 
cognitive deficit*" OR "caus* language deficit*" OR "caus* memory deficit*" OR "caus* plasticity 
deficit*" OR "caus* behavioral deficit*" OR "caus* saccade deficit*" OR "caus* learning deficit*" OR 
"caus* neuropsychological deficit*" OR "caus* cognitive impair*" OR "caus* vascular impair*" OR "caus* 
memory impair*" OR "caus* neurogenesis impair*" OR "caus* neuropsychological impair*" OR "caus* 
mind impair*" OR "caus* functional impair*" OR "caus* learning impair*" OR "caus* executive function 
impair*" OR "caus* cognitive loss*" OR "caus* neuronal loss*" OR "caus* synaptic loss*" OR "caus* 
memory loss*" OR "caus* loss of memory" OR "caus* hearing loss*" OR "caus* volume loss*" OR "caus* 
Impair* face recognition" OR "caus* Impair* reasoning" OR "caus* Impair* judgment" OR "caus* 
Impair* problem solving" OR "caus* inflamm*" OR "caus* oxidative stress" OR "caus* neuropathology" 
OR "caus* diabetes" OR "caus* hypertension" OR "caus* high cholesterol" OR "caus* 
hypercholesterolemia" OR "caus* obesity" OR "caus* metabolic syndrome" OR "induc* Alzheimer*" OR 
"induc* dementia" OR "induc* cognitive decline" OR "induc* brain* decline" OR "induc* functional 
decline" OR "induc* memory decline" OR "induc* cognitive deficit*" OR "induc* language deficit*" OR 
"induc* memory deficit*" OR "induc* plasticity deficit*" OR "induc* behavioral deficit*" OR "induc* 
saccade deficit*" OR "induc* learning deficit*" OR "induc* neuropsychological deficit*" OR "induc* 
cognitive impair*" OR "induc* vascular impair*" OR "induc* memory impair*" OR "induc* neurogenesis 
impair*" OR "induc* neuropsychological impair*" OR "induc* mind impair*" OR "induc* functional 
impair*" OR "induc* learning impair*" OR "induc* executive function impair*" OR "induc* cognitive 
loss*" OR "induc* neuronal loss*" OR "induc* synaptic loss*" OR "induc* memory loss*" OR "induc* loss 
of memory" OR "induc* hearing loss*" OR "induc* volume loss*" OR "induc* Impair* face recognition" 
OR "induc* Impair* reasoning" OR "induc* Impair* judgment" OR "induc* Impair* problem solving" OR 
"induc* inflamm*" OR "induc* oxidative stress" OR "induc* neuropathology" OR "induc* diabetes" OR 
"induc* hypertension" OR "induc* high cholesterol" OR "induc* hypercholesterolemia" OR "induc* 
obesity" OR "induc* metabolic syndrome" OR "produc* Alzheimer*" OR "produc* dementia" OR 
"produc* cognitive decline" OR "produc* brain* decline" OR "produc* functional decline" OR "produc* 
memory decline" OR "produc* cognitive deficit*" OR "produc* language deficit*" OR "produc* memory 
deficit*" OR "produc* plasticity deficit*" OR "produc* behavioral deficit*" OR "produc* saccade 
deficit*" OR "produc* learning deficit*" OR "produc* neuropsychological deficit*" OR "produc* 
cognitive impair*" OR "produc* vascular impair*" OR "produc* memory impair*" OR "produc* 
neurogenesis impair*" OR "produc* neuropsychological impair*" OR "produc* mind impair*" OR 
"produc* functional impair*" OR "produc* learning impair*" OR "produc* executive function impair*" 
OR "produc* cognitive loss*" OR "produc* neuronal loss*" OR "produc* synaptic loss*" OR "produc* 
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memory loss*" OR "produc* loss of memory" OR "produc* hearing loss*" OR "produc* volume loss*" 
OR "produc* Impair* face recognition" OR "produc* Impair* reasoning" OR "produc* Impair* judgment" 
OR "produc* Impair* problem solving" OR "produc* inflamm*" OR "produc* oxidative stress" OR 
"produc* neuropathology" OR "produc* diabetes" OR "produc* hypertension" OR "produc* high 
cholesterol" OR "produc* hypercholesterolemia" OR "produc* obesity" OR "produc* metabolic 
syndrome" OR "increas* Alzheimer*" OR "increas* dementia" OR "increas* cognitive decline" OR 
"increas* brain* decline" OR "increas* functional decline" OR "increas* memory decline" OR "increas* 
cognitive deficit*" OR "increas* language deficit*" OR "increas* memory deficit*" OR "increas* plasticity 
deficit*" OR "increas* behavioral deficit*" OR "increas* saccade deficit*" OR "increas* learning deficit*" 
OR "increas* neuropsychological deficit*" OR "increas* cognitive impair*" OR "increas* vascular 
impair*" OR "increas* memory impair*" OR "increas* neurogenesis impair*" OR "increas* 
neuropsychological impair*" OR "increas* mind impair*" OR "increas* functional impair*" OR "increas* 
learning impair*" OR "increas* executive function impair*" OR "increas* cognitive loss*" OR "increas* 
neuronal loss*" OR "increas* synaptic loss*" OR "increas* memory loss*" OR "increas* loss of memory" 
OR "increas* hearing loss*" OR "increas* volume loss*" OR "increas* Impair* face recognition" OR 
"increas* Impair* reasoning" OR "increas* Impair* judgment" OR "increas* Impair* problem solving" OR 
"increas* inflamm*" OR "increas* oxidative stress" OR "increas* neuropathology" OR "increas* 
diabetes" OR "increas* hypertension" OR "increas* high cholesterol" OR "increas* 
hypercholesterolemia" OR "increas* obesity" OR "increas* metabolic syndrome" OR "exacerbat* 
Alzheimer*" OR "exacerbat* dementia" OR "exacerbat* cognitive decline" OR "exacerbat* brain* 
decline" OR "exacerbat* functional decline" OR "exacerbat* memory decline" OR "exacerbat* cognitive 
deficit*" OR "exacerbat* language deficit*" OR "exacerbat* memory deficit*" OR "exacerbat* plasticity 
deficit*" OR "exacerbat* behavioral deficit*" OR "exacerbat* saccade deficit*" OR "exacerbat* learning 
deficit*" OR "exacerbat* neuropsychological deficit*" OR "exacerbat* cognitive impair*" OR 
"exacerbat* vascular impair*" OR "exacerbat* memory impair*" OR "exacerbat* neurogenesis impair*" 
OR "exacerbat* neuropsychological impair*" OR "exacerbat* mind impair*" OR "exacerbat* functional 
impair*" OR "exacerbat* learning impair*" OR "exacerbat* executive function impair*" OR "exacerbat* 
cognitive loss*" OR "exacerbat* neuronal loss*" OR "exacerbat* synaptic loss*" OR "exacerbat* memory 
loss*" OR "exacerbat* loss of memory" OR "exacerbat* hearing loss*" OR "exacerbat* volume loss*" OR 
"exacerbat* Impair* face recognition" OR "exacerbat* Impair* reasoning" OR "exacerbat* Impair* 
judgment" OR "exacerbat* Impair* problem solving" OR "exacerbat* inflamm*" OR "exacerbat* 
oxidative stress" OR "exacerbat* neuropathology" OR "exacerbat* diabetes" OR "exacerbat* 
hypertension" OR "exacerbat* high cholesterol" OR "exacerbat* hypercholesterolemia" OR "exacerbat* 
obesity" OR "exacerbat* metabolic syndrome" OR "trigger* Alzheimer*" OR "trigger* dementia" OR 
"trigger* cognitive decline" OR "trigger* brain* decline" OR "trigger* functional decline" OR "trigger* 
memory decline" OR "trigger* cognitive deficit*" OR "trigger* language deficit*" OR "trigger* memory 
deficit*" OR "trigger* plasticity deficit*" OR "trigger* behavioral deficit*" OR "trigger* saccade deficit*" 
OR "trigger* learning deficit*" OR "trigger* neuropsychological deficit*" OR "trigger* cognitive impair*" 
OR "trigger* vascular impair*" OR "trigger* memory impair*" OR "trigger* neurogenesis impair*" OR 
"trigger* neuropsychological impair*" OR "trigger* mind impair*" OR "trigger* functional impair*" OR 
"trigger* learning impair*" OR "trigger* executive function impair*" OR "trigger* cognitive loss*" OR 
"trigger* neuronal loss*" OR "trigger* synaptic loss*" OR "trigger* memory loss*" OR "trigger* loss of 
memory" OR "trigger* hearing loss*" OR "trigger* volume loss*" OR "trigger* Impair* face recognition" 
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OR "trigger* Impair* reasoning" OR "trigger* Impair* judgment" OR "trigger* Impair* problem solving" 
OR "trigger* inflamm*" OR "trigger* oxidative stress" OR "trigger* neuropathology" OR "trigger* 
diabetes" OR "trigger* hypertension" OR "trigger* high cholesterol" OR "trigger* hypercholesterolemia" 
OR "trigger* obesity" OR "trigger* metabolic syndrome" OR "accelerat* Alzheimer*" OR "accelerat* 
dementia" OR "accelerat* cognitive decline" OR "accelerat* brain* decline" OR "accelerat* functional 
decline" OR "accelerat* memory decline" OR "accelerat* cognitive deficit*" OR "accelerat* language 
deficit*" OR "accelerat* memory deficit*" OR "accelerat* plasticity deficit*" OR "accelerat* behavioral 
deficit*" OR "accelerat* saccade deficit*" OR "accelerat* learning deficit*" OR "accelerat* 
neuropsychological deficit*" OR "accelerat* cognitive impair*" OR "accelerat* vascular impair*" OR 
"accelerat* memory impair*" OR "accelerat* neurogenesis impair*" OR "accelerat* neuropsychological 
impair*" OR "accelerat* mind impair*" OR "accelerat* functional impair*" OR "accelerat* learning 
impair*" OR "accelerat* executive function impair*" OR "accelerat* cognitive loss*" OR "accelerat* 
neuronal loss*" OR "accelerat* synaptic loss*" OR "accelerat* memory loss*" OR "accelerat* loss of 
memory" OR "accelerat* hearing loss*" OR "accelerat* volume loss*" OR "accelerat* Impair* face 
recognition" OR "accelerat* Impair* reasoning" OR "accelerat* Impair* judgment" OR "accelerat* 
Impair* problem solving" OR "accelerat* inflamm*" OR "accelerat* oxidative stress" OR "accelerat* 
neuropathology" OR "accelerat* diabetes" OR "accelerat* hypertension" OR "accelerat* high 
cholesterol" OR "accelerat* hypercholesterolemia" OR "accelerat* obesity" OR "accelerat* metabolic 
syndrome" OR "Alzheimer* * caused by" OR "dementia caused by" OR "cognitive decline caused by" OR 
"brain* decline caused by" OR "functional decline caused by" OR "memory decline caused by" OR 
"cognitive deficit* caused by" OR "language deficit* caused by" OR "memory deficit* caused by" OR 
"plasticity deficit* caused by" OR "behavioral deficit* caused by" OR "saccade deficit* caused by" OR 
"learning deficit* caused by" OR "neuropsychological deficit* caused by" OR "cognitive impair* caused 
by" OR "vascular impair* caused by" OR "memory impair* caused by" OR "neurogenesis impair* caused 
by" OR "neuropsychological impair* caused by" OR "mind impair* caused by" OR "functional impair* 
caused by" OR "learning impair* caused by" OR " executive function impair* caused by" OR "cognitive 
loss* caused by" OR "neuronal loss* caused by" OR "synaptic loss* caused by" OR "memory loss* caused 
by" OR "loss of memory caused by" OR "hearing loss* caused by" OR "volume loss* caused by" OR 
"Impair* face recognition caused by" OR "Impair* reasoning caused by" OR "Impair* judgment caused 
by" OR "Impair* problem solving caused by" OR "inflamm* caused by" OR "oxidative stress caused by" 
OR "neuropathology caused by" OR "diabetes caused by" OR "hypertension caused by" OR "high 
cholesterol caused by" OR "hypercholesterolemia caused by" OR "obesity caused by" OR "metabolic 
syndrome caused by" OR "Alzheimer* * induced by" OR "dementia induced by" OR "cognitive decline 
induced by" OR "brain* decline induced by" OR "functional decline induced by" OR "memory decline 
induced by" OR "cognitive deficit* induced by" OR "language deficit* induced by" OR "memory deficit* 
induced by" OR "plasticity deficit* induced by" OR "behavioral deficit* induced by" OR "saccade deficit* 
induced by" OR "learning deficit* induced by" OR "neuropsychological deficit* induced by" OR 
"cognitive impair* induced by" OR "vascular impair* induced by" OR "memory impair* induced by" OR 
"neurogenesis impair* induced by" OR "neuropsychological impair* induced by" OR "mind impair* 
induced by" OR "functional impair* induced by" OR "learning impair* induced by" OR " executive 
function impair* induced by" OR "cognitive loss* induced by" OR "neuronal loss* induced by" OR 
"synaptic loss* induced by" OR "memory loss* induced by" OR "loss of memory induced by" OR "hearing 
loss* induced by" OR "volume loss* induced by" OR "Impair* face recognition induced by" OR "Impair* 
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reasoning induced by" OR "Impair* judgment induced by" OR "Impair* problem solving induced by" OR 
"inflamm* induced by" OR "oxidative stress induced by" OR "neuropathology induced by" OR "diabetes 
induced by" OR "hypertension induced by" OR "high cholesterol induced by" OR "hypercholesterolemia 
induced by" OR "obesity induced by" OR "metabolic syndrome induced by")  
OR 
2B. LIFESTYLE-SPECIFIC COMPONENT 
2B1. LIFESTYLE-SPECIFIC COMPONENT - TOPIC 
("2,3-Pentanedione" OR "acidogenic diet*" OR "acrylamide" OR "activity restriction" OR "acute stress" 
OR "additives" OR "advanced glycation end product*" OR "Advanced glycosylation end product*" OR 
"adverse food" OR "alcohol abuse*" OR "alcohol consum*" OR "alcohol intake" OR "alcoholic*" OR 
"alcohol-induc*" OR "alcoholism" OR "Amanita phalloides" OR "amphetamine*" OR "anabolic steroid*" 
OR "areca nut chewing" OR arnica OR "aspartame" OR "betel nut chewing" OR "binge eating" OR 
"biomass fuel for cooking" OR "bitter orange"   OR "caffeine" OR "childhood adversity" OR "chinese 
herb*" OR "chlorogenic acid" OR "cholesterol-induced" OR "cigarette*" OR "cocaine" OR "cola" OR 
"competitive strength exercise training" OR cortinarius OR "dehydration" OR "depression-caus*" OR 
"depression-induc*" OR dextrose OR diet* near/1 effect* OR diet*-caus* OR diet*-induc* OR dietborne 
OR "djenkol beans" OR "early-life abuse" OR "eating fast" OR "effort-reward imbalance" OR "emotional 
abuse" OR ephedra OR "exercise-caus*" OR "folic acid-induc*" OR "food additive" OR "food poisoning" 
OR "free-fatty-acid-induced" OR "fructose" OR "germ-free" OR "glucose-induc*" OR "glucose-peaks-
short-term" OR "gluten" OR glycerin OR guarana OR "heat stroke" OR "heroin" OR "high home 
temperature" OR "high insulin" OR "high meat" OR "high selenium diet" OR "high-fat-diet*" OR "high-
glucose-induc*" OR "High-glycemic-load diet*" OR "high-phosphate" OR "high-phosphorous-diet*" OR 
"high-protein-diet*" OR "high-protein-induc*" OR "high-protein-intake*" OR "high-salt-diet*" OR "high-
salt-intake*" OR "high-saturated-fat diet*" OR "high-sodium-diet*" OR "high-sodium-intake*" OR "high-
soybean oil" OR "high-sucrose-diet*" OR "high-sugar-diet*" OR "high-tryptophan-diet*" OR "Highway 
proximity" OR hypothermia OR "hypoxia-induced" OR "insufficient sleep" OR "job strain" OR "laxative 
abuse" OR "low fiber diet*" OR "low fiber intake" OR "low legumes intake" OR "low manganese intake" 
OR "low melatonin" OR "low potassium intake" OR "low pulses intake" OR "low-Vitamin D intake" OR 
"meat" OR "milk processing" OR "morphine" OR mothball* OR "mushrooms" OR noise OR "overfeeding" 
OR palmitate OR "palmitic acid" OR "parental hypertension" OR "parental occupation*" OR "parental 
sucrose" OR "persistent organic pollutants" OR "phosphorus additive*" OR "physical inactivity" OR 
"prenatal hypoxia" OR "preserved food*" OR "preserved meat*" OR "prolonged sitting" OR 
"psychogenic polydipsia" OR "psychological trauma" OR "refined carbohydrate*" OR "refined cereal*" 
OR "refined grain*" OR "refined flour" OR "residential remoteness" OR "salt-induced" OR "saturated 
fat*" OR "sedentary" OR "short sleep duration" OR "sitting time" OR "sleep deprivation" OR "smoking" 
OR "social environment" OR "sodium additive*" OR "soft drink*" OR "soybean oil heated repeatedly" OR 
"soy-rich diet" OR "star fruit" OR "sucralose" OR "sunflower oil" OR "tobacco" OR "trans-fat*" OR 
"water-borne" OR "zinc-deficient diet" OR low near/2 sunlight OR waterborne)  
OR 
2B2. LIFESTYLE-SPECIFIC COMPONENT - TITLE 
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(diet* near/1 effect* OR "adverse food" OR "additives" OR exercise-induc* OR diet*-induc* OR exercise-
caus*  OR diet*-caus* OR waterborne OR "water-borne" OR dietborne OR "acidogenic diet*" OR 
"activity restriction" OR "advanced glycation end product*" OR "Advanced glycosylation end product*" 
OR "alcohol abuse*" OR "alcohol consum*" OR "alcohol intake" OR "alcoholic*" OR "alcohol-induc*" OR 
"alcoholism" OR "amphetamine*" OR "anabolic steroid*" OR "areca nut chewing" OR "betel nut 
chewing" OR "binge eating" OR "caffeine" OR "childhood adversity" OR "chinese herb*" OR "cholesterol-
induced" OR "cigarette*" OR "cocaine" OR "cola" OR "milk processing" OR "dehydration" OR 
"depression-induc*" OR "depression-caus*" OR "effort-reward imbalance" OR "emotional abuse" OR 
"Exercise-induced" OR "folic acid-induc*" OR "free-fatty-acid-induced" OR "fructose" OR "germ-free" OR 
"glucose-induc*" OR "glucose-peaks-short-term" OR "gluten" OR "heat stroke" OR "heroin" OR "high-
fat-diet*" OR "high-glucose-induc*" OR "High-glycemic-load diet*" OR "high home temperature" OR 
"high insulin" OR "high meat" OR "high-phosphate" OR "high-phosphorous-diet*" OR "high-protein-
diet*" OR "high-protein-intake*" OR "high-protein-induc*" OR "high-salt-diet*" OR "high-salt-intake*" 
OR "high-saturated-fat diet*" OR "high selenium diet" OR "high-sodium-intake*" OR "high-sodium-
diet*" OR "high-soybean oil" OR "high-sucrose-diet*" OR "high-tryptophan-diet*" OR "job strain" OR 
"laxative abuse" OR "psychological trauma" OR "competitive strength exercise training" OR "low fiber 
diet*" OR "low fiber intake" OR "low legumes intake" OR "low manganese intake" OR "low melatonin" 
OR "low potassium intake" OR "low pulses intake" OR "low-Vitamin D intake" OR "meat" OR "morphine" 
OR "mothball abuse" OR "mushrooms" OR "parental sucrose" OR "phosphorus additive*" OR "physical 
inactivity" OR "refined cereal*" OR "residential remoteness" OR "salt-induced" OR "sedentary" OR 
"short sleep duration" OR "sitting time" OR "sleep deprivation" OR "smoking" OR "social environment" 
OR "sodium additive*" OR "soybean oil heated repeatedly" OR "soy-rich diet" OR "star fruit" OR "stress-
induced" OR "sunflower oil" OR "tobacco" OR "overfeeding" OR "zinc-deficient diet" OR "TRANS-FAT*" 
OR "2,3-Pentanedione" OR "acute stress" OR "biomass fuel for cooking" OR "early-life abuse" OR 
"Highway proximity" OR "parental occupation*" OR "Sugar" OR "Refined Carbohydrate*" OR 
"Acrylamide" OR "Aspartame" OR "Sucralose" OR "Preserved Meat*" OR "Refined Flour" OR "Saturated 
Fat*" OR "Soft Drink*" OR "Preserved Food*" OR "Insufficient Sleep") 
OR 
  
3. MESH FIELD TERMS 
RUN 3A1 AND 3B1 AS ONE QUERY 
3A. MESH QUALIFIERS - MESH HEADING 
3A1. NON-LIFESTYLE-SPECIFIC COMPONENT 
(/"chemically induced" OR /toxicity OR /poisoning)  
OR 
3B. MESH GENERIC TERMS - MESH HEADING NO EXPLODE  
3B1. NON-LIFESTYLE-SPECIFIC COMPONENT - MESH HEADING NO EXPLODE 
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Abnormalities, Drug-Induced OR Aids Related Opportunistic Infections OR Air Pollutants, Occupational 
OR Bacterial Infections OR Congenital Abnormalities OR Congenital Disorders Of Glycosylation OR 
Dermatitis, Occupational OR Drug Eruptions OR Drug Hypersensitivity OR Drug Toxicity OR 
Environmental Exposure OR Environmental Illness OR Environmental Monitoring OR Environmental 
Pollutants OR Fossil Fuels OR Hazardous Substances OR Herbicides OR Household Products OR HTLV I 
Infections OR Iatrogenic Disease OR Inhalation Exposure OR Insecticides OR Marine Toxins OR Maternal 
Exposure OR Mutagens OR Mycotoxins OR Neurotoxins OR Nonprescription Drugs OR Occupational 
Diseases OR Occupational Exposure OR Occupations OR Opportunistic Infections OR Organic Chemicals 
OR Paternal Exposure OR Pesticides OR Plant Poisoning OR Plants, Toxic OR Poisoning OR Poisons OR 
Prenatal Exposure Delayed Effects OR Simplexvirus OR Soil Pollutants OR Solvents OR Streptococcal 
Infections OR Vehicle Emissions OR Water Pollutants, Chemical OR Welding 
OR 
3B2. LIFESTYLE-SPECIFIC COMPONENT - MESH HEADING NO EXPLODE 
Alcohol Drinking OR Alcoholic Intoxication OR Alcoholism OR Alcohol-Related Disorders OR 
Amphetamine-Related Disorders OR Amphetamines OR Appetite Depressants OR Carbonated Beverages 
OR Cocaine OR Cocaine-Related Disorders OR Cola OR Contraceptive Agents OR Contraceptives, Oral OR 
Cooking And Eating Utensils OR Cosmetics OR Diet, High-Fat OR Fast Foods OR Food Additives OR Food 
Contamination OR Food Habits OR Food Preservatives OR Fructose OR Glycemic Index OR Glycosylation 
End Products, Advanced/adverse effects OR Hair Dyes OR Hallucinogens OR Hazardous Substances OR 
Heat Stroke OR Heroin OR Heroin Dependence OR Laxatives OR Leisure Activities OR Marijuana Abuse 
OR Methadone OR Mushroom Poisoning OR Narcotics OR Nonprescription Drugs OR Plant Poisoning OR 
Plants, Toxic OR Prenatal Exposure Delayed Effects OR Smoking OR Sodium Chloride, Dietary OR Sodium, 
Dietary OR Street Drugs OR Substance-Related Disorders OR Sweetening Agents OR Tattooing OR 
Tobacco OR Tobacco Smoke Pollution OR Tobacco Use Disorder OR Substance Withdrawal Syndrome OR 
Obesity OR Meat OR Foodborne Diseases OR Food Handling OR Dietary Fats OR Dietary Carbohydrates 
OR Plants Genetically Modified OR Sucrose OR Behavior Addictive OR Meat Products OR Poverty OR 
Maternal Exposure OR Flavoring Agents OR Diet High Fat OR Coffee OR Dairy Products OR Nutrition 
Disorders OR Prenatal Care OR Child Abuse OR Television OR Hygiene OR Doping In Sports OR Maternal 
Behavior OR Dietary Sucrose OR Thiamine Deficiency OR Folic Acid Deficiency OR Vitamin D Deficiency 
OR Cholesterol Dietary OR Lifestyle OR Sedentary Lifestyle OR Eating Disorders OR Sleep Disorders OR 
Paternal Exposure  
OR 
MESH TERMS DRUGS 
3B3a. TITLE 
("poison*" OR "ecotoxologic* effect*" OR "occupation*" OR pollut* OR "*virus*" OR environmental OR 
"induc*" OR "damage-caus*" OR "drug*-caus*" OR "infect*-caus*" OR "chemotherapy-caus*" OR 
"treat*-caus*" OR "anesthesia-caus*" OR "chemical*-caus*" OR "cytokine*-caus*" OR "surg*-caus*" OR 
"radiation-caus*" OR "steroid-caus*" OR "mechanically-caus*" OR "promot* progression" OR "caus* 
accumulation" OR "caus* * accumulation" OR "progression of" OR expos* OR contamina* OR abuse* OR 
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induc* OR "long-term effect*" OR "inhibit* *protection" OR dysfunction* OR aggregation OR 
accumulation OR "disease link* to" OR "chemical initiator*" OR "stimulat* microglia" OR "activat* 
microglia" OR "increas* risk*" OR "increas* the risk*" OR "adverse event*" OR "adverse reaction*" OR 
"adverse * event*" OR "adverse * reaction" OR "adverse effect*" OR "adverse * effect*" OR 
hypersensitivity OR aggravat* OR exacerbat* OR detriment* OR "caus* *toxi*" OR "increas* *toxi" OR 
"produc* *toxi*" OR "enhanc* *toxi*" OR "stimulat* *toxi*" OR "accelerat* *toxi*" OR "caus* degrad*" 
OR "increas* degrad*" OR "caus* damag*" OR "increas* damag*" OR "caus* * *toxi*" OR "increas* * 
*toxi" OR "produc* * *toxi*" OR "enhanc* * *toxi*" OR "stimulat* * *toxi*" OR "accelerat* * *toxi*" OR 
"caus* * degrad*" OR "increas* * degrad*" OR "caus* * damag*" OR "increas* * damag*" OR "*toxi* 
caus* by" OR "*toxi* increas* by" OR "*toxi* produc* by" OR "*toxi* enhanc* by" OR "*toxi* stimulat* 
by" OR "*toxi* accelerat* by" OR "damag* caus* by" OR "*damag* increas* by" OR deleterious OR 
deteriorat* OR trigger* OR  worsen* OR harm* OR hazard* OR "side-effect*" OR dangerous OR 
destructive OR injurious OR unsafe) 
AND 
MESH HEADING NO EXPLODE 
Antineoplastic Agents OR Anticoagulants OR Antineoplastic Combined Chemotherapy Protocols OR Anti-
Inflammatory Agents, Non-Steroidal OR Hypoglycemic Agents OR Anti-Bacterial Agents OR Antipsychotic 
Agents OR Immunosuppressive Agents OR Anticonvulsants OR Platelet Aggregation Inhibitors OR 
Glucocorticoids OR Analgesics, Opioid OR Drug-Related Side Effects and Adverse Reactions OR Warfarin 
OR Analgesics OR Doxorubicin OR Cisplatin OR Protein Kinase Inhibitors OR Fibrinolytic Agents OR 
Fluorouracil OR Antirheumatic Agents OR Antihypertensive Agents OR Pyridines OR Cyclophosphamide 
OR Bone Density Conservation Agents OR Antiviral Agents OR Bleomycin OR Antidepressive Agents OR 
Serotonin Uptake Inhibitors OR Thiophenes OR Antibiotics, Antineoplastic OR Angiogenesis Inhibitors OR 
Drug Hypersensitivity OR Proton Pump Inhibitors OR Deoxycytidine OR Ticlopidine OR Organoplatinum 
Compounds OR Anti-Arrhythmia Agents OR Angiotensin-Converting Enzyme Inhibitors OR Anti-HIV 
Agents OR Paclitaxel OR Chemotherapy, Adjuvant OR Acetaminophen OR Quinazolines OR Taxoids OR 
Vasodilator Agents OR Pilocarpine OR Triazoles OR Benzodiazepines OR Anti-Infective Agents OR 
Estrogens OR Thiazolidinediones OR Antineoplastic Agents, Hormonal OR Antineoplastic Agents, 
Phytogenic OR Cyclooxygenase 2 Inhibitors OR  Anti-Ulcer Agents OR Cyclosporine OR Vasoconstrictor 
Agents OR Anthracyclines OR Anticarcinogenic Agents OR Convulsants OR Calcium Channel Blockers OR 
Cardiotonic Agents OR Dermatologic Agents OR Isoproterenol OR Antifungal Agents OR Ribavirin OR 
Antiparkinson Agents OR Clozapine OR Carboplatin OR Tamoxifen OR Antiretroviral Therapy, Highly 
Active OR Vincristine OR Cholinesterase Inhibitors OR Antidepressive Agents, Second-Generation OR 
Antitubercular Agents OR Hypolipidemic Agents OR Antineoplastic Agents, Alkylating OR 
Gastrointestinal Agents OR Aromatase Inhibitors OR Antithyroid Agents OR Organophosphonates OR 
Cyclooxygenase Inhibitors OR Antidepressive Agents, Tricyclic OR Antimanic Agents OR 
Phosphodiesterase 5 Inhibitors OR Dipeptidyl-Peptidase IV Inhibitors OR Anti-Retroviral Agents OR 
Methyl Ethers OR Chelating Agents OR Anticholesteremic Agents OR Contraceptive Agents, Female OR 
Anti-Asthmatic Agents OR Dopamine Uptake Inhibitors OR HIV Protease Inhibitors OR N-Methyl-3,4-
methylenedioxyamphetamine OR Mycophenolic Acid OR Bronchodilator Agents OR Hydroxychloroquine 
OR Neurotransmitter Agents OR Anti-Obesity Agents OR Anabolic Agents OR Anesthetics OR 
Cardiovascular Agents OR Histone Deacetylase Inhibitors OR Alkylating Agents OR Chloroquine OR 
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Antifibrinolytic Agents OR Benzoxazines OR Protease Inhibitors OR Fertility Agents, Female OR 
Dopamine Agents OR Anti-Infective Agents, Local OR Reverse Transcriptase Inhibitors OR 
Neuromuscular Agents OR Anti-Allergic Agents OR Monoamine Oxidase Inhibitors OR Neuromuscular 
Nondepolarizing Agents OR Nootropic Agents OR Photosensitizing Agents OR 5-alpha Reductase 
Inhibitors OR Sweetening Agents OR Sensory System Agents OR Adrenergic Agents OR Adrenergic 




("increas* amyloid-beta" OR "increas* beta-amyloid" OR "increas* abeta" OR "increas* senile plaque*" 
OR "increas* tau aggregat*" OR "increas* T-tau" OR "increas* P-tau" OR "increas*total tau" OR 
"increas* phospho-tau" OR "increas* tau protein*" OR "increas* hyperphosphorylated tau" OR 
"increas* neurofibrillary tangle*" OR "enhanc* amyloid-beta" OR "enhanc* beta-amyloid" OR "enhanc* 
abeta" OR "enhanc* senile plaque*" OR "enhanc* tau aggregat*" OR "enhanc* T-tau" OR "enhanc* P-
tau" OR "enhanc*total tau" OR "enhanc* phospho-tau" OR "enhanc* tau protein*" OR "enhanc* 
hyperphosphorylated tau" OR "enhanc* neurofibrillary tangle*" OR "stimulat* amyloid-beta" OR 
"stimulat* beta-amyloid" OR "stimulat* abeta" OR "stimulat* senile plaque*" OR "stimulat* tau 
aggregat*" OR "stimulat* T-tau" OR "stimulat* P-tau" OR "stimulat*total tau" OR "stimulat* phospho-
tau" OR "stimulat* tau protein*" OR "stimulat* hyperphosphorylated tau" OR "stimulat* neurofibrillary 
tangle*" OR "elevat* amyloid-beta" OR "elevat* beta-amyloid" OR "elevat* abeta" OR "elevat* senile 
plaque*" OR "elevat* tau aggregat*" OR "elevat* T-tau" OR "elevat* P-tau" OR "elevat*total tau" OR 
"elevat* phospho-tau" OR "elevat* tau protein*" OR "elevat* hyperphosphorylated tau" OR "elevat* 
neurofibrillary tangle*" OR "induc* amyloid-beta" OR "induc* beta-amyloid" OR "induc* abeta" OR 
"induc* senile plaque*" OR "induc* tau aggregat*" OR "induc* T-tau" OR "induc* P-tau" OR "induc*total 
tau" OR "induc* phospho-tau" OR "induc* tau protein*" OR "induc* hyperphosphorylated tau" OR 
"induc* neurofibrillary tangle*" OR "produc* amyloid-beta" OR "produc* beta-amyloid" OR "produc* 
abeta" OR "produc* senile plaque*" OR "produc* tau aggregat*" OR "produc* T-tau" OR "produc* P-
tau" OR "produc*total tau" OR "produc* phospho-tau" OR "produc* tau protein*" OR "produc* 
hyperphosphorylated tau" OR "produc* neurofibrillary tangle*" OR "accelerat* amyloid-beta" OR 
"accelerat* beta-amyloid" OR "accelerat* abeta" OR "accelerat* senile plaque*" OR "accelerat* tau 
aggregat*" OR "accelerat* T-tau" OR "accelerat* P-tau" OR "accelerat*total tau" OR "accelerat* 
phospho-tau" OR "accelerat* tau protein*" OR "accelerat* hyperphosphorylated tau" OR "accelerat* 
neurofibrillary tangle*" OR "amyloid-beta induc* by" OR "beta-amyloid induc* by" OR "abeta induc* by" 
OR "senile plaque* induc* by" OR "tau aggregat* induc* by" OR "T-tau induc* by" OR "P-tau induc* by" 
OR "total tau induc* by" OR "phospho-tau induc* by" OR "tau protein* induc* by" OR 
"hyperphosphorylated tau induc* by" OR "neurofibrillary tangle* induc* by" OR "amyloid-beta produc* 
by" OR "beta-amyloid produc* by" OR "abeta produc* by" OR "senile plaque* produc* by" OR "tau 
aggregat* produc* by" OR "T-tau produc* by" OR "P-tau produc* by" OR "total tau produc* by" OR 
"phospho-tau produc* by" OR "tau protein* produc* by" OR "hyperphosphorylated tau produc* by" OR 
"neurofibrillary tangle* produc* by" OR "caus* Alzheimer*" OR "caus* dementia" OR "caus* cognitive 
decline" OR "caus* brain* decline" OR "caus* functional decline" OR "caus* memory decline" OR "caus* 
cognitive deficit*" OR "caus* language deficit*" OR "caus* memory deficit*" OR "caus* plasticity 
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deficit*" OR "caus* behavioral deficit*" OR "caus* saccade deficit*" OR "caus* learning deficit*" OR 
"caus* neuropsychological deficit*" OR "caus* cognitive impair*" OR "caus* vascular impair*" OR "caus* 
memory impair*" OR "caus* neurogenesis impair*" OR "caus* neuropsychological impair*" OR "caus* 
mind impair*" OR "caus* functional impair*" OR "caus* learning impair*" OR "caus* executive function 
impair*" OR "caus* cognitive loss*" OR "caus* neuronal loss*" OR "caus* synaptic loss*" OR "caus* 
memory loss*" OR "caus* loss of memory" OR "caus* hearing loss*" OR "caus* volume loss*" OR "caus* 
Impair* face recognition" OR "caus* Impair* reasoning" OR "caus* Impair* judgment" OR "caus* 
Impair* problem solving" OR "caus* inflamm*" OR "caus* oxidative stress" OR "caus* neuropathology" 
OR "caus* diabetes" OR "caus* hypertension" OR "caus* high cholesterol" OR "caus* 
hypercholesterolemia" OR "caus* obesity" OR "caus* metabolic syndrome" OR "induc* Alzheimer*" OR 
"induc* dementia" OR "induc* cognitive decline" OR "induc* brain* decline" OR "induc* functional 
decline" OR "induc* memory decline" OR "induc* cognitive deficit*" OR "induc* language deficit*" OR 
"induc* memory deficit*" OR "induc* plasticity deficit*" OR "induc* behavioral deficit*" OR "induc* 
saccade deficit*" OR "induc* learning deficit*" OR "induc* neuropsychological deficit*" OR "induc* 
cognitive impair*" OR "induc* vascular impair*" OR "induc* memory impair*" OR "induc* neurogenesis 
impair*" OR "induc* neuropsychological impair*" OR "induc* mind impair*" OR "induc* functional 
impair*" OR "induc* learning impair*" OR "induc* executive function impair*" OR "induc* cognitive 
loss*" OR "induc* neuronal loss*" OR "induc* synaptic loss*" OR "induc* memory loss*" OR "induc* loss 
of memory" OR "induc* hearing loss*" OR "induc* volume loss*" OR "induc* Impair* face recognition" 
OR "induc* Impair* reasoning" OR "induc* Impair* judgment" OR "induc* Impair* problem solving" OR 
"induc* inflamm*" OR "induc* oxidative stress" OR "induc* neuropathology" OR "induc* diabetes" OR 
"induc* hypertension" OR "induc* high cholesterol" OR "induc* hypercholesterolemia" OR "induc* 
obesity" OR "induc* metabolic syndrome" OR "produc* Alzheimer*" OR "produc* dementia" OR 
"produc* cognitive decline" OR "produc* brain* decline" OR "produc* functional decline" OR "produc* 
memory decline" OR "produc* cognitive deficit*" OR "produc* language deficit*" OR "produc* memory 
deficit*" OR "produc* plasticity deficit*" OR "produc* behavioral deficit*" OR "produc* saccade 
deficit*" OR "produc* learning deficit*" OR "produc* neuropsychological deficit*" OR "produc* 
cognitive impair*" OR "produc* vascular impair*" OR "produc* memory impair*" OR "produc* 
neurogenesis impair*" OR "produc* neuropsychological impair*" OR "produc* mind impair*" OR 
"produc* functional impair*" OR "produc* learning impair*" OR "produc* executive function impair*" 
OR "produc* cognitive loss*" OR "produc* neuronal loss*" OR "produc* synaptic loss*" OR "produc* 
memory loss*" OR "produc* loss of memory" OR "produc* hearing loss*" OR "produc* volume loss*" 
OR "produc* Impair* face recognition" OR "produc* Impair* reasoning" OR "produc* Impair* judgment" 
OR "produc* Impair* problem solving" OR "produc* inflamm*" OR "produc* oxidative stress" OR 
"produc* neuropathology" OR "produc* diabetes" OR "produc* hypertension" OR "produc* high 
cholesterol" OR "produc* hypercholesterolemia" OR "produc* obesity" OR "produc* metabolic 
syndrome" OR "increas* Alzheimer*" OR "increas* dementia" OR "increas* cognitive decline" OR 
"increas* brain* decline" OR "increas* functional decline" OR "increas* memory decline" OR "increas* 
cognitive deficit*" OR "increas* language deficit*" OR "increas* memory deficit*" OR "increas* plasticity 
deficit*" OR "increas* behavioral deficit*" OR "increas* saccade deficit*" OR "increas* learning deficit*" 
OR "increas* neuropsychological deficit*" OR "increas* cognitive impair*" OR "increas* vascular 
impair*" OR "increas* memory impair*" OR "increas* neurogenesis impair*" OR "increas* 
neuropsychological impair*" OR "increas* mind impair*" OR "increas* functional impair*" OR "increas* 
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learning impair*" OR "increas* executive function impair*" OR "increas* cognitive loss*" OR "increas* 
neuronal loss*" OR "increas* synaptic loss*" OR "increas* memory loss*" OR "increas* loss of memory" 
OR "increas* hearing loss*" OR "increas* volume loss*" OR "increas* Impair* face recognition" OR 
"increas* Impair* reasoning" OR "increas* Impair* judgment" OR "increas* Impair* problem solving" OR 
"increas* inflamm*" OR "increas* oxidative stress" OR "increas* neuropathology" OR "increas* 
diabetes" OR "increas* hypertension" OR "increas* high cholesterol" OR "increas* 
hypercholesterolemia" OR "increas* obesity" OR "increas* metabolic syndrome" OR "exacerbat* 
Alzheimer*" OR "exacerbat* dementia" OR "exacerbat* cognitive decline" OR "exacerbat* brain* 
decline" OR "exacerbat* functional decline" OR "exacerbat* memory decline" OR "exacerbat* cognitive 
deficit*" OR "exacerbat* language deficit*" OR "exacerbat* memory deficit*" OR "exacerbat* plasticity 
deficit*" OR "exacerbat* behavioral deficit*" OR "exacerbat* saccade deficit*" OR "exacerbat* learning 
deficit*" OR "exacerbat* neuropsychological deficit*" OR "exacerbat* cognitive impair*" OR 
"exacerbat* vascular impair*" OR "exacerbat* memory impair*" OR "exacerbat* neurogenesis impair*" 
OR "exacerbat* neuropsychological impair*" OR "exacerbat* mind impair*" OR "exacerbat* functional 
impair*" OR "exacerbat* learning impair*" OR "exacerbat* executive function impair*" OR "exacerbat* 
cognitive loss*" OR "exacerbat* neuronal loss*" OR "exacerbat* synaptic loss*" OR "exacerbat* memory 
loss*" OR "exacerbat* loss of memory" OR "exacerbat* hearing loss*" OR "exacerbat* volume loss*" OR 
"exacerbat* Impair* face recognition" OR "exacerbat* Impair* reasoning" OR "exacerbat* Impair* 
judgment" OR "exacerbat* Impair* problem solving" OR "exacerbat* inflamm*" OR "exacerbat* 
oxidative stress" OR "exacerbat* neuropathology" OR "exacerbat* diabetes" OR "exacerbat* 
hypertension" OR "exacerbat* high cholesterol" OR "exacerbat* hypercholesterolemia" OR "exacerbat* 
obesity" OR "exacerbat* metabolic syndrome" OR "trigger* Alzheimer*" OR "trigger* dementia" OR 
"trigger* cognitive decline" OR "trigger* brain* decline" OR "trigger* functional decline" OR "trigger* 
memory decline" OR "trigger* cognitive deficit*" OR "trigger* language deficit*" OR "trigger* memory 
deficit*" OR "trigger* plasticity deficit*" OR "trigger* behavioral deficit*" OR "trigger* saccade deficit*" 
OR "trigger* learning deficit*" OR "trigger* neuropsychological deficit*" OR "trigger* cognitive impair*" 
OR "trigger* vascular impair*" OR "trigger* memory impair*" OR "trigger* neurogenesis impair*" OR 
"trigger* neuropsychological impair*" OR "trigger* mind impair*" OR "trigger* functional impair*" OR 
"trigger* learning impair*" OR "trigger* executive function impair*" OR "trigger* cognitive loss*" OR 
"trigger* neuronal loss*" OR "trigger* synaptic loss*" OR "trigger* memory loss*" OR "trigger* loss of 
memory" OR "trigger* hearing loss*" OR "trigger* volume loss*" OR "trigger* Impair* face recognition" 
OR "trigger* Impair* reasoning" OR "trigger* Impair* judgment" OR "trigger* Impair* problem solving" 
OR "trigger* inflamm*" OR "trigger* oxidative stress" OR "trigger* neuropathology" OR "trigger* 
diabetes" OR "trigger* hypertension" OR "trigger* high cholesterol" OR "trigger* hypercholesterolemia" 
OR "trigger* obesity" OR "trigger* metabolic syndrome" OR "accelerat* Alzheimer*" OR "accelerat* 
dementia" OR "accelerat* cognitive decline" OR "accelerat* brain* decline" OR "accelerat* functional 
decline" OR "accelerat* memory decline" OR "accelerat* cognitive deficit*" OR "accelerat* language 
deficit*" OR "accelerat* memory deficit*" OR "accelerat* plasticity deficit*" OR "accelerat* behavioral 
deficit*" OR "accelerat* saccade deficit*" OR "accelerat* learning deficit*" OR "accelerat* 
neuropsychological deficit*" OR "accelerat* cognitive impair*" OR "accelerat* vascular impair*" OR 
"accelerat* memory impair*" OR "accelerat* neurogenesis impair*" OR "accelerat* neuropsychological 
impair*" OR "accelerat* mind impair*" OR "accelerat* functional impair*" OR "accelerat* learning 
impair*" OR "accelerat* executive function impair*" OR "accelerat* cognitive loss*" OR "accelerat* 
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neuronal loss*" OR "accelerat* synaptic loss*" OR "accelerat* memory loss*" OR "accelerat* loss of 
memory" OR "accelerat* hearing loss*" OR "accelerat* volume loss*" OR "accelerat* Impair* face 
recognition" OR "accelerat* Impair* reasoning" OR "accelerat* Impair* judgment" OR "accelerat* 
Impair* problem solving" OR "accelerat* inflamm*" OR "accelerat* oxidative stress" OR "accelerat* 
neuropathology" OR "accelerat* diabetes" OR "accelerat* hypertension" OR "accelerat* high 
cholesterol" OR "accelerat* hypercholesterolemia" OR "accelerat* obesity" OR "accelerat* metabolic 
syndrome" OR "Alzheimer* * caused by" OR "dementia caused by" OR "cognitive decline caused by" OR 
"brain* decline caused by" OR "functional decline caused by" OR "memory decline caused by" OR 
"cognitive deficit* caused by" OR "language deficit* caused by" OR "memory deficit* caused by" OR 
"plasticity deficit* caused by" OR "behavioral deficit* caused by" OR "saccade deficit* caused by" OR 
"learning deficit* caused by" OR "neuropsychological deficit* caused by" OR "cognitive impair* caused 
by" OR "vascular impair* caused by" OR "memory impair* caused by" OR "neurogenesis impair* caused 
by" OR "neuropsychological impair* caused by" OR "mind impair* caused by" OR "functional impair* 
caused by" OR "learning impair* caused by" OR " executive function impair* caused by" OR "cognitive 
loss* caused by" OR "neuronal loss* caused by" OR "synaptic loss* caused by" OR "memory loss* caused 
by" OR "loss of memory caused by" OR "hearing loss* caused by" OR "volume loss* caused by" OR 
"Impair* face recognition caused by" OR "Impair* reasoning caused by" OR "Impair* judgment caused 
by" OR "Impair* problem solving caused by" OR "inflamm* caused by" OR "oxidative stress caused by" 
OR "neuropathology caused by" OR "diabetes caused by" OR "hypertension caused by" OR "high 
cholesterol caused by" OR "hypercholesterolemia caused by" OR "obesity caused by" OR "metabolic 
syndrome caused by" OR "Alzheimer* * induced by" OR "dementia induced by" OR "cognitive decline 
induced by" OR "brain* decline induced by" OR "functional decline induced by" OR "memory decline 
induced by" OR "cognitive deficit* induced by" OR "language deficit* induced by" OR "memory deficit* 
induced by" OR "plasticity deficit* induced by" OR "behavioral deficit* induced by" OR "saccade deficit* 
induced by" OR "learning deficit* induced by" OR "neuropsychological deficit* induced by" OR 
"cognitive impair* induced by" OR "vascular impair* induced by" OR "memory impair* induced by" OR 
"neurogenesis impair* induced by" OR "neuropsychological impair* induced by" OR "mind impair* 
induced by" OR "functional impair* induced by" OR "learning impair* induced by" OR " executive 
function impair* induced by" OR "cognitive loss* induced by" OR "neuronal loss* induced by" OR 
"synaptic loss* induced by" OR "memory loss* induced by" OR "loss of memory induced by" OR "hearing 
loss* induced by" OR "volume loss* induced by" OR "Impair* face recognition induced by" OR "Impair* 
reasoning induced by" OR "Impair* judgment induced by" OR "Impair* problem solving induced by" OR 
"inflamm* induced by" OR "oxidative stress induced by" OR "neuropathology induced by" OR "diabetes 
induced by" OR "hypertension induced by" OR "high cholesterol induced by" OR "hypercholesterolemia 
induced by" OR "obesity induced by" OR "metabolic syndrome induced by") 
AND 
MESH HEADING NO EXPLODE 
Antineoplastic Agents OR Anticoagulants OR Antineoplastic Combined Chemotherapy Protocols OR Anti-
Inflammatory Agents, Non-Steroidal OR Hypoglycemic Agents OR Anti-Bacterial Agents OR Antipsychotic 
Agents OR Immunosuppressive Agents OR Anticonvulsants OR Platelet Aggregation Inhibitors OR 
Glucocorticoids OR Analgesics, Opioid OR Drug-Related Side Effects and Adverse Reactions OR Warfarin 
OR Analgesics OR Doxorubicin OR Cisplatin OR Protein Kinase Inhibitors OR Fibrinolytic Agents OR 
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Fluorouracil OR Antirheumatic Agents OR Antihypertensive Agents OR Pyridines OR Cyclophosphamide 
OR Bone Density Conservation Agents OR Antiviral Agents OR Bleomycin OR Antidepressive Agents OR 
Serotonin Uptake Inhibitors OR Thiophenes OR Antibiotics, Antineoplastic OR Angiogenesis Inhibitors OR 
Drug Hypersensitivity OR Proton Pump Inhibitors OR Deoxycytidine OR Ticlopidine OR Organoplatinum 
Compounds OR Anti-Arrhythmia Agents OR Angiotensin-Converting Enzyme Inhibitors OR Anti-HIV 
Agents OR Paclitaxel OR Chemotherapy, Adjuvant OR Acetaminophen OR Quinazolines OR Taxoids OR 
Vasodilator Agents OR Pilocarpine OR Triazoles OR Benzodiazepines OR Anti-Infective Agents OR 
Estrogens OR Thiazolidinediones OR Antineoplastic Agents, Hormonal OR Antineoplastic Agents, 
Phytogenic OR Cyclooxygenase 2 Inhibitors OR  Anti-Ulcer Agents OR Cyclosporine OR Vasoconstrictor 
Agents OR Anthracyclines OR Anticarcinogenic Agents OR Convulsants OR Calcium Channel Blockers OR 
Cardiotonic Agents OR Dermatologic Agents OR Isoproterenol OR Antifungal Agents OR Ribavirin OR 
Antiparkinson Agents OR Clozapine OR Carboplatin OR Tamoxifen OR Antiretroviral Therapy, Highly 
Active OR Vincristine OR Cholinesterase Inhibitors OR Antidepressive Agents, Second-Generation OR 
Antitubercular Agents OR Hypolipidemic Agents OR Antineoplastic Agents, Alkylating OR 
Gastrointestinal Agents OR Aromatase Inhibitors OR Antithyroid Agents OR Organophosphonates OR 
Cyclooxygenase Inhibitors OR Antidepressive Agents, Tricyclic OR Antimanic Agents OR 
Phosphodiesterase 5 Inhibitors OR Dipeptidyl-Peptidase IV Inhibitors OR Anti-Retroviral Agents OR 
Methyl Ethers OR Chelating Agents OR Anticholesteremic Agents OR Contraceptive Agents, Female OR 
Anti-Asthmatic Agents OR Dopamine Uptake Inhibitors OR HIV Protease Inhibitors OR N-Methyl-3,4-
methylenedioxyamphetamine OR Mycophenolic Acid OR Bronchodilator Agents OR Hydroxychloroquine 
OR Neurotransmitter Agents OR Anti-Obesity Agents OR Anabolic Agents OR Anesthetics OR 
Cardiovascular Agents OR Histone Deacetylase Inhibitors OR Alkylating Agents OR Chloroquine OR 
Antifibrinolytic Agents OR Benzoxazines OR Protease Inhibitors OR Fertility Agents, Female OR 
Dopamine Agents OR Anti-Infective Agents, Local OR Reverse Transcriptase Inhibitors OR 
Neuromuscular Agents OR Anti-Allergic Agents OR Monoamine Oxidase Inhibitors OR Neuromuscular 
Nondepolarizing Agents OR Nootropic Agents OR Photosensitizing Agents OR 5-alpha Reductase 
Inhibitors OR Sweetening Agents OR Sensory System Agents OR Adrenergic Agents OR Adrenergic 
Uptake Inhibitors OR Indicators and Reagents OR Antitussive Agents OR Surface-Active Agents OR 
Antimutagenic Agents 
OR 
MESH TERMS CHEMICALS 
3B4a - TITLE 
("poison*" OR "ecotoxologic* effect*" OR "occupation*" OR pollut* OR "*virus*" OR environmental OR 
"induc*" OR "damage-caus*" OR "drug*-caus*" OR "infect*-caus*" OR "chemotherapy-caus*" OR 
"treat*-caus*" OR "anesthesia-caus*" OR "chemical*-caus*" OR "cytokine*-caus*" OR "surg*-caus*" OR 
"radiation-caus*" OR "steroid-caus*" OR "mechanically-caus*" OR "promot* progression" OR "caus* 
accumulation" OR "caus* * accumulation" OR "progression of" OR expos* OR contamina* OR chemicals 
OR abuse* OR induc* OR "long-term effect*" OR "inhibit* *protection" OR dysfunction* OR aggregation 
OR accumulation OR "disease link* to" OR "chemical initiator*" OR "stimulat* microglia" OR "activat* 
microglia" OR "increas* risk*" OR "increas* the risk*" OR "adverse event*" OR "adverse reaction*" OR 
"adverse * event*" OR "adverse * reaction" OR "adverse effect*" OR "adverse * effect*" OR 
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hypersensitivity OR aggravat* OR exacerbat* OR detriment* OR *TOXI* OR "caus* * degrad*" OR 
"increas* * degrad*" OR "caus* * damag*" OR "increas* * damag*" OR "*toxi* caus* by" OR "*toxi* 
increas* by" OR "*toxi* produc* by" OR "*toxi* enhanc* by" OR "*toxi* stimulat* by" OR "*toxi* 
accelerat* by" OR "damag* caus* by" OR "*damag* increas* by" OR deleterious OR deteriorat* OR 
trigger* OR  worsen* OR harm* OR hazard* OR "side-effect*" OR dangerous OR destructive OR injurious 
OR unsafe)  
AND 
MESH HEADING NO EXPLODE 
Lipopolysaccharides OR Malondialdehyde OR Neurotoxicity Syndromes OR Carbon Tetrachloride OR 
Formaldehyde OR 9,10-Dimethyl-1,2-benzanthracene OR Trinitrobenzenesulfonic Acid OR Insecticides 
OR Endocrine Disruptors OR Diethylnitrosamine OR Hydrogen Peroxide OR Benzhydryl Compounds OR 
Chemical Warfare Agents OR Asbestos OR Herbicides OR Organometallic Compounds OR Scopolamine 
Hydrobromide OR Silicon Dioxide OR Polychlorinated Biphenyls OR 1-Methyl-4-phenyl-1,2,3,6-
tetrahydropyridine OR Benzo(a)pyrene OR Fluorocarbons OR Nitrogen Dioxide OR Polycyclic 
Hydrocarbons, Aromatic OR Tetrachlorodibenzodioxin OR Metals, Heavy OR Hydrocarbons, Chlorinated 
OR Chemical Industry OR 1,2-Dimethylhydrazine OR Ethylene Glycol OR Nitrosamines OR Benzene OR 
Fluorides OR Agricultural Workers' Diseases OR Bromodeoxyuridine OR Chromium OR 
Organophosphorus Compounds OR Organic Chemicals OR Carbon Monoxide OR Benzalkonium 
Compounds OR Chlorpyrifos OR Organophosphates OR Organophosphate Poisoning OR Volatile Organic 
Compounds OR Diethylhexyl Phthalate OR Sulfur Dioxide OR Petroleum OR Methylmercury Compounds 
OR Chlorine OR Dichlorodiphenyl Dichloroethylene OR Hydrocarbons OR Trichloroethylene OR Carbon 
Tetrachloride Poisoning OR 3,4-Dihydroxyphenylacetic Acid OR Alkanesulfonic Acids OR Plasticizers OR 
Halogenated Diphenyl Ethers OR Benzene Derivatives OR Dinitrofluorobenzene OR Toluene 2,4-




 ("increas* amyloid-beta" OR "increas* beta-amyloid" OR "increas* abeta" OR "increas* senile plaque*" 
OR "increas* tau aggregat*" OR "increas* T-tau" OR "increas* P-tau" OR "increas*total tau" OR 
"increas* phospho-tau" OR "increas* tau protein*" OR "increas* hyperphosphorylated tau" OR 
"increas* neurofibrillary tangle*" OR "enhanc* amyloid-beta" OR "enhanc* beta-amyloid" OR "enhanc* 
abeta" OR "enhanc* senile plaque*" OR "enhanc* tau aggregat*" OR "enhanc* T-tau" OR "enhanc* P-
tau" OR "enhanc*total tau" OR "enhanc* phospho-tau" OR "enhanc* tau protein*" OR "enhanc* 
hyperphosphorylated tau" OR "enhanc* neurofibrillary tangle*" OR "stimulat* amyloid-beta" OR 
"stimulat* beta-amyloid" OR "stimulat* abeta" OR "stimulat* senile plaque*" OR "stimulat* tau 
aggregat*" OR "stimulat* T-tau" OR "stimulat* P-tau" OR "stimulat*total tau" OR "stimulat* phospho-
tau" OR "stimulat* tau protein*" OR "stimulat* hyperphosphorylated tau" OR "stimulat* neurofibrillary 
tangle*" OR "elevat* amyloid-beta" OR "elevat* beta-amyloid" OR "elevat* abeta" OR "elevat* senile 
plaque*" OR "elevat* tau aggregat*" OR "elevat* T-tau" OR "elevat* P-tau" OR "elevat*total tau" OR 
"elevat* phospho-tau" OR "elevat* tau protein*" OR "elevat* hyperphosphorylated tau" OR "elevat* 
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neurofibrillary tangle*" OR "induc* amyloid-beta" OR "induc* beta-amyloid" OR "induc* abeta" OR 
"induc* senile plaque*" OR "induc* tau aggregat*" OR "induc* T-tau" OR "induc* P-tau" OR "induc*total 
tau" OR "induc* phospho-tau" OR "induc* tau protein*" OR "induc* hyperphosphorylated tau" OR 
"induc* neurofibrillary tangle*" OR "produc* amyloid-beta" OR "produc* beta-amyloid" OR "produc* 
abeta" OR "produc* senile plaque*" OR "produc* tau aggregat*" OR "produc* T-tau" OR "produc* P-
tau" OR "produc*total tau" OR "produc* phospho-tau" OR "produc* tau protein*" OR "produc* 
hyperphosphorylated tau" OR "produc* neurofibrillary tangle*" OR "accelerat* amyloid-beta" OR 
"accelerat* beta-amyloid" OR "accelerat* abeta" OR "accelerat* senile plaque*" OR "accelerat* tau 
aggregat*" OR "accelerat* T-tau" OR "accelerat* P-tau" OR "accelerat*total tau" OR "accelerat* 
phospho-tau" OR "accelerat* tau protein*" OR "accelerat* hyperphosphorylated tau" OR "accelerat* 
neurofibrillary tangle*" OR "amyloid-beta induc* by" OR "beta-amyloid induc* by" OR "abeta induc* by" 
OR "senile plaque* induc* by" OR "tau aggregat* induc* by" OR "T-tau induc* by" OR "P-tau induc* by" 
OR "total tau induc* by" OR "phospho-tau induc* by" OR "tau protein* induc* by" OR 
"hyperphosphorylated tau induc* by" OR "neurofibrillary tangle* induc* by" OR "amyloid-beta produc* 
by" OR "beta-amyloid produc* by" OR "abeta produc* by" OR "senile plaque* produc* by" OR "tau 
aggregat* produc* by" OR "T-tau produc* by" OR "P-tau produc* by" OR "total tau produc* by" OR 
"phospho-tau produc* by" OR "tau protein* produc* by" OR "hyperphosphorylated tau produc* by" OR 
"neurofibrillary tangle* produc* by" OR "caus* Alzheimer*" OR "caus* dementia" OR "caus* cognitive 
decline" OR "caus* brain* decline" OR "caus* functional decline" OR "caus* memory decline" OR "caus* 
cognitive deficit*" OR "caus* language deficit*" OR "caus* memory deficit*" OR "caus* plasticity 
deficit*" OR "caus* behavioral deficit*" OR "caus* saccade deficit*" OR "caus* learning deficit*" OR 
"caus* neuropsychological deficit*" OR "caus* cognitive impair*" OR "caus* vascular impair*" OR "caus* 
memory impair*" OR "caus* neurogenesis impair*" OR "caus* neuropsychological impair*" OR "caus* 
mind impair*" OR "caus* functional impair*" OR "caus* learning impair*" OR "caus* executive function 
impair*" OR "caus* cognitive loss*" OR "caus* neuronal loss*" OR "caus* synaptic loss*" OR "caus* 
memory loss*" OR "caus* loss of memory" OR "caus* hearing loss*" OR "caus* volume loss*" OR "caus* 
Impair* face recognition" OR "caus* Impair* reasoning" OR "caus* Impair* judgment" OR "caus* 
Impair* problem solving" OR "caus* inflamm*" OR "caus* oxidative stress" OR "caus* neuropathology" 
OR "caus* diabetes" OR "caus* hypertension" OR "caus* high cholesterol" OR "caus* 
hypercholesterolemia" OR "caus* obesity" OR "caus* metabolic syndrome" OR "induc* Alzheimer*" OR 
"induc* dementia" OR "induc* cognitive decline" OR "induc* brain* decline" OR "induc* functional 
decline" OR "induc* memory decline" OR "induc* cognitive deficit*" OR "induc* language deficit*" OR 
"induc* memory deficit*" OR "induc* plasticity deficit*" OR "induc* behavioral deficit*" OR "induc* 
saccade deficit*" OR "induc* learning deficit*" OR "induc* neuropsychological deficit*" OR "induc* 
cognitive impair*" OR "induc* vascular impair*" OR "induc* memory impair*" OR "induc* neurogenesis 
impair*" OR "induc* neuropsychological impair*" OR "induc* mind impair*" OR "induc* functional 
impair*" OR "induc* learning impair*" OR "induc* executive function impair*" OR "induc* cognitive 
loss*" OR "induc* neuronal loss*" OR "induc* synaptic loss*" OR "induc* memory loss*" OR "induc* loss 
of memory" OR "induc* hearing loss*" OR "induc* volume loss*" OR "induc* Impair* face recognition" 
OR "induc* Impair* reasoning" OR "induc* Impair* judgment" OR "induc* Impair* problem solving" OR 
"induc* inflamm*" OR "induc* oxidative stress" OR "induc* neuropathology" OR "induc* diabetes" OR 
"induc* hypertension" OR "induc* high cholesterol" OR "induc* hypercholesterolemia" OR "induc* 
obesity" OR "induc* metabolic syndrome" OR "produc* Alzheimer*" OR "produc* dementia" OR 
Prevention and Reversal of Chronic Disease                           Copyright © 2019 RN Kostoff 
119 
 
"produc* cognitive decline" OR "produc* brain* decline" OR "produc* functional decline" OR "produc* 
memory decline" OR "produc* cognitive deficit*" OR "produc* language deficit*" OR "produc* memory 
deficit*" OR "produc* plasticity deficit*" OR "produc* behavioral deficit*" OR "produc* saccade 
deficit*" OR "produc* learning deficit*" OR "produc* neuropsychological deficit*" OR "produc* 
cognitive impair*" OR "produc* vascular impair*" OR "produc* memory impair*" OR "produc* 
neurogenesis impair*" OR "produc* neuropsychological impair*" OR "produc* mind impair*" OR 
"produc* functional impair*" OR "produc* learning impair*" OR "produc* executive function impair*" 
OR "produc* cognitive loss*" OR "produc* neuronal loss*" OR "produc* synaptic loss*" OR "produc* 
memory loss*" OR "produc* loss of memory" OR "produc* hearing loss*" OR "produc* volume loss*" 
OR "produc* Impair* face recognition" OR "produc* Impair* reasoning" OR "produc* Impair* judgment" 
OR "produc* Impair* problem solving" OR "produc* inflamm*" OR "produc* oxidative stress" OR 
"produc* neuropathology" OR "produc* diabetes" OR "produc* hypertension" OR "produc* high 
cholesterol" OR "produc* hypercholesterolemia" OR "produc* obesity" OR "produc* metabolic 
syndrome" OR "increas* Alzheimer*" OR "increas* dementia" OR "increas* cognitive decline" OR 
"increas* brain* decline" OR "increas* functional decline" OR "increas* memory decline" OR "increas* 
cognitive deficit*" OR "increas* language deficit*" OR "increas* memory deficit*" OR "increas* plasticity 
deficit*" OR "increas* behavioral deficit*" OR "increas* saccade deficit*" OR "increas* learning deficit*" 
OR "increas* neuropsychological deficit*" OR "increas* cognitive impair*" OR "increas* vascular 
impair*" OR "increas* memory impair*" OR "increas* neurogenesis impair*" OR "increas* 
neuropsychological impair*" OR "increas* mind impair*" OR "increas* functional impair*" OR "increas* 
learning impair*" OR "increas* executive function impair*" OR "increas* cognitive loss*" OR "increas* 
neuronal loss*" OR "increas* synaptic loss*" OR "increas* memory loss*" OR "increas* loss of memory" 
OR "increas* hearing loss*" OR "increas* volume loss*" OR "increas* Impair* face recognition" OR 
"increas* Impair* reasoning" OR "increas* Impair* judgment" OR "increas* Impair* problem solving" OR 
"increas* inflamm*" OR "increas* oxidative stress" OR "increas* neuropathology" OR "increas* 
diabetes" OR "increas* hypertension" OR "increas* high cholesterol" OR "increas* 
hypercholesterolemia" OR "increas* obesity" OR "increas* metabolic syndrome" OR "exacerbat* 
Alzheimer*" OR "exacerbat* dementia" OR "exacerbat* cognitive decline" OR "exacerbat* brain* 
decline" OR "exacerbat* functional decline" OR "exacerbat* memory decline" OR "exacerbat* cognitive 
deficit*" OR "exacerbat* language deficit*" OR "exacerbat* memory deficit*" OR "exacerbat* plasticity 
deficit*" OR "exacerbat* behavioral deficit*" OR "exacerbat* saccade deficit*" OR "exacerbat* learning 
deficit*" OR "exacerbat* neuropsychological deficit*" OR "exacerbat* cognitive impair*" OR 
"exacerbat* vascular impair*" OR "exacerbat* memory impair*" OR "exacerbat* neurogenesis impair*" 
OR "exacerbat* neuropsychological impair*" OR "exacerbat* mind impair*" OR "exacerbat* functional 
impair*" OR "exacerbat* learning impair*" OR "exacerbat* executive function impair*" OR "exacerbat* 
cognitive loss*" OR "exacerbat* neuronal loss*" OR "exacerbat* synaptic loss*" OR "exacerbat* memory 
loss*" OR "exacerbat* loss of memory" OR "exacerbat* hearing loss*" OR "exacerbat* volume loss*" OR 
"exacerbat* Impair* face recognition" OR "exacerbat* Impair* reasoning" OR "exacerbat* Impair* 
judgment" OR "exacerbat* Impair* problem solving" OR "exacerbat* inflamm*" OR "exacerbat* 
oxidative stress" OR "exacerbat* neuropathology" OR "exacerbat* diabetes" OR "exacerbat* 
hypertension" OR "exacerbat* high cholesterol" OR "exacerbat* hypercholesterolemia" OR "exacerbat* 
obesity" OR "exacerbat* metabolic syndrome" OR "trigger* Alzheimer*" OR "trigger* dementia" OR 
"trigger* cognitive decline" OR "trigger* brain* decline" OR "trigger* functional decline" OR "trigger* 
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memory decline" OR "trigger* cognitive deficit*" OR "trigger* language deficit*" OR "trigger* memory 
deficit*" OR "trigger* plasticity deficit*" OR "trigger* behavioral deficit*" OR "trigger* saccade deficit*" 
OR "trigger* learning deficit*" OR "trigger* neuropsychological deficit*" OR "trigger* cognitive impair*" 
OR "trigger* vascular impair*" OR "trigger* memory impair*" OR "trigger* neurogenesis impair*" OR 
"trigger* neuropsychological impair*" OR "trigger* mind impair*" OR "trigger* functional impair*" OR 
"trigger* learning impair*" OR "trigger* executive function impair*" OR "trigger* cognitive loss*" OR 
"trigger* neuronal loss*" OR "trigger* synaptic loss*" OR "trigger* memory loss*" OR "trigger* loss of 
memory" OR "trigger* hearing loss*" OR "trigger* volume loss*" OR "trigger* Impair* face recognition" 
OR "trigger* Impair* reasoning" OR "trigger* Impair* judgment" OR "trigger* Impair* problem solving" 
OR "trigger* inflamm*" OR "trigger* oxidative stress" OR "trigger* neuropathology" OR "trigger* 
diabetes" OR "trigger* hypertension" OR "trigger* high cholesterol" OR "trigger* hypercholesterolemia" 
OR "trigger* obesity" OR "trigger* metabolic syndrome" OR "accelerat* Alzheimer*" OR "accelerat* 
dementia" OR "accelerat* cognitive decline" OR "accelerat* brain* decline" OR "accelerat* functional 
decline" OR "accelerat* memory decline" OR "accelerat* cognitive deficit*" OR "accelerat* language 
deficit*" OR "accelerat* memory deficit*" OR "accelerat* plasticity deficit*" OR "accelerat* behavioral 
deficit*" OR "accelerat* saccade deficit*" OR "accelerat* learning deficit*" OR "accelerat* 
neuropsychological deficit*" OR "accelerat* cognitive impair*" OR "accelerat* vascular impair*" OR 
"accelerat* memory impair*" OR "accelerat* neurogenesis impair*" OR "accelerat* neuropsychological 
impair*" OR "accelerat* mind impair*" OR "accelerat* functional impair*" OR "accelerat* learning 
impair*" OR "accelerat* executive function impair*" OR "accelerat* cognitive loss*" OR "accelerat* 
neuronal loss*" OR "accelerat* synaptic loss*" OR "accelerat* memory loss*" OR "accelerat* loss of 
memory" OR "accelerat* hearing loss*" OR "accelerat* volume loss*" OR "accelerat* Impair* face 
recognition" OR "accelerat* Impair* reasoning" OR "accelerat* Impair* judgment" OR "accelerat* 
Impair* problem solving" OR "accelerat* inflamm*" OR "accelerat* oxidative stress" OR "accelerat* 
neuropathology" OR "accelerat* diabetes" OR "accelerat* hypertension" OR "accelerat* high 
cholesterol" OR "accelerat* hypercholesterolemia" OR "accelerat* obesity" OR "accelerat* metabolic 
syndrome" OR "Alzheimer* * caused by" OR "dementia caused by" OR "cognitive decline caused by" OR 
"brain* decline caused by" OR "functional decline caused by" OR "memory decline caused by" OR 
"cognitive deficit* caused by" OR "language deficit* caused by" OR "memory deficit* caused by" OR 
"plasticity deficit* caused by" OR "behavioral deficit* caused by" OR "saccade deficit* caused by" OR 
"learning deficit* caused by" OR "neuropsychological deficit* caused by" OR "cognitive impair* caused 
by" OR "vascular impair* caused by" OR "memory impair* caused by" OR "neurogenesis impair* caused 
by" OR "neuropsychological impair* caused by" OR "mind impair* caused by" OR "functional impair* 
caused by" OR "learning impair* caused by" OR " executive function impair* caused by" OR "cognitive 
loss* caused by" OR "neuronal loss* caused by" OR "synaptic loss* caused by" OR "memory loss* caused 
by" OR "loss of memory caused by" OR "hearing loss* caused by" OR "volume loss* caused by" OR 
"Impair* face recognition caused by" OR "Impair* reasoning caused by" OR "Impair* judgment caused 
by" OR "Impair* problem solving caused by" OR "inflamm* caused by" OR "oxidative stress caused by" 
OR "neuropathology caused by" OR "diabetes caused by" OR "hypertension caused by" OR "high 
cholesterol caused by" OR "hypercholesterolemia caused by" OR "obesity caused by" OR "metabolic 
syndrome caused by" OR "Alzheimer* * induced by" OR "dementia induced by" OR "cognitive decline 
induced by" OR "brain* decline induced by" OR "functional decline induced by" OR "memory decline 
induced by" OR "cognitive deficit* induced by" OR "language deficit* induced by" OR "memory deficit* 
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induced by" OR "plasticity deficit* induced by" OR "behavioral deficit* induced by" OR "saccade deficit* 
induced by" OR "learning deficit* induced by" OR "neuropsychological deficit* induced by" OR 
"cognitive impair* induced by" OR "vascular impair* induced by" OR "memory impair* induced by" OR 
"neurogenesis impair* induced by" OR "neuropsychological impair* induced by" OR "mind impair* 
induced by" OR "functional impair* induced by" OR "learning impair* induced by" OR " executive 
function impair* induced by" OR "cognitive loss* induced by" OR "neuronal loss* induced by" OR 
"synaptic loss* induced by" OR "memory loss* induced by" OR "loss of memory induced by" OR "hearing 
loss* induced by" OR "volume loss* induced by" OR "Impair* face recognition induced by" OR "Impair* 
reasoning induced by" OR "Impair* judgment induced by" OR "Impair* problem solving induced by" OR 
"inflamm* induced by" OR "oxidative stress induced by" OR "neuropathology induced by" OR "diabetes 
induced by" OR "hypertension induced by" OR "high cholesterol induced by" OR "hypercholesterolemia 
induced by" OR "obesity induced by" OR "metabolic syndrome induced by")  
AND 
MESH HEADING NO EXPLODE 
Lipopolysaccharides OR Malondialdehyde OR Neurotoxicity Syndromes OR Carbon Tetrachloride OR 
Formaldehyde OR 9,10-Dimethyl-1,2-benzanthracene OR Trinitrobenzenesulfonic Acid OR Insecticides 
OR Endocrine Disruptors OR Diethylnitrosamine OR Hydrogen Peroxide OR Benzhydryl Compounds OR 
Chemical Warfare Agents OR Asbestos OR Herbicides OR Organometallic Compounds OR Scopolamine 
Hydrobromide OR Silicon Dioxide OR Polychlorinated Biphenyls OR 1-Methyl-4-phenyl-1,2,3,6-
tetrahydropyridine OR Benzo(a)pyrene OR Fluorocarbons OR Nitrogen Dioxide OR Polycyclic 
Hydrocarbons, Aromatic OR Tetrachlorodibenzodioxin OR Metals, Heavy OR Hydrocarbons, Chlorinated 
OR Chemical Industry OR 1,2-Dimethylhydrazine OR Ethylene Glycol OR Nitrosamines OR Benzene OR 
Fluorides OR Agricultural Workers' Diseases OR Bromodeoxyuridine OR Chromium OR 
Organophosphorus Compounds OR Organic Chemicals OR Carbon Monoxide OR Benzalkonium 
Compounds OR Chlorpyrifos OR Organophosphates OR Organophosphate Poisoning OR Volatile Organic 
Compounds OR Diethylhexyl Phthalate OR Sulfur Dioxide OR Petroleum OR Methylmercury Compounds 
OR Chlorine OR Dichlorodiphenyl Dichloroethylene OR Hydrocarbons OR Trichloroethylene OR Carbon 
Tetrachloride Poisoning OR 3,4-Dihydroxyphenylacetic Acid OR Alkanesulfonic Acids OR Plasticizers OR 
Halogenated Diphenyl Ethers OR Benzene Derivatives OR Dinitrofluorobenzene OR Toluene 2,4-
Diisocyanate OR Benzopyrenes OR Cyclohexenes OR Nitrobenzenes OR Plastics OR Trihalomethanes OR 
Hydrocarbons, Brominated 
 
SDM-2A - Appendix 2 - Streamlined Approach - Unambiguous MeSH Terms  
 ("Drug-Related Side Effects AND Adverse Reactions" OR Abnormalities, Drug Induced OR Abnormalities, 
Radiation-Induced OR Agricultural Workers Diseases OR Aids Related Opportunistic Infections OR Air 
Pollutants OR Air Pollutants, Occupational OR Air Pollutants, Radioactive OR Air Pollution OR Air 
Pollution, Indoor OR Air Pollution, Radioactive OR Alcohol Drinking OR Alcohol Related Disorders OR 
Alcoholic Beverages OR Alcoholic Intoxication OR Alcoholism OR Amphetamine Related Disorders OR 
Amphetamines OR Arsenic Poisoning OR Asthma, Aspirin-Induced OR Asthma, Exercise-Induced OR 
Asthma, Occupational OR Behavior, Addictive OR Bullying OR Cadmium Poisoning OR Carbon Monoxide 
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Poisoning OR Carbon Tetrachloride Poisoning OR Carcinogenicity Tests OR Carcinogens OR Carcinogens, 
Environmental OR Causality OR Cardiomegaly, Exercise-Induced OR Chemical Warfare Agents OR 
Chemically-Induced Disorders OR Child Abuse OR Child Abuse, Sexual OR Cholesterol, Dietary OR 
Ciguatera Poisoning OR Cocaine Related Disorders OR Cytomegalovirus Infections OR Dermatitis, 
Occupational OR Diet, Atherogenic OR Diet, High Fat OR Dietary Carbohydrates OR Dietary Fats OR 
Dietary Fats, Unsaturated OR Dietary Fiber OR Dietary Sucrose OR Domestic Violence OR Drug 
Contamination OR Drug Eruptions OR Drug Hypersensitivity OR Drug Overdose OR Drug-Induced Liver 
Injury OR Dyskinesia, Drug Induced OR Eating Disorders OR Environmental Exposure OR Environmental 
Illness OR Environmental Pollutants OR Environmental Pollution OR Environmental Pollution OR 
Escherichia Coli Infections OR Fast Foods OR Fluoride Poisoning OR Food Additives OR Food 
Contamination OR Food Hypersensitivity OR Foodborne Diseases OR Gas Poisoning OR Hazardous 
Substances OR Hazardous Waste OR Hearing Loss, Noise Induced OR Heavy Metal Poisoning, Nervous 
System OR Hepatitis A, Chronic OR Hepatitis B, Chronic OR Hepatitis C, Chronic OR Heroin Dependence 
OR Herpesviridae Infections OR Htlv I Infections OR Hypersensitivity OR Hypersensitivity, Delayed OR 
Hypersensitivity, Immediate OR Iatrogenic Disease OR Inhalation Exposure OR Iron Overload OR Lead 
Poisoning OR Lead Poisoning, Nervous System OR Lead Poisoning, Nervous System, Adult OR Lead 
Poisoning, Nervous System, Childhood OR Leukemia, Radiation Induced OR Manganese Poisoning OR 
Marijuana Abuse OR Maternal Exposure OR Mercury Poisoning OR Mercury Poisoning, Nervous System 
OR Morphine Dependence OR Mptp Poisoning OR Mushroom Poisoning OR Mutagenicity Tests OR 
Mutagens OR Neoplasms, Radiation Induced OR Neurotoxicity Syndromes OR Occupational Diseases OR 
Occupational Exposure OR Opioid Related Disorders OR Opportunistic Infections OR Organophosphate 
Poisoning OR Paternal Exposure OR Plant Poisoning OR Pneumonia, Ventilator-Associated OR Poisoning 
OR Poisons OR Prenatal Exposure Delayed Effects OR Psychoses, Substance Induced OR Radiation Effects 
OR Radiation Injuries OR Radioactive Hazard Release OR Radioactive Pollutants OR Respiratory 
Hypersensitivity OR Salmonella Food Poisoning OR Sedentary Lifestyle OR Shellfish Poisoning OR Sleep 
Deprivation OR Sleep Disorders OR Sodium Chloride, Dietary OR Sodium, Dietary OR Soil Pollutants OR 
Soil Pollutants, Radioactive OR Spouse Abuse OR Staphylococcal Food Poisoning OR Staphylococcal 
Infections OR Streptococcal Infections OR Substance Abuse, Intravenous OR Substance Withdrawal 
Syndrome OR Substance-Related Disorders OR Teratogens OR Tobacco Smoke Pollution OR Tobacco Use 
Disorder OR Toxicity Tests, Chronic OR Virus Diseases OR Vitamin D Deficiency OR Water Pollutants OR 




 The overall strategy for identifying AD causes, treatments, and characteristics was essentially 
the same, although the implementation of the strategy differed slightly as we gained knowledge during 
the evolution of the study.  The strategy components are: 
• Select source database (Medline/Pubmed was selected as the primary source database, 
although the Thomson-Reuters version was used when proximity searching was performed). 
• Generate a core AD database (a Pubmed query was used to generate a core AD database).   
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• Retrieve records relevant to AD treatments (or AD causes or AD characteristics) from the core 
AD database (a combination of MeSH-based, text-based, and visual examination approaches 
was used to retrieve records relevant to AD treatments, AD causes, and AD characteristics, and 
to extract the desired AD treatments, AD causes, and AD characteristics from these retrieved 
records).  
6B. Methodology for Identifying Existing AD Treatments 
6B1. Overview 
 To identify existing AD treatments, a query consisting of MeSH terms and text terms was 
developed to retrieve Medline records that had high probability of describing AD treatments.  These 
retrieved Medline records were imported into our VP text mining software [2] and parsed into phrases.  
Many of these parsed record abstract phrases were visually inspected to identify existing AD treatments 
and identify consequences of those treatments (e.g., increased cerebral blood flow, reduced Abeta, 
reduced tau hyperphosphorylation, etc). 
6B2. Identifying Existing AD Treatments 
6B2a. MeSH-based Approach 
 The MeSH-based approach consisted of two components: MeSH Qualifiers related to 
treatments/therapies relatively strongly (e.g., diet therapy, drug therapy, prevention & control, 
therapeutic use, therapy, etc), and MeSH Headings related to treatments/therapies relatively 
unambiguously (e.g., Treatment Outcome, Neuroprotective Agents, Nootropic Agents, Plant Extracts, 
Phytotherapy, Dietary Supplements, Drugs, Chinese Herbal, etc).  Each of the two components was 
intersected with a core AD Medline query (e.g., Alzheimer* OR dementia OR "mild cognitive 
impairment") to retrieve records describing AD treatments.  The retrieved records were inspected 
visually, and the relevant articles extracted. 
 As a very simple example of the above, a query term might be "diet therapy" in the MeSH 




6B2b.  Text-based Approach 
 The text-based approach was developed and used because of the following MeSH-based 
approach limitations:  
 1) not all Medline records have MeSH terms assigned;  
 2) for those records with MeSH terms, the terms do not always form a comprehensive set;  
 3) for records with MeSH terms, the Qualifiers appended to the Heading are not always 
complete.   
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Thus, the text-based approach complements (and overlaps) the MeSH-based approach. 
 Fundamentally, the text-based approach 1) identified linking terms that were strongly 
associated with AD treatments and their consequences, and then 2) used these linking terms to search 
for the AD treatments and consequences of interest.  These linking terms were obtained from reading 
the records retrieved with the MeSH-based approach, and selecting those terms strongly associated 
with AD treatments and their consequences.  Some of the more useful linking terms identified included 
the following: treat*, therap*, prevent*, protect*, improv*, reduc*, attenuat*, ameliorat*, enhanc*,  
revers*, promot*, alleviat*, inhibit*, remov*, suppress*, mitigat*, restor*, lower*, preserv*, regenerat*, 
rescu*, slow*.   
 The text-based approach was used at three distinct points in the study: 
 1) It was used as part of the total AD Medline database query to retrieve records strongly 
associated with AD treatments. 
 2) It was applied to the parsed abstract phrases of the retrieved records imported into the VP 
software to surgically extract the existing AD treatments and their consequences.   
 3) It was used to develop patterns of terms for searching the non-AD Medline literature to 
generate literature-based discovery of potential AD treatments.   
 The main text mining advance in this study was development and demonstration of this AD 
treatment pattern filter for  
 1) querying the Medline database,  
 2) extracting AD treatments and their consequences from the parsed abstract phrases, and  
 3) discovering potential AD treatments from the non-AD biomedical literature. 
 The first chronological application of the linking terms was to help generate the initial query 
used for retrieving the AD treatment records from the Medline database.  In the query, the linking terms 
were added to the MeSH terms described in 6B2a.  The linking terms were only applied to the title field 
to minimize retrieval of excessive non-relevant records. 
 The second chronological application of the linking terms was to help extract existing AD 
treatments and their consequences from the parsed abstract phrases of the retrieved AD treatment 
records in the VP software.  Approximately 52,000 records constituted the retrieved Medline AD 
treatments database, and approximately 3.5 million abstract phrases were parsed from the abstracts by 
the VP software.  There was a dramatic increase in the number of phrases as the frequency of their 
appearance decreased.  For example, there were 20,000 phrases that appeared in 22 records or more 
(roughly the number of phrases that were examined visually).  There were 3,437,961 phrases that 
appeared in 21 records or less.  In particular, there were 3,322,873 phrases that appeared in three 
records or less!  It is these lower frequency phrases that may represent promising emerging AD 
treatments, or AD treatments that for one reason or another may have been suppressed in the 
literature. 
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 The higher frequency phrases could be inspected visually, but a text mining filtering approach 
was necessary to extract the desired treatment and treatment consequence information from the 
millions of lower frequency phrases.  Linking terms were used to search these lower frequency phrases 
and efficiently extract the requisite treatment and consequences information. 
 As a very simple example, we might search the ~3.5 million abstract phrases in the database of 
AD treatment records using the linking term "improv*".  Typically, this term might appear in the larger 
text string of e.g. "substance X improved Abeta clearance".  Thus, "substance X" would be the AD 
treatment identified, "Abeta" would be the AD characteristic of interest, and "Abeta clearance" would 
show the AD characteristic having moved in the desired direction.  As the next paragraph will show, if 
the above text sub-string "improved Abeta clearance" were used to query the non-AD literature, then 
treatments/mechanisms from non-AD literatures could be identified and extrapolated ('re-purposed') 
for possible use in treating/understanding AD pathology. 
6C. Identify Potential AD Treatments (Discovery) 
 The third chronological application of the linking terms was for use as a query in literature-based 
discovery of potential AD treatments.  Linking phrases that formed patterns characteristic of successful 
AD treatments were generated, and applied to the Medline non-AD literature.  These linking phrases 
consisted of linking terms combined with the AD characteristics to which they were linked (e.g., increase 
glutathione, inhibit GSK-3, increase CREB phosphorylation, etc.)  In practice, the linking phrases were 
constructed more broadly, such as increas* NEAR/3 glutathione, inhibit* NEAR/3 GSK-3, etc.  For the 
literature-based discovery application, combinations of the more fundamental and less AD-specific 
linking phrases were used  
(e.g., (((increas* OR enhanc* OR restor*) NEAR/3 "norepinephrine") AND ((increas* OR enhanc* OR 
restor*) NEAR/3 "Nrf2")) NOT ((alzheimer* OR dementia OR "mild cognitive impairment") OR {existing 
AD treatments}).   
 While terms such as 'reduce Abeta' or 'reduce tau phosphorylation' may be efficient for 
extracting existing AD treatments from the AD literature, they are very inefficient, either in isolation or 
especially in combination, for AD treatment discovery from the non-AD literature.  It is difficult to 
imagine people doing research in reducing Abeta or reducing tau hyperphosphorylation not emphasizing 
the AD/dementia applications in their publications. 
6D. Identify Existing AD Characteristics 
 Existing AD characteristics were identified mainly using the text-based approach.  The first step 
in this approach was reading thousands of higher frequency abstract phrases parsed from treatment 
records retrieved with the MeSH-based query, as described in section 6B2b.  This step had two benefits: 
identifying the higher frequency AD characteristics, and identifying terms closely linked to those 
characteristics.   
 Some of the more useful linking terms identified included the following: treat*, therap*, 
prevent*, protect*, improv*, reduc*, attenuat*, ameliorat*, enhanc*, revers*, promot*, alleviat*, 
inhibit*, remov*, suppress*, mitigat*, restor*, lower*, preserv*, regenerat*, rescu*, slow*, 
neuroprotect*, neurorestorati*, decreas*, increas*, eliminat*.  Some of these terms had higher 
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efficiencies of identifying the treatment consequences of interest than others.  Terms like prevent*, 
protect*, improv*, restor*, alleviat*, ameliorat*, mitigat*, etc, almost always gave the desired AD 
characteristics and the direction in which they changed as a result of treatment.  Terms like decreas*, 
increas*, reduc*, etc, could go either way.  The former group of terms had the 'sense' of improvement, 
while the latter group of terms reflected change (positive or negative).  In all cases, each retrieved 
phrase was validated before it could be included as an AD characteristic. 
 The second step was identifying the lower frequency AD characteristics.  Many of the linking 
terms obtained in the first step were applied to all the abstract phrases in the full AD core Medline 
database, and ~250 major and semi-major existing AD characteristics were identified. 
 However,  
• additional linking terms could have been identified;  
• linking term patterns (combinations of linking terms) could have been identified for greater 
precision;  
• not all linking terms identified were used;  
• not all existing AD characteristics appeared in text in proximity to the identified linking terms;  
• software limitations on extracted phrase length excluded those existing AD characteristics not in 
very close proximity to the identified linking terms.   
An expanded study could easily overcome these limitations, and possibly double the number of existing 
AD characteristics identified.   
6E. Identify Potential AD Characteristics (Discovery) 
 The concept is to identify patterns of AD characteristics that tend to co-occur frequently in the 
AD literature, then use these patterns as a search query in the non-AD literature.  New patterns may be 
identified in the non-AD literature consisting of the search query pattern plus additional characteristics 
not in the AD literature.  These additional characteristics would then be candidates for discovery as new 
AD characteristics that not have been identified previously.   
 For example, IL-1 and IL-6 and TNF-alpha and NF-KappaB tend to co-occur in many AD articles 
relating to inflammation.  These four terms would be combined as a query for the non-AD literature: "IL-
1 and IL-6 and TNF-alpha and NF-KappaB".  Any records retrieved would be examined for additional 
characteristics, and these additional characteristics would be validated if they did not occur in the AD 
literature. 
 Myriad other patterns are possible.  For example, existing AD treatments and existing AD causes 
move AD characteristics in known directions.  Non-AD literatures could be searched for characteristics  
impacted by these known AD treatments and AD causes, and not contained in the core AD literature.  
Combinations of these AD treatments and AD causes could be used to increase the likelihood that any 
new characteristics identified would have higher relevance to AD.   
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 As a specific example, consider the following query: (high-fat-diet* NEAR/5 (increas* OR 
decreas*) AND chitosan NEAR/5 (increas* OR decreas*)) NOT alzheimer*.  This will retrieve all records 
reflecting an increase or decrease of characteristic values (in the non-AD literature) due to the presence 
of the existing AD cause "high-fat-diet" and the existing AD treatment "chitosan".  Applying this query to 
the Medline database leads to the identification of a potential AD characteristic "mup17" (major urinary 
protein 17) [3].  This potential AD characteristic is not found in the AD literature, but it is altered in one 
direction by an existing AD cause, and is altered in the opposing direction by an existing AD treatment.  
So, it might be a valuable characteristic for AD researchers to track. 
 The number of existing AD characteristics identified appeared to be far more than could be used 
in practice.  Therefore, identification of additional potential AD characteristics was not deemed a first-
order priority in the present study.  No attempt was made to identify specific potential AD 
characteristics, beyond the illustrative example above. 
 
(return to TOC) 
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APPENDIX 4 – PN/PAD CONTRIBUTING FACTOR AND TREATMENT IDENTIFICATION METHODOLOGY 
6A2. Strategy 
Table 6-1 - Approaches Used to Identify Causes/Treatments/Characteristics (Biomarkers/Symptoms) 
APPROACH    
VISUAL INSPECTION ABSTRACT X X X 
LINKING TERMS TITLE X X X 
LINKING TERMS ABSTRACT X X X 
MESH TERMS UNAMBIGUOUS X X X 
MESH TERMS QUALIFIERS X X X 
DOT PRODUCT ABSTRACT X   
CATEGORIES-----> CAUSES TREATMENTS CHARACTERISTICS 
 
 The overall conceptual strategy for identifying existing PN/PAD causes, treatments, and 
characteristics was based upon the conceptual strategy used in [Kostoff, Porter, Buchtel, 2018], 
although the implementation of the conceptual strategy differed slightly as knowledge was gained 
during the evolution of the study.   
 The strategy components used in the present study are: 
• Select source database (Medline/Pubmed was selected as the primary source database, 
although the Thomson-Reuters version was used when proximity searching was performed). 
• Generate a core PN/PAD database (a Pubmed query was used to generate a core PN/PAD 
database).   
• Retrieve records relevant to PN/PAD treatments, contributing factors, or characteristics from 
the core PN/PAD database (methods will be shown in following sections) 
• Extract existing contributing factors, treatments, and characteristics from retrieved records 
(methods will be shown in following sections) 
 A combination of MeSH-based and text-based examination approaches was used to retrieve 
records relevant to PN/PAD treatments, contributing factors, and characteristics, and to extract the 
desired PN/PAD treatments, contributing factors, and characteristics from these retrieved records.  
Table 6-1 summarizes the specific approaches used to identify contributing factors, treatments, and 
characteristics.  Because of resource limitations, not all approaches were applied to all targets.  
6B. Methodology for Identifying Existing and Potential PN/PAD Contributing Factors, Treatments, and 
Characteristics 




 As stated above, a MeSH-based approach and a text-based approach were used in tandem to 
identify existing PN/PAD contributing factors, treatments, and characteristics.  The text-based approach 
was developed and used because of the following MeSH-based approach limitations:  
 1) not all Medline records have MeSH terms assigned;  
 2) for those records with MeSH terms, the terms do not always form a comprehensive set;  
 3) for records with MeSH terms, the Qualifiers appended to the Heading are not always 
complete.   
Thus, the text-based approach complements (and overlaps) the MeSH-based approach. 
6B2. Identifying Existing PN/PAD Contributing Factors 
6B2a. Text-based Approach 
6B2a1. Visual Inspection 
 The text-based approach had three components: a visual inspection component, a linking term 
component, and a dot-product component.  The parsed Abstract field, containing about 4,000,000 
phrases reflecting the 43056 records that constituted the core PN/PAD database, was used for all three 
components.  The visual inspection component involved reading the 30,000 highest frequency Abstract 
phrases, and selecting those phrases deemed to be candidate contributing factors.  The Vantage Point 
(VP) software [VP, 2019] containing these phrases displays both the phrases and the Titles and Abstracts 
of the records in which they appear.  This allows validation of each candidate contributing factor 
selected. 
6B2a2. Linking Term 
 To identify candidate contributing factors in the lower frequency portion of the parsed Abstract 
field, a text-mining approach was necessary. Linking terms strongly associated with contributing factors 
were generated through visually inspecting many records containing foundational contributing factors in 
the Titles, and identifying those terms that appeared frequently with the foundational contributing 
factors.  The remainder of the parsed Abstract field was searched with use of these linking terms.  The 
additional candidate contributing factors were extracted from the retrieved phrases, and validated as 
contributing factors. 
 These linking terms included: -induced; caused by; induced by; -contaminated; exposure to; 
exposure(s) [at end of phrase]; exposed to; poisoning [at end]; -exposed [at end]; -related; -associated; -
infected; abuse*; toxicity; risk factors; deficiency; neurotoxicity; risk factor; causes; workers; toxic; 
occupational; intoxication; toxicities; neurotoxic; excessive; deficiencies; contributing factors; worker; 
contributing factor; occupation; overload. 
6B2a3. Dot Product  
 While the visual inspection approach identifies comprehensively the higher-frequency 
foundational causes, the linking term approach is less efficient.  Not all foundational causes are 
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associated with the finite list of linking terms used.  Even if a foundational cause is associated (in the 
same Abstract) with a linking term, the software effectively limits the proximity of the linking 
term/foundational cause to four words.  Some foundational causes can be located much further away 
from a linking term than four words in an Abstract.   
 To identify additional foundational causes that may have slipped through the cracks from the 
visual inspection and linking term approaches, the dot product approach was developed.  Approximately 
12,350 potentially toxic substances from myriad other sources (including past foundational causes 
studies, government-approved lists of toxic substances, MeSH-derived causes, etc) were generated, and 
intersected with the ~4,000,000 Abstract phrases in the core PN/PAD literature.  While the dot product 
approach was developed specifically for identifying causes, a similar approach could be used for 
identifying treatments, biomarkers, mechanisms, etc. Moreover, given that many authors don't place 
detailed substances in the Title or Abstract, there could be substantial benefits gained by using full-text 
rather than Abstracts.  
6B2b. MeSH-based Approach 
6B2b1. MeSH Qualifiers 
 MeSH Headings have a number of Qualifiers associated with them to allow focus on items of 
interest. Thus, the MeSH term Cadmium/toxicity allows records to be retrieved related to the toxicity of 
Cadmium.  There were 83 topical MeSH Qualifiers (in Pubmed) used for indexing and cataloging in 
conjunction with MeSH Heading descriptors when this concept was developed. All 83 were examined in 
more or less detail for applicability to identifying foundational causes of disease. Four were selected 
(after extensive validation) as producing highly relevant results when used in isolation: adverse effects, 
toxicity, pathogenicity, poisoning. A few limited combinations of the remaining MeSH Qualifiers were 
examined for the streamlined approach, but none were deemed to have sufficient relevance.  All MeSH 
terms that contained at least one of these Qualifiers were extracted, and the related records examined 
for potential foundational causes.  While this MeSH Qualifier linking approach was developed for, and 
applied to, identifying existing foundational causes, it was easily modified for identifying existing 
treatments and biomarkers, and could be further modified for identifying mechanisms, etc. 
6B2b2. MeSH Headings 
 MeSH Headings related relatively unambiguously to foundational causes were identified two 
ways. First, results from past studies were examined, especially [Kostoff, Porter, Buchtel, 2018; Kostoff 
and Patel, 2015], and relevant MeSH Headings were extracted. Second, a few of the most unambiguous 
MeSH terms identified from past studies were entered into Pubmed as query terms, and all the MeSH 
terms in the resultant retrieval (i.e., those that co-occurred with the entry MeSH terms) were examined 
for relevance.  The final list of relevant MeSH terms was intersected with the total list of MeSH terms in 
the retrieved database, and the resulting records were examined for potential PN/PAD foundational 
causes.   
 Sample MeSH terms related relatively unambiguously to foundational causes included: "Drug-
Related Side Effects AND Adverse Reactions"; Abnormalities, Drug Induced; Air Pollutants, Occupational; 
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Amphetamine Related Disorders; Carcinogens; Chemical Warfare Agents; Chemically-Induced Disorders, 
etc. 
 Again, while this focused MeSH Heading approach was developed for identifying foundational 
causes, it was adapted to identifying treatments, and could be readily adapted to identifying 
biomarkers, mechanisms, etc. 
6B3. Identifying Existing PN/PAD Treatments 
6B3a. Text-based Approach 
6B3a1. Visual Inspection 
 The text-based approach had two components: a visual inspection component, and a linking 
term component.  The parsed Abstract field, containing about 4,000,000 phrases,  was used for both 
components.  The visual inspection component involved reading the 30,000 highest frequency phrases, 
and selecting those phrases deemed to be candidate treatments.  The Vantage Point (VP) software 
containing these phrases displays both the phrases and the Titles and Abstracts of the records in which 
they appear.  This allows validation of each candidate treatment selected. 
6B3a2. Linking Term 
 To identify candidate treatments in the lower frequency portion of the parsed Abstract field, a 
text-mining approach was necessary. Linking terms strongly associated with treatments were generated 
through visually inspecting many records containing treatments in the Titles, and identifying those terms 
that appeared frequently with the treatments.  The remainder of the parsed Abstract field was searched 
with use of these linking terms.  The additional candidate treatments were extracted from the retrieved 
phrases, and validated as treatments. 
 Some of the more useful linking terms identified included the following: treat*, therap*, 
prevent*, protect*, improv*, reduc*, attenuat*, ameliorat*, enhanc*,  revers*, promot*, alleviat*, 
inhibit*, remov*, suppress*, mitigat*, restor*, lower*, preserv*, regenerat*, rescu*, slow*, 
neuroprotect*, neurorestorati*, decreas*, increas*, eliminat*.   
 Not all these terms are of equal value, or efficiency in identifying the desired text concepts.  
Some of these terms had higher efficiencies of identifying the PN/PAD treatment consequences of 
interest (PN/PAD characteristics) than others.  Terms like prevent*, protect*, improv*, restor*, alleviat*, 
ameliorat*, mitigat*, etc, almost always were associated with treatments, and gave the desired PN/PAD 
characteristics and the direction in which they changed as a result of PN/PAD treatment.  Terms like 
decreas*, increas*, reduc*, etc, could go either way.  The former group of terms had the 'sense' of 
improvement, while the latter group of terms reflected change (positive or negative).   
6B3b. MeSH-based Approach 
6B3b1. MeSH Qualifiers 
 MeSH Headings have a number of Qualifiers associated with them to allow focus on items of 
interest. Thus, the MeSH term Cadmium/toxicity allows records to be retrieved related to the toxicity of 
Cadmium.  There were 83 topical MeSH Qualifiers (in Pubmed) used for indexing and cataloging in 
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conjunction with MeSH Heading descriptors when this concept was developed. All 83 were examined in 
more or less detail for applicability to identifying treatments.  For the initial Visual Inspection approach 
query, seven were selected (after extensive validation) as producing highly relevant results when used in 
isolation: diet therapy, drug therapy, prevention & control, radiotherapy, surgery, therapeutic use, 
therapy. A few limited combinations of the remaining MeSH Qualifiers were examined for the 
streamlined approach, but none were deemed to have sufficient relevance.  All MeSH terms that 
contained at least one of these Qualifiers were extracted, and the related records examined for 
treatments.   
6B3b2. MeSH Headings 
 MeSH Headings related relatively unambiguously to treatments were identified two ways. First, 
results from past studies were examined, especially [Kostoff, Porter, Buchtel, 2018; Kostoff and Patel, 
2015], and relevant MeSH Headings were extracted. Second, a few of the most unambiguous MeSH 
terms identified from past studies were entered into Pubmed as query terms, and all the MeSH terms in 
the resultant retrieval (i.e., those that co-occurred with the entry MeSH terms) were examined for 
relevance.  The final list of relevant MeSH terms was intersected with the total list of MeSH terms in the 
retrieved database, and the resulting records were examined for candidate PN/PAD treatments.   
 Sample MeSH terms related relatively unambiguously to treatments included Treatment 
Outcome, Neuroprotective Agents, Nootropic Agents, Plant Extracts, Phytotherapy, Dietary 
Supplements, Drugs, Chinese Herbal, etc. 
6B4. Identifying Existing PN/PAD Characteristics 
6B4a. Text-based Approach 
6B4a1. Visual Inspection 
 The text-based approach had two components: a visual inspection component, and a linking 
term component.  The parsed Abstract field, containing about 4,000,000 phrases,  was used for both 
components.  The visual inspection component involved reading the 30,000 highest frequency phrases, 
and selecting those phrases deemed to be candidate characteristics.  The Vantage Point (VP) software 
containing these phrases displays both the phrases and the Titles and Abstracts of the records in which 
they appear.  This allows validation of each candidate characteristic selected. 
6B4a2. Linking Term 
 To identify candidate characteristics in the lower frequency portion of the parsed Abstract field, 
a text-mining approach was necessary. Linking terms strongly associated with characteristics were 
generated through visually inspecting many records containing characteristics in the Titles, and 
identifying those terms that appeared frequently with the characteristics.  The remainder of the parsed 
Abstract field was searched with use of these linking terms.  The additional candidate characteristics 
were extracted from the retrieved phrases, and validated as characteristics. 
 For the streamlined approach, the linking terms used for identifying treatments were selected 
as the linking terms to be used for identifying characteristics.  These linking terms included: treat*, 
therap*, prevent*, protect*, improv*, reduc*, attenuat*, ameliorat*, enhanc*,  revers*, promot*, 
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alleviat*, inhibit*, remov*, suppress*, mitigat*, restor*, lower*, preserv*, regenerat*, rescu*, slow*, 
neuroprotect*, neurorestorati*, decreas*, increas*, eliminat*.   
6B4b. MeSH-based Approach 
6B4b1. MeSH Qualifiers 
 MeSH Headings have a number of Qualifiers associated with them to allow focus on items of 
interest. Thus, the MeSH term Cadmium/toxicity allows records to be retrieved related to the toxicity of 
Cadmium.  There were 83 topical MeSH Qualifiers (in Pubmed) used for indexing and cataloging in 
conjunction with MeSH Heading descriptors when this concept was developed. All 83 were examined in 
more or less detail for applicability to identifying characteristics. None were identified as being 
unambiguously related to characteristics, and this approach was not pursued further.   
6B4b2. MeSH Headings 
 MeSH Headings related relatively unambiguously to characteristics were identified two ways. 
First, results from past studies were examined, especially [Kostoff, Porter, Buchtel, 2018; Kostoff and 
Patel, 2015], and relevant MeSH Headings were extracted. Second, a few of the most unambiguous 
MeSH terms identified from past studies were entered into Pubmed as query terms, and all the MeSH 
terms in the resultant retrieval (i.e., those that co-occurred with the entry MeSH terms) were examined 
for relevance.  The only MeSH term related relatively unambiguously to characteristics was Biomarkers. 
6B4c. Spinoff from Contributing Factor and Treatment Identification Approaches 
 Contributing factor or treatment records typically identify one or more characteristics that are 
impacted by the contributing factor(s) or treatment(s) in the record.  In the present streamlined 
approach, most of the characteristics were identified during the validation process for a contributing 
factor or treatment.  The records were read for validation, and any characteristics were then extracted 
from the record. 
6B5. Identifying Potential PN/PAD Treatments 
 Existing treatments identified in the present monograph were deemed successful when they 
moved the values of characteristics in desired directions.  Thus, if high oxidative stress or high 
inflammation reflected an undesired disease state, then one component of a successful treatment for 
this undesired disease state would be reduction of oxidative stress or reduction of inflammation.   One 
of the outcomes of the present study was identification of myriad characteristics and the directions in 
which they changed as a result of successful treatments. 
 For Discovery (identification of potential PN/PAD treatments), this process is reversed.  A query 
is formed consisting of critical characteristics and the directions in which they would be changed if 
successful treatments were applied.  This query is then applied to the full Medline database excluding 
the PN/PAD literature.  Chemicals/radiations/supplements etc, and other forms of potential PN/PAD 
treatments are identified that move these characteristics in desired directions, and they are viewed as 
candidate potential PN/PAD treatments.  A validation is performed to insure these candidate potential 
PN/PAD treatments are not part of the core PN/PAD literature. 
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 The number of terms in the query could range from one to many.  The more terms in the query, 
the more restricted the retrievals would be in volume and focus.  The fewer terms in the query, the 
greater the chances for radical discovery, but the larger the volume of retrieval to be evaluated for 
validation.   
 As an example, consider the above case of an undesired disease state, characterized by high 
oxidative stress and high inflammation.  A query would be generated, consisting of "reduce oxidative 
stress AND "reduce inflammation".  All treatments for any disease in Medline (with the exception of 
PN/PAD) that reduced oxidative stress and reduced inflammation would be retrieved.  After much 
experimentation, it was found that queries consisting of combinations of two biomarkers (with desired 
directions of change) provided a good balance between content of discovery and volume of retrieval. 
 The detailed methodology that was used in the present study is described in Appendix 6-1, and 
in the broader context of treatment re-purposing in [Kostoff, 2018]. 
6B6. Identifying Potential PN/PAD Contributing Factors 
 Potential PN/PAD contributing factors were not identified in the present study because of time 
and resource limitations.  However, the conceptual approach is the same as that for identifying potential 
PN/PAD treatments, with the exception that the directions in which characteristics changes are desired 
are reversed.  In the example provided in section 6B5 for treatments, the query for identifying potential 
contributing factors would be "increase oxidative stress" AND "increase inflammation".  All contributing 
factors for any disease in Medline (with the exception of PN/PAD) that increased oxidative stress and 
increased inflammation would be retrieved.   
6B7. Identifying Potential PN/PAD Characteristics 
 Potential PN/PAD characteristics were not identified in the present study because of time and 
resource limitations.  If potential PN/PAD characteristics were desired, the identification concept would 
be to identify patterns of PN/PAD characteristics that tend to co-occur frequently in the PN/PAD 
literature, then use these patterns as a search query in the non-PN/PAD literature.  New patterns may 
be identified in the non-PN/PAD literature consisting of the search query pattern plus additional 
characteristics not in the PN/PAD literature.  These additional characteristics would then be candidates 
for discovery as new PN/PAD characteristics that not have been identified previously.   
 For example, IL-1 and IL-6 and TNF-alpha and NF-KappaB tend to co-occur in many PN/PAD 
articles relating to inflammation.  These four terms would be combined as a query for the non-AD 
literature: "IL-1 AND IL-6 AND TNF-alpha AND NF-KappaB".  Any records retrieved would be examined 
for additional characteristics, and these additional characteristics would be validated if they did not 
occur in the PN/PAD literature. 
 Myriad other patterns are possible.  For example, existing PN/PAD treatments and existing 
PN/PAD causes move PN/PAD characteristics in known directions.  Non-PN/PAD literatures could be 
searched for characteristics  impacted by these known PN/PAD treatments and PN/PAD causes, and not 
contained in the core PN/PAD literature.  Combinations of these PN/PAD treatments and PN/PAD causes 
could be used to increase the likelihood that any new characteristics identified would have higher 
relevance to PN/PAD.   
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 As a specific example, consider the following query that was demonstrated in the Alzheimer's 
Disease (AD) study [Kostoff, Porter, Buchtel, 2018]: (high-fat-diet* NEAR/5 (increas* OR decreas*) AND 
chitosan NEAR/5 (increas* OR decreas*)) NOT alzheimer*.  This will retrieve all records reflecting an 
increase or decrease of characteristic values (in the non-AD literature) due to the presence of the 
existing AD cause "high-fat-diet" and the existing AD treatment "chitosan".  Applying this query to the 
Medline database leads to the identification of a potential AD characteristic "mup17" (major urinary 
protein 17) [Wang, Zhang, Wang et al, 2017].  This potential AD characteristic is not found in the AD 
literature, but it is altered in one direction by an existing AD cause, and is altered in the opposing 




(return to TOC) 
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APPENDIX 5 – FOUNDATIONAL CAUSES OF AD 
2-7C. Specific Foundational Causes of AD 
 Table 2-7C shows the AD potential foundational causes in this detailed taxonomic structure.  
There are four columns listed.  The first column on the left (CAT) is the foundational cause category as 
shown in Table 2-7A.  The next column is the foundational cause.  To keep the volume of results 
manageable, in some cases only the cause in aggregate was shown, rather than listing all the members 
(e.g., vegetables).  The third column is the effect(s) produced by the foundational cause, and the entry 
tags are those listed in Table 2-7B.  The fourth column contains relevant references that confirm the 
foundational cause. 
 In most cases, there were multiple papers linking each foundational cause listed either directly to 
AD or indirectly to one or more surrogate endpoints.  Referencing every single relevant paper for every 
detailed foundational cause would have produced an overly voluminous unreadable table and write-up.  
In order to balance comprehensiveness with readability, multiple compromises were made. 
 First, one or two representative papers for each foundational cause were selected and 
referenced.  Second, foundational causes that had relatively minor differences were aggregated.  Some 
were listed separately under a categorical heading, and others were subsumed within the heading.  Third, 
the effects/impacts of the foundational causes were extracted from at least the papers referenced, and 
sometimes from other relevant papers that were not selected for referencing.  Thus, the effects/impacts 
shown for any potential cause should be viewed as a "floor" of all potential effects, not a "ceiling".   
 It should also be noted that all the effects/impacts were derived from papers whose central theme 
was AD/dementia, because of the criteria used to extract these records from Medline.  So, a foundational 
cause that, e.g., "damaged mitochondria" (A6) did so within the overall context of relating to AD or 
dementia.  If the four different levels shown, and the items contained in each level, are viewed as potential 
"pathways" to AD, then conventional wisdom implies that the more pathways impacted by a potential 
contributing factor, the greater likelihood that factor would be an important "cause" of AD.  However, not 
only are the numbers of pathways impacted important, but the strength of the contributing factor's 
impact on each pathway is important.  This strength of impact is not shown in the table, reflecting its 
ambiguity in the literature. 
 The foundational causes identified are at different levels of importance to AD, and are at different 
levels of verification/validation. In the Medline literature examined, some foundational causes were 
identified through:  
 1) in vitro cell or tissue tests;  
 2) animal experiments;  
 3) epidemiological studies;  
 4) individual case studies; and,  
 5) trials with large numbers of subjects.  
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Conventional wisdom implies that those foundational causes associated with large numbers of papers 
published and large numbers of test subjects would have greater credibility. However, as shown in [2-3], 
there may be (many) important foundational causes being withheld from the literature deliberately, so 
numbers of papers is not a definitive metric for credibility. 
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Table 2-7C - Foundational Causes of AD 
(adapted from reference [1]) 
CAT CAUSE EFFECTS REF 
I  
 
LIFESTYLE   
I-A  DIET   
I-A1 EXCESSES   







-maternal high fat diet 
A2, B1, B2, C1, C3, D1, 
D4, D5 
[3-12] 
 Diabetogenic diet B2 [13] 
 High calorie diet A1, B1, B12, C3, D1, 
D5 
[14-16] 
 High salt diet B2, C3, D1 [17] 




-high glycemic index diet 
A1, A3, A4, A7, B2, B4, 
B11, B12, B13, C1, C3, 
D1, D2 
[18-25] 
 High advanced glycation end products diet 
-high temperature food heating  
-food irradiation 
-high glucose 
-high nutrient-bound AGEs 
-animal foods high in fat and protein 
A6, A7, B1, B2, B3, C1, 
C3, D1, D2  
[26-31] 
 
 High cholesterol diet A1, A4 [32] 
 High iron diet 
-high red meat 
-high processed meat 
A1, C3, D1 [33-35] 
 High meat diet D1 [36] 
 High arachidonic acid B1 [37] 
 High methionine diet A1, A2, A7, B1, B8, B2, 
C1, C3 
[38-40] 
 High copper diet C3, D1 [35, 41] 
 High zinc A3, A7, B1, B2 [42-43] 
 High pickle diet D1 [44] 
 High unfermented soy D1 [45] 
I-A2 DEFICIENCIES   
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 Vitamin B deficiency 
-myriad B-Vitamin deficiency 
-B2/B6/B12 deficiency 
-folate/folic acid deficiency 
-thiamine deficiency 
A3, A4, A6, A7, B1, B2, 
C1, C3 
[46-49] 
 Vitamin C deficiency A7, C2 [50] 
 Vitamin D deficiency A1, A4, A6, B1, B2, B5, 
B8, C3, D1 
[51-52] 
 Vitamin E deficiency D1 [53] 
 Vitamin K deficiency 
-fluindone 
C3 [54] 
 Potassium deficiency A1, A3, A7, B1, B2, C3 [55-56] 
 Iron deficiency C3 [57] 
 Zinc deficiency A3, C3, D1 [58] 
 Magnesium deficiency C3 [59] 
 Calcium deficiency A3, A7 [60] 
 Selenium deficiency B2 [61] 
 Starvation B2 [62] 
 Dehydration B5, D1, D2, D5 [63] 
 Malnutrition D1 [64] 
 Early life nutrient restriction B2, D1 [65] 
 Glucose deprivation A3, B1, B2 [66] 
 Glutathione depletion A1, A2, A4 [67] 
 Linoleic acid deficiency A4, D1 [68] 
 Low docosahexaenoic acid A3 [53] 
 Low tryptophan diet B2 [69] 
 Nondrinkers C3, D1 [70] 
 Low cocoa A1, A7, C3 [71] 
 Low coffee C3, D1 [72] 
 Low flavonoids/flavanols: 
acacetin, aminogenistein, apigenin,  
kaempferol, 7,8-Dihydroxyflavone, 
anthocyanins, atriplex laciniata L, blueberries, 
Curcumin, cyanidin, datiscetin, delphinidin, 
EGCG, epicatechin, Epimedium brevicornum, 
fisetin, genistein, Ginkgo, glycitein, icariin,  
isoscutellarein 7-O-[6'''-O-acetyl-beta-D-
allopyranosyl-(12)]-beta-D-glucopyranoside, 
isovitexin, morin, myricetin, Nobiletin, 
pelargonidin, phloridzin, rutin, salvigenin, 
Scutellaria baicalensis Georgi, Sideritis 
flavonoids, vitexin, xanthomicrol, luteolin, 
morin, PD98059, quercetin,  taxifolin, β-
naphthoflavone   
A1, A7, B2, C3, D1 [71, 73-74] 
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 Low fruit: 
low: blackberries, blueberries, strawberries, 
raspberries, cherries, oranges, plums, prunes, 
red grapes, pomegranates, date palm fruits 
A7, B2, B3, B13, C1, 
C3, D1  
[21, 75-76] 
 Low vegetables 
-cruciferous 
-dark and green leafy 
A7, B13, C3, D1  [8] 
 Low fatty fish B2, C3, D1 [77] 
I-A3 FOOD ADDITIVES/POLLUTANTS   
 Industrialized/preserved food D1 [78] 
 Monosodium glutamate A2, A3, B2, B9 [79] 
 Menadione A3, A7 [80] 
 Cysteine A7 [81] 
 Diacetyl A2, B2 [82] 
I-B ACTIVITY   
I-B1 SEDENTARY LIFESTYLE   
 Physical inactivity/low daily gardening, walking A6, A7, D1 [83-84] 
 Chronic immobilization stress A4, B1, B2, B9, C3 [85] 
 Cognitive inactivity D1 [86] 
 Lack of exercise D1, D2 [23] 
 Low cardiovascular fitness D1 [87] 
I-B2 SLEEP   
 Sleep deprivation C3, D1 [20, 88] 
 Circadian disruption C1, C3 [89-90] 
I-C SUBSTANCE ABUSE   
I-C1 RECREATIONAL DRUGS   
 Amphetamine C3 [91] 
 3,4-Methylenedioxyamphetamine; MDMA; 
Ecstacy 
A2, A7, B1, C1, C3 [92] 
 Cocaine/opiates A2, A4  [93-94] 
 Phencyclidine C3 [95] 
I-C2 SMOKING   
 Tobacco smoke A4 [96] 
 Ethanol/excess alcohol A7, B9, C1, C3, D1 [97] 
II IATROGENIC   
II-A DRUGS   
II-A1 ANTI-NEOPLASTIC AGENTS   
 Chemotherapy A2, A4, B9 [98] 
 Chemical castration C3 [99] 
 Camptothecin A2, A3 [100] 
 Epoxomicin A3, A6 [101] 
 Staurosporine/Etoposide A3, A4 [102-103] 
 Methylmethane sulfonate A5 [104] 
 Paclitaxel/Doxorubicin A3, A4, B1 [105] 
 Doxycyclin B2 [106] 
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 Cyclophosphamide/cytophosphane A2, A7 [107] 
 Letrozole B9, C1 [108] 
 Methotrexate B9, C1, C3 [109] 
 Choline mustard Az/Nitrogen mustard B9, C1 [110] 
 Anastrozole B2, B9 [111] 
 d,l-buthionine-S,R-sulfoximine/BSO A3, A6, A7, B14 [112] 
 Fostriecin/Fos B1 [113] 
 carbobenzoxy-Leu-Leu-leucinal/MG132 A2, A4 [114] 
 Streptozocin B14, D1 [115] 
II-A2 ANTI-INFECTIVE AGENTS   
 Chloroquine(CQ); CQ; lysosomotropic agent B2 [116] 
 Ionomycin A6, B2 [117] 
II-A3 ANTI-INFLAMMATORY AGENTS   
 colchicine A1, A4, C1, D1 [118] 
II-A4 CARDIOVASCULAR AGENTS   
 isoproterenol B1, C1 [119] 
 atropine B2 [120] 
 D-ribose A3, B1, B3 [121] 
 Muscarinic receptor antagonists C1, C3 [122] 
II-A5 CENTRAL NERVOUS SYSTEM AGENTS   























A2, A3, A4, A6, B1, B2, 
B9, C1, C3, D1 
[123-129] 
II-A5b Movement Stabilizers   
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A3, A7, B1, C3, D1 [130-132] 
II-A5C Depressants/Anti-Depressants and Stimulants   
 selective serotonin re-uptake inhibitors D1 [133] 
 benzodiazepine D1 [134] 
 dizocilpine C1, C3 [135] 
 3-quinuclidinyl benzilate C3 [136] 





C1, C3 [137] 
 anisomycin A7, B2 [138] 
II-A6 IMMUNE SYSTEM AGENTS   
II-A6a Immunosuppressive Agents/ 
Immunosuppression 
  
 Cyclosporin B1, C1 [139] 
II-A6b Immunostimulation Agents   
 polyinosinic:polycytidylic acid B2, C3 [140] 
II-A7 Hematologic Agents   
II-A7b Anti-Coagulants   
 Sulfated glycosaminoglycans 






II-A7c Other   
 mitochondrial toxins 
-1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine/MPTP 
A1, A3, A6, A7 [142] 




A1, A3, A4, B1, B5 [143-145] 
 Anabolic androgenic steroids 
-nandrolone 
-stanozolol 
B8, B9, C1, C3 [146] 
 Corticosterone B1, B2, C3 [147] 
 Wortmannin A7, B1 [148] 
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 17beta-trenbolone A3, A4, B2 [149] 
 Salmon calcitonin B2 [150] 
 Human chorionic gonadotropin B2 [151-152] 
 Corticotrophin releasing factor B2 [153] 
 Sex steroid hormones 
-transient testosterone treatment 
-flutamide 
B2 [154] 
 U18666A A3, A7, B2 [155] 
 Allopregnanolone B9, C1, C3 [156] 
 Medroxy-progesterone acetate C3, D1 [157] 
 Androgen deprivation therapy D1 [158] 
 Postmenopausal hormone therapy C3 [159] 
 Testosterone depletion A1, D1, D2 [160] 
 Leptin deficiency B1 [161] 
 Prenatal sex hormone exposure D1 [162] 
II-A9 ANTI-HYPERTENSIVE AGENTS   
 ACE inhibitor D1 [163] 
 ICI 118,551/Selective beta2AR antagonist B1, B2, C3 [164] 
 Telmisartan/Olmesartan B2 [165] 
 Mecamylamine C3 [166] 
II-A10 GASTROINTESTINAL AGENTS   
 Thiorphan/Phosphoramidon B2 [167] 






B2, D1 [168-169] 
II-A13 ANTI-BONE-LOSS AGENTS   
 PGE2 B2 [170] 
II-A14 ANTI-DIABETIC AGENTS   
 Intralipid and insulin B2 [171] 
 Metformin B2 [172] 
II-A16 ANTI-ALLERGIC AGENTS   
 Anticholinergics 




II-A18 ANTI-THYROID AGENTS   
 Propythiouracyl A1, B1, B2, B5, B8, C1 [174] 
II-A19 Other   
 Carbachol B8, B14 [175] 
 MDL72974/Mofegiline A3, A7 [176] 
 Pilocarpine A3, B1, B2 [177] 
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 Clenbuterol hydrochloride B2 [178] 
 Semagacestat C3 [179] 
II-B RADIOTHERAPY   
 Head radiotherapy C3, D1 [180-181] 
II-C SURGERY/ INVASIVE TREATMENTS   
II-C1 TRANSPLANTATION   
 Liver transplant B2, C3 [182] 
II-C2 CARDIOVASCULAR   
 Cardiac surgery/bypass A1, B1, B2, C3 [183-185] 
II-C5 KIDNEY/UROLOGIC   
 Dialysis C1, C3 [186-187] 
 Gonadectomy B2 [188]  
II-C7 DENTAL/ORAL/NOSE/EAR   
 Olfactory bulbectomy A4, A6, A7, B2, C1 [189-190] 
 Occlusal disharmony B2 [191] 
II-C8 GYNECOLOGIC   
 Hysterectomy/oophorectomy C3 [192] 
 Premature surgical menopause/Premature 
ovarian failure 
C3 [193] 
II-C17 OTHER   
 Axotomy A3, A7 [194] 
 Cerebral artery occlusion A3, A4, A7, B8, C1, C3 [195-198] 
 Intermittent hypoxia/ischemia A3, A4, A7, B2, B12, 
C1, C3 
[199-202] 
 Brain embolism A4, B1, B2, C1, C3 [203-204] 
 Aortic coarctation A1, B2 [205] 
 Forebrain lesions C1, C3 [206-207] 
 Adrenalectomy B2 [208] 
 Pituitary hormone injections with Abeta B2 [209] 
 Abdominal surgery B2, C3 [210] 
III BIOTOXIC AGENTS   





A2, A3, A4, A7, B1, C1, 
C3, D1 
[211-214] 
 3-nitropropionic acid A6 [215] 
III-B EXOTOXINS   
 Excitotoxins 





A1, A2, A3, A4, B9, C1, 
C2, C3,  
[216-220] 
 Phosphatase inhibitor B1 [221] 
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-okadaic acid  
 Excitatory amino acids D1 [222] 
 Malonate B9 [223] 







A2, B1, B2, B14 [225-228] 
 Diphtheria toxin B2 [229] 




B1, B2, B13, C3 [231-233] 
 Cycad plant 
-cycasin/methylazoxymethanol 
A2, A4, A5 [234] 
 Glutamate/Glutamine synthetase A2, A3, A4, A6, B2 [235-237] 







III-C BACTERIA/FUNGI/PARASITES   





















A1, A4, A7, B1, B2, B3, 
C3, D1  
[239-253] 



























-Trypanosoma brucei rhodesiense 









III-D VIRUSES   
 Viruses/Viral infections/Virulence factors 
Bornaviridae  
-Mammalian 1 bornavirus  
Bunyaviridae  
-Hantavirus  
-La Crosse encephalitis virus  
Coronaviridae  
-Human coronavirus OC43  
-Murine hepatitis virus  
Flaviviridae  
-Hepatitis C virus  
A1, A3, A4, B1, B2, C3, 
D1  
[254-260] 
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-Japanese encephalitis virus 
-Murray Valley encephalitis virus  
-St. Louis encephalitis virus  
-West Nile virus  
Hepadnaviridae  
-Hepatitis B virus  
Herpesviridae  
-Cytomegalovirus  
-Epstein-Barr virus  
-Herpes simplex virus 1  
-Human herpesvirus 6  
Orthomyxoviridae  
-Influenza A virus (H1N1)  
-Influenza A virus (H3N2)  
-Influenza A virus (H5N1)  
Paramyxoviridae  
-Hendra virus  
-Measles virus  
Picornaviridae  
-Enterovirus 71  
-Theiler's murine encephalomyelitis virus  
Polyomaviridae  
-Simian 40 virus large T antigen  
Retroviridae  
-Human immunodeficiency virus 1  
-Human T-cell leukemia virus  
-Moloney murine leukemia virus  
Rhabdoviridae  
-Chandipura virus  
Togaviridae  
-Chikungunya virus  
-Eastern equine encephalitis virus  
-Venezuelan equine encephalitis virus 
III-E OTHER   
 Abeta 




A1, A2, A3, A4, A6, B2, 
B8, B14, C1, C3 
[261-271] 
 Homocysteine/3-Mercaptopropionic Acid B8, B12, C1 [272-273] 
 Lipopolysaccharide A7, B3, C1 [274] 





A1, A2, A3, A4, B1, B2, 
B9, C1, C3 
[278-288] 









 Lipoperoxydation proteins 
-advanced lipoperoxydation products 
-oxidized low density lipoprotein 
A1, A2, A3 [289-290] 
 Trophic factor withdrawal A3, A4, B2 [291-293] 
 Amylin A1, A2, A4, A6, A7 [294] 
 Lysophosphatidic acid B2 [295] 
 S100B A1, B1, B2 [296] 
 3-hydroxykynurenine/3-hydroxyanthranilic acid A4, A7, B2 [297] 
 Abscisic acid A1 [298] 
 Phorbol myristate acetate A1 [298] 
 Acid phosphatase D1 [299] 
 2-deoxy-D-glucose B2 [300] 




 Asymmetric dimethylarginine A2, A7, B2, C3 [303-304] 
 Dolichyl phosphate B12 [305] 
 N-(2-chloroethyl)-N-ethyl-bromo-
benzylamine/dsp4 
A1, A3, A4, B2, B13, 
C1 
[306] 
 Galanin C1, C3 [307] 
 GW4869/hydrochloride hydrate B2 [308] 
 Cottonseed B1, B2 [309] 
 Homocysteic acid/Homocysteate A3, A7 [310] 
 Isoprostane B2 [311] 
 Lysophosphatidylcholine A2, A3, A7, B2 [312] 
 Saturated non-esterified fatty acids B2 [313] 
 Palmitic acid A3, C3 [314] 
 Oncostatin M A2, B11 [315] 
 S100A9 A1, B2, C3 [316] 
 Salsolinol A2, A3 [317] 
 Sulfatide A3 [318] 
 Brefeldin A A3, A6, A7 [319] 
 Thapsigargin A3, A6, A7 [319] 
 GF-109203X B1 [320] 
 Isopropyl-1-beta-D-thiogalactopyranoside A3, A6, B1 [321] 










 alpha7 nAChR subunit alpha7(1-208) A1, B2, C3 [324] 
 Adenosine triphosphate/ATP B1 [325] 
 Recombinant BiP/GRP78 B2 [326] 
 Bradykinin B1, B14 [327] 
 CD40/CD40L B2 [328] 
 Collagen B2 [329] 
 Cyclic dipeptides A3 [330] 
 D-serine A7 [331] 
 Elastase A7, B1 [332] 
 4-Hydroxyhexenal/HHE A3, B11, B13 [333] 
 High-mobility group box-1/HMGB1 C3 [334] 










A1, B2, C1 [336-337] 
 Myostatin precursor protein B2 [338] 
 N-acetylcholinesterase A3, B1 [339] 
 Secreted phospholipase A2-IIA/sPLA2-IIA A1 [340] 
 Spermine A2 [341] 
 Xanthine oxidase A3, A7 [342] 
 3-hydroxykynurenine/3-HK A2, A3, A6 [343] 
 Mitochondrial lysates A1 [344] 
 Phytohemagglutinin A3, B14 [345] 
 Angiotensin II B1, B2, C3 [346] 
 3beta-hydroxy-5-oxo-5,6-secocholestan-6-al/ 
ChSeco 
A2, A3, A7, B2 [347] 





-5,6-alpha cholesterol epoxide 
-5,6-beta cholesterol epoxide 
-cholesterol triol 
-lathosterol 
-beta cholesterol epoxide 
-cholesterol triol 
A1, A2, A7 [348-349] 
 Calyculin A A2, A7, B1 [350] 
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 Chromogranin A A1 [351] 
 Forskolin B1 [352] 
 N-methyl-D-aspartate A3, B9 [353] 
 PGJ2 A1, A3, B1 [354-355] 
 Quisqualate A3, B9, C2 [356] 
 Tunicamycin A3, B14 [357] 
 2-chloro-2'-deoxyadenosine/2-CDA/ cladribine B2, C3 [358] 





 Glycogen synthase kinase 3-beta/GSK3beta B1 [361] 
 HMG-CoA reductase D1 [362] 
 Pam(3)CSK(4) A1 [363] 








IV-A1a Hydrocarbons   
 20-methylcholanthrene/methylcholanthrene A1 [365] 
IV-A1b Solvents   













 Dimethyl sulfoxide/DMSO B1 [368] 








IV-A1c Chemical Compounds   
 Neurotoxins A3, A7 [371-372] 











A2, A3, A4, A7, B1, B2, 
B3, B8 
[373-378] 
 Nitrosamine/N-nitrosodiethylamine A3, A4, B4, C3 [379] 
 Adenosine, 3', 5'-cyclic monophosphate/ cAMP B2 [380] 
 Carbon tetrachloride A1, A4, A7, B4, B13 [381] 












A3, A7 [383-385] 
 Formaldehyde B1, C1 [386] 
 Hydrogen Peroxide/H2O2 A2, A3, A6, A7 [387] 
 Lipophilic chemicals 
-persistent organic pollutants 
-bisphenol A 
-phthalates 
-low molecular weight hydrocarbons 
-polynuclear aromatic hydrocarbons 
-endocrine disruptors 
C3, D1 [388] 




-DEHP metabolites  
B1, B4, B14, C3 [390] 
 Brominated flame retardants 
-hexabromocyclo-dodecane/HBCD  
-tetrabromobisphenol-Al/TBBPA  
-decabromodiphenyl ether/DBDE  
-polybrominated diphenyl ethers/PBDEs 
A2, A3, A6, A7, B2 [391-392] 
 Ammonia A1, B2, B8 [393-394] 
 Hypochlorous acid/HOCl A2, A6, B13 [395-396] 
 Methanol A3, B1, C1 [397] 
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 Peroxynitrite B1 [398] 
 Sodium azide A3, B1, B2 [399] 
 Acetaldehyde A3, A7 [400] 
 3-Bromopyruvate B13, C3 [401] 
 Vehicular emission oxides 
-nitrogen dioxide/NO2  
-carbon monoxide/CO 
C3, D1 [402] 
 Sodium fluoride C1, C3 [403 
 Membrane-mimicking detergents 
-sodium dodecyl sulfate  
-lithium dodecyl sulfate 
B2 [404-405] 




 Amorphous aluminosilicates B2 [408] 
 Sodium nitrite A3, A4, B1, B2, B9, 
B11, C1 
[409] 
 Tert-butyl hydroperoxide/t-BHP A3, A7 [410] 
 Alloxan B1, B2 [411] 
 Ammonium chloride A4, A6 [412] 





 Aroclor 1254 A3 [414] 
 Cobalt chloride A2, A3, A6, A7, C1, C3 [415] 




 Methylglyoxal/Glyoxal A1, A2, A7, B12 [378, 418] 





 Pyrithiamine B1, B2, C1 [421] 
 Pyrogallol A3, A7 [422] 
 Glyceraldehyde-3-phosphate/GAPDH A3, A6, B2 [423] 
IV-A1d Other   
 Ethylcholine mustard aziridinium ion/ AF64A B8, C1 [424] 
 1-methyl-4-phenylpyridinium ion A2, A3, A6, A7 [425] 
 2,2'-dithiodipyridine B14 [426] 
 Aftin-4 A7, B2, B8, C3 [427] 
 Kaolin B2 [428] 
 Ozone A3, A7, C1, C3 [429] 
 2;3;7;8-tetrachlorodibenzo-p-dioxin A2, D1 [430-431] 
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A1, A2, A3, A5, A6, A7, 
B1, B2, B11, B14, C1, 
C3, D1,  
[391, 431-
443] 
Prevention and Reversal of Chronic Disease                           Copyright © 2019 RN Kostoff 
154 
 
IV-A3 MATERIALS   
IV-A3a Heavy Metals   
















A1, A2, A3, A4, A6, A7, 





IV-A3b Particulates   




A1, A4, A7, B1, B2, D1 [456-458] 













A1, A2, A3, A4, A7, B2, 
B8, B12; B14 
[459-462] 
IV-B Physical/Mechanical   
IV-B1 Electromagnetic Radiation   
IV-B1a Ionizing   
 Gamma radiation 
-dental X-ray 
-gamma rays 
A3, B1 [463-464] 
 Particle radiation 
-56Fe-particle radiation 
-cosmic radiation 
-HZE particle radiation 
B2, B8, B9, B12, C3 [465-466] 
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A7, C1, C3, D1 [467-468] 
IV-B1b Non-Ionizing   
IV-B1b1 Non-Visible   
 Electromagnetic fields 





B1, B2, B8, B9, C1, C3, 
D1 
469-473] 
IV-B1b2 Visible   
 photolysis of 1-(2-nitrophenyl)ethyl sulfate B2 [474] 
IV-B2 SOUND   
 Noise 
-chronic noise exposure 
-short-lasting impulse noise 
-ultrasound sonication 
A1, A4, B2, B3, D1 [475-477] 
IV-B3 TEMPERATURE; HEAT/COLD   




A6, A7, B1, B2 [478-481] 
 Cold stress 
-cold water stress 
-cold water hypothermia 
A3, B1, B2, C1, C3 [482] 
IV-B4 Force/ Pressure/ Physical Trauma   
 Traumatic brain injury A4, B2, B9, C1, C3, D1 [483-486] 
 Head trauma 
-history of head trauma 
-closed head injury 
-axonal injury 
 
A1, B1, B8, B9, C1, C3, 
D1 
[487-490] 
 Spinal cord injury A1, A4, C3 [491] 
 Mechanical stress 
-Valsalva maneuver 
-repetitive heavy lifting 
-repetitive strong cough 
-accumulated mechanical stress 
A1, A3, B1, B2, D1 [492-493] 
IV-C OTHER   
 Oxygen alterations 
-hyperoxia 
-hypoxia 
A1, A3, A4, A7, B2, C3 [494-495] 
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V PSYCHOSOCIAL/SOCIOECONOMIC   
V-A PSYCHOLOGICAL   
 Chronic stress 
-repeated stress 
-chronic mild stress 
-chronic psychological stress 




-chronic restraint stress 
-high job stress 
-low level of job control 
 
A4, A6, A7, B1, B2, B9, 
C1, C3, D1 
[496-503] 
 Low mental activity 
-low cognitively engaging activity 
-low purposeful activities 
-low leisure activities/low hobbies 
--low music/drawing/meditation/reading/arts/ 
crafts 
B5, C3, D1 [504-507] 
V-B SOCIOLOGICAL   






-low social activity index 
-low social support at work 
-constricted life space 
 
A3, B1, B2, B8, C1, C3, 
D1 
[508-513] 
 Low education 
-illiteracy 
D1 [514-516] 
V-C ECONOMIC   
 Early life socioeconomic circumstances C3 [517] 
    
 
2-7C1.  Analysis of Results in Table 2-7C 
 The findings in the Lifestyle, Iatrogenic, Biotoxic Agents, Occupational/ Environmental Exposures, 
and Psychosocial/Socioeconomic categories will now be examined by sub-category.  The sub-category 
alphanumerical headings correspond to those in Table 2-7C. 
 
I.  Lifestyle 
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 Lifestyle includes choices mainly under individual control, and is divided arbitrarily into Diet, 
Activity, Substance Abuse, Other. 
I-A.  Diet 
 Poor diet reflects the adverse effects of excesses and deficiencies of dietary components.  It has 
been used to induce myriad diseases in test animals, and it was a critical disease factor from many 
epidemiological and case studies.   
I-A1. Dietary Excesses 
 Dietary excesses include: high-fat; diabetogenic diet; high-calorie; high-salt; high-carbohydrate; 
high advanced glycation end products (AGEs); high-cholesterol; high-iron; high-meat; high arachidonic 
acid; high methionine; high copper; high zinc; high pickle diet; high unfermented soy; and high-
temperature cooking that results in harmful products (e.g., AGEs, nitrosamines, polycyclic aromatic 
hydrocarbons, and acrylamides). 
 As Table 2-7C shows, high-fat diet (from the specific types of fat listed in the table) had impacts 
at the cellular, biomarker, performance, and disease categories listed in Table 2-7B.  These high-fat diets 
were 1) directly related to AD, 2) indirectly related to AD through their direct impact on other diseases 
directly related to AD (e.g., metabolic syndrome, diabetes), and 3) indirectly related to AD through their 
direct impact on the pre-disease surrogate endpoints directly related to AD.  High-fats were also a key 
component of the diabetogenic diet listed in the table. 
 High-calorie and high-salt diets had both direct and indirect relationships to AD.  High-
carbohydrate diet, especially refined carbohydrates/sugars, also had full spectrum impacts.  They also 
contributed to the diabetogenic diet. 
 High-AGEs, high-cholesterol, high-iron, and high-meat diets are intertwined, to a large extent.  
Meat tends to be high-cholesterol, high-iron, and, especially when cooked at high temperatures, 
associated with production of high AGEs.  Most of the articles related to meat consumption and AD 
emphasized adverse effects. Unfortunately, in most of these meat studies, especially epidemiological 
studies on humans, there was no separation of confounding effects. 
 Most meat available to the American public comes from CAFO (confined animal feeding 
operations). These animals are raised confined in very close quarters. To reduce infections from such close 
confinement, animals are given antibiotics, and to increase growth more rapidly, animals are given 
synthetic growth hormones. Their feed is grain-based, not the grass they would have if pasture-raised.  
Would the  dementia-related diseases associated with meat consumption in the articles be as copious and 
serious for pasture/grass-fed animals not raised under confined conditions, and not given antibiotics and 
synthetic growth hormones? 
 Most meat eaten is cooked, much of it at high temperatures, usually in the presence of 
endogenous and exogenous additional fats. High-temperature cooking, especially of animal foods that are 
high in protein and fat, results in substantial production of AGEs and other harmful substances (e.g., 
nitrosamines, polycyclic aromatic hydrocarbons, and acrylamides).  How are the harmful effects of the 
cooking separated from the harmful effects of the meat?  Separation was not evident in any papers 
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examined.  The bulk of the biomedical literature has not demonstrated that meat from 'organic' pasture-
raised grass-fed animals not fed antibiotics and growth hormones and not cooked at high temperatures 
is equally harmful to CAFO meat consumed by the vast majority of the American public, and there is some 
evidence that a moderate amount of high-quality meat may be beneficial. 
 Finally, diets high in arachidonic acid, methionine, copper, zinc, pickles, and unfermented soy 
contribute directly or indirectly to the development of AD. 
1A2. Dietary Deficiencies 
 Many deficiencies listed in the literature may be symptoms of metabolic problems, not 
foundational causes in the present sense.  Thus, a Vitamin A deficiency may be caused by 1) insufficient 
Vitamin A intake (foundational cause), or 2) some metabolic problem that results in reduced Vitamin A 
levels (symptom).   Dietary deficiencies include low: vitamins, especially Vitamins B (B2, B6, B12, 
folate/folic acid, thiamine), C, D, E; minerals, especially potassium, iron, zinc, magnesium, calcium, 
selenium; calories (starvation, malnutrition, early life nutrient restriction); water (dehydration); glucose; 
glutathione; linoleic acid; docosahexaenoic acid; tryptophan; alcohol (nondrinkers); flavonoids/flavanols 
(cocoa, coffee, acacetin, aminogenistein, apigenin,  kaempferol, 7,8-Dihydroxyflavone, anthocyanins, 
atriplex laciniata L, curcumin, cyanidin, datiscetin, delphinidin, EGCG, epicatechin, Epimedium 
brevicornum, fisetin, genistein, ginkgo, glycitein, icariin,  isoscutellarein 7-O-[6'''-O-acetyl-beta-D-
allopyranosyl-(12)]-beta-D-glucopyranoside, isovitexin, morin, myricetin, nobiletin, pelargonidin, 
phloridzin, rutin, salvigenin, Scutellaria baicalensis Georgi, Sideritis flavonoids, vitexin, xanthomicrol, 
luteolin, morin, PD98059, quercetin,  taxifolin, β-naphthoflavone); fruit (blackberries, blueberries, 
strawberries, raspberries, cherries, oranges, plums, prunes, red grapes, pomegranates, date palm fruits); 
vegetables, especially cruciferous, dark and green leafy; fatty fish. 
 A very clear message about the dietary contribution to AD can be extracted from the above 
picture of dietary excesses and deficiencies.  From the macro perspective, the amounts of fat, salt, sugar, 
refined carbohydrates, calories, and meat need to be reduced strongly, along with high temperature 
cooking, and the amounts of vitamin and mineral-laden fruits, vegetables, and fatty fish need to be 
increased substantially to reduce the risk of AD and perhaps contribute to reversal of AD. 
I-A3. Food Additives 
 Many food additives are accompanied by adverse effects, and these effects may be under-
diagnosed and under-researched.  Many of the excesses and deficiencies mentioned above are the result 
of substances being added to, or removed from, the fresh whole food.   
 Additives include preservatives, monosodium glutamate, menadione, cysteine, diacetylcysteine, 
and diacetyl.  Depending on how one defines "food additives", those additives with the widest impacts 
tend to include the major items listed under excesses above, such as fat, sugar, and salt.  These 
components are typically added to foods for taste enhancement, not nutritional improvement.  The 
effects of these additives appear to be at the cellular and biomarker levels. 
I-B.  Activity 
 The main sub-categories of Activity are exercise, sedentary lifestyle, and sleep.   
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I-B1. Sedentary Lifestyle/Lack of Exercise 
 The sedentary lifestyle, including low exercise, low physical activity, low daily gardening, low 
walking, and chronic immobilization, was mentioned quite often, and cognitive inactivity also received 
some mention. The resultant low cardiovascular fitness was also emphasized. 
Sleep 
 Circadian disruption and poor sleep/sleep deprivation were also mentioned, although the main 
foundational components of poor sleep would be 1) choosing to sleep less or 2) not practicing good sleep-
preparation habits.  Other contributing factors to poor sleep, such as excessive pain, anxiety, etc, may be 
less under one's control, and are not regarded as foundational under the definition in the present 
monograph. 
I-C.  Substance Abuse 
 Substance abuse includes "recreational" drugs of all types (cocaine, methamphetamine, etc), 
other substances such as laxatives, common household products not usually identified as recreational 
drugs (such as mothballs), and especially excessive cigarette smoking and alcohol. The main substance 
abuse contributing factors to AD for the present study were 1) recreational drugs (especially cocaine, 
amphetamines/3,4-Methylenedioxyamphetamine (MDMA - Ecstacy), phencyclidine, opioids) and 2) 
excessive smoking and alcohol.  The bulk of the studies showed the recreational drugs' contributions to 
AD surrogate endpoints, such as neurodegeneration markers and cognitive dysfunction. 
Potential Synergies 
 The individual AD foundational causes identified with Lifestyle are usually studied in isolation, and 
synergistic effects are typically not identified.  Given the number of Lifestyle component combinations 
that could potentially be synergistic, and adding in  
1) the foundational causes from the remaining categories (identified in Table 2-7C) to the potential 
combinations, and  
2) potential foundational causes that surface only when operating in synergy but which have not yet been 
identified in Table 2-7C as individual foundational causes, 
it is clear that only the tip of AD foundational causes iceberg is being identified in this study. 
 
II.  Iatrogenic 
 Iatrogenic reflects diseases, symptoms, and injuries resulting from medical treatment, and is 
divided into four sub-categories: Drugs; Radiotherapy; Surgeries/ Invasive Procedures; Diagnostic 
Agents/Procedures.  Iatrogenic is a substantial category, due mainly to the large numbers of drugs and 
surgeries that have side-effects and complications.  The main categories, along with detailed drugs and 
surgeries, are presented in Table 2-7C.   
II-A. Drugs 
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 While the drug categories have some overlap, each drug is listed in one category only in Table 2-
7C for purposes of brevity when generating the drug categories.  The more frequently a drug is used, or 
the more frequently surgery or invasive treatments are employed, the more opportunity for side-effects 
and complications, and the more opportunity for publications describing these side-effects and 
complications.  This study does not provide an indication of how often such side-effects and complications 
would occur as a percentage of use. 
 There were eighteen major drug categories identified in Table 2-7C, but only those with 
substantial entries will be discussed in this narrative.  These include anti-neoplastic agents, cardiovascular 
agents, the massive category of central nervous system agents, hematologic agents, steroids/hormones, 
antihypertensive agents, and gastrointestinal agents. 
 What the table does not show is the effect of drug-drug combinations, or drug-other agent 
combinations.  The effects of these combinations could be important, but might not surface in some types 
of studies.  A study on drug-drug combinations concluded that, of approximately 11,000 drug products on 
the US market, trillions of clinical trials would be required to provide an evidentiary basis of safety for all 
combinations of ten drugs [518].  Even for all combinations of three drugs, the number of clinical trials 
required to evaluate safety, or lack thereof, would be astronomical. 
 Thus, there are many ways that 1) a drug that has been shown to contribute to AD in isolation, 
when combined with two other drugs that have not been shown to contribute to AD in isolation, could in 
aggregate have a much stronger contribution to AD, and/or 2) three drugs that have been shown to have 
a modest contribution to AD in isolation, when combined, could in aggregate have a much stronger 
contribution to AD, and/or 3) three drugs that have been shown to have negligible contribution to AD in 
isolation, when combined, could in aggregate have a strong contribution to AD.  Even if there are small 
numbers for any one combination of three drugs, when they are aggregated over the total number of 
potential combinations, this could add up to a large number of strong contributions.  This effect might not 
surface in any epidemiological study because 1) it would fall beneath the statistical radar screen, 2) 
temporal variation in the combinations would be difficult to assess, and 3) the numbers of clinical trials 
required to assess the impact of drug combinations are astronomical and would be impractical.  For 
combinations of drugs larger than three, which increase for people as they age [518], the numbers of 
combinations and clinical trials to demonstrate safety increase rapidly. 
II-A1. Antineoplastic Agents 
 This is a powerful class of drugs, and they tend to exert toxic/destructive effects on cancer cells.  
It is therefore unsurprising that these drugs would result in surrogate endpoint effects such as 
neurotoxicity/neurodegeneration/apoptoses on some healthy cells as well.  The types of impacts in Table 
2-7C bear this out.  Neurotoxic-type effects are seen for many of the agents, as well as the accompanying 
memory degradation, but direct links to AD are not reported as frequently.  The old dictum "absence of 
evidence is not evidence of absence" should be a warning flag on drawing hard conclusions about direct 
links. 
II-A4. Cardiovascular Agents 
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 The impacts of the four agents/agent classes (isoproterenol, atropine, D-ribose, muscarinic 
receptor antagonists) presented in Table 2-7C concentrate on the surrogate endpoints, with emphasis on 
the biomarkers (increase tau, Abeta) and performance (decrease memory, cognition). 
II-A5. Central Nervous System Agents 
 This was by far the largest category of potential contributors to AD.  This should not be surprising, 
since the members of this category act on the central nervous system (and some on the peripheral 
nervous system as well), and the brain is an integral part of the central nervous system.  The impacts of 
the myriad contributing factors in this category differ somewhat by sub-category. 
 The analgesics and pain relievers (anesthetics/opiods) sub-category, consisting of 
acetaminophen, barbital, barbitone, desflurane, dexmedetomidine, diethylbarbituric acid, diethylmalonyl 
urea, enflurane, halothane, isoflurane, ketamine, medinal, morphine, nitrous oxide, pentobarbital, 
propofol, psychotropic drugs, sevoflurane, sodium diethylbarbiturate, veronal, affected all four impact 
areas.  There was a substantial literature on the AD-related impacts of these sub-category members.  One 
analytic problem deriving from this observation is that the relationship between the types of surgery to 
AD is conflated with the relationship between the anesthetic to AD, and it is difficult to separate the two, 
since anesthetics are used almost universally in surgery, especially major surgery. 
 The movement stabilizer sub-category, consisting of the anticholinergic medications doxepin, 
chlorpheniramine, oxybutynin, trihexyphenidyl, propiverine, L-DOPA/dopamine, was less numerous in 
terms of publications than the anesthetic sub-category, but covered the four impact classes as well. 
 The depressant/antidepressant sub-category, consisting of selective serotonin re-uptake 
inhibitors, benzodiazepine, dizocilpine, and 3-quinuclidinyl benzilate, had impact on performance and AD 
in the references shown.  The absence of impact at the cellular and biomarker levels could mean that 
these classes of impacts were not the objectives of the research that was conducted, or they were 
reported in other papers not presented here. 
 The mood stabilizer sub-category, consisting of clozapine, methyllycaconitine, dihydro-beta-
erythrodine, and anisomycin, impacted across the surrogate endpoints. 
II-A7. Hematologic Agents 
 The main component of this category is the anti-coagulant sub-category, consisting mainly of the 
sulfated glycosaminoglycans heparin/heparan sulfate, dextran sulfate, pentosan polysulfate, chondroitin 
sulfate, dermatan sulfate, and fluindione. 
II-A8. Steroids/Hormones 
 The substances in this category include corticosteroids (methylprednisolone, dexamethasone), 
anabolic androgenic steroids (nandrolone, stanozolol), corticosterone, Wortmannin, 17beta-trenbolone, 
salmon calcitonin, human chorionic gonadotropin, corticotrophin releasing factor, sex steroid hormones 
(transient testosterone treatment, flutamide), U18666A, allopregnanolone, medroxy-progesterone 
acetate, androgen deprivation therapy, postmenopausal hormone therapy, testosterone depletion, 
human chorionic gonadotropin, prenatal sex hormone exposure, and the deficiency of leptin.  This class 
of pharmaceuticals (especially the corticosteroids) is used for a wide spectrum of medical conditions, and 
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the broad scope of potential impacts is concerning.  While some of the drugs in the larger Iatrogenic 
category have rather narrow applications, the long-term effects on neurodegenerative diseases of widely 
used drugs such as anesthetics and steroids should be cause for serious concern. 
II-A9. Antihypertensive Agents 
 These agents include ACE inhibitors, ICI 118,551/Selective beta2AR antagonists, 
telmisartan/olmesartan, and Mecamylamine.  Some of the anti-hypertensive agents listed are widely used 
because of the prevalence of hypertension, and their long-term effects need to be examined more closely.  
The main impacts listed are those on the surrogate endpoints, although the ACE inhibitors are linked to 
AD.  The referenced papers don't report impacts at the cellular level, although, again, that does not imply 
the absence of such impacts. 
II-A10. Gastrointestinal Agents 
 These agents include thiorphan/phosphoramidon, and the large class of proton pump inhibitors 
(omeprazole, pantoprazole, lansoprazole, esomeprazole, and rabeprazole).  Again, this is disturbing for 
the long-term, because of the almost common-place used of this family of drugs for digestive problems. 
II-B. Radiotherapy 
 Radiotherapy that involves the head region impacts cognition and AD. 
II-C. Surgery/Invasive Treatments 
 The following categorization is not unique.  Some procedures could be assigned to multiple 
categories.  Surgeries/invasive procedures that contribute to AD tend to involve vessel occlusion, cerebral 
ischemia, broader cardiac surgery, estrogen depletion, and myriad forms of dialysis.   
 One interesting observation is that the surgery impacts are all on AD surrogate endpoints, not on 
AD directly, for the references selected.  This may be due to personal choice of the authors.  Some authors 
identified a number of surrogate endpoints that were impacted, and referred to the aggregate as 
Alzheimer's-like.  Other authors would refer to the aggregate as Alzheimer's Disease.  Since inhalation 
anesthesia seems to be a strong contributing factor, almost any major surgery employing this type of 
anesthesia would have to involve some potential risk for AD, either through the surrogate endpoints, or 
directly.  
 
III.  Biotoxic Agents 
 Biotoxic Agents reflect mainly the biological substances to which we are exposed naturally, but 
sometimes accidentally, and sometimes by design.  This category is divided into five sub-categories: 
Mycotoxins; Exotoxins; Bacteria/ Fungi/ Parasites; Viruses; Other.  Biotoxins contributing to AD include 
some mycotoxins, but mainly exotoxins, bacteria, and viruses. 
III-A. Mycotoxins 
 Only a few mycotoxins were identified, including ochratoxin A, fumonisin B1, and macrocyclic 
trichothecenes.  Their impacts cover all four levels. 




 Many exotoxins were identified, including excitotoxins (kainic acid/kainate, quisqualic acid, 
ibotenic acid, domoic acid, quinolinic acid/quinolinate), phosphatase inhibitors (okadaic acid), excitatory 
amino acids, malonate, annonaceaeous  acetogenins, cyanobacteria (beta-N-methylamino-L-
alanine/BMAA, saxitoxin, anatoxin-a, blue-green algae, microcystin), diphtheria toxin, pseudomonas 
aeruginosa exotoxin Y, saporins (192 IgG-saporin, p75-saporin), cycad plant 
(cycasin/methylazoxymethanol), glutamate/glutamine synthetase, mitochondrial inhibitors (rotenone, 3-
NPA, antimycin, KCN, oligomycin).  Some substances in the Other category could have been assigned to 
the Exotoxin category.  The impacts were heavily weighted toward the cellular and biomarker levels, less 
so toward the performance level, and even less toward the disease level. 
III-C. Bacteria/Fungi/Parasites 
 Myriad bacteria, fungi, and parasites (shown in Table 8-3) are dominant in sub-category III-C.  The 
bacteria/bacterial infections include bacterial endotoxins, bacterial lipopolysaccharide, gram-negative 
bacterium, spirochetes, Chlamydophyla pneumoniae, Helicobacter pylori, Escherichia coli, Treponema 
pallidum, Tannerella forsythia, Treponema denticola, T. socranskii, T. pectinovorum, T. medium, T. 
amylovorum, T. maltophilum, Fusobacterium nucleatum, Prevotella intermedia, Chlamydia pneumoniae, 
Porphyromonas gingivalis, propionibacterium acnes, Treponemas, T. lecithinolyticum, and Borrelia 
burgdorferi.  Bacteria are somewhat ubiquitous, so the flexibility of cause removal for items in this sub-
category is much less than for items in the Lifestyle and Iatrogenic categories.   
 The fungi/fungal infections include Cryptococcus, Coccidioides, Aspergillus, Histoplasma, 
Blastomyces, C. famata, C. parapsilosis, C. glabrata, C. krusei, Candida albicans, Candida ortholopsis, 
Candida tropicalis, Cladosporium, Malassezia globosa, Malassezia restricta, Neosartorya hiratsukae, 
Phoma, Sacharomyces cerevisae, and Sclerotinia borealis.   
 The parasites include Trypanosoma brucei rhodesiense, Trypanosoma brucei gambiense, 
Acanthamoeba, Balamuthia mandrillaris, Toxoplasma gondii, Taenia solium, Toxocara canis, T. cati, 
Toxocara ova, and Leishmania amazonensis. 
III-D. Viruses 
 Myriad viruses (shown in Table 2-7C) are dominant in sub-category III-D.  These viruses include 
Bornaviridae (Mammalian 1 bornavirus), Bunyaviridae (Hantavirus, La Crosse encephalitis virus), 
Coronaviridae (Human coronavirus OC43, Murine hepatitis virus), Flaviviridae (Hepatitis C virus, Japanese 
encephalitis virus, Murray Valley encephalitis virus, St. Louis encephalitis virus, West Nile virus), 
Hepadnaviridae (Hepatitis B virus), Herpesviridae (Cytomegalovirus, Epstein-Barr virus, Herpes simplex 
virus 1, Human herpesvirus 6), Orthomyxoviridae (Influenza A virus (H1N1), Influenza A virus (H3N2), 
Influenza A virus (H5N1)), Paramyxoviridae (Hendra virus, Measles virus), Picornaviridae (Enterovirus 71, 
Theiler's murine encephalomyelitis virus), Polyomaviridae (Simian 40 virus large T antigen), Retroviridae 
(Human immunodeficiency virus 1, Human T-cell leukemia virus, Moloney murine leukemia virus), 
Rhabdoviridae (Chandipura virus), Togaviridae (Chikungunya virus, Eastern equine encephalitis virus, 
Venezuelan equine encephalitis virus). 
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 Based on the volume of records examined in the bacteria/fungi/viruses categories, linkages to tau 
and Abeta pathologies were mentioned often, as were direct linkages to AD.  Neuroinflammation induced 
by bacterial and viral infections appeared to be responsible for some of the tau pathology.  
III-E. Other 
 The category named Other contains myriad substances, which are listed in Table 2-7C.  It includes 
some plant-based contributing factors (e.g., 12-myristate 13-acetate, Forskolin, arecoline hydrobromide, 
quisqualate, etc), and a very substantial number of endogenous substances that were administered 
exogenously (e.g., 27-hydroxycholesterol, acetylcholinesterase, Bradykinin, CD40, etc). 
   Ordinarily, endogenous substances are not foundational causes, but intermediate causes, since 
their harmful effects typically are driven by other foundational causes.  However, for consistency, if an 
endogenous substance was administered exogenously for purposes of experimentation or trial, it was 
considered as an exotoxin or other foundational cause for the purposes of this monograph.  Thus, amyloid 
beta, an endogenous substance, could be viewed as an endotoxin when internal processes are being 
discussed, but also as an exotoxin when administered in laboratory experiments.   
 Because of the heterogeneity of the myriad substances in this class, specific impact statements 
need to be tailored to the specific members of this class.  However, from an overall perspective, the 
majority of impacts are at the cellular and biomarker levels, much fewer impacts at the performance level, 
and very few impacts at the disease level.  It should be cautioned again that the absence of impacts 
reported should not be interpreted as their non-existence.  They may not exist, they may exist and were 
not an objective of the research, or they may exist and were not reported.  
 
IV.  Occupational/Environmental Exposures 
IV-A. Chemicals/Materials 
IV-A1. Industrial and Household Chemicals/Materials 
 This sub-category is very broad.  There is overlap among the next level  taxonomy elements; for 
example, some of the solvents are hydrocarbons and some of the chemical compounds are hydrocarbons.   
 This sub-category includes hydrocarbons, solvents, chemical compounds, and Other. 
 The hydrocarbons sub-category includes, e.g., methylcholanthrene, polycyclic aromatic 
hydrocarbons, diesel fuel, kerosene, etc. 
 The solvents sub-category includes, e.g., petroleum-based solvents (mineral turpentine, diesel 
fuel, fuel oil, kerosene, etc), chlorinated solvents (trichloroethylene, perchlorethylene, trichloroethane, 
dichloromethane, benzene), organic solvents (benzene, toluene, phenols, alcohols, ketones, 
methylmethacrylate), dimethyl sulfoxide/ DMSO, etc.  The impacts from the members of this sub-
category, as reported in the references selected, tended to focus on performance and disease.  This was 
due to a number of epidemiology studies of occupational impacts, which tend to focus on higher level 
impacts. 
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 The chemical compounds/Other sub-categories include a full spectrum of chemical compounds, 
especially chlorine, bromine, nitrogen, sodium, sulfur, and carbon compounds.  Members of these sub-
categories include, e.g., Neurotoxins (6-hydroxydopamine/6-OHDA, 5,6-dihydroxytryptamine/ 5,6-DHT, -
5,7-dihydroxytryptamine/5,7-DHT, Type-2 Alkenes/Reactive aldehydes (Acrolein, 4-
Hydroxynonenal/HNE, Acrylamide, Methyl glyoxal), Nitrosamine/ N-nitrosodiethylamine, Adenosine, 3', 
5'-cyclic monophosphate/cAMP, Carbon tetrachloride, Chemical warfare agents/ nerve agents 
(organophosphates, soman, sarin, ethyl S-2-di-isopropylaminoethyl-phosphonothiolate, VX, tabun), 
Cyanide (Potassium cyanide, Sodium cyanide), Formaldehyde, Hydrogen Peroxide/H2O2, Lipophilic 
chemicals (persistent organic pollutants, bisphenol A, phthalates, low molecular weight hydrocarbons, 
polynuclear aromatic hydrocarbons, endocrine disruptors), Sulfur dioxide/SO2, Phthalates (Di-(2-
ethylhexyl)-phthalate/DEHP, mono-2-ethylhexyl phthalate/MEHP, DEHP metabolites), Brominated flame 
retardants (hexabromocyclo-dodecane/HBCD, tetrabromobisphenol-Al/TBBPA, decabromodiphenyl 
ether/DBDE, polybrominated diphenyl ethers/PBDEs), Ammonia, Hypochlorous acid/HOCl, Methanol, 
Peroxynitrite, Sodium azide, Acetaldehyde, 3-Bromopyruvate, Vehicular emission oxides (nitrogen 
dioxide/NO2, carbon monoxide/CO), Sodium fluoride, Membrane-mimicking detergents (sodium dodecyl 
sulfate, lithium dodecyl sulfate), Nitric oxide donors (sodium nitroprusside, DETA NONOate), Amorphous 
aluminosilicates, Sodium nitrite, Tert-butyl hydroperoxide/t-BHP, Alloxan, Ammonium chloride, Anionic 
dyes (Congo Red, Thiazine Red, Thioflavin S), Aroclor 1254, Cobalt chloride, Magnesium chloride, 2,2'-
azobis(2-methylpropionamidine) dihydrochloride/AAPH, Methylglyoxal/ Glyoxal, Disuccinimidyl suberate, 
Naphthazarin/5,8-dihydroxy-1,4-naphthoquinone/ 5,8-dihydroxy-1,4-naphthalenedione, Pyrithiamine, 
Pyrogallol, Glyceraldehyde-3-phosphate/GAPDH, Ethylcholine mustard aziridinium ion/AF64A, 1-methyl-
4-phenylpyridinium ion, 2,2'-dithiodipyridine, Aftin-4, Kaolin, Ozone, 2;3;7;8-tetrachlorodibenzo-p-dioxin. 
 The largest sub-category, by far, is the chemical compounds.  This sub-category is associated with 
roughly even impacts at the cellular, biomarker, and performance levels.  There is much less reported 
direct association at the disease level, for the selected references.  
IV-A2. Agricultural Chemicals 
 This sub-category emphasizes pesticides, herbicides, insecticides, and fungicides, and includes, 
e.g., Organochlorine pesticides, Organophosphate pesticides, 2,4,5-trichlorophenoxyacetic acid, 2,4-
dichlorophenoxyacetic acid, Agent Orange, Aldrin, Alkylphenolpolyethoxylates, APEOs, Arsenic, Beta-
hexachlorocyclohexane/beta-HCH, Bipyridyles, Carbamates, Carbofuran, Chlorfenvinphos, Chlorpyrifos/ 
CPF, Cycloheximide, Cypermethrin, Deltamethrin, Dichlorodiphenyldichloroethylene/DDE, 
Dichlorodiphenyltrichloroethane/DDT, Dichlorodiphenyldichloroethane/DDD, Dieldrin, Dimethyl 
parathion, Endosulfan, Famoxadone, Fenamidone, Glyphosate, Hexachlorobenzene, 
Hexachlorocyclohexane/HCH, Imidacloprid, Lindane, Maneb, Methamidophos, Methyl parathion, 
Neonicotinoids, Nonylphenol, Octylphenol, Paraquat, Parathion, Pyraclostrobin, Pyrethroids, Trans-
nonachlor, Trichlorfon/TCF, Trifloxystrobin, etc. 
 Adverse impacts span the cellular, biomarker, performance, and disease levels.  These chemicals 
impact the larger population through the food supply, and have devastating effects on the agricultural 
workforce.  Given the ubiquitous nature of agricultural chemicals and industrial/household chemicals in 
daily life, eliminating them will be challenging. 
IV-A3. Materials 
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 The materials/particulates that constitute this category are broadly-based, and in many cases 
have become part of the average lifestyle.  Some examples include: 
-heavy metals (e.g., aluminum, arsenic, cadmium, calcium/Ca2/CaCl, calcium ionophore/A-
23187/calcimycin , cobalt, copper, iron, lead, manganese, mercury , methylmercury, selenium, tin, zinc, 
etc) 
-particulates (e.g., air pollution, surgical smoke, dust, etc) 
-nanoparticles (e.g., iron nanoparticles, titanium dioxide nanoparticles, CdSe quantum dots, diesel 
exhaust nanoparticles, alumina nanoparticles, manganese oxide nanoparticles, copper nanoparticles, 
silicon dioxide nanoparticles, zinc oxide nanoparticles, silver nanoparticles, nickel nanoparticles, etc) 
 Impacts of these materials through diverse ingestion pathways cover the full spectrum of levels.  
Both metals and small sized particles have adverse effects.  When the two are combined, the synergy 
becomes problematical.  Metallic particles within the nanoparticle range (<100 nm) are able to cross many 
internal protective barriers, including the blood-brain-barrier (BBB), and cause myriad problems.  While 
penetration of the BBB by nanoparticles is sometimes used for drug delivery, unwanted penetration (as 
reflected in the present study's references) can be quite harmful. 
IV-B. Physical/Mechanical 
 This sub-category includes ionizing radiation, non-ionizing non-visible radiation, non-ionizing 
visible radiation, sound radiation, temperature fields, and force fields.   
 The ionizing radiation component includes, e.g., gamma radiation (dental X-rays, gamma rays, 
etc), particle radiation (56Fe-particle radiation, cosmic radiation, HZE particle radiation), radionuclide 
pollutants (uranium, cesium, cobalt, radon).  The main impacts focus on the biomarker and performance 
levels, with some at the cellular levels and much less at the disease level. 
 The non-ionizing non-visible radiation component includes, e.g.,  electromagnetic fields at myriad 
frequencies, such as extremely low frequency/ELF-EMF, 900 MHz radiofrequency (RF), electromagnetic 
pulse/EMP, electroconvulsive shock/ECS, UV irradiation, etc.  The references selected emphasize 
biomarker level impact, then performance level impacts, and some links to AD. 
 The non-ionizing visible radiation component includes e.g., UV irradiation, photolysis of 1-(2-
nitrophenyl)ethyl sulfate, with impacts emphasizing Abeta production. 
 The sound radiation component includes, e.g., short-lasting impulse noise, chronic noise 
exposure, night-time aircraft noise, ultrasound sonication, etc.  While impacts are identified at the cellular, 
biomarker, and disease levels, Abeta generation and exacerbation are emphasized. 
 The thermal component includes, e.g., cold water hypothermia, cold water stress, heat shock, 
heat stress, heating, hyperthermia, etc, and impacts the cellular, biomarker, and performance levels.   
 The physical force component includes, e.g., blasts, blast traumatic brain injury, hippocampal 
injury, accumulated mechanical stress, spinal cord injury, frequent strong Valsalva maneuvers, long hours 
of repetitive heavy lifting, sequences of blows during the playing of a wind instrument, forceful and 
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repetitive cough, bearing-down efforts during parturition, history of head trauma, etc.  The impacts cover 
all four levels, with perhaps added emphasis on AD.  
 The main components of this sub-category, the different types of physical fields with which we 
interact (electromagnetic, sound, temperature, pressure, force) are ubiquitous.  Avoiding exposure to 
these emissions/interactions would require a major change in lifestyle (and probably location) for most 
people.  The 'Other' category is small, and contains adverse effects from over- and under-exposure to 
oxygen. 
 
V.  Psychosocial/Socioeconomic 
 Psychosocial/Socioeconomic are those foundational causes that reflect personal problems, social 
interactions, larger societal interactions, and economic relationships.  Psychological and sociological stress 
were major causative factors; economic types of stress seemed to play less of a direct role.   
V-A. Psychological 
 This sub-category includes, e.g., chronic stress (repeated stress, chronic mild stress, chronic 
psychological stress, multiple chronic stresses, behavioral stress, childhood trauma, bereavement, chronic 
restraint stress, high job stress), low mental activity (low cognitively engaging activity, low purposeful 
activities, low leisure activities/low hobbies, low music/drawing/meditation/reading/arts/crafts), etc.  
Impacts seemed to spread out over all four levels. 
V-B. Sociological 
 This sub-category includes, e.g., social isolation (isolation, loneliness, living alone, unmarried, 
maternal separation, low social activity index, low social support at work, constricted life space), low 
education (illiteracy), etc.  Impacts cover all four levels, with emphasis on the biomarker, performance, 
and disease levels. 
V-C. Economic 
 This sub-category includes, e.g., economic stress (childhood socioeconomic circumstance), etc.  In 
this small sub-category, impact focused on cognitive deficits. 
 
(return to TOC) 
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APPENDIX 6 – TAXONOMY OF IMPACTS FROM AD FOUNDATIONAL CONTRIBUTING FACTORS 
Table 2-7B - Taxonomy of Effects/Impacts from AD Foundational Causes 
(adapted from reference [1]) 
CODE LEVEL 
 CELLULAR LEVEL 
A1 increase neuroinflammation 
A2 increase neurotoxicity 
A3 increase neuronal death 
A4 increase neurodegeneration 
A5 induce DNA damage 
A6 damage mitochondria 
A7 increase neuronal oxidative stress 
 BIOMARKER LEVEL 
B1 increase tau pathology/neurofibrillary tangles 
B2 increase Abeta generation 
B3 increase AGEs 
B4 increase insulin resistance 
B5 reduce brain volume 
B6 produce low tostesterone 
B7 produce tissue lesions 
B8 induce synaptic/neurotransmission dysfunction 
B9 induce hippocampal damage 
B10 induce olfactory dysfunction 
B11 impair glutamate uptake 
B12 compromise BBB integrity 
B13 impair glucose homeostasis 
B14 impair metal homeostasis 
 PERFORMANCE LEVEL 
C1 increase memory loss 
C2 increase seizures 
C3 induce cognitive dysfunction 
 DISEASE LEVEL 
D1 increase AD risk 
D2 increase diabetes risk 
D3 induce hypothyroidism 
D4 induce metabolic syndrome 
D5 increase obesity 
 
 These effects/impacts are divided into four categories:  
• Cellular Level,  
• Biomarker Level,  
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• Performance Level,  
• Disease Level.   
Each lowest-level sub-category was obtained by inspecting visually many abstracts and titles of records 
that related cause to effect/impact, and extracting those effects mentioned multiple times. 
 The lowest-level sub-categories are not orthogonal; there is some partial overlap and redundancy.  
Much of this is due to the different less-than-precise language of the article authors themselves.  For 
example, some authors may use neurotoxicity to refer to neural damage, others may use neuro-
degeneration or neuronal death or .....  
 The value of incorporating the members of the above table in the final results is that it conveys 
(to the research community, the medical clinician community, and the consumer community) how the 
research is linked either  
 1) directly to AD, or  indirectly to AD through  
 2) strong disease precursors of AD (e.g., diabetes), or  
 3) strong behavioral precursors of AD (e.g., cognitive decline), or  
 4) strong biomarker precursors of AD (e.g., increase tau hyperphosphorylation), or  
 5) strong cellular precursors of AD (e.g., increase neuronal death).   
Why is this important? 
 Consider two potential foundational causes of AD identified in the present study, high-fat diets 
and wireless radiation.  High-fat-diets have been studied for a long time, and there appears to be good 
evidence that such diets are strong contributors to AD.  The long-term data are sufficient to conclude 
there is a direct link between high-fat diets and AD. 
 Wireless radiation at cell phone radiofrequencies or WiFi frequencies has been in 
commercial/military use for perhaps thirty years, and in wide-scale use for perhaps ten+ years.  It might 
take 50-60 years to identify impacts of this segment of the radiation spectrum on the development of AD.  
We have a choice.  We can wait many decades for the types of conclusive evidence that would satisfy the 
statisticians, or we can start to take precautions based on the impact of wireless radiation on surrogate 
endpoints/biomarkers/AD characteristics already demonstrated.  This is the Precautionary Principle, and 
the results contained in Table 2-7C provide a starting point for implementation of the Precautionary 
Principle for prevention and reversal of AD. 
(return to TOC) 
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APPENDIX 7 – AD TREATMENTS 
Table 2-6 
Existing AD Treatments 
(arranged in decreasing order of number of records in database) 
# RECORDS TREATMENT 




1154 antiinflammatory agents 
958 memantine 
903 antipsychotic agents 
874 Rivastigmine 
734 galantamine 




428 secretase inhibitors 
421 psychotropic agents 
408 NSAID 




312 plant extract 
295 nerve growth factor 
294 stem cell 
285 vitamin E 
284 risperidone 
235 antihypertensive agents 
232 Curcumin 
212 nicotine 
210 hormone replacement therapy 
210 polyphenol 
209 brain-derived neurotrophic factor 
195 melatonin 
192 cognitive therapy 











159 17 beta-estradiol 
157 NMDA receptor antagonist 
152 physostigmine 
148 lithium 
147 estrogen replacement therapy 
146 vitamin B-12 
144 serotonin reuptake inhibitor 
143 neurotrophin 
142 BACE1 inhibitor 
142 quetiapine 
134 omega-3 fatty acid 
133 Haloperidol 





122 aggregation inhibitor 
121 music therapy 
118 ACE inhibitor 
110 occupational therapy 
105 acupuncture 
104 social interaction 
102 phenol 
100 resveratrol 
97 polyunsaturated fatty acids 
96 neural stem cells 
96 transcranial magnetic stimulation 






83 folic acid 
83 vitamin C 
82 electroconvulsive therapy 
81 MAO-B inhibitor 
80 muscarinic agonist 
77 Epigallocatechin-3-gallate 











66 calcium channel blocker 
66 cannabinoid 
64 EGB 761 
62 tetrahydroaminoacridine 
61 alpha tocopherol 
61 antiepileptic drugs 
61 leisure activity 
60 Ginseng 






57 mesenchymal stem cells 
56 trazodone 
55 Retinoic acid 
54 Cerebrolysin 
54 GSK-3 inhibitor 
53 humanin 
53 reminiscence therapy 




50 aerobic exercise 
50 pioglitazone 





48 insulin therapy 
48 Intravenous immunoglobulin 
47 antidiabetic agents 
47 galanin 


















42 cholesterol-lowering agents 
41 COX-2 inhibitor 
41 Physiotherapy 
40 Aripiprazole 
38 bright light therapy 
38 quercetin 





34 alpha lipoic acid 
34 amylin 
34 environmental enrichment 
34 PPARgamma agonist 
34 Propentofylline 
34 social activity 
34 vitamin B6 
33 cobalamin 
33 flurbiprofen 
33 methylene blue 
33 sensory stimulation 
32 anti-tau treatments 
32 metformin 
32 rasagiline 
31 Group Therapy 
30 catechin 
30 coumarin 
30 lipoic acid 





29 ferulic acid 
29 latrepirdine 











25 transcutaneous electrical nerve stimulation 
24 amantadine 
24 anti-diabetic 
24 ascorbic acid 





24 red wine 
23 behavioral therapy 











22 lipid lowering 
22 raloxifene 
22 RXR agonist 
22 transcranial direct current stimulation 
22 validation therapy 
22 ziprasidone 
21 arecoline 










20 angiotensin receptor blockers 
20 anti-depressant 
20 Chondroitin sulfate 
20 etanercept 
20 genetic deletion 
20 hydergine 
20 piperidine 
20 sodium valproate 
20 sulfonamide 




19 multisensory stimulation 
18 allopregnanolone 
18 buspirone 
18 butyrylcholinesterase inhibitor 
18 clonidine 









17 embryonic stem cell 
17 escitalopram 
17 Higher education level 
17 hydrogen sulfide 
16 Alpha2 macroglobulin 
16 Amaryllidaceae 
16 aminoguanidine 
16 art therapy 
16 benzothiazole 
16 Caffeic acid 
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16 resistance training 











15 Reality orientation therapy 
15 rifampicin 

















13 Panax notoginseng 












12 hyperbaric oxygen 
12 linopirdine 
12 multinutrient 





11 anticoagulant therapy 
11 captopril 
11 lycopene 
11 nootropic agents 
11 piperazine 




10 antibiotic therapy 
10 beer 
10 clomipramine 
10 dance therapy 
10 Doll therapy 
10 fatty acid supplementation 
10 gold nanoparticles 
10 Huannao Yicong 



















9 glatiramer acetate 
9 horticultural therapy 









8 Centella asiatica 
8 Danshen 
8 edaravone 
8 focused ultrasound 
8 HP 029 
8 Huprine 
8 milieu therapy 
8 paeoniflorin 
8 R-flurbiprofen 
8 Sodium selenate 
8 Withania somnifera 








7 genetic reduction 
7 laser therapy 





7 pet therapy 
7 ponezumab 
7 Pyritinol 
7 Rehmannia glutinosa 
7 Salidroside 
7 Salvianolic acid 



















6 Oleuropein aglycone 
6 sodium butyrate 
6 talsaclidine 





5 asiatic acid 
5 benzylpiperidine 
5 Capsaicin 





5 ellagic acid 
5 fingolimod 
5 FLZ 
5 glycosaminoglycan polysulfate 





5 protocatechuic acid 
5 Qingxin Kaiqiao 
5 S14G-HN 




5 umbilical cord blood cells 
5 vagus nerve stimulation 











4 Hericium erinaceus 
4 JTP-4819 
4 L-theanine 
4 low molecular weight heparin 
4 Namaste Care 
4 Naoling 
4 neotrofin 
4 Noninvasive Brain Stimulation 
4 NRG1 
4 Oligonol 
4 red mold 
4 S-allyl-l-cysteine 
4 Scutellaria baicalensis 
4 spatial training 
4 SuHeXiang 
4 Tolfenamic acid 
4 Tong Luo Jiu Nao 
4 touch intervention 







3 Arundic acid 








3 corticotropin-releasing factor receptor 
3 Cranberry 
3 diallyl disulfide 










3 s-Ethyl cysteine 










2 4% figs 
2 6-shogaol 
2 A-887755 




2 apple juice concentrate 




2 bone morphogenetic protein 9 
2 compound-1 
2 CREB-binding protein CBP 
2 crocetin 
2 Cystatin B deletion 
2 dasatinib 
2 delta-9-tetrahydrocannabinol 
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2 derivative of benzothiazole aniline 
2 diazoxide 
2 Dl-PHPB 




2 glutaminyl cyclase inhibitor 
2 glycyrrhizic acid 
2 Gossypium herbaceam 
2 Human amniotic epithelial cells 
2 hunger 
2 Hydroxysafflor yellow 











2 MMP9 gene 
2 Ophiopogon japonicus 
2 PEI-conjugated R8-Abeta(25-35) 
2 phloroglucinol 
2 PLD2 ablation 
2 prolyl endopeptidase inhibitor 
2 protein-iPSCs 
2 RNS60 
2 Safflower yellow 
2 salubrinal 
2 saxagliptin 
2 Sendai virus 
2 single-walled carbon nanotubes 
2 Smart Soup 












1 2S -neoeriocitrin 
1 3,4-dihydroxyphenylethanol 
1 3-alpha-akebonoic acid 




1 Abeta-HBc VLPs 
1 ACAT1 gene ablation 
1 Activase rt-PA 
1 activation-inhibitory Lactobacillus pentosus 
1 AD-35 




















1 Cassia obtusifolia 
1 Centipedegrass 
1 chitosan oligosaccharides 
1 chloroquine derivatives 
1 ciproxifan 
1 collagen VI 
1 Cudrania cochinchinensis 
1 Cyperus rotundus 







1 Dalesconol B 
1 Daucosterol palmitate 
1 DcR3 
1 Dehydroevodiamine 
1 deleting Nogo 
1 Dendrobium Nobile Lindl 
1 deoxyschisandrin 
1 dexamethasone exposure during pregnancy 
1 Dietary niacin 
1 Dihydromyricetin 
1 dipotassium N-stearoyltyrosinate 
1 dynorphin A-(1-13) 
1 dZip1 inhibition 
1 ephrinB1/Fc 
1 Eugenia jambolana 
1 EUK1001 
1 exogenous Abeta fibrillar seeds 
1 fenugreek seed powder 
1 Fructus mume 
1 Fumanjian 
1 Gami-Chunghyuldan 
1 genetic deletion of 12/15LO 




1 hemizygous deletion of Synj1 
1 high potassium intakes 
1 human ApoE4 allele 
1 HX630 
1 hypericin 
1 IL-1R blocking Ab 
1 illite 







1 kallikrein 7 




1 kappacarrageenanderived pentasaccharide 
1 L-NNNBP 
1 laminin 1 
1 Lentiviral ABN 
1 low-intensity pulsed LIP ultrasound 
1 LX2343 
1 Magnesium sulfate treatment 




















1 pharmacological inducer of HO-1 
1 PHF13 
1 Pleurotus ostreatus 
1 PP-3copy-Abeta1-6-loop123 
1 pratensein 
1 proteolytic nanobodies 
1 Pterocarpus marsupium 
1 pulsed ultrasound 
1 Qifu-Yin 
1 recombinant brain-targeted neprilysin ASN12 
1 reduced InsP3R1 expression 
1 Reduction of exosome secretion 
1 repeated cognitive enrichment 
1 Rhizophora mucronata 
1 RP-1 
1 S1 peptide 




1 Salvia sahendica 
1 Satureja bachtiarica 
1 scanning ultrasound 
1 Schisantherin B 
1 selenofuranoside 
1 Shengmai 
1 shRNA in the dentate 
1 Sia hydroxamate 












1 Tongmai Yizhi Decoction 
1 tri-lithium pyrroloquinoline quinone 
1 tricyclodecan-9-xanthogenate 




1 Zataria multiflora Boiss 
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APPENDIX 8 – AD TREATMENT IMPACTS 
Table 2-4 
DETAILED TAXONOMY OF AD TREATMENT BENEFITS 
BENEFITS FROM AD TREATMENT 
IMPROVE MAINLINE BIOMARKER DEFICITS 
1. Neurotransmission modulation 
1.101 incr cholinergic 
1.102 restor SLAI 
1.15 Improve synapse plasticity 
1.1501 improv PLASTICITY 
1.1502 reduc SREBP2 
1.1503 regen neural network 
1.1504 incr PSD95 
1.1505 incr Ras activity 
1.1506 incr CMRglc 
1.1507 incr MAP1B 
1.1508 reduc TOMOSYN 
1.1509 reduc myoinositol 
1.151 reduc S6K1 
1.1511 rescu PI(4,5)P(2) 
1.1512 restor SNAP-25 
1.1513 decr PAK 
1.1514 amelior excessive NO 
1.1515 incr magnesium 
1.1516 incr EAAT2 
1.1517 reduc glut excitotoxicity 
1.1518 decr calcineurin 
1.2 Antagonize NMDA receptors 
1.201 antag NMDA 
1.3 GABAergic modulation 
1.301 incr GABA 
1.302 restor gephyrin 
1.4 Serotonin receptor modulation 
1.401 incr SEROTONIN 
1.402 inhibit MAO 
1.5 Histamine receptor modulation 
1.501 incr histamine 
1.502 incr T-MEHA 
1.6 Adenosine receptor modulation 
1.601 incr ATP 
1.7 Other neurotransmitter modulation 
1.701 incr norepinephrine 
1.702 activat M1 
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1.703 incr N-acetylaspartate 
1.704 incr NAAG 
1.705 incr brain activation 
2. Tau modulation 
2.1 Tau phosphorylation inhibition 
2.101 reduc hyperphosphorylation 
2.2 Microtubule stabilization   
2.201 restor tubulin 
2.202 decr NFT 
2.203 incr glutathione 
2.3 Reducing Tau oligomerization/pathology 
2.301 reduc tau pathology 
2.302 decr paired helical filament 
2.303 inhibit Hsp90alpha 
2.304 prevent hsv 
2.305 incr anti-tau antibod 
3. Abeta modulation 
3.1 Reduce Abeta 
3.101 reduc Abeta 
3.102 reduc mTOR 
3.103 incr AMPK 
3.104 incr Brn-4 
3.105 incr p75ECD 
3.106 incr LR11 
3.107 inhibit CatB 
3.108 reduc PRAS40 phosphorylation 
3.109 restor glymphatic drainage 
3.2 Amyloid transport 
3.201 restor BBB 
3.202 incr Claudin-5 
3.3 Preventing amyloid aggregation 
3.302 incr iPLA2 
3.303 inhibit ADDL 
3.304 reduc C3 convertase 
3.305 incr TTR 
3.306 incr LRP1 
3.307 incr NEP 
3.308 incr ECE-2 
3.309 incr tyrosine hydroxylase 
3.4 Promoting amyloid clearance 
3.401 enhanc phagocytosis 
3.402 restor lysosomal acidification 
3.403 incr ABCA1 
3.404 incr ABCA7 
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3.405 inhibit CD33 
3.406 incr LXR 
3.407 enhanc megalin 
3.408 incr gelsolin 
3.409 restor Pgp 
3.5 Amyloid based immunotherapy 
3.501 enhanc antibod 
3.6 Secretase enzymes modulation 
3.601 incr alpha-secretase 
3.602 incr sAPP 
3.603 incr nonamyloidogenic 
3.604 reduc GSAP 
3.605 reduc PS1 
3.606 incr ADAM10 
3.607 incr ADAM9 
3.608 reduc BACE1 
3.609 incr SIRT1 
3.61 decr PICALM 
3.7 Improve structural deficits 
3.701 decr brain atrophy 
3.8 Other 
3.801 decr homocysteine 
3.802 incr methionone 
IMPROVE METABOLISM BIOMARKERS 
4. Insulin and Energy metabolism 
4.1 Insulin metabolism 
4.101 allev diabet 
4.102 reduc IRS-1 
4.103 improv hyperglycemia 
4.104 incr IDE 
4.105 incr GLP-1 
4.106 incr Akt 
4.107 incr BAG3 
4.108 incr GLUT4 
4.2 Neuronal metabolism 
4.201 improv metabol 
4.202 incr O-GlcNAc 
5. Oxidative stress reduction 
5.1 Augmenting endogenous defense 
5.101 improv antioxidant defense 
5.102 reduc oxidative stress 
5.103 incr glutathione peroxidase 
5.104 decr nitrotyrosine 
5.105 incr plasma Vitamin E 
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5.106 reduc Pr-SSG 
5.107 decr ROS 
5.108 incr Nrf2 
5.109 incr IGF-1 
5.11 reduc ADMA 
5.111 decr GSK-3 
5.112 improv endotheli 
5.113 restor BH4 
5.114 incr cerebral blood flow 
5.2 AGEs reduction 
5.201 reduc AGEs 
6. Mitochondrial function improvement 
6.101 protect mitochondria 
6.102 incr SIR1 
6.103 incr PGC-1alpha 
6.104 decr Drp1 
7. Modulation of cellular calcium homeostasis 
7.101 decr calcium 
7.102 reduc SOCE 
8. Inflammation alleviation 
8.101 reduc inflamm 
8.102 decr TNF-alpha 
8.103 decr CRP 
8.104 incr cAMP 
8.105 decr IL-1 
8.106 decr IL-6 
8.107 incr IL-4 
8.108 reduc NF-kappaB 
8.109 decr p16 
8.11 incr cyclinD1 
8.111 incr PPAR-gamma 
8.112 inhib cyclooxygenase-1 
8.113 incr resolvin D1 
8.114 reduc CXCR2 
8.115 reduc TLR-4 
8.116 reduc MKL1 
8.117 reduc s100B 
9. Others 
9.1 Hormone dyshomeostasis 
9.101 incr progesterone 
9.102 incr testosterone 
9.103 replace estrogen 
9.104 incr androgen 
9.105 reduc luteinizing hormone 
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9.106 incr DHEA 
9.107 incr Allopregnanolone 
9.108 incr pregnenolone 
9.2 Lipid dyshomeostasis 
9.201 reduc cholesterol level 
9.202 decr 24-hydroxycholesterol 
9.203 decr 27-hydroxycholesterol 
9.204 incr HDL 
9.205 decr LDL 
9.206 incr HMGCoAr 
9.207 reduc chromosome mis-segregation 
9.208 ameliorat hyperlipidemia 
9.209 incr leptin 
9.3 Growth factor restoration 
9.301 incr NGF 
9.302 incr VEGF 
9.4 Metal homeostasis improvement 
9.401 restor metal homeostasis 
9.402 decr copper 
9.403 inhib MAPK 
9.5 Epigenetic modification 
9.501 incr DNA methylation 
9.502 amelior B6 
9.503 amelior B12 
9.504 amelior folate 
9.511 inhib HDAC 
9.512 incr histone acetylation 
9.513 incr histone H3K9 
9.521 incr miR-339-5p  
9.522 decr miR-30a-5p 
9.523 decr mir-206 
9.524 decr miRNA-146a 
9.6 Caspase inhibition  
9.601 reduc caspase 
9.602 reduc JNK 
9.603 restor IGFBP3 
9.7 Nitric oxide synthase modulation 
9.701 reduc iNOS 
9.8 Combinatorial improvements 
9.801 activat multiple pathways 
IMPROVE PERFORMANCE DEFICITS 
10. Cognition/Memory/Learning 
10.1 Cognition 
10.101 improv cogniti 
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10.102 amelior cerebrovascular dysfunction 
10.103 revers hypervascularity 
10.104 incr CXCL1 
10.105 improv MoCA 
10.106 improv MMSE 
10.107 reduc palmitoleic acid 
10.108 incr DHA 
10.109 incr c-fos 
10.11 incr Egr-1 
10.111 incr adiponectin 
10.112 incr TPI 
10.2 Memory 
10.201 improv memory 
10.202 incr B2R 
10.203 incr B1R 
10.204 incr GCSF 
10.205 incr LTP 
10.206 incr RLT 
10.207 inhib Cdk5 
10.208 inhib MAC 
10.209 restor TrkB 
10.21 restor melatonin 
10.211 reduc CX3CR1 
10.212 decr ATF4 
10.213 incr dopamine 
10.214 incr EphB2 
10.3 Learning 
10.301 improv learning 
10.302 decr RORgammat 
IMPROVE BEHAVIORAL DEFICITS 
11. Behavioral problems 
11.1 Behavior  
11.101 improv behavior 
11.2 Quality of Life 
11.201 prevent nutritional deficien 
11.201 improv quality of life 
11.201 improv quality-of-life 
11.202 allev menopausal 
11.203 amelior dysphagia 
11.204 restor IADL 
11.205 allev ataxia 
11.206 improv mobility 
11.207 incr 25-OHD 
11.208 reduc reduce stress 




11.301 reduc agitat 
11.302 decr cortisol 
11.4 Aggression 
11.401 decr aggressi 
11.5 Anxiety 
11.501 reduc anxiety 
11.6 Depression 
11.601 reduc depression 
11.7 Attention 
11.701 improv attention 
11.8 Apathy 
11.801 reduc apathy 
11.9 Sleep 
11.901 improv sleep 
11.902 reduc insomnia 
REVERSE NEUROPATHOLOGY AND AD/DEMENTIA 
12. Prevent and reverse neuropathology  
12.1 Ameliorate neurodegeneration 
12.101 reduc neuro degenerat 
12.102 reduc astrogli 
12.103 suppress activation microgli 
12.104 attenuat NFAT 
12.105 incr CNPase 
12.106 incr Bcl-2 
12.107 decr Bax 
12.108 decr MDA 
12.109 incr BDNF 
12.11 incr neurotrophin 
12.111 incr UCH-L1 
12.112 inhibit PAI-1 
12.113 rescu TGF-beta1 
12.114 decr axonal dystrophy 
12.115 incr PP2A 
12.116 reduc LDH 
12.117 incr PGRN 
12.2 Attenuate neurotoxicity  
12.201 alleviat neurotoxic 
12.202 incr Ngb 
12.3 Prevent apoptosis 
12.301 inhib apopto 
12.302 rescu dendritic spine 
12.303 reduc Ephexin5 
12.304 incr seladin-1 
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12.305 incr Hsp70 
12.306 reduc TRPM2 
12.307 reduc WT1 
12.308 restor TERT 
12.309 reduc p38MAPK 
12.4 Protect neurons  
12.401 protect neuron 
12.402 enhanc autophagy 
12.403 decr Beclin-1 
12.404 decr SQSTM1 
12.405 reduc synj1 
12.406 incr CREB 
12.407 decr IL-12p40/p70 
12.5 Promote neurogenesis  
12.501 incr neurogenesis 
12.502 restor DCX 
12.503 incr PCNA 
12.504 incr 5-bromo-2'-deoxyuridine 
12.505 incr heat shock transcription factor 
12.506 incr Wnt3 
PREVENT AND REVERSE AD/DEMENTIA 
13. AD and Dementia 
13.1 AD/Dementia 
13.101 prevent AD 
13.102 reduc prostaglandin 
13.103 prevent dementia 
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APPENDIX 9 – PN/PAD BIOMARKERS AND SYMPTOMS 
 
TABLE 7A-9a - Existing PN/PAD Biomarkers 




2277 nerve conduction 
velocity 
2038 ankle brachial index 
1549 blood pressure 
1402 stenosis 
1156 body mass index 
1142 neurotoxic 
1139 total cholesterol 
1138 blood glucose levels 
1091 degeneration 
1061 hemoglobin A1c 








671 growth factor 
640 Schwann cell 
616 demyelination 
610 pain-free walking 
distance 




495 low-density lipoprotein 
cholesterol 
489 angiogenesis 
455 axonal degeneration 
435 Systolic blood pressure 
426 circulation 
425 high-density lipoprotein 
cholesterol 
419 oxidative stress 
413 plaque 
412 occlusions 
402 albumin level 
399 glomerular filtration rate 
391 ventricular ejection 
fraction 
382 calcification 
365 nerve damage 
354 neurodegeneration 
349 IgM 




322 heart rate 
318 edema 
318 nitric oxide 
309 apoptosis 
308 fibrinogen 
284 endothelial dysfunction 
283 denervation 




263 vitamin B(12) deficiency 
262 stenoses 
261 high homocysteine 
251 angiotensin converting 
enzyme 
247 amyloid 
240 myelinated fibers 
237 vibration perception 
threshold 
222 weight loss 
210 fatty acid 
208 carotid artery intima-
media thickness 
206 nerve growth factor 









185 insulin resistance 
183 pulse wave velocity 
175 diastolic blood pressure 
170 nerve regeneration 
168 platelet aggregation 
162 glycated haemoglobin 
159 lymphocytes 
158 nerve fiber density 
154 B-cell 
152 Reactive oxygen species 
151 arterial stiffness 
147 capsaicin 
147 lipid profile 




126 vitamin E deficiency 
125 apolipoprotein 
125 Vitamin D deficiency 
123 acetylcholine 
122 mechanical hyperalgesia 
119 glutathione 




115 nitric oxide synthase 
115 white blood cell 
114 creatine 
110 waist circumference 
108 creatinine clearance 
107 lactate 
106 von Willebrand factor 
105 plasminogen activator 
inhibitor-1 
104 pulse pressure 
104 thrombin 
103 urea 
102 atherosclerotic plaque 
102 IgA 
101 vasculopathy 
100 intercellular adhesion 
molecule-1 
99 antioxidants 
98 calcitonin gene-related 
peptide 
96 uric acid 
95 blood viscosity 
94 Lipoprotein(a) 
92 albumin excretion rate 
92 substance P 
84 fiber loss 
84 malondialdehyde 
81 Endothelial progenitor 
cells 
81 orthostatic hypotension 
80 fibrin 
80 fibroblast growth factor 
80 folic acid 
78 transcutaneous oxygen 
pressure 
74 creatine kinase 
74 matrix metalloproteinase 
74 thromboxane 
73 thiamine 
72 systemic sclerosis 
70 IL-10 
70 peak oxygen 
consumption 
69 lipid peroxidation 
69 prostacyclin 
69 superoxide dismutase 
69 troponin 
68 D-dimer 
66 mRNA levels 
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64 Red Blood Cell 
61 monoclonal antibodies 
61 oxygen saturation 
61 P-selectin 
60 heat shock 
60 rheumatoid factor 





55 Venous occlusion 
54 glial fibrillary acidic 
protein 
53 chemokines 
53 Tissue Plasminogen 
Activator 
52 Angiogenic growth 
factors 
52 BDNF 
52 hepatocyte growth factor 
52 l-arginine 
52 MetS 
51 cardiac troponin T 
51 epidermal growth factor 
51 glucose metabolism 
51 prothrombin 
50 NF-kappaB 
49 adenosine diphosphate 
49 bone mineral density 










45 neuronal damage 
44 adiponectin 
44 alanine 








41 alkaline phosphatase 
41 apolipoprotein B 
41 CD34 
41 free radicals 
41 N-terminal pro-brain 
natriuretic peptide 







39 apolipoprotein A-I 
39 bacterial infection 
39 cyclic AMP 
39 endothelial damage 
38 connexin 32 
38 glycine 
38 Noradrenaline 
38 vitamin K 
37 blood urea nitrogen 
37 E-selectin 
37 endothelin-1 
37 matrix metalloproteinase 
9 
36 arachidonic acid 
36 heme 





35 interferon gamma 
34 actin 
34 catalase 
34 cystatin C 
34 histamine 
34 Streptococcal 






33 cerebral ischemia 
33 ferritin 
33 glial activation 
33 hypoperfusion 
33 oxidative damage 
32 anti-MAG antibodies 
32 insulin levels 
32 polyunsaturated fatty 
acids 
31 parathyroid hormone 
31 progesterone 
30 beta 2 microglobulin 







29 Chlamydia pneumoniae 




28 brain atrophy 
28 carotid-femoral pulse 
wave velocity 
28 CD31 





28 thromboxane A2 
27 antinuclear antibodies 
27 Apolipoprotein E 
27 cholinesterase 




27 high total cholesterol 
27 methylmalonic acid 
27 RAGE 
27 vascular reactivity 
26 Endothelin 
26 glutathione peroxidase 
26 growth hormone 
26 HMG-CoA reductase 
26 Hydrogen peroxide 
26 leptin 
26 miRNA 
25 amyloid beta 
25 cysteine 
25 GP IIb/IIIa 
25 Helicobacter pylori 
25 Iron Deficiency 







23 copper deficiency 






22 Vitamin B1 deficiency 
21 bradykinin 
21 Escherichia coli 
21 glutamic acid 
21 methicillin-resistant 
Staphylococcus aureus 
21 Oxidized low-density 
lipoprotein 
21 prostate-specific antigen 
20 acylcarnitine 
20 adenosine triphosphate 
20 aldosterone 
20 arterial obstruction 
20 CD40 ligand 
20 folate deficiency 
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20 insulin-like growth factor 
I 




19 serum calcium 
19 thrombomodulin 
19 vascular calcifications 
18 amyloid fibrils 
18 c-Fos 
18 caspase 3 
18 docosahexaenoic acid 
18 eicosapentaenoic acid 
18 endothelial activation 
18 estradiol 
18 heme oxygenase 1 
18 HIF-1alpha 
18 luminal diameter 




17 aortic pulse wave 
velocity 
17 arterial compliance 
17 bone density 









17 High-mobility group box 
1 
17 IL-2 
17 lactic acid 
17 lead levels 
17 porphobilinogen 
17 prothrombin time 
16 androgen 




16 phytanic acid 
16 proline 
16 pyridoxal 
15 activated partial 
thromboplastin time 





15 DNA polymerase gamma 
15 osteopontin 
14 anti-GM1 antibody 










13 atheromatous plaque 
13 ceruloplasmin 
13 complement levels 
13 cyclic guanine 
monophosphate 












12 anticardiolipin antibodies 
12 arterial calcifications 







12 Chondroitin sulfate 
12 hydrogen sulfide 
12 IgE 









11 anti-gliadin antibodies 
11 Coxsackie 
11 dendritic cells 
11 dipeptidyl peptidase 






11 Myelin breakdown 









10 glycogen synthase 
10 low birth weight 










9 Aortic augmentation 
index 
9 beta-galactosidase 







9 fibrin D-dimer 
9 fungi 
9 heparan sulfate 
9 iodine 




9 vascular stiffness 




















7 aldehyde dehydrogenase 
7 amines 
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7 angiotensin II type 1 
7 CD14 
7 coronary calcification 
7 HIV RNA levels 
7 horseradish peroxidase 
7 linoleic acid 








6 arterial elasticity 
6 citrulline 
6 Cu 
6 dimethylarsinic acid 
6 factor XIII 
6 fibroblast growth factor 
23 
6 FVII 
6 glucuronic acid 
6 GRP78 
6 histone deacetylase 6 
6 IL-18 
6 kallikrein 
6 lipid hydroperoxides 
6 Methylglyoxal 
6 N-acetylglucosamine 
6 neurotoxic esterase 








5 apolipoprotein A-II 








5 Glyoxalase 1 
5 guanosine 
monophosphate 






5 luteinizing hormone 
5 monoamine oxidase 
5 omega-3 index 
5 perforin 
5 phenyl valerate 
5 platelet factor 4 
5 pregnenolone 










4 apolipoprotein B-48 
4 apolipoprotein C-III 







4 erythrocyte aggregation 
4 GHb 
4 glutathione transferase 
4 glycated albumin 
4 homovanillic acid 
4 hydroxymethylbilane 
synthase 
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4 nitrogen oxide 
4 Nox2 
4 S100A12 
4 Sirtuin 1 
4 SO2 
4 soluble guanylyl cyclase 
4 succinate dehydrogenase 
4 tetrahydrobiopterin 
4 tissue inhibitors of 
metalloproteinases 
4 ubiquinone 
4 valvular calcification 
4 vasoactive intestinal 
peptide 
3 acetaldehyde 
3 acyl-CoA oxidase 
3 Allograft inflammatory 
factor-1 
3 arginase 
3 B vitamin deficiency 
3 brain iron accumulation 
3 butyric acid 
3 CFU 
3 chorionic gonadotropin 
3 connective tissue growth 
factor 
3 CXCL10 
3 eosinophil cationic 
protein 
3 factor XII 
3 Fusobacterium 
3 glucagon-like peptide 1 
3 Glucokinase 
3 glutathione reductase 
3 GTP cyclohydrolase 
3 hemosiderin 
3 hydroperoxide 
3 hydroxyl radical 
antioxidant capacity 
3 hyperoxia 






















3 serum nitrate 
3 sTWEAK 
3 trimethylamine 
3 waist-to-height ratio 
3 xanthine oxidase 
2 3-nitrotyrosine 
2 32P 
2 acid phosphatase 
2 adenosine deaminase 
2 adenosine kinase 
2 adenylyl cyclases 
2 agrin 
2 aminolevulinic acid 
2 aminopeptidases 
2 apoB/apoA-I ratio 
2 apolipoprotein A-IV 
2 apolipoprotein AI-CIII-AIV 
gene cluster 
2 aspartic acid 





2 Cardiometabolic index 
(CMI) 
2 caspase 9 
2 CCL4 
2 Ceramide antibody levels 




2 docosapentaenoic acid 
2 endostatin 
2 estrone 
2 follicle stimulating 
hormone 
2 glutaredoxin 
2 herpes simplex virus 1 
2 hippuric acid 
2 histone deacetylases 
2 hydroxyproline 
2 Janus kinase 1 
2 JC virus 
2 Ketones 
2 kininase II 
2 kininogen fractions 
2 kynurenic acid 






2 omentin-1 level 
2 phenylglyoxylic acid 
2 polymorphonuclear 
neutrophils 
2 Prevotella intermedia 
2 protein tyrosine 
phosphatases 
2 pyruvic acid 
2 saturated fatty acid 
2 suPAR level 
2 tachykinins 
2 transcription factor CHOP 
2 TREM-1 


















1 adenylate kinase 
1 aniline hydroxylase 
1 Anti-Mullerian hormone 
1 antiphospholipids-
induced 
1 apolipoprotein D 
1 Apolipoprotein L1 
1 aryl hydrocarbon 
hydroxylases 





1 caspase 12 




1 complement C3b 
1 complex II deficiency 
1 complex IV deficiency 
1 cyclic ADP-ribose 
1 cyclooxygenase 1 
1 cystathionine gamma-
lyase 






1 elevated copper 









1 High adiponectin 
1 histone 
acetyltransferases 




1 L-ascorbic acid 
1 lathosterol 



















1 pyruvate carboxylase 
1 S-nitrosoglutathione 
1 sex steroid hormones 
1 ulifloxacin 
 Urine kidney injury 
molecule-1 
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TABLE 7A-9b - Existing PN/PAD Symptoms/Diseases 
 
# REC SYMPTOM/DISEASE  
17050 neuropathy 
13577 peripheral neuropathy 
9627 diabetes mellitus 
9078 artery disease 
8114 peripheral artery disease 






2861 neuropathic pain 
2612 stroke 
2152 diabetic peripheral neuropathy 
2071 infection 
2056 myocardial infarction 
2051 cardiovascular disease 
1983 intermittent claudication 
1913 polyneuropathy 
1796 coronary artery disease 
1585 heart disease 
1571 type 2 diabetes mellitus 
1547 critical limb ischemia 
1533 diabetic foot ulcer 
1519 Disorder 
1440 heart failure 
1135 weakness 
879 neutropenia 
878 cerebrovascular disease 
833 sensory neuropathy 
832 retinopathy 




747 renal failure 
731 thrombosis 
705 ataxia 
675 abdominal aortic aneurysm 
660 nephropathy 
645 angina 
645 renal disease 
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625 Congestive heart failure 
623 multiple myeloma 
621 peripheral artery occlusive disease 
618 bleeding 
618 hyperalgesia 
613 chronic kidney disease 
612 vasculitis 
607 ischemic heart disease 
602 restenosis 
578 chronic obstructive pulmonary disease 
578 fatigue 










433 atrial fibrillation 
417 balance 
412 chronic pain 
400 mononeuropathy 
391 lymphoma 
389 rheumatoid arthritis 
388 End stage renal disease 
387 autonomic neuropathy 
385 dementia 
380 axonal neuropathy 







354 ischemic stroke 
352 Guillain-Barre syndrome 
345 carpal tunnel syndrome 
343 hyperlipidemia 
332 leprosy 
319 type 1 diabetes mellitus 
314 hepatitis 
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308 renal insufficiency 
306 encephalopathy 
305 demyelinating peripheral neuropathy 
304 motor neuropathy 
303 Coronary Syndrome 
295 neurological symptoms 
285 neurologic disease 
284 muscle weakness 
280 Atherothrombosis 
275 arrhythmia 
273 inflammatory demyelinating polyneuropathy 
271 metabolic syndrome 
266 systemic lupus erythematosus 
257 stiffness 
254 amyloidosis 
250 left ventricular hypertrophy 






224 diabetic retinopathy 
220 hypotension 
213 multiple sclerosis 
205 coronary disease 
202 paresthesia 
199 constipation 
199 monoclonal gammopathy 
190 proteinuria 
187 diabetic nephropathy 
187 Mixed Cryoglobulinemia 
187 Sjogren's syndrome 
179 nerve dysfunction 
178 arterial hypertension 
169 demyelinating polyradiculoneuropathy 
169 sensorimotor polyneuropathy 
165 Mononeuritis 
162 angina pectoris 
160 axonopathy 
158 lung disease 
157 Parkinson's disease 
157 renal dysfunction 
152 autoimmune disease 
150 albuminuria 




149 liver disease 
149 sensorimotor neuropathy 
147 hyperplasia 
133 erectile dysfunction 
126 renal impairment 
125 artery calcification 
124 vasculitic neuropathy 
123 amyotrophic lateral sclerosis 
123 systemic atherosclerosis 
120 axonal polyneuropathy 
119 hypothyroidism 
119 myocardial ischemia 
117 neurodegenerative disease 
113 Alzheimer's disease 
113 POEMS syndrome 
110 atherosclerotic vascular disease 
110 Osteoporosis 
107 carotid artery disease 
107 peripheral polyneuropathy 
107 reactive hyperemia 
103 neuromuscular disease 
103 optic neuropathy 
102 impaired glucose tolerance 
101 endocrinopathy 
101 Macrovascular disease 
88 motor neuron disease 
86 cerebral infarction 
84 arterial stenosis 




76 acquired immunodeficiency syndrome 
75 Hyperhomocysteinemia 
73 left ventricular dysfunction 
73 peripheral atherosclerosis 
72 complex regional pain syndrome 
72 microvascular disease 
70 dysphagia 
70 polyarteritis nodosa 
69 HIV disease 
69 organ damage 
68 granulomatosis 
68 neuroarthropathy 




67 Restless legs syndrome 
66 vascular calcification 
65 hypoglycemic 
65 polyangiitis 
63 Churg-Strauss syndrome 
61 amyloidotic polyneuropathy 
61 neurodegenerative disorders 
59 metabolic disease 
58 impaired renal function 
56 celiac disease 
56 Crohn's disease 
55 demyelinating disease 
54 coronary atherosclerosis 
54 inflammatory bowel disease 
54 macroalbuminuria 
53 sleep apnea 
52 nephrotic syndrome 
51 carotid atherosclerosis 
48 gammopathies 
47 connective tissue disease 
47 proliferative retinopathy 
46 cardiac autonomic neuropathy 
43 Buerger's disease 
43 Lyme disease 
41 arteriosclerosis obliterans 
41 polyvascular disease 
41 vascular dysfunction 
38 cutaneous vasculitis 
37 Fabry disease 
37 Miller Fisher syndrome 
33 hypercoagulability 
31 hypoalbuminemia 
31 mitochondrial diseases 
31 muscle ischemia 
30 Castleman's disease 
30 diplopia 
30 Hansen's disease 
29 Behcet's disease 
29 chronic liver disease 
28 sicca syndrome 
26 hyperuricemia 
25 gluten sensitivity 
25 peripheral ischemia 
21 Hypereosinophilic syndrome 
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20 aortic stiffness 
18 coronary artery stenosis 
17 normoalbuminuria 




12 mechanical stress 
12 rheumatoid vasculitis 
11 hypomagnesemia 
11 neurone disease 
10 neurosyphilis 
10 social isolation 
9 low physical activity 















(return to TOC) 
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